sofosbuvir has been researched along with Chronic Hepatitis C in 1325 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 978 (73.81) | 24.3611 |
| 2020's | 347 (26.19) | 2.80 |
| Authors | Studies |
|---|---|
| Abd El-Moghny, MG; Abdel-Tawab, MA; El Nashar, RM | 1 |
| Abdouljoud, M; Agopian, VG; Akoad, ME; Anderson, MP; Anderson, MS; Aucejo, F; Cameron, A; Cannon, RM; Chapman, WC; Chavarriaga, A; Delman, AM; Dhanireddy, K; Doyle, M; Emamaullee, J; Esquivel, CO; Feizpour, CA; Foley, DP; Ganesh, SR; Humar, A; Kazimi, MM; Kim, A; Kim, SC; Kubal, CA; Locke, JE; Magliocca, JF; Maithel, SK; Moris, D; Moro, A; Nguyen, MH; Olyaei, A; Orloff, SL; Salgia, RJ; Shah, SA; Simpson, MA; Sonnenday, CJ; Subramanian, V; Sudan, DL; Tran, BV; Turgeon, MK; Vagefi, PA; Wedd, JP; Wongjirad, CP | 1 |
| Craft, JF; Ryscavage, P | 1 |
| Arteaga, L; Brinkley, S; Brooner, RK; Falade-Nwulia, O; Haselhuhn, T; Herne, K; Katz, S; Latkin, C; Mehta, SH; Moon, J; Sulkowski, MS; Sutcliffe, CG; Ward, KM | 1 |
| Hou, MC; Huang, YH; Lan, KH; Lee, WP; Wang, YW | 1 |
| Abbass, A; Abdeen, N; Afify, S; Alboraie, M; El Kassas, M; ELshazly, HM; Eltabbakh, M; Emadeldeen, M; Ezzat, S; Farghaly, R; Ghalwash, A; Hamdy, H; Omar, H; Omran, D; Salaheldin, M; Sweedy, A; Tahoon, M | 1 |
| Bado, P; Djigma, FW; Kabré, MK; Kiendrebeogo, IT; Obiri-Yeboah, D; Ouattara, AK; Simpore, J; Sombie, HK; Sorgho, AP; Tao, I; Yelemkoure, ET; Yonli, AT; Zeba, MTA; Zohoncon, TM; Zongo, AW; Zouré, AA | 1 |
| Álvares-DA-Silva, MR; Dihl, RR; Librelotto, CS; Simon, D; Souza, AP | 1 |
| Flamm, SL; Martin, MT; Patel, S | 1 |
| Alavian, SM; Anvar, A; Azizi-Saraji, A; Behnava, B; Namvar, A; Salimi, S; Sharafi, H | 1 |
| Agrati, C; Ammassari, A; Antinori, A; Bellagamba, R; Cicalini, S; Fabbri, G; Grilli, E; Lorenzini, P; Mastrorosa, I; Notari, S; Tempestilli, M; Vergori, A | 1 |
| Beier, C; Cornberg, M; Kordecki, N; Maasoumy, B; Ohlendorf, V; Sandmann, L; Tergast, TL; Wedemeyer, H | 1 |
| Ansari, MA; Barnes, E; Bowden, R; Bukh, J; Chaturvedi, N; Fellay, J; Fernandez-Antunez, C; Foster, GR; Irving, WL; Magri, A; McLauchlan, J; Pedergnana, V; Ramirez, S; Simmonds, P; Smith, DA | 1 |
| Abdel-Bary, HM; El Sayed, IET; Ghanm, SE; Othman Saad, W; Saad, BF; Shebl, NA | 1 |
| Hasan, SS; Javed, A; Kow, CS; Ramachandram, D | 1 |
| Aimono, Y; Kamoshida, T; Kogo, M; Kohyama, N; Yamamoto, T | 2 |
| AbdAllah, M; Abdel Maksoud, MH; Abdelaziz, H; Ali, L; Cordie, A; Doss, W; El Garhy, N; El Serafy, M; Esmat, G; Khalil, M; Mohamed, R; Omar, H | 1 |
| Chu, CJ; Hou, MC; Huang, YH; Lee, FY; Lee, SD; Lin, CC; Su, CW; Su, PS; Wang, YJ; Wu, SH | 1 |
| Alsrhani, A; Alzahrani, B; Ejaz, H; Gohar, UF; Junaid, K; Mukhtar, H; Qamar, MU; Younas, S | 1 |
| Abd-Elsalam, S; AbdElrahman, M; Bader El Din, NG; Barakat, AZ; El Awady, MK; Elbatae, H; Farouk, S; Ibrahim, MK; Omran, D; Tawfik, S | 1 |
| Barbour, Y; Bruden, DJT; Espera, HGF; Gove, JE; Hewitt, AM; Homan, CE; Johnston, JM; McGilvray, J; McMahon, BJ; Plotnik, JN; Rhodes, W; Roik, E; Simons, BC; Snowball, MM; Stevenson, TJ; Townshend-Bulson, L | 1 |
| Camus, G; Chang, TT; Chen, CY; Chen, JJ; Chen, PJ; Chien, RN; Chu, CJ; Chuang, WL; Gaggar, A; Hsu, YC; Hu, TH; Jiang, D; Liu, CJ; Lo, GH; Massetto, B; Peng, CY; Sheen, IS; Suri, V; Tseng, KC; Wang, HY; Yang, J; Zhang, F | 1 |
| Chayama, K; Hayes, CN; Imamura, M; Tanaka, J | 1 |
| Anthony, D; Avihingsanon, A; Bennet, JA; Benson, CA; Brates, I; Cheinquer, N; Kityo, C; Kliemann, DA; Linas, B; Naggie, S; Nunes, EP; Robbins, G; Santana-Bagur, J; Scello, C; Smeaton, L; Solomon, SS; Son, A; Sowah, LA; Sulkowski, M; Supparatpinyo, K; Tebas, P; Van Schalkwyk, M; Wagner-Cardoso, S; Wimbish, C; Wyles, D | 1 |
| Bailey, H; Collins, IJ; Malik, F; Malyuta, R; Thorne, C; Volokha, A | 1 |
| Nguyen, MH; Wong, YJ | 1 |
| AbdEl-Maksoud, HA; Alsaab, SM; El-Hamid, OA; El-Sorady, EM; Elharrif, MG | 1 |
| Al-Judaibi, B; Carleton, BC; Chang, WC; Crotty, P; Drögemöller, BI; Farivar, JF; Ford, JA; Kim, RB; Lee, SS; Li, KH; Lin, JJ; Loucks, CM; Ramji, A; Ross, CJD; Schwarz, UI; Tam, E; Trueman, JN; Walston, LL; Wright, GEB; Yoshida, EM | 1 |
| Bansal, S; Giacomet, V; Hsueh, CH; Indolfi, G; Iorio, R; Kelly, D; Kersey, K; Mangia, A; Mania, A; Nebbia, G; Parhy, B; Pawlowska, M; Sang Yue, M; Shao, J; Szenborn, L | 1 |
| Bricker-Ford, R; Brumenschenkel, A | 1 |
| Bair, MJ; Chang, CC; Chang, TS; Chen, CH; Chen, CT; Chen, CY; Chen, GY; Cheng, PN; Chong, LW; Chuang, WL; Dai, CY; Hsieh, TY; Hsiung, CK; Hu, JT; Huang, CF; Huang, CS; Huang, JF; Huang, YH; Hung, CH; Kao, CN; Kao, JH; Kuo, HT; Lee, MH; Lee, PL; Lee, TH; Lin, CL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Mo, LR; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Wang, CC; Wang, SJ; Wu, WC; Yang, CC; Yang, SS; Yeh, ML; Yu, ML | 1 |
| AlBayati, SM; Faraj, OA | 1 |
| Ebeid, FSE; El-Haddad, A; El-Sayed, MH; Elsayed, W; Gaggar, A; Kersey, K; Massetto, B; Zekri, AR; Zhang, F | 1 |
| Abdelazim, AH; Ramzy, S | 1 |
| Endo, S; Ishida, H; Kageyama, F; Kato, J; Kaya, M; Kinae, A; Matsushita, K; Nagura, M; Nakamura, K; Odagiri, K; Sugiue, K; Sugiyama, K; Suzuki, T; Ujiie, C; Ukita, H; Yamaguchi, H | 1 |
| Attia, A; Baudoin, M; Boyer, S; Carrieri, P; Kouanfack, C; Lacombe, K; Lemoine, M; Maradan, G; Moh, R; Mourad, A; Nishimwe, ML; Rouveau, N; Santos, M; Seydi, M; Sylla, B; Woode, ME | 1 |
| Camus, G; Grant, PM; Gupta, N; Kabihizi, J; Kateera, F; Makuza, JD; Manirambona, L; Mukabatsinda, C; Murangwa, A; Musabeyezu, E; Muvunyi, CM; Nsanzimana, S; Serumondo, J; Shumbusho, F | 1 |
| Camus, G; Grant, PM; Gupta, N; Kabakambira, JD; Kabihizi, J; Kateera, F; Makuza, JD; Manirambona, L; Murangwa, A; Muvunyi, CM; Nsanzimana, S; Serumondo, J; Shumbusho, F; Sylvain, H | 1 |
| Kao, JH; Liu, CH; Liu, CJ | 1 |
| Dobrzeniecka, A; Marczyńska, M; Pokorska-Śpiewak, M | 2 |
| Jacob, DA; Kolberg, JL; Rumph, DM; Straley, CM | 1 |
| Coşar, AM; Durak, S | 1 |
| Abd-Aal, MS; Abdel-Hafez, AS; Abdel-Hamid, TM; Abdel-Rahman, RZ; Abdelsalam, MFA; Elaatar, MB; Elgohary, MA; Elkady, AO; Elnagar, MT; Elnagdy, TR; Elsaied, MA; Emam, ME; Fatoh, AR; Hamada, MM; Hasan, EM; Helmy, S; Ibrahim, AA; Lotfy, HH; Mubark, MA; Nawar, OM; Sakr, MA; Seadawy, MG; Selem, MA; Shehata, MM; Zaki, AI | 1 |
| Al-Dhamin, Z; An, J; Cui, L; Han, T; Hou, Y; Li, L; Li, W; Liang, J; Liu, L; Nan, Y; Xue, N; Zhang, L; Zhao, W | 1 |
| A Wahsh, E; Ahmed, M; Ahmed, S; Elsayed, A; Esamat, G; Gomaa, A; Hassan, E; Ramadan, A | 1 |
| Chen, JJ; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Lee, PL; Tung, HD | 1 |
| Chen, ZM; Cui, GL; Dong, XP; Ji, F; Lv, J; Wang, B; Yu, ZJ; Zeng, QL; Zhang, HX | 1 |
| Bae, SH; Chang, UI; Choi, JY; Han, JW; Jang, JW; Kim, CW; Kim, HY; Kim, SH; Kwon, JH; Lee, HL; Lee, J; Lee, SK; Lee, SW; Nam, H; Nam, SW; Song, DS; Song, MJ; Sung, PS; Yang, H; Yang, JM; Yoo, SH; Yoon, SK | 1 |
| Guo, M; Ke, L; Liu, J; You, R | 1 |
| Dong, M; Evon, DM; Lok, AS; Michael, L; Nelson, DR; Peter, J; Reeve, BB; Stewart, PW | 1 |
| Bova, SE; Freedman, SR; Pluckrose, DM; Szczepanik, A | 1 |
| Alavian, SM; Hajarizadeh, B; Hl Borba, H; Sabermahani, A; Sharafi, H; Tasavon Gholamhoseini, M | 1 |
| Ebell, M; Elshafie, S; Trivedi-Kapoor, R | 1 |
| Rabarioely, SS; Rabenjanahary, TH; Rakotozafindrabe, ALR; Ramanampamonjy, RM; Randriamifidy, NH; Rasolonjatovo, AS; Razafimahefa, SH; Razafindrazoto, CI | 1 |
| Esteves, J; Forehand, J; Gradus, JL; Gui, J; Hoyt, JE; Huybrechts, K; Jiang, T; Ray, K; Rozema, L; Schnurr, PP; Shiner, B; Watts, BV | 1 |
| Chang, YL; Hou, MC; Huang, YH; Lan, KH; Lee, WP; Lu, CL; Wang, YK; Wang, YW | 1 |
| Hui, VK; Kao, JH; Kumar, R; Liu, CH; Tan, J; Tan, SS; Thurairajah, PH; Wong, GH; Wong, YJ | 1 |
| Abdelaziz, A; Abdelgaied, MY; Abdelkawy, KS; Belal, F; El-Khodary, NM; Elmekawy, HA | 1 |
| Falade-Nwulia, O; Karimi-Sari, H; Lim, JK; Rezaee-Zavareh, MS | 1 |
| Chang, TH; Chen, WC; Cheng, JS; Liu, PF; Shu, CW; Sun, WC; Tsai, WL | 1 |
| AbouBakr, O; El Sayed Zaki, M; Ezz El Regal, M; Noaman, A; Sarhan, AA | 1 |
| Gowda, C; Honegger, JR | 1 |
| Kao, JH; Liu, CH | 1 |
| Bilal, M; Hussain, N; Sumrin, A; Younas, S | 1 |
| Dai, H; Fang, C; Guo, Y; Hu, S; Lan, G; Liu, Q; Nie, M; Peng, F; Peng, L; Tan, L; Xie, X; Zhang, H; Zhong, M | 1 |
| Akbulut, A; Akıncı, E; Bal, T; Barut, Ş; Batırel, A; Baykam, N; Çabalak, M; Can, G; Çelebi, G; Çuvalcı Öztoprak, N; Duygu, F; Erben, N; Esen Yıldız, İ; Esen, Ş; Gül, HC; Günal, Ö; Gündüz, A; Güner, R; Hızel, K; İnan, D; İnce, N; Karaali, R; Karabay, O; Karsen, H; Kaya, S; Köksal, İ; Kömür, S; Köse, Ş; Kumbasar Karaosmanoğlu, H; Kurtaran, B; Namıduru, M; Önlen, Y; Sarı, ND; Sarıgül Yıldırım, F; Şenateş, E; Şener, A; Sırmatel, F; Sünnetçioğlu, M; Tabak, F; Tosun, S; Türker, K; User, Ü; Yamazhan, T; Yörük, G; Zerdali, E | 1 |
| El-Demerdash, E; Saeed, NM; Wahdan, SA; Wasef, AK | 1 |
| Chen, S; Dzakah, EE; Gong, P; Liu, S; Rashid, F; Sun, Q; Tang, S; Wang, H; Wang, J; Wu, J; Yang, X | 1 |
| Buti, M; Castellanos Fernández, MI; Chan, WK; Duseja, A; El-Kassas, M; Esmat, G; Gordon, SC; Hamid, S; Henry, L; Isakov, V; Lam, B; Méndez-Sánchez, N; Nader, F; Ong, JP; Papatheodoridis, G; Racila, A; Romero-Gómez, M; Stepanova, M; Yilmaz, Y; Younossi, I; Younossi, ZM; Yu, ML; Ziayee, M | 1 |
| Bishai, N; Fiki, ME; Garem, NE; Ibrahim, M; Nabawy, WE | 1 |
| Aoki, K; Force, L; Ishizaki, A; Konishi, H; Liu, LJ; Mita, E; Mizutani, H; Nakamoto, D; Ng, LJ; Shing, D | 1 |
| Angelidakis, G; Granwehr, BP; Hosry, J; Jiang, Y; Mustafayev, K; Torres, HA; Yepez Guevara, E; Yibirin, M | 1 |
| Au, CL; Chan, HL; Hui, VW; Lai, JC; Lam, ASM; Tse, YK; Wong, GL; Wong, VW; Yip, TC | 1 |
| Abdelghafour, R; AbdelRazek, W; Dabees, H; Said, M; Shousha, HI | 1 |
| Anushree, N; Seetharaman, K; Venkatesh, V | 1 |
| Abd El-Hameed, M; Dawood, RM; El Ray, AA; Mahmoud Diab, T; Mashaal, AR; Seyam, M; Shemis, MA | 1 |
| Ajdarkosh, H; Amirkalali, B; Faraji, AH; Karbalaie Niya, MH; Khoonsari, M; Maadi, M; Motamed, N; Nikkhah, M; Safarnezhad Tameshkel, F; Sobrakhshankhah, E; Sohrabi, M; Vafaeimanesh, J; Zamani, F | 1 |
| Dusunceli, I; Gok Sargin, Z | 1 |
| Cordie, A; Esmat, G; Kamel, AM; Sabry, N | 1 |
| Li, J; Wang, L; Xie, W; Zhou, Y; Zhu, X | 1 |
| Abdel Alem, S; Abdelbary, MS; Cordie, A; El Garhy, N; El Khateeb, E; Elsharkawy, A; Esmat, G; Fouad, R; Khalil, M | 1 |
| Fujita, K; Manabe, T; Masaki, T; Morishita, A; Nakahara, M; Ogawa, C; Ohura, K; Tadokoro, T; Tani, J | 1 |
| Casado, MÁ; Domínguez-Hernández, R; Esteban, R; Martín-Escudero, V | 1 |
| Gamil, AN; Hassuna, NA; Khairy, R; Mahmoud, MS; Mohamed, WK | 1 |
| Balagna, R; Maletta, F; Martini, S; Romagnoli, R; Saracco, M; Tandoi, F | 1 |
| Katz, R; Mod, AT | 1 |
| Diculescu, MM; Gheorghe, L; Iacob, SM; Iliescu, L; Istratescu, D; Manuc, M; Manuc, T; Popescu, CP; Preda, C; Stanciu, C; Stroie, TG; Tieranu, CG; Trifan, A | 1 |
| Pan, Y; Wang, Z; Xu, S; Zhang, L; Zhang, W | 1 |
| Han, Y; Huang, J; Jin, Q; Ma, B; Shang, T; Tu, Z; Wang, Y; Wen, X | 1 |
| Ansari, MA; Barnes, E; Chau, NVV; Cooke, GS; Dang Trong, T; Day, JN; Flower, B; Hoglund, RM; Hung, LM; Kestelyn, E; Kingsley, C; Le Ngoc, C; Le Thi, T; Mccabe, L; Nguyen Bao, T; Nguyen Thi Ngoc, P; Pett, SL; Phuong, LT; Quang, VM; Rahman, M; Smith, D; Tarning, J; Thwaites, GE; Turner, H; van Doorn, R; Van Nuil, JI; Vo Thi, T; Vu Thi Kim, H; Walker, AS | 1 |
| Bhattacharya, D; Brates, I; Kreter, B; Linas, B; Robbins, GK; Smeaton, L; Solomon, S; Sowah, LA; Sulkowski, M; Wagner-Cardoso, S | 1 |
| Batista, R; Blanchet, B; Cabanes, L; Chouchana, L; Goldwasser, F; Huillard, O; Khoudour, N; Monribot, A; Pallet, N; Préta, LH; Sogni, P; Thomas-Schoemann, A | 1 |
| Balagopal, A; Bowden, K; Leep-Lazar, J; Quinn, J; Ribeiro, RM; Sachithanandham, J; Sulkowski, MS; Ward, K | 1 |
| Enomoto, M; Fujii, H; Hagihara, A; Higashiyama, S; Kageyama, K; Kawabe, J; Kawada, N; Kawamura, E; Kotani, K; Kozuka, R; Motoyama, H; Odagiri, N; Tamori, A; Uchida-Kobayashi, S; Yamamoto, A; Yoshida, A; Yukawa-Muto, Y | 1 |
| Byrns, J; Kiser, JJ; Maziarz, E; Naggie, S; Narayanasamy, S; Steinbrink, JM; Wolfe, CR | 1 |
| Bourgeois, S; Foster, GR; Gerken, G; Hernandez, C; Jacobson, IM; Mathurin, P; Osinusi, A; Ryder, SD; Scherbakovsky, S; Tedesco, D; Thuluvath, P; Vanstraelen, K | 1 |
| Chang, ML; Chen, CJ; Chen, YC; Chien, RN; Hsu, CW; Huang, YH; Lin, CY; Shen, YH | 1 |
| Anderson, KE; Bonkovsky, HL; Faust, D; Hallberg, C; Hedstrom, K; Ma, CD; Moghe, A; Naik, H; Overbey, JR; Rudnick, SP; Wang, K | 1 |
| Ahn, SH; Cho, SB; Chung, WJ; Jang, ES; Jeong, SH; Kim, IH; Kim, KA; Kim, S; Kim, YS; Lee, BS; Lee, S; Lee, YJ; Park, HJ | 1 |
| Hampejskova, L; Hasnain, A; Shah, S | 1 |
| Azzeri, A; Dahlui, M; Jaafar, H; McDonald, SA; Mohamed, R; Shabaruddin, FH | 1 |
| Bukh, J; Fahnøe, U; Fernandez-Antunez, C; Gottwein, JM; Mikkelsen, LS; Ramirez, S; Wang, K | 1 |
| Ahn, HJ; Han, H; Kim, BO; Kim, GA; Kwon, KM; Shim, JJ | 1 |
| Ayadi, S; Ayari, M; Ghithia, N; Zaimi, Y | 1 |
| Charlton, C; Hlavay, BA; Klein, MB; Ogando, N; Power, C; Stapleton, JT; Zhuo, R | 1 |
| Congly, SE; El-Kassas, M; El-Raey, F; Emadeldeen, M; Esmat, G; Gomaa, AA; Hassany, M; Lee, SS; Liu, H | 1 |
| Mahgoub, A; Schulz, P; Wiginton, A | 1 |
| Cheng, ML; Li, H; Qin, YJ; Zhou, XN | 1 |
| Awasthi, A; Deep, A; Goel, A; Katiyar, H; Kumar, A; Kumar, V; Rungta, S; Tiwari, P | 1 |
| El-Marakby, MG; Sabri, NA; Solayman, MH | 1 |
| Buonomo, AR; Cattaneo, L; De Filippis, F; Ercolini, D; Gentile, I; Gison, F; Maraolo, AE; Pinchera, B; Schiano Moriello, N; Scotto, R; Viceconte, G; Villari, R; Zappulo, E | 1 |
| Bhagat, N; Charak, S; De, A; Duseja, A; Goel, K; Premkumar, M; Rathi, S; Sharma, A; Singh, V; Taneja, S; Verma, N | 1 |
| Hsin, YH; Huang, CW; Ko, CY; Tsai, QZ; Tsai, YC; Yu, ML | 1 |
| Aniszewska, M; Dobrzeniecka, A; Indolfi, G; Marczyńska, M; Pluta, M; Pokorska-Śpiewak, M; Talarek, E | 1 |
| Kottilil, S; Lee, MH; O'Brien, TR; Wilson, E | 1 |
| Bukh, J; Fahnøe, U; Filskov, J; Jenssen, H; Pedersen, MS; Schønning, K; Sølund, C; Weis, N | 1 |
| Briones, C; de Ávila, AI; Domingo, E; Durán-Pastor, A; Gallego, I; García-Crespo, C; Gómez, J; Gregori, J; Martínez-González, B; Perales, C; Quer, J; Somovilla, P; Soria, ME | 1 |
| Shin, HP | 1 |
| Ahn, SH; Byun, KS; Cho, JY; Heo, J; Jang, BK; Jang, JW; Jeong, SH; Jung, YJ; Kim, HJ; Kim, IH; Kim, JH; Kim, YJ; Kwon, JH; Kwon, KM; Lee, BS; Lee, SW; Lee, YJ; Lim, YS; Paik, SW; Park, NH; Suri, V; Tak, WY; Wu, P; Yang, SH; Yoon, KT | 1 |
| Elmowafy, AY; Elrakaiby, MT; Mohamed Abdelnajid, D; Rostaing, L | 1 |
| Biomy, R; Haseeb, WA; Maher, KA; Youssef, MM; Zaghloul, MS | 2 |
| Coppola, N; Devan, P; Mohan, BP; Neo, JE; Preda, CM; Tam, YCS; Tiong, KLA; Wijarnpreecha, K; Wong, YJ | 1 |
| AlAshery, H; Ashour, R; Baghat, M; El Menshawy, N; Hassan, N; Khariza, M | 1 |
| Akhtar, MF; Anwar, F; Khan, A; Shah, SA; Yasmeen, S | 1 |
| Kampmann, C; Weiland, O; Wejstål, R; Westin, J; Ydreborg, M | 1 |
| Martinello, M; Matthews, GV; Naggie, S; Rockstroh, JK | 1 |
| Alonzo-García, C; Contreras, AG; Fernández-Ramírez, A; García-Juárez, I; Romero-Hernández, F; Ruiz, I; Servín-Rojas, M | 1 |
| Duong, V; Guo, M; Han, L; Liu, C; Lu, J; Nouhin, J; Tong, Y; Xiang, X; Xie, Q; Zhong, J | 1 |
| Collins, M; Conway, B; Dylla, DE; Khan, T; Marcinak, J; Martinez, A; Saget, B | 1 |
| Luetkemeyer, AF; McDonell, C; McKinney, J; Morris, MD; Price, JC; Thawley, R | 1 |
| Chiang, KM; El Moustaid, F; Kaushik, A; Nyberg, AH; Nyberg, LM; Smith, N; Yang, SJ; Yehoshua, A | 1 |
| Alsina, A; Borg, B; Chang, C; Charlton, M; Flamm, S; Hernandez, C; Hézode, C; Landis, C; Lawitz, E; Mercier, RC; Ravendhran, N; Reddy, KR; Samuel, D; Scherbakovsky, S; Shiffman, M | 1 |
| Assem, NM; Atoom, AM; Hafez, HA; Kamel, MA; Khafaga, RHM; Mahmoud, SA; Shaker, SA | 1 |
| Afshar Mogaddam, MR; Anushiravani, A; Ghanbari, R; Hassanpour Sabet, R; Jouyban, A; Jouyban-Gharamaleki, V; Khoubnasabjafari, M; Marzi Khosrowshahi, E; Rayatpisheh, M | 1 |
| Daryani, N; Imam, U; Mumtaz, F; Parkash, A | 1 |
| Abdelmahmoud, MB; AlAlwan, AM; AlGhamdi, HS; AlHabobi, AA; Aljumah, AA; AlOun, AA; AlQahtani, RS; AlThiab, KM; AlTraif, IH; Ghomraoui, FA | 1 |
| Dvory-Sobol, H; Han, B; Martin, R; Mo, H; Parvangada, A; Svarovskaia, ES; Xu, S | 1 |
| Agarwal, K; Cannon, M; Childs, K; Davis, C; Dusheiko, G; Filipe, A; Montague, S; Simmonds, P; Smith, D; Thomson, EC; Tong, L | 1 |
| Fried, MW; Hassan, MA; Hinestrosa, F; Jacobson, IM; Kort, JJ; Larsen, L; Lok, AS; Lu, W; Michael, LC; Morelli, G; Nelson, DR; Pearlman, BL; Peter, JA; Reddy, KR; Shiffman, ML; Sulkowski, MS; Vainorius, M; Wang, GP; Willner, I | 1 |
| Aghemo, A; Alberti, A; Bonfanti, P; Carolo, G; Carriero, C; Centenaro, R; Degasperi, E; Fabris, P; Faggiano, G; Fagiuoli, S; Gatti, F; Giorgini, A; Grossi, G; Lampertico, P; Landonio, S; Lombardi, A; Lomonaco, L; Maggiolo, F; Noventa, F; Paolucci, S; Paon, V; Pasin, F; Pasulo, L; Pozzoni, P; Puoti, M; Romano, A; Rossi, MC; Rovere, P; Russo, FP; Soffredini, R; Soria, A; Spinetti, A; Vario, A; Vinci, M; Zoncada, A | 1 |
| Birerdinc, A; Curry, M; de Avila, L; Escheik, C; Estep, JM; Gerber, L; Golabi, P; Price, JK; Stepanova, M; Weinstein, AA; Younossi, ZM | 1 |
| Chen, JJ; Cheng, PN; Chiu, HC; Chiu, YC; Lee, PL; Tung, HD | 1 |
| Antón, JJ; Arenas, JI; Bernal, E; Casado, M; Chueca, N; Collado, A; De la Iglesia, A; Espinosa, MD; García, F; García-Bujalance, S; García-Deltoro, M; García-Herola, A; Hernández-Quero, J; Hidalgo-Tenorio, C; Lozano, AB; Macías, J; Martínez, O; Omar, M; Pascasio, JM; Pérez, AB; Pineda, JA; Rincón, P; Ríos, MJ; Rivero-Juárez, A; Rosales, JM; Salmerón, J; Santos, J; Selfa, A; Téllez, F; Vélez, M; Von-Wichmann, MÁ | 1 |
| Alcantarini, C; Angelini Zucchetti, T; Bargiacchi, O; De Carlis, L; Ferla, F; Lauterio, A; Merli, M; Puoti, M; Rossotti, R; Travi, G | 1 |
| Boglione, L; D'Avolio, A; De Nicolò, A; Di Perri, G | 1 |
| Grønbaek, H; Kazankov, K; Kristensen, LH; Laursen, AL; Laursen, TL; Leutscher, P; Møller, HJ; Sandahl, TD; Siggaard, CB; Tarp, B | 1 |
| Merat, S | 1 |
| Abdel-Aziz, SA; Adawy, NM; Allam, AA; Ayoub, BA; Basiouny, HEDM; Behairy, BE; El-Araby, HA; El-Guindi, MA; Elhenawy, IA; Fouad, OA; Khedr, MA; Salem, ME; Sira, AM; Sobhy, GA | 1 |
| Guan, Y; Guo, X; Jia, J; Jiang, X; Li, C; Li, G; Mao, Q; Ning, J; Pan, H; Qin, H; Rao, H; Song, G; Wang, C; Wei, L; Wu, X; Yang, Y; Zhang, Y | 1 |
| Aguiar, BF; Bittar, C; Campos, GRF; Marques, NN; Martinelli, ALC; Molina, BF; Pereira, LRL; Rahal, P; Rodrigues, JPV; Souza, FF | 1 |
| Darwish, NHE; Elbasiony, M; Mousa, SA; Shiha, G; Soliman, R | 1 |
| Berg, C; Eigentler, T; Forschner, A; Geipel, A; Kofler, K; Kofler, L; Lipp, HP; Müller, A | 1 |
| Andreoni, M; Aragri, M; Cerva, C; Ferrari, L; Foroghi Biland, L; Gentile, A; Malagnino, V; Salpini, R; Sarmati, L; Svicher, V; Teti, E | 1 |
| Cariti, G; Di Perri, G | 1 |
| Abutidze, A; Adamia, E; Afdhal, N; Arora, S; Averhoff, F; Butsashvili, M; Chkhartishvili, N; Gamkrelidze, A; Gvinjilia, L; Kerashvili, V; Kuchuloria, T; Lagvilava, M; Metreveli, D; Nasrullah, M; Sergeenko, D; Shadaker, S; Sharvadze, L; Skaggs, B; Thornton, K; Tsertsvadze, T; Zeuzem, S | 1 |
| Abdelaty, LN; Elnaggar, AA; Hussein, RRS; Said, AA | 1 |
| Abe-Chayama, H; Aikata, H; Chayama, K; Fujino, H; Hayes, CN; Imamura, M; Kawaoka, T; Miki, D; Murakami, E; Nakahara, T; Ono, A; Osawa, M; Saito, Y; Serikawa, M; Teraoka, Y; Tsuge, M; Uchida, T | 1 |
| Berg, T; Boeker, KHW; Buggisch, P; C-Registry, GH; Günther, R; Hinrichsen, H; Klinker, H; Manns, MP; Mauss, S; Müller, T; Serfert, Y; Wiegand, J; Zeuzem, S | 1 |
| Cescon, M; De Pace, V; Galli, S; Maggi, F; Morelli, MC; Pistello, M; Ravaioli, M; Re, MC; Vero, V | 1 |
| Alvarez, M; Bartlett, S; Binka, M; Butt, ZA; Chong, M; Cook, D; Darvishian, M; Janjua, NZ; Krajden, M; Pearce, ME; Ramji, A; Rossi, C; Samji, H; Tyndall, M; Wong, J; Wong, S; Yoshida, EM; Yu, A | 1 |
| Amarsanaa, J; Baatarkhuu, O; Enkhtuya, D; Enkhzaya, S; Hsu, SJ; Ivshinkhorol, D; Jargalsaikhan, B; Kao, JH; Khosbayar, T; Lin, YY; Naranzul, N; Tsai, CH; Tseng, TC; Wang, TS | 1 |
| Costa, VD; Lago, BV; Lampe, E; Mello, FCA; Nunes, EP; Pellegrini, P; Pittella, AM; Rotman, V | 1 |
| Attia, D; Doss, W; Ebeid, B; El Raziky, M; El Serafy, M; El-Khayat, H; Esmat, G; Fouad, Y; Gomaa, A; Hasseb, A; Kamal, EM; Mahmoud, H; Sameh, Y | 1 |
| Calil-Elias, S; Crisante, VC; Cursino, CN; de Almeida, RMVR; Duarte, GDS; Giordani, F; Monteiro, PGO; Vieira, TBQ; Xavier, AR | 1 |
| Abd El-Wahab, EW; Helmy, SH; Nagaty, A | 1 |
| Attia, D; El-Khayat, H; El-Shabrawi, M; Fouad, Y; Kamal, EM; Sameh, Y; Yakoot, M | 1 |
| Cheema, SS; Cheema, SUR; Gilani, N; Hussain, G; Rehman, MS | 1 |
| Abdelkareem, M; Abozeid, M; Akl, M; Elsakhawy, M; Fayoumi, AE; Kohla, MAS; Waheed, S | 1 |
| Chayama, K; Gonzalez, YS; Kawaguchi, I; Kumada, H; Mitchell, D; Virabhak, S; Yuen, C | 1 |
| Abdelkawy, KS; Ebaid, NF; El-Haggar, SM; El-Magd, MA; Elbarbry, FA; Ziada, DH | 1 |
| Fernández-Cuenca, F; López-Hernández, I; Palacios-Baena, ZR; Paniagua-García, M; Ríos-Villegas, MJ | 1 |
| Aghemo, A; Annalisa, S; Bella, D; Bhoori, S; Borghi, M; Brocchieri, A; Buscarini, E; Centenaro, R; Colombo, AE; Colombo, S; D'Ambrosio, R; Di Marco, M; Dionigi, E; Fagiuoli, S; Fanetti, I; Giorgini, A; Grossi, P; Invernizzi, P; Lampertico, P; Lazzaroni, S; Lombardi, A; Maggiolo, F; Mendeni, M; Menzaghi, B; Messina, E; Molteni, C; Monforte, AD; Noventa, F; Pan, A; Pasulo, L; Pigozzi, MG; Poggio, PD; Pozzoni, P; Puoti, M; Spinelli, O; Spinetti, A; Taddei, MT; Terreni, N; Viganò, P; Vinci, M; Zaltron, S; Zuin, M | 1 |
| Chaikledkaew, U; Due, OT; Genuino, AJM; Sobhonslidsuk, A; Thakkinstian, A | 1 |
| Bukh, J; Fernandez-Antunez, C; Li, YP; Mikkelsen, LS; Pedersen, J; Ramirez, S | 1 |
| Hikita, H; Takehara, T | 1 |
| Abdel Haleem, H; Abdel-Razek, W; Anees, M; El-Sayed, MH; El-Serafy, M; El-Shazly, Y; Eletreby, R; Elkhouly, R; Elshenawy, M; Esmat, G; Hamdy, M; Hassany, M; Kamal, E; Kasem, G; Salama, M; Salama, R; Shafeek, A | 1 |
| Al-Ahmed, SH; Aldrazi, FA; Alfouzan, WA; Alsuliman, SA; Bazzi, AM; Haque, S; Rabaan, AA | 1 |
| Berg, C; Byrns, J; Harris, M; Laub, M; Sanoff, S | 1 |
| Chung, RT; Holmes, JA | 1 |
| Bair, MJ; Chen, WC; Cheng, JS; Lo, CC; Tsai, WL; Wang, CF | 1 |
| Abutidze, A; Averhoff, F; Butsashvili, M; Chkhartishvili, N; Ezugbaia, M; Gamkrelidze, A; Gvinjilia, L; Kerashvili, V; Kvaratskhelia, V; Metreveli, D; Morgan, J; Nasrullah, M; Shadaker, S; Sharvadze, L; Tsertsvadze, T | 1 |
| Abdel Alem, S; Abdel Aziz, H; Abdellatif, Z; Al Askalany, M; Cordie, A; El Akel, W; Elsharkawy, A; Esmat, G; Kamal, W; Kamel, S; Kandeel, A; Meshaal, S | 1 |
| McAuliffe, L; Mogul, A; Promrat, K; Teixeira, E; Zullo, AR | 1 |
| Cui, LY; Liu, LD; Nan, YM; Zhao, W | 1 |
| Bonora, S; Cingolani, A; d'Arminio Monforte, A; Lo Caputo, S; Marinaro, L; Mussini, C; Puoti, M; Rossotti, R; Saracino, A; Soria, A; Tavelli, A; Uberti-Foppa, C | 1 |
| Giannini, EG; Indolfi, G | 1 |
| Aghemo, A; Aimo, G; Baiguera, C; Bella, D; Bernasconi, DP; Bhoori, S; Boldizzoni, R; Bonfanti, P; Capretti, A; Carderi, I; Carriero, C; Centenaro, R; Ciaccio, A; Colella, E; Cologni, G; Colombo, A; Colombo, S; D'Ambrosio, R; d'Arminio Monforte, A; De Bona, A; Degasperi, E; Del Poggio, P; Di Marco, M; Dionigi, E; Fagiuoli, S; Fava, M; Gatti, F; Giglio, O; Giorgini, A; Graffeo, M; Grossi, PA; Hasson, H; Lampertico, P; Landonio, S; Lapadula, G; Lazzaroni, S; Liani, C; Lombardi, A; Menzaghi, B; Migliorino, GM; Molteni, C; Noventa, F; Pagnucco, L; Pan, A; Pasulo, L; Perini, P; Pigozzi, MG; Polo, S; Puoti, M; Rizzardini, G; Rossotti, R; Rumi, MG; Schiavini, M; Soria, A; Spinelli, O; Spinetti, A; Terreni, N; Uberti-Foppa, C; Valenti, L; Valsecchi, MG; Viganò, M; Viganò, P; Vinci, M | 1 |
| Chung, WJ; Jang, ES; Jeong, SH; Kim, IH; Kim, KA; Kim, YS; Lee, BS; Lee, YJ | 1 |
| Ayoub, BA; Basiouny, HM; Behairy, BE; El-Araby, HA; El-Guindi, MA; Fouad, OA; Marei, AM; Sira, MM | 1 |
| Alimohammadi, A; Conway, B; Yamamoto, L | 1 |
| Althoff, KN; Elion, RA; Eron, JJ; Gillman, J; Huhn, GD; Jayaweera, DT; Mills, A; Mounzer, K; Moyle, G; Patel, SV; Radtchenko, J; Santiago, S; Sax, PE | 1 |
| Abdelmalek, MO; Abu-Faddan, NH; Ibrahim, ME; Kheila, AE; Mahmoud, AA; Makhlouf, NA | 1 |
| Alloway, RR; Eckman, MH; Sherman, KE; Thakar, CV; Woodle, ES | 1 |
| Abbasy, M; Abdu Allah, AM; Elimam, H; Elnaidany, N; Essa, A; Mohamed Ibraheem, KI; Nada, A; Sabry, A; Shehab-Eldeen, S | 1 |
| Abbas, MS; Abobaker, A; El-Gendy, A; Saafan, AE | 1 |
| Germano, I; Gomes, A; Manata, MJ; Martins, A; Mendez, J; Miranda, AC; Pacheco, P; Pazos, R; Pereira, R; Pinto, S; Reis, AP; Rocha, S; Sarmento-Castro, R; Serrão, R; Vale, F; Valente, C | 1 |
| Allah-Kouadio, E; Allouka, KCE; Gnépéhi, OB; Kohi, DS; N'guessan-Irié, AG; Siransy-Kouakou, NG | 1 |
| Sirinawasatien, A; Techasirioangkun, T | 1 |
| Bunchorntavakul, C; Charatcharoenwitthaya, P; Chonprasertsuk, S; Komolmit, P; Piratvisuth, T; Sanpajit, T; Sethasine, S; Siripipattanamongkol, C; Sobhonslidsuk, A; Sukeepaisarnjaroen, W; Sutthivana, C; Tangkijvanich, P; Tanwandee, T; Wongpaitoon, V | 1 |
| Aghayeva, S; Asiller, ÖÖ; Balkan, A; Çalışkan Kartal, A; Demir, M; Erarslan, E; Gülşen, MT; Güner, R; Köksal, I; Örmeci, N; Sezgin, O; Yaraş, S | 1 |
| Burger, DM; Colbers, A; Cullen, L; Eastick, K; Knol, H; Samson, AD; van Seyen, M | 1 |
| AbdAlla, M; Abdel Gawad, S; Abdel Megid, S; Abdel-Razek, W; Abo Sliman, M; Abou Hashem, K; Ammar, I; Cordie, A; Dabbous, H; Doss, W; El Akel, W; El Nahas, N; El Shazly, Y; El Sobky, A; El Sonbaty, S; El Tabakh, H; El-Sayed, MH; El-Serafy, M; Elsharkawy, A; Elshishiney, G; Emad, E; Esmat, G; Gemeah, H; Ghalab, R; Hashem, A; Hashish, A; Hassany, M; Hefnawy, N; Hemida, AN; Kabil, K; Kamal, E; Khadary, A; Labib, K; Mahmoud, F; Mamoun, S; Marei, T; Mekky, S; Meshref, A; Omar, Y; Othman, A; Ragab, O; Ramadan, E; Rehan, A; Saad, T; Saeed, R; Salah, A; Sharshar, M; Shawky, H; Shawky, M; Shehata, W; Soror, H; Taha, M; Talha, M; Tealaab, A; Waked, I; Zaid, H; Zein, M | 1 |
| Abou-Samra, AB; Butt, AA; Nasir, B; Rasool, S; Rubi, G; Tayyab, GUN | 1 |
| Feng, Z; Gao, H; Huang, R; Li, Z; Liang, X; Lin, T; Liu, S; Ma, J; Wang, X; Xu, L; Zhang, L | 1 |
| Asselah, T; Bailly, F; Combis, JM; Dumortier, J; Glorian-Petraud, D; Guyader, D; Heluwaert, F; Hézode, C; Larrey, D; Leroy, V; Libert, O; Ouzan, D; Pol, S; Ramroth, H; Remy, AJ; Riachi, G; Roche, B; Rosa, I; Roulot, D; Thabut, D; Thiefin, G; Truchi, R | 1 |
| Bojkova, D; Broering, R; Ciesek, S; Costa, R; Funkenberg, N; Heinrichs, S; Korencak, M; Lang, KS; Streeck, H; Timmer, L; Vondran, F; Westhaus, S | 1 |
| Al Balakosy, A; Alboraie, M; Ashraf Ahmed Mohamed, O; Dabbous, H; Doss, W; El Badry, M; El Kassas, M; El Sheemy, RY; El Tahan, A; El-Raey, F; Ezzat, S; Gamal Naguib Meleak, G; Hassan Ahmed Fouad, M; Omar, H; Tahoon, M; Wifi, MN; Youssef, N; Zaky, S | 1 |
| Akarca, US; Danış, N; Ersöz, G; Günşar, F; Oruç, N; Pullukçu, H; Sipahi, OR; Taşbakan, M; Tekin, F; Turan, İ; Ünal, NG; Vardar, R; Yamazhan, T | 1 |
| Chang, TS; Chen, CH; Chen, MY; Chen, WM; Chiu, WN; Hu, JH; Hu, TH; Hung, CH; Lu, CK; Lu, SN; Tung, SY; Wei, KL | 1 |
| Che, D; Lu, Y; Wu, B; Zhou, H | 1 |
| Bonacini, M; Kim, Y; Landis, C; McKoin, L; Pitney, C; Tran, M | 1 |
| Abd-Elsalam, SM; Abdulaziz, BA; El Attar, IH; El Kassas, M; Emadeldeen, M; Said, EM | 1 |
| Barash, D; Chayama, K; Churkin, A; Cotler, SJ; Dahari, H; Dasgupta, S; Etzion, O; Gorstein, E; Imamura, M; Nakahara, T; Tsuge, M; Uprichard, SL; Yardeni, D | 1 |
| Bajis, S; Dore, GJ; Martinello, M | 1 |
| Bernhard, B; Stickel, F | 1 |
| Chu, JN; Collins, J; Eweje, F; Faiz, MT; Gwynne, D; Hayward, A; Hess, K; Hua, T; Ishida, K; Katz, S; Koeppen, R; Langer, R; Lopes, A; McManus, R; Miller, JB; Salama, JAF; Slocum, AH; Soares, V; Steiger, C; Sulkowski, MS; Tamang, SM; Thomas, DL; Traverso, G; Verma, M | 1 |
| Day, J; Le, HM; Le, PT; Nghiem, NM; Nguyen, DT; Rahman, M; Tran, TTT; Vo, QM | 1 |
| Bronowicki, JP; Carrat, F; Chazouillères, O; Chevaliez, S; de Lédinghen, V; Dorival, C; Fontaine, H; Larrey, D; Lusivika-Nzinga, C; Marcellin, P; Metivier, S; Pawlotsky, JM; Pol, S; Samuel, D; Tran, A; Zoulim, F | 1 |
| Borgia, SM; Brown, RS; Carrat, F; Doucette, K; Fagiuoli, S; Khalili, M; Lampertico, P; Losappio, R; Mangia, A; Mertens, M; Milligan, S; Ntalla, I; Ouzan, D; Papatheodoridis, G; Pérez-Hernandez, F; Ramji, A; Ramroth, H; Shafran, SD; Turnes, J; Vanstraelen, K; Wedemeyer, H; Wick, N | 1 |
| Barnes, E; Magri, A; Nguyen, D; Simmonds, P; Smith, D; Vaughan-Jackson, A | 1 |
| Bares, SH; Havens, JP; Regan, NN | 1 |
| Altıntaş, E; Ateş, F; Özdoğan, O; Sezgin, O; Üçbilek, E; Yaraş, S | 1 |
| Batista, AD; da Silva Sacerdote, AB; de Barros Barreto, S; Filgueira, NA; Lopes, EP | 1 |
| Da, BL; Dieterich, D; Kushner, T; Lourdusamy, V; Saberi, B | 1 |
| Alhusseini, MM; Mohamed, GA; Salama, MM; Saleh, SA | 1 |
| Chen, DS; Chen, PJ; Kao, JH; Liu, CH; Liu, CJ; Su, TH | 1 |
| Abdel Moez, AT; Al Balakosy, AM; El Hawary, YA | 1 |
| Ahmed, H; Elsadek, HM; Elsayed, IA; Gendia, MA; Gouda, TM; Lbrahim, NF; Magdy, MM; Sadek, AMEM; Shafeik, H; Shendi, AM; Yousif, MM; Zahran, MH; Zaki, AM | 1 |
| Claar, E; Coppola, N; De Pascalis, S; Fraia, AD; Messina, V; Minichini, C; Occhiello, L; Pisaturo, M; Sangiovanni, V; Starace, M | 1 |
| Funakoshi, H; Kitaguchi, K; Monoe, C; Shimizu, H | 1 |
| Healy, B; Islam, M; Nicholas, S; Oakley, R | 1 |
| Bertrand, D; Bouvier, N; Büchler, M; Caillard, S; Chevallier, E; Colosio, C; Garrouste, C; Gatault, P; Le Meur, Y; Rerolle, JP; Rivalan, J; Rostaing, L; Sayegh, J; Thierry, A | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Lai, WT; Lee, HC; Liang, PC; Lin, YH; Lin, ZY; Yeh, ML; Yu, ML | 1 |
| Aikata, H; Chayama, K; Fukuhara, T; Hayes, CN; Imamura, M; Mori, N; Ohya, K; Takaki, S; Tsuji, K; Yamaguchi, S | 1 |
| Attia, A; Baudoin, M; Boyer, S; Kouanfack, C; Lacombe, K; Lemoine, M; Moh, R; Nishimwe, ML; Rouveau, N; Seydi, M; Sylla, B; Woode, ME | 1 |
| Chander, PN; Chugh, S; Singh, J; Solanki, S; Wolf, DC | 1 |
| Abdel Alem, S; Abdellatif, Z; Abdo, M; Moustafa, A; Rabiee, A | 1 |
| Rodriguez-Reyes, M; Ruiz-Boy, S; Sotoca-Momblona, JM | 1 |
| Antonucci, R; Bartolini, E; Calvo, PL; Cananzi, M; Cangelosi, AM; D'Antiga, L; Di Dato, F; Dodi, I; Forlanini, F; Gaio, P; Garazzino, S; Giacomet, V; Indolfi, G; Iorio, R; Lenge, M; Mastrangelo, G; Nebbia, G; Nicastro, E; Nuti, F; Pinon, M; Ricci, S; Riva, S; Serranti, D; Silvestro, E; Trapani, S; Vajro, P | 1 |
| Shi, L; Sun, X; Yun, H; Zhao, G | 1 |
| Fujiyama, N; Hedskog, C; Littman, M; Liu, LJ; Mizokami, M; Ng, LJ; Sekiya, T; Yuan, J | 1 |
| Cázares-Cortazar, A; Chapararro-Sánchez, A; de la Luz Martínez-Rodríguez, M; Gaytán-Martínez, J; Mata-Marín, JA; Mauss, S; Ocaña-Mondragón, A; Uribe-Noguez, LA; Villavicencio-Ferrel, PE | 1 |
| Ahmed-Belkacem, A; Ahnou, N; Brillet, R; Chevaliez, S; Demontant, V; Donati, F; Fourati, S; Gricourt, G; Hamadat, S; Pawlotsky, JM; Poiteau, L; Rodriguez, C; Soulier, A | 1 |
| Ahlenstiel, G; Bowden, S; Dore, GJ; Douglas, M; Doyle, J; Farrell, G; Fisher, L; George, J; Haque, M; Hazeldine, S; Hellard, M; Levy, M; MacQuillan, G; McGarity, B; New, K; O'Beirne, J; O'Keefe, J; Papaluca, T; Prewett, E; Roberts, SK; Sawhney, R; Sievert, W; Sinclair, M; Sood, S; Stoove, M; Strasser, SI; Stuart, KA; Thomas, J; Thompson, AJ; Tse, E; Valaydon, Z; Valiozis, I; Wade, AJ; Weltman, M; Wigg, A; Wilson, M; Woodward, A | 1 |
| Chang, TT; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Wu, CH; Wu, IC; Yang, EH | 1 |
| Chen, YC; Cheng, YT; Chien, RN; Hsieh, YC; Jeng, WJ; Lin, CY; Liu, YC; Sheen, IS; Teng, W | 1 |
| Anees, M; Doss, W; El Akel, W; Eletreby, R; Esmat, G; Hashem, A; Hassany, M; Helmy, A; Khalaf, N; Kobtan, A; Mansour, S; Naguib, M | 1 |
| Barralon, M; Bijl, M; Cavenaugh, C; Chasela, CS; Chew, KW; Drame, N; Freiman, MJ; Gandhi, MM; Kyi, KP; Lwin, AA; Marange, F; Min Thaung, Y; Minior, T; Mohamed, S; Naing, AY; Rosen, S; Sanne, I; Sein, YY; Thura, S; Thwin, HT; van der Horst, C; Wose Kinge, C; Xulu, T | 1 |
| Andrade, TG; Azeredo, EL; Gandini, M; Lacerda, G; Leite, PEC; Medeiros, T; Rosário, NF; Saraiva, GDN; Silva, AA; Xavier, AR | 1 |
| Cornberg, M; Deterding, K; Jung, MC; Klinker, H; Manns, MP; Sarrazin, C; Schulze Zur Wiesch, J; Serfert, Y; Simon, KG; Stoehr, A; Teuber, G; Vermehren, J; Wedemeyer, H; Zeuzem, S | 1 |
| Akuta, N; Asahina, Y; Enomoto, N; Hiasa, Y; Hikita, H; Ido, A; Itoh, Y; Kanto, T; Kato, N; Kawada, N; Kodama, T; Kurosaki, M; Matsuura, K; Miki, D; Mochida, S; Nakamoto, Y; Nakao, K; Sakamori, R; Shimizu, M; Suda, G; Tahata, Y; Takami, T; Takehara, T; Takikawa, Y; Tateishi, R; Tatsumi, T; Terai, S; Ueno, Y; Yamada, R; Yamada, T; Yamashita, T; Yatsuhashi, H; Yoshiji, H | 1 |
| Gandjour, A | 1 |
| Avorn, J; Barenie, RE; Kesselheim, AS; Tessema, FA | 1 |
| De, A; Dhiman, RK; Duseja, A; Kohli, HS; Kumar, V; Mehta, M; Premkumar, M; Ramachandran, R; Ratho, RK; Singh, MP; Singh, V; Taneja, S; Verma, N | 1 |
| Andrade, DC; Eckardt, PA; Huffman, V; Niu, J; Sherman, E | 1 |
| Ding, Y; Gao, Y; Gao, Z; Guan, Y; Hu, J; Jia, J; Jia, Z; Kong, F; Li, C; Li, G; Li, L; Lin, J; Mao, Q; Mou, Z; Ning, J; Ning, Q; Niu, J; Pan, H; Qin, H; Wang, X; Wen, X; Wu, G; Wu, X; Xing, H; Yang, Y; Zheng, S; Zhou, D | 1 |
| Abo-Talib, NF; Almehizia, AA; Amr, AEE; Asiri, YA; Ezzeldin, E; Tammam, MH | 1 |
| Barrett, BK; Chan, J; Feld, JJ; Hamadeh, A; Kim, JJ; Wong, WWL | 1 |
| Aho, I; Amele, S; Bhagani, S; Chkhartisvili, N; Clarke, A; Domingo, P; Falconer, K; Fonquernie, L; Jabłonowska, E; Leen, C; Lundgren, J; Maltez, F; Matulionyte, R; Mocroft, A; Peters, L; Rockstroh, J; Rodger, A; Sarcletti, M; Stephan, C; Szlavik, J; Wandeler, G; Zaccarelli, M; Østergaard, L | 1 |
| Chen, EQ; Chen, XB; Jiang, W; Li, J; Tao, YC; Wang, ML; Wang, YH; Wu, DB; Xiao, GB | 1 |
| Chang, HC; Lin, SY; Tsai, HH | 1 |
| Mendizabal, M; Piñero, F; Ridruejo, E; Silva, M | 1 |
| Abutaleb, A; Chua, JV; Frumkin, LR; Ghosh, A; Husson, J; Kottilil, S; Lam, KW; Lee, S; Luz Pascual, M; Mutumbi, L; Ntem-Mensah, A; Poonia, B; Romani, S | 1 |
| Chen, SC; Cheng, TS; Chuang, WL; Dai, CY; Hsieh, PH; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, ZY; Yeh, ML; Yu, ML | 1 |
| Al-Tawashi, AS; Alaa, AM; Awwad, MA; El-Derany, MO; Eltobgy, MM; Gharib, MM; Kasem, MH; Mostafa, AM; Moubarak, AS; Omar, HM; Saafan, HA | 1 |
| Chen, YM; Mei, YY; Wu, YK; Xu, WX; Zhang, XH | 1 |
| Ahmed-Belkacem, A; Chevaliez, S; Demontant, V; Donati, F; Fourati, S; François, M; N'Debi, M; Pawlotsky, JM; Poiteau, L; Rodriguez, C; Ruiz, I; Scoazec, G; Soulier, A | 1 |
| Cao, Y; Chen, P; Jin, M; Li, H | 1 |
| Abdelbaser, ES; Elsadek, HM; Emara, MH; Farag, AA; Soliman, HH | 1 |
| Ang, TL; Fock, KM; Koh, J; Kumar, LS; Kumar, R; Kwek, A; Law, NM; Lee, ZC; Li, W; Tan, J; Tan, YB; Teo, EK; Thurairajah, PH; Wong, YJ | 1 |
| Boglione, L; Ceccherini-Silberstein, F; de Salazar, A; Degasperi, E; Di Maio, VC; Dietz, J; Fernández-Fuertes, E; Figueruela, B; García, F; Gennari, W; Ghisetti, V; Graf, C; Kremer, AE; Lampertico, P; Lara, M; Merino, D; Muñoz-Medina, L; Paolucci, S; Pardo, MR; Peiffer, KH; Santos, J; Sarrazin, C; Schreiber, J; Sighinolfi, L; Stauber, R; Téllez, F; Vermehren, J; Zeuzem, S; Zoller, H | 1 |
| Farooq, MO; Malik, K; Mengal, FUA; Salim, A | 1 |
| Choi, IS; Kim, KM; Shim, SG | 1 |
| Aluzaite, K; Fraser, M; Giles, H; Johnson, S; Schultz, M | 1 |
| Chen, H; Li, C; Liang, J; Tian, J; Xiang, H | 1 |
| Ali, M; Ali, S; Haque, S; Lougher, E; Nawaz, MS; Paudyal, V; Rasheed, F; Ur-Rehman, T | 1 |
| Kottilil, S; Masur, H; Meissner, EG; Orr, C; Xu, W | 1 |
| Amara, D; Blumberg, E; Dove, L; Durand, CM; Emond, J; Fishbein, T; Florman, S; Grab, J; Haydel, B; Huprikar, S; Husson, J; Kottilil, S; Luetkemeyer, AF; Masur, H; Olthoff, K; Peters, MG; Rogers, R; Smith, C; Stock, PG; Sulkowski, MS; Terrault, N | 1 |
| Morillo-Verdugo, R; Sicras-Mainar, A | 1 |
| Abdallah, A; El Zeiny, SM; Fahmy, DM; Jonas, MM; Shokeir, M | 1 |
| Bahrami, G; Hatami, R; Keshavarzi, S; Majnooni, MB; Miraghaee, SS; Mohammadi, B; Sajadimajd, S | 1 |
| Chang, CC; Chang, CH; Chang, CY; Chen, CY; Chen, JJ; Chen, PY; Fang, YJ; Hsieh, TY; Huang, CS; Huang, JJ; Huang, KJ; Huang, YJ; Kao, JH; Kao, WY; Lai, HC; Lee, FJ; Lee, PL; Liu, CH; Liu, CJ; Lo, CC; Peng, CY; Shih, YL; Su, PY; Su, WW; Tsai, MC; Tseng, CW; Tseng, KC; Yang, SS | 1 |
| Damascene Makuza, J; Grant, PM; Gupta, N; Kabahizi, J; Kateera, F; Liu, AF; Musabeyezu, E; Muvunyi, C; Nsanzaimana, S; Serumondo, J; Shumbusho, F | 1 |
| Abdallah, OE; Abdel Hammed, OM; Elharrif, MG; Elwan, AW; Mahfouz, MK; Maksoud H A, A; Ragab AboZaid, OA | 1 |
| Chen, L; Huang, C; Jia, J; Kong, F; Li, G; Li, X; Lin, J; Lin, S; Liu, Q; Ning, Q; Niu, D; Niu, J; Su, M; Tong, L; Tong, Z; Wang, J; Wang, L; Wang, X; Wang, Z; Wei, W; Wen, X; Wu, G; Wu, X; Xin, Y; Xing, H; Yan, X; Zhang, L; Zhang, Y; Zheng, S; Zhu, Q | 1 |
| Bourliere, M; Buti, M; Chokkalingam, A; Colombo, M; Esteban, R; Gaggar, A; Henry, L; Mangia, A; Manns, M; Muir, A; Nader, F; Papatheodoridis, GV; Racila, A; Stepanova, M; Younossi, I; Younossi, ZM; Zeuzem, S | 1 |
| Aghemo, A; Andreoni, M; Angelico, M; Babudieri, S; Baldanti, F; Barbaliscia, S; Bruzzone, B; Calvaruso, V; Ceccherini-Silberstein, F; Coppola, N; Craxì, A; Di Maio, VC; Fiorentino, G; Foroghi, L; Gennari, W; Lenci, I; Micheli, V; Milana, M; Morsica, G; Paolucci, S; Parruti, G; Pasquazzi, C; Perno, CF; Polilli, E; Pollicino, T; Raimondo, G; Sarmati, L; Starace, M; Teti, E; Yu La Rosa, K | 1 |
| Aregay, A; Björkström, NK; Cornberg, M; Deterding, K; Du, Y; Hardtke, S; Hardtke-Wolenski, M; Hengst, J; Khera, T; Manns, MP; Port, K; Steinmann, E; Strunz, B; Todt, D; Wedemeyer, H | 1 |
| Carda-Auten, J; Edwards, A; Evon, DM; Fried, MW; Golin, CE; Kim, HP; Reeve, BB | 1 |
| Abd-Elsalam, S; Abdellatif, RS; Abo-Amer, YE; Elbedewy, TA; Elsebaey, MA; Fouad, A; Mostafa, SM; Youssef, M | 1 |
| Cole, JL; Stark, JE | 1 |
| Han, QY; He, S; Liu, ZW; Wang, XY | 1 |
| Maajani, K; Majd Jabbari, S; Merat, S; Poustchi, H; Sepanlou, SG | 1 |
| Abdullatif, H; Alem, SA; El-Karaksy, H; El-Raziky, MS; Eldeen, HG; Mogahed, EA; Nagy, A; Yasin, NA | 1 |
| Abd-Elsalam, S; Alhefnawy, M; Almekaty, K; Eissa, A; Fathi, A; Hagras, A; Mansour, A; Mohey, A; Puliatti, S | 1 |
| Adenugba, A; Geissler, EK; Hornung, M; Junger, H; Kupke, P; Lang, H; Marquardt, JU; Peschel, G; Schlitt, HJ; Weigand, K; Werner, JM; Zimmermann, T | 1 |
| Callegaro, FS; de Camargo Vieira, MC; Gonçalves, WRB; Guerra, RA; Lazaretti-Castro, M; Maeda, SS | 1 |
| Akarca, US; Akarsu, M; Akbulut, S; Akın, M; Aladağ, M; Albayrak, B; Alkım, H; Atalay, R; Balkan, A; Balkan, Y; Çoban, M; Coşar, AM; Danış, N; Değertekin, B; Demir, M; Demircan, M; Dinçer, D; Doğanay, L; Dursun, H; Erarslan, E; Göktürk, HS; Gündüz, F; Güneş, Ş; Gürel, S; Güzelbulut, F; Harputluoğlu, M; İnci, İ; Irak, K; Kaçar, S; Kani, HT; Kartal, A; Kefeli, A; Koklu, H; Mert, A; Nuriyev, K; Özakyol, A; Özdoğan, O; Öztaşkın, S; Sen, İ; Şimşek, H; Soylu, A; Sümer, H; Temel, T; Üçbilek, E; Uğurlu, ÇB; Uyanıkoğlu, A; Vatansever, S; Yalçın, K; Yaras, S; Yıldırım, E | 1 |
| Doi, A; Hikita, H; Kodama, T; Sakamori, R; Shigekawa, M; Shinkai, K; Tahata, Y; Takehara, T; Tatsumi, T; Yamada, R; Yamada, T | 1 |
| Bair, MJ; Chang, CC; Chen, CH; Chen, CT; Chen, CY; Chen, GY; Cheng, PN; Chong, LW; Chuang, WL; Dai, CY; Hsieh, TY; Hsiung, CK; Hu, JT; Huang, CF; Huang, CS; Huang, JF; Huang, YH; Hung, CH; Kao, CN; Kao, JH; Kuo, HT; Lee, MH; Lee, PL; Lee, TH; Lin, CL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Mo, LR; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Wang, CC; Wang, SJ; Wu, WC; Yang, CC; Yang, SS; Yeh, ML; Yu, ML | 1 |
| Adeboyejo, K; Agarwal, K; Aranday-Cortes, E; Ball, JK; Cramp, ME; da Silva Filipe, A; Davis, C; Irving, WL; McClure, CP; McLauchlan, J; Mutimer, D; Sreenu, V; Stone, B; Thomson, EC; Tong, L | 1 |
| Booth, J; Borgia, SM; Conway, B; Cooper, C; Feld, JJ; Lee, S; Lilly, LB; Morales, H; Onofrio, FQ; Ramji, A; Sattar, I; Vachon, ML; Wong, A | 1 |
| Chang, CC; Chang, CH; Chang, CY; Chen, CY; Chen, JJ; Chen, PY; Fang, YJ; Hsieh, TY; Huang, CS; Huang, JJ; Huang, KJ; Huang, YJ; Hung, CC; Kao, JH; Kao, WY; Lai, HC; Lee, FJ; Lee, PL; Liu, CH; Liu, CJ; Lo, CC; Peng, CY; Shih, YL; Su, PY; Su, WW; Tsai, MC; Tseng, CW; Tseng, KC; Yang, SS | 1 |
| Fedorchenko, SV; Klimenko, Z; Martynovych, T; Solianyk, I | 1 |
| Sarrazin, C | 1 |
| Buti, M; Campos, C; Cañizares, A; Carrión, JA; Castro-Iglesias, A; Costa, JG; Esteban, JI; Garcia-Cehic, D; Gregori, J; Macenlle, R; Pamplona, J; Quer, J; Rando, A; Rodriguez-Frias, F; Tabernero, D | 1 |
| Antala, S; Grobman, WA; Jhaveri, R; Murphy, M; Shah, SK; Yee, LM | 1 |
| Chuma, M; Fukuda, H; Hara, K; Kondo, M; Maeda, S; Morimoto, M; Moriya, S; Nozaki, A; Numata, K; Sakamaki, K; Tanaka, K; Yamanaka, T | 1 |
| El-Sayed, EM; Hassanien, KS; Helal, GK; Ismail, RS; Zakarya, ZM | 1 |
| Hidaka, I; Hirao, T; Ishida, H; Sakaida, I; Suenaga, R; Suka, M | 1 |
| Martin, P; McQuaid, T; Sise, ME | 1 |
| Draper, B; Hellard, M; Pedrana, A | 1 |
| Andrieux-Meyer, I; Avihingsanon, A; Bompart, F; Chan, WK; Cressey, TR; Goyal, V; Hassan, MRA; Khemnark, S; Kumar, S; Menétrey, C; Murad, S; Ngo-Giang-Huong, N; Omar, H; Pécoul, B; Said, HRHM; Salvadori, N; Simon, F; Siva, S; Swanson, A; Tan, SS; Tee, HP; Thanprasertsuk, S; Thetket, K; Thongsawat, S; Yerly, S | 1 |
| Burden, AM; Burkard, T; Hayes, KN; Tadrous, M; Weiler, S | 1 |
| Aldunate, F; Chiodi, D; Cristina, J; Echeverría, N; Hernández, N; López, P; Moratorio, G; Moreno, P; Sánchez-Cicerón, A; Soñora, M | 1 |
| AbdAllah, M; Abdel-Razek, W; Alalfy, M; Alboraie, M; Ammar, I; Doss, W; El Akel, W; El-Bendary, M; El-Sayed, MH; El-Serafy, M; Elbaz, T; Esmat, G; Gomaa, A; Hassany, M; Hefny, Z; Kamal, E; Okasha, A; Shaaban, E | 1 |
| Boudabbous, M; Chaker, H; Gargouri, S; Hmida, MB; Jarraya, F; Kammoun, K; Kissou, FP; Tahri, N; Tchoupe, MD; Toumi, S; Yaich, S | 1 |
| Dehghan Manshadi, SA; Kalantari, S; Karimi, J; Malekzadeh, R; Malekzadeh, Z; Mardani, M; Merat, D; Merat, S; Mirminachi, B; Mohraz, M; Nikbin, M; Norouzi, A; Poustchi, H; Rasoolinejad, M; Sali, S; Sedghi, R; Sharifi, AH; Somi, MH; Tabarsi, P; Tayeri, K | 1 |
| Akhan, S; Aktuğ Demir, N; Arslan Özel, S; Asan, A; Aygen, B; Barut, Ş; Batırel, A; Bilgin, H; Çağatay, A; Çelen, MK; Çelik, İ; Çetinkaya, RA; Demirtürk, N; Doğan, N; Ersöz, G; Gürbüz, Y; Hakyemez, İN; İnan, D; Kamalak Güzel, D; Karakeçili, F; Kınıklı, S; Konya, P; Korkmaz, P; Kuruüzüm, Z; Mıstık, R; Örmen, B; Öztürk, S; Saltoğlu, N; Şener, A; Şimşek, F; Şimşek, S; Suer, K; Tarakçı, H; Tülek, N; Tuna, N; Tuncer Ertem, G; Türker, N; Türkoğlu, E; Ural, O; Yıldız, O; Yıldız, U | 1 |
| Chang, KC; Chang, TS; Chen, WM; Chiu, WN; Ding, YJ; Hsieh, YY; Hung, CH; Lu, CK; Lu, SN; Shen, CH; Tung, SY; Wei, KL; Yen, CW | 1 |
| Inoue, J; Iwata, T; Kakazu, E; Masamune, A; Ninomiya, M; Sano, A; Sato, K; Tsuruoka, M | 1 |
| Amano, N; Genda, T; Ikeda, Y; Kabemura, D; Kita, Y; Murata, A; Sato, S; Shimada, Y; Tsuzura, H; Yatagai, N | 1 |
| Ansari, MA; Aranday-Cortes, E; Barnes, E; Benselin, J; Bibby, DF; Bradshaw, D; Brown, A; da Silva Filipe, A; Healy, B; Hudson, E; Irving, WL; Manso, CF; Mbisa, JL; McLauchlan, J; Singer, JB; Smith, DA; Thomson, EC; Troke, P | 1 |
| Bourlière, M; Meszaros, M; Ouzan, D; Pageaux, GP; Tran, A; Truchi, R | 1 |
| Miyasaka, A; Suzuki, A; Takikawa, Y; Yoshida, Y | 1 |
| Enomoto, M; Fujii, H; Hai, H; Kawada, N; Kozuka, R; Nonomura, A; Tamori, A; Uchida-Kobayashi, S | 1 |
| Amelia, F; Hapsari, AI; Karjadi, TH; Natali, V; Sulaiman, AS; Wicaksana, B; Widhani, A; Yunihastuti, E | 1 |
| Chiu, YW; Huang, CF; Wei, YJ; Wu, YT; Yu, ML | 1 |
| Baek, YH; Cho, HC; Heo, NY; Hong, Y; Kang, YW; Lee, SS; Lee, SW; Park, SJ; Seo, KI; Shin, JW; Yoon, JS; Yoon, KT | 1 |
| Barbaliscia, S; Bruzzone, B; Cassol, C; Caudai, C; Ceccherini-Silberstein, F; Coppola, N; Cuomo, N; Di Maio, VC; Micheli, V; Monno, L; Montagnani, F; On Behalf Of The Hcv Virology Italian Resistance Network Vironet, C; Paglicci, L; Paolucci, S; Rossetti, B; Santantonio, T; Zanelli, G; Zazzi, M | 1 |
| Gschwantler, M; Gutic, E; Haltmayer, H; Lang, T; Pirker, R; Reiberger, T; Schmidbauer, C; Schubert, R; Schütz, A; Schwanke, C; Schwarz, M | 1 |
| D'Antiga, L; Di Giorgio, A; Indolfi, G; Nicastro, E; Norsa, L | 1 |
| Chang, KC; Chang, TS; Chen, WM; Hsieh, YY; Huang, YT; Hung, CH; Lu, CK; Lu, SN; Shen, CH; Tung, SY; Wei, KL; Yen, CW | 1 |
| Feng, K; Huang, P; Ke, L; Lin, C; Liu, J; Pan, S; Yang, X; Zeng, Y | 1 |
| Abdine, HH; Aboras, SI; Korany, MA; Ragab, MAA | 1 |
| Bellan, M; Crobu, MG; D'Avolio, A; Gualerzi, A; Pirisi, M; Smirne, C | 1 |
| Akahane, T; Arai, H; Furuta, K; Hasebe, C; Ide, Y; Izumi, N; Joko, K; Kimura, H; Kobashi, H; Kojima, Y; Kondo, M; Kurosaki, M; Kusakabe, A; Marusawa, H; Mitsuda, A; Mori, N; Nakamura, S; Narita, R; Ogawa, C; Sato, T; Tada, T; Tsuji, K; Uchida, Y; Yagisawa, H | 1 |
| Abbassi, MM; Ebeid, FS; El-Baraky, IA; El-Sayed, MH; Hassany, M; Sabry, NA | 1 |
| Fraser, H; Havens, JR; Hoven, A; Lofwall, M; Schaninger, T; Staton, M; Vickerman, P; Walsh, SL; Young, AM | 1 |
| Dobrzeniecka, A; Marczyńska, M; Ołdakowska, A; Pokorska-Śpiewak, M | 1 |
| Darling, JM; Di Bisceglie, A; Dong, M; Evon, DM; Fishbein, DA; Fried, MW; Hinestrosa, F; Horne, PM; Khalili, M; Kixmiller, S; Lok, AS; Michael, L; Moon, JS; Morelli, G; Muir, AJ; Nelson, DR; Pearlman, B; Peter, J; Rajender Reddy, K; Segal, JB; Sherman, KE; Shiffman, ML; Sloan, A; Stewart, PW; Sulkowski, MS; Vainorius, M; Wadsworth, S | 1 |
| Chang, CC; Chang, CH; Chang, CY; Chen, CY; Chen, JJ; Chen, PY; Fang, YJ; Hsieh, TY; Huang, CS; Huang, KJ; Huang, YJ; Hwang, JJ; Kao, JH; Kao, WY; Lai, HC; Lee, FJ; Lee, PL; Liu, CH; Liu, CJ; Lo, CC; Peng, CY; Shih, YL; Su, PY; Su, WW; Tsai, MC; Tseng, CW; Tseng, KC; Wu, JH; Yang, SS | 1 |
| Borgia, SM; Shafran, SD | 1 |
| Malla, I; Selzer Soria, EM | 1 |
| Abbassi, M; Al-Nahari, M; Cressey, TR; Easterbrook, P; El-Sayed, MH; Farid, S; Indolfi, G; Lallemant, M; Penazzato, M | 1 |
| Chen, XY; Chen, Y; He, HL; Liu, ZH; Meng, NN; Tao, X; Wang, NY; Yu, LT; Zhou, SY | 1 |
| Chen, YC; Ko, PH; Lee, CC; Li, CH; Syu, RJ; Tseng, CW; Tseng, KC | 1 |
| De, A; Duseja, A; Mishra, S; Premkumar, M; Roy, A; Singh, V; Taneja, S; Verma, N | 1 |
| Furuya, K; Iio, E; Ito, J; Izumi, T; Katagiri, M; Kawagishi, N; Kimura, M; Konno, J; Kumagai, K; Morikawa, K; Nakai, M; Natsuizaka, M; Ogawa, K; Ohara, M; Sakamoto, N; Shimada, N; Sho, T; Suda, G; Tanaka, Y; Tsubota, A; Umemura, M; Yamamoto, Y | 1 |
| Everson, GT; Kiser, JJ; Langness, JA; Nguyen, M; Wieland, A | 1 |
| Bhamidimarri, KR; Burke, G; Chen, L; Ciancio, G; Guerra, G; Kupin, W; Ladino, M; Martin, P; Mattiazzi, A; Pedraza, F; Roth, D | 1 |
| Alston, S; Di Bisceglie, AM; Evon, DM; Fried, MW; Golin, CE; Lim, JK; Lok, AS; Nelson, DR; Reau, N; Reddy, KR; Reeve, B; Sarkar, S; Sterling, RK; Stewart, P | 1 |
| Bourlière, M; Carrat, F; Carrieri, MP; Fontaine, H; Hézode, C; Marcellin, F; Petrov-Sanchez, V; Protopopescu, C; Vilotitch, A; Younossi, Z | 1 |
| Stafford, N | 1 |
| Bansal, A; Dutta, U; Goyal, O; Grover, R; Kishore, H; Malhi, NS; Nanda, V; Saluja, H; Sehgal, A; Sidhu, JS; Sidhu, S; Sidhu, SS; Singh, G; Singh, R | 1 |
| El Sayed, MH; Giaquinto, C; Gonzalez-Peralta, RP; Indolfi, G; Thorne, C | 1 |
| Fernández-Cuenca, F; López-Hernández, I; Paniagua-García, M; Ríos-Villegas, MJ | 1 |
| Bider-Canfield, Z; Cheetham, TC; Gharibian, D; Latt, NL; Louie, V; Mittal, R; Sahota, A; Yanny, BT | 1 |
| Chevaliez, S; Fourati, S; François, M; Hézode, C; Mallat, A; Pawlotsky, JM; Roudot-Thoraval, F; Ruiz, I; Scoazec, G; Soulier, A; Varaut, A | 1 |
| Pullen, LC | 1 |
| Connolly, JJ; Lim, JK; Ooka, K | 1 |
| Ahmed, A; Cholankeril, G; Jayasekera, CR; Perumpail, RB; Yoo, ER | 1 |
| Biliotti, E; Esvan, R; Franchi, C; Palazzo, D; Serani, M; Silvestri, AM; Sorrentino, F; Spaziante, M; Taliani, G; Volpicelli, L | 1 |
| Angarano, G; Bruno, G; Milella, M; Saracino, A | 1 |
| Cheng, N; Ford, R; Maheshwari, R; Mgbemena, O; Norvell, JP; Parekh, S; Patel, A; Pillai, AA; Spivey, JR; Vora, R; Wedd, JP; Young, N | 1 |
| Ammirati, SR; Darnell, TA; Hartis, CE; Johnson, SW; Morgan, MR; Priest, DH; Schmidlin, HN; Silwal, A; Weber, SF | 1 |
| Abraham, GM; Spooner, LM | 2 |
| Agarwal, K; Asselah, T; Berg, T; Bhandari, BR; Borgia, SM; Brainard, DM; Bräu, N; Davis, M; Dore, GJ; Dvory-Sobol, H; Feld, JJ; Foster, GR; Gane, EJ; Hyland, RH; Jacobson, IM; Lawitz, E; McHutchison, JG; Nahass, RG; Pearlman, B; Roberts, SK; Ruane, PJ; Shafran, SD; Stamm, LM; Stedman, CAM; Subramanian, GM; Svarovskaia, E; Thompson, AJ; Willems, BE; Workowski, KA; Zhu, Y | 1 |
| Barocas, JA; Beiser, M; Gaeta, JM; León, C; Linas, BP; O'Connell, JJ | 1 |
| Brown, RS; Charlton, M; Curry, MP; Hunt, S; O'Leary, JG; Stepanova, M; Younossi, ZM | 1 |
| Fischer, MA; Liao, JM | 2 |
| Alavian, SM; Behnava, B; Dolatimehr, F; Gholami-Fesharaki, M; Karimi-Sari, H; Rezaee-Zavareh, MS; Sharafi, H | 1 |
| Akriviadis, E; Arvaniti, P; Bellou, A; Dalekos, GN; Goulis, I; Karatapanis, S; Kattamis, A; Koskinas, J; Kountouras, D; Kourakli, A; Maragkos, K; Papatheodoridis, GV; Petropoulou, F; Sinakos, E; Tampaki, M; Toli, B; Triantos, C; Tsiaoussis, G; Vassiliadis, T; Vlachaki, E; Zachou, K | 1 |
| Arai, M; Chiba, T; Haga, Y; Imazeki, F; Kanda, T; Kato, N; Maruyama, H; Nakamoto, S; Nakamura, M; Ogasawara, S; Ooka, Y; Saito, T; Sasaki, R; Suzuki, E; Takahashi, K; Tawada, A; Wu, S; Yasui, S; Yokosuka, O | 1 |
| Nehra, V; Rizza, SA; Temesgen, Z | 2 |
| Chan, HL; Lo, AO; Wong, GL; Wong, VW | 1 |
| El Raziky, M; Elakel, W; Eletreby, R; Esmat, G | 1 |
| Durante-Mangoni, E; Parrella, A; Vitrone, M | 1 |
| Everson, GT; Jackson, WE | 1 |
| Al Marzooqi, SH; Cerocchi, O; Duarte-Rojo, A; Feld, JJ; Harrell, SM; Janssen, HLA; Karkada, J; Klair, JS; Kowgier, M; Maan, R; Rhodes, KD | 1 |
| Ali, A; Idrees, M; Rafique, S; Saleem, K; Wahid, B | 1 |
| Griffin, SM; Johnson, SW; Teachey, AL; Valanejad, SM; Weber, SF | 1 |
| D'Avolio, A; D'Offizi, G; De Nicolò, A; Garbuglia, AR; Montalbano, M; Taibi, C; Tempestilli, M | 1 |
| Abdallah, M; Eletreby, R; Elsharkawy, A; Esmat, G; Fouad, R; Mohey, M; Negm, M; Soliman, Z | 1 |
| Brainard, DM; Davis, MN; Dvory-Sobol, H; Etzkorn, K; Gane, EJ; Hinestrosa, F; Huang, KC; McHutchison, JG; McNally, J; Morelli, G; Osinusi, A; Shiffman, ML; Stedman, CAM; Sulkowski, MS; Thompson, AJ | 1 |
| Abe, H; Arai, T; Atsukawa, M; Iio, E; Itokawa, N; Iwakiri, K; Kato, K; Kondo, C; Okubo, T; Shimada, N; Tanaka, Y; Tsubota, A | 1 |
| Brainard, DM; Hyland, RH; Lanzkron, S; McHutchison, JG; Moon, J; Sulkowski, M; Zhang, F | 1 |
| Bailey, R; Borgia, S; Brainard, DM; Cooper, C; Elkhashab, M; Feld, JJ; Greenbloom, S; Huang, KC; Huchet, E; Hyland, RH; Marotta, P; Massetto, B; McHutchison, JG; Ramji, A; Shafran, SD; Svarovskaia, ES; Swain, MG; Tam, E; Vachon, ML; Willems, B; Yoshida, EM; Yun, C | 1 |
| Arnon, R; Balistreri, WF; Brainard, DM; Gonzalez-Peralta, RP; Hardikar, W; Jonas, MM; Kanwar, B; Kersey, K; Kirby, B; Lin, CH; Massetto, B; Murray, KF; Rosenthal, P; Schwarz, KB; Shao, J; Svarovskaia, E; Wirth, S | 1 |
| Fujikawa, T; Iwabuchi, S; Matsui, K; Nagata, M; Nakano, M; Nakazaki, H; Shimizu, H; Takatsuka, K; Tanemura, H; Watanabe, T | 1 |
| Bock, HH; Filke, S; Häussinger, D; Kaiser, R; Lübke, N; Obermeier, M; Timm, J; Walker, A | 1 |
| Peterson, D; Van Ermen, A | 1 |
| Cheng, PN; Chiu, YC; Sun, HY; Tsai, WJ; Tseng, CY; Young, KC | 1 |
| Furusyo, N; Hayashi, T; Murata, M; Ogawa, E; Toyoda, K; Ura, K | 1 |
| Antinori, S; Binda, F; Giacomelli, A; Milazzo, L; Sollima, S; Torre, A | 1 |
| Gancedo-Bringas, P; Larrubia-Marfil, JR; Lucendo-Villarín, A; Martínez-Alfaro, E; Moreno-Planas, JM; Morillas-Ariño, J; Patón-Arenas, R; Sáiz-Chumillas, RM; Sánchez-Ruano, JJ; Solera-Muñoz, M; Tébar-Romero, E; Vicente-Gutiérrez, MDM | 1 |
| McEwan, P; Mishina, S; Wang, F; Ward, T; Webster, S; Wygant, G | 1 |
| Burman, B; Edwards, AM; Kozarek, RA; Lee, H; Shin, HP; Siddique, A; Wang, C; Zehr, T; Zeigler, A | 1 |
| Angarano, G; Bruno, G; Dell'Acqua, R; Fabrizio, C; Lo Caputo, S; Milano, E; Milella, M; Monno, L; Saracino, A; Scudeller, L | 1 |
| Aggarwal, R; Bhargava, R; Goel, A; Rai, P | 1 |
| Aikata, H; Chayama, K; Daijo, K; Hayes, CN; Honda, F; Honda, Y; Imamura, M; Kan, H; Kawakami, Y; Kawaoka, T; Kobayashi, T; Miki, D; Mori, N; Morio, K; Nagaoki, Y; Nakahara, T; Nakamura, Y; Ochi, H; Takaki, S; Teraoka, Y; Tsuge, M; Tsuji, K | 1 |
| Caruso, V; Cenderello, G; Copetti, M; Forni, G; Gamberini, R; Ganga, R; Mangia, A; Piazzolla, V; Piga, A; Quarta, A; Santoro, R; Sarli, R | 1 |
| Jacobson, IM; Voaklander, R | 1 |
| Miller, MM | 1 |
| Abdel Alem, S; Abdellatif, Z; Adel, E; Elsharkawy, A; Esmat, G; Fouad, R; Hussein, MS; Musa, S; Nagy, A; Yosry, A | 1 |
| Afdhal, NH; Bacon, B; Curry, MP; Dieterich, D; Flamm, SL; Guest, L; Kowdley, KV; Lee, Y; Milligan, S; Tapper, EB; Tsai, N; Younossi, Z | 1 |
| Balslev, U; Belard, E; Dalgard, O; Färkkilâ, M; Hallager, S; Heggelund, L; Karlsen, L; Krarup, H; Lagging, M; Lund Laursen, A; Madsen, LG; Noraberg, G; Skalshøi Kjær, M; Thorup Røge, B; Weiland, O; Weis, N; Øvrehus, A | 1 |
| Mauss, S; Tacke, F | 1 |
| Baumgarten, A; Berger, F; Boesecke, C; Busch, H; Christensen, S; Hueppe, D; Ingiliz, P; Kimhofer, T; Lutz, T; Mauss, S; Rockstroh, J; Schewe, K; Schmutz, G; Schulze Zur Wiesch, J; Simon, KG; Wehmeyer, MH | 1 |
| Amrose, P; Anand, S; Kumar, MS; McFall, AM; Mehta, SH; Ramasamy, B; Solomon, SS; Srikrishnan, AK; Sulkowski, MS; Thomas, DL | 1 |
| Baghazza, S; Bencherif, R; Chaabna, K; Djezzar, S; Guehimeche, R; Mallem, D; Rouabhia, S; Sadelaoud, M; Sadouki, H | 1 |
| Alhussain, K; Kamal, K; Patel, J; Shah, D; Zhao, X | 1 |
| Ganz, ML; Gorsh, B; Hede, S; Moorjaney, D; Saint-Laurent Thibault, C; Sill, B; Yuan, Y | 2 |
| Asselah, T; Bourgeois, S; Brainard, DM; Feld, JJ; Foster, GR; Gane, EJ; Han, L; Mangia, A; McNally, J; Osinusi, A; Pianko, S; Subramanian, GM; Sulkowski, M; Zeuzem, S | 1 |
| Abdo, M; Abouelkhair, M; Doss, W; Elakel, W; Elbaz, T; Elgarem, N; Elsayed, MH; Elserafy, M; Elshazly, Y; Esmat, G; Gaballa, A; Hassany, M; Mahran, Z; Mehrez, M; Mohey, MA; Omar, A; Waked, I; Yosry, A | 1 |
| Bolte, FJ; Ghany, M; Liang, TJ; O'Keefe, AC; Rehermann, B; Rivera, E; Serti, E; Webb, LM | 1 |
| Brainard, DM; Lohse, AW; Mogalian, E; Scheurich, C; Schulze Zur Wiesch, J; von Felden, J; Yamamura, J | 1 |
| Andriulli, A; Barone, M; Brancaccio, G; Conti, F; Di Leo, A; Francavilla, R; Gatti, P; Iannone, A; Ippolito, AM; Lauletta, G; Masetti, C; Messina, V; Milella, M; Morisco, F; Napoli, N; Pesce, F; Santantonio, T; Shahini, E; Smedile, A; Termite, AP; Tundo, P | 1 |
| Amer, SA; Said, M; Shahin, AA; Zayed, HS | 1 |
| Carrai, P; Coppola, C; Cordone, G; Lenci, I; Lionetti, R; Martini, S; Melazzini, M; Montilla, S; Morelli, C; Pani, L; Petraglia, S; Piai, G; Pietrosi, G; Romano, A; Russo, FP; Russo, P; Tamé, M; Toniutto, P; Trotta, MP | 1 |
| Asrani, SK; Gonzalez-Stawinski, GV; Gottlieb, RL; Hall, SA; Joseph, SM; Lima, B; Sam, T; Trotter, JF; Wada, SY | 1 |
| Burman, B; Kozarek, RA; Park, JA; Shin, HP; Siddique, A | 1 |
| Connolly, MP; Kotsopoulos, N; Ustianowski, A | 1 |
| Brainard, DM; Corsa, AC; Hedskog, C; Kitrinos, KM; Miller, MD; Mo, H; Worth, A | 1 |
| Mellen, CK; Rindone, JP | 1 |
| Kramer, L; Laurain, A; Méritet, JF; Pol, S; Rosenberg, AR; Sultanik, P; Trémeaux, P | 1 |
| Barnes, E; Brown, A; de Vree, JML; Klenerman, P; Kootstra, NA; Reesink, HW; Sinnige, MJ; Stelma, F; Swadling, L; van der Ree, MH; van der Valk, M; van Nuenen, AC; Willemse, SB | 1 |
| Abutidze, A; Chkhartishvili, N; Dolmazashvili, E; Karchava, M; Sharvadze, L; Tsertsvadze, T | 1 |
| Guedj, J; Kohli, A; Kottilil, S; Nguyen, THT; Perelson, AS; Uprichard, SL | 1 |
| Kim, HJ; Lee, HW; Won, JW; Yoo, KY | 1 |
| Arends, JE; Bijmolen, M; Blokzijl, H; Burger, DM; de Kanter, CTMM; de Knegt, RJ; Dofferhoff, ASM; Drenth, JPH; Lieveld, FI; Maan, R; Smolders, EJ; van der Valk, M; van Erpecum, KJ; van Tilborg, M | 1 |
| Fukuda, H; Fukuda, S; Irie, M; Kunimoto, H; Morihara, D; Sakamoto, K; Sakisaka, S; Shakado, S; Takata, K; Takeyama, Y; Tanaka, T; Umeda, K; Yamauchi, R; Yokoyama, K | 1 |
| Abou-Samra, AB; Butt, AA; Simon, TG; Yan, P | 1 |
| Caraceni, P; Carrai, P; Donato, MF; Fagiuoli, S; Filì, D; Gianstefani, A; Martini, S; Mazzarelli, C; Melazzini, M; Montilla, S; Pani, L; Petraglia, S; Rendina, M; Russo, P; Trotta, MP; Visco-Comandini, U | 1 |
| Huang, JW; Liao, HT; Tan, P; Yuan, KF | 1 |
| Jindracek, L; Stark, J | 1 |
| Li, T; Liu, F; Qu, YD; Wang, L; Xue, Y; Zhang, LX | 1 |
| Ahn, SH; Lim, TS | 1 |
| Bassiony, MAA; Hanafy, AS; Hussein, S; Mohamed, MS | 1 |
| Balistreri, W; Bansal, S; Hunt, S; Murray, KF; Rosenthal, P; Schwarz, K; Stepanova, M; Younossi, ZM | 1 |
| Abdalla, U; Abdel-Khalek, EE; Abdel-Wahab, M; Al-Refaey, AK; Al-Shobari, M; Ali, M; El-Gilany, AH; Elghawalby, AN; Elmorshedi, M; Sadani, M; Salah, T; Shiha, U; Sultan, AM; Yassen, AM | 1 |
| Beumont, M; Bourgeois, S; Hillewaert, V; Horsmans, Y; Luo, D; Moreno, C; Nevens, F; Ouwerkerk-Mahadevan, S; van de Logt, J; van Eygen, V; Van Remoortere, P; van Vlierberghe, H; Vijgen, L | 1 |
| Anvesh, G; Rajesh, G; Raju, N; Raju, SB; Sridhar, N; Surendra, M; Vijay Kiran, B | 1 |
| Abd El-Wahab, EW; Nagaty, A | 1 |
| Amoroso, A; Dellario, M; Dickson, C; Flores, Y; Kottilil, S; Parker, A; Tang, L; Wilson, E | 1 |
| Abergel, A; Asselah, T; Brainard, DM; Camus, G; Dvory-Sobol, H; Han, B; Hsieh, D; Kersey, K; Lu, J; Martin, R; Miller, MD; Mo, H; Parhy, B; Svarovskaia, E | 1 |
| Reddy, KR; Weinberg, EM | 1 |
| Chen, DS; Chen, PJ; Chen, YS; Hong, CM; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Wang, SS; Yang, HC | 1 |
| Hayashi, Y; Imoto, S; Kato, A; Kim, CW; Kim, KI; Kim, SK; Kim, SR; Kobayashi, M; Kudo, M; Morimoto, E; Ohtani, A; Saijo, Y; Seo, K; Yano, Y | 1 |
| Aoki, T; Gatanaga, H; Kikuchi, Y; Kinai, E; Mizokami, M; Mizushima, D; Oka, S; Sugiyama, M; Teruya, K; Tsukada, K; Uemura, H; Watanabe, K | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, YH; Lin, ZY; Yang, JF; Yeh, ML; Yu, ML | 1 |
| Chan, HLY; Dan, YY; Kruger, E; Lee, MH; Lim, YS; Tan, SC; Younossi, ZM | 1 |
| Birnkrant, D; Chan-Tack, K; Naeger, LK; Qi, K; Struble, K | 1 |
| Aburawash, A; Elsisi, GH; Waked, E | 1 |
| Alric, L; Bellissant, E; Bourlière, M; de Lédinghen, V; Gibowski, S; Hézode, C; Jézéquel, C; Laforest, C; Larrey, D; Métivier, S; Pailhé, A; Pawlotsky, JM; Pol, S; Renault, A; Samuel, D; Tran, A; Tual, C; Zoulim, F | 1 |
| Do, S; Henry, L; Nguyen, MH; Nguyen, P; Nguyen, T; Trinh, H | 1 |
| Brown, AN; Drusano, GL; Li, E; Liu, L; Neely, MN; Rodriquez, JL; Schuster, L; Wang, GP; Yamada, W; Zhao, L | 1 |
| Cairó, M; Carrion, JA; Cifuentes, C; Crespo, M; Cucurull, J; Erice, E; Force, L; Guardiola, JM; Laguno, M; Marco, A; Navarro, J; Roget, M; Vilaró, J; Vilchez, HH | 1 |
| Bruzzone, B; Canepa, P; Icardi, G; Magnani, O; Rappazzo, E; Setti, M; Sticchi, L | 1 |
| Brown, RS; Camus, G; Copans, A; Ghali, P; Guyer, B; Haubrich, R; Kang, M; Luetkemeyer, AF; Mantry, PS; Ni, L; Rossaro, L; Satapathy, SK; Shen, X; Tam, E | 1 |
| Wise, J | 1 |
| Agrati, C; Ammassari, A; Antinori, A; Bellagamba, R; Fabbri, G; Libertone, R; Lupi, F; Mastrorosa, I; Notari, S; Tempestilli, M; Timelli, L; Zaccarelli, M | 1 |
| Kottilil, S; O'Brien, TR; Pfeiffer, RM | 1 |
| Frey, A; Gerken, G; Herzer, K; Piras-Straub, K; Timm, J; Walker, A | 1 |
| Bhardwaj, N; Brainard, D; Chang, S; Chodavarapu, K; Feld, JJ; Mangia, A; Martin, R; McNally, J; Miller, MD; Mo, H; Murrell, B; Osinusi, A; Ragonnet-Cronin, M; Sulkowski, M; Svarovskaia, ES; Wertheim, JO | 1 |
| Ferenci, P; Gschwantler, M; Gutic, E; Haltmayer, H; Kozbial, K; Laferl, H; Lang, T; Luhn, J; Moser, S; Reiberger, T; Schleicher, M; Schubert, R; Schütz, A; Schwabl, P; Schwanke, C; Steindl-Munda, P | 1 |
| Agudelo, EZ; Campos-Varela, I; Roberts, JP; Sarkar, M; Terrault, NA | 1 |
| Boeker, K; Buggisch, P; Günther, R; Mauss, S; Niederau, C; Pathil, A; Schott, E; Simon, KG; Teuber, G; Vermehren, J; Vornkahl, HP; Wedemeyer, H; Zeuzem, S; Zimmermann, T | 1 |
| Abdo, AM; El-Khayat, HR; El-Shabrawi, MH; Yakoot, M | 1 |
| Andini, R; Atripaldi, L; Durante-Mangoni, E; Maiello, C; Mattucci, I; Vitrone, M; Zampino, R | 1 |
| Clark, A; Dusheiko, G; Fathi, H; Hill, NR | 1 |
| Bourliere, M; Cooper, C; Flamm, S; Gordon, S; Hunt, S; Jacobson, I; Kowdley, K; Mann, MP; Reddy, KR; Stepanova, M; Younossi, I; Younossi, ZM; Zeuzem, S | 1 |
| Anderson, R; Avellar, AM; Castro, R; Hyde, C; Jorge, MJ; Mujica-Mota, R; Perazzo, H; Romero, C; Silva, JC; Silva, PS; Veloso, VG | 1 |
| Asselah, T; Foster, GR; Gane, EJ; Henry, L; Jacobson, IM; Lawitz, E; Pearlman, B; Racila, A; Roberts, SK; Stepanova, M; Thompson, AJ; Welzel, TM; Willems, BE; Younossi, I; Younossi, ZM | 1 |
| Ambrifi, M; Colafigli, M; Cristaudo, A; Latini, A; Orsini, D; Zaccarelli, M | 1 |
| AbdAllah, M; Doss, W; El Akel, W; El Kassas, M; El Shazly, H; El Shazly, Y; Elbaz, T; Elsaeed, K; Esmat, G; Gomaa, AA; Ismail, SA; Korany, M; Nasr, A; Omar, H; Said, M; Shaker, MK; Waked, I; Yousif, M | 1 |
| Gonzalez-Peralta, R; Henry, L; Hunt, S; Murray, K; Rosenthal, P; Schwarz, KB; Stepanova, M; Wirth, S; Younossi, ZM | 1 |
| Ahn, SH; Chan, HL; Chuang, WL; Han, KH; Henry, L; Kao, JH; Kinh, N; Lai, CL; Lai, W; Lim, YS; Stepanova, M; Younossi, ZM; Yuen, MF | 1 |
| Al-Zoairy, R; Beinhardt, S; Ferenci, P; Graziadei, I; Hofer, H; Kozbial, K; Maieron, A; Rasoul-Rockenschaub, S; Stättermayer, AF; Stauber, R; Strasser, M; Trauner, M; Zoller, H | 1 |
| Angus, PW; George, J; Gow, P; Jeffrey, G; Mason, S; McCaughan, GW; Mitchell, J; Morales, B; Parker, FC; Roberts, SK; Strasser, SI; Tallis, C; Thompson, AJ; Thwaites, PA; Wigg, A | 1 |
| Iqbal, S; Yousaf, MI; Yousuf, MH | 1 |
| Allegre, T; Alric, L; Amri, I; Aumaitre, H; Bailly, F; Bellissant, E; Billaud, E; Bourlière, M; Carrieri, MP; Chas, J; Chevaliez, S; Cotte, L; De Truchis, P; Dominguez, S; Dupon, M; Fougerou-Leurent, C; Garraffo, R; Girard, PM; Jeantils, V; Lacombe, K; Leroy, V; Marcellin, F; Metivier, S; Molina, JM; Morlat, P; Naqvi, A; Neau, D; Pabic, EL; Pageaux, GP; Pailhé, A; Perré, P; Piroth, L; Poizot-Martin, I; Pol, S; Raffi, F; Renault, A; Reynes, J; Rosenthal, E; Salmon-Ceron, D; Teicher, E; Tual, C; Valantin, MA; Yazdanpanah, Y; Zucman, D | 1 |
| Brainard, DM; Doehle, BP; Dvory-Sobol, H; Hedskog, C; Hezode, C; McNally, J; Miller, MD; Mo, H; O'Leary, JG; Osinusi, A; Reau, N; Roberts, SK; Shafran, SD; Shanmugam, R; Svarovskaia, ES; Zeuzem, S | 1 |
| Birkemose, I; Christensen, PB; Ernst, A; Holm, DK; Krarup, H; Mössner, B; Øvrehus, ALH | 1 |
| Fiel, MI; Putra, J; Schiano, TD | 1 |
| Chevaliez, S; Fourati, S; Francois, M; Guedj, J; Hézode, C; Mallat, A; Nguyen, THT; Pawlotsky, JM; Poiteau, L; Roudot-Thoraval, F; Ruiz, I; Scoazec, G; Soulier, A; Varaut, A | 1 |
| Enomoto, M; Fujii, H; Hagihara, A; Hai, H; Kawada, N; Kozuka, R; Morikawa, H; Motoyama, H; Murakami, Y; Tamori, A; Uchida-Kobayashi, S | 1 |
| Dore, GJ; Grebely, J; Hajarizadeh, B; Martinello, M; Matthews, GV | 1 |
| Beumont, M; Corregidor, AM; Feld, JJ; Felizarta, F; Gamil, M; Ghalib, R; Kakuda, TN; Khalid, O; Lawitz, E; Luo, D; Ouwerkerk-Mahadevan, S; Smith, WB; Sulkowski, MS; Van Eygen, V; Van Remoortere, P; Vijgen, L | 1 |
| Fujita, K; Masaki, T; Morishita, A; Nomura, T; Oura, K; Sakamoto, T; Tadokoro, T; Tani, J; Yoneyama, H | 1 |
| Andres, J; Lott, S; Qureshi, K | 1 |
| Calabrese, MJ; de Bittner, MR; Hynicka, LM; Shaya, FT | 1 |
| de Avila, L; Doyle, J; Stepanova, M; Thompson, A; Younossi, I; Younossi, ZM | 1 |
| Asahina, Y; Brainard, DM; Dvory-Sobol, H; Enomoto, N; Genda, T; Ikeda, F; Itoh, Y; Jiang, D; Kawada, N; Massetto, B; Matsuda, T; Matsuzaki, Y; McHutchison, JG; Osinusi, AO; Takikawa, Y; Ueno, Y; Yatsuhashi, H | 1 |
| Bunchorntavakul, C; Palecki, J; Reddy, KR; Tan Dat, H; Thu Thuy, PT | 1 |
| Akushevich, L; Ben-Ari, Z; Fried, MW; Gallant, J; Hassan, M; Kuo, A; Landis, CS; Liapakis, AM; Lim, JK; Lok, AS; Michael, L; Nelson, DR; Park, JS; Pockros, PJ; Shiffman, ML; Terrault, NA; Vainorius, M; Zeuzem, S | 1 |
| Amin, J; Applegate, TL; Bruggmann, P; Bruneau, J; Byrne, J; Conway, B; Cooper, C; Cunningham, EB; Dalgard, O; Dillon, JF; Dore, GJ; Dunlop, A; Feld, JJ; Fraser, C; Gane, E; Grebely, J; Hajarizadeh, B; Hellard, M; Kronborg, I; Lacalamita, M; Litwin, AH; Marks, P; Matthews, GV; Powis, J; Quiene, S; Read, P; Shaw, D; Siriragavan, S; Swan, T; Thurnheer, MC; Weltman, M | 1 |
| Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kominami, Y; Kumada, H; Ohya, K; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Gschwantler, M; Gutic, E; Haltmayer, H; Lang, T; Luhn, J; Moser, S; Schleicher, M; Schubert, R; Schütz, A; Schwanke, C | 1 |
| Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Pinna, SM | 1 |
| Dohmen, K; Ichiki, Y; Ishibashi, H; Kawano, A; Miki, K; Morita, C; Nomura, H; Shigematsu, H; Shimoda, S; Takahashi, K; Yanagita, K | 1 |
| Aggarwal, R; Bhadauria, DS; Goel, A; Gupta, A; Kaul, A; Mehrotra, M; Rai, P; Sharma, RK; Verma, P | 1 |
| Enomoto, M; Kawada, N; Tamori, A; Tateishi, C; Tsuruta, D | 1 |
| Younossi, ZM | 1 |
| Danta, M; Sanagapalli, S | 1 |
| Attia, D; Ayoub, H; El Sheemy, RY; El-Khayat, HR; El-Sayed, MH; El-Shabrawi, M; Fouad, YM; Kamal, EM; Maher, M; RizK, A | 1 |
| Bessone, F; Borzi, SM; Cartier, M; D'Amico, C; Descalzi, VI; Fainboim, HA; Figueroa Escuti, S; Frías, S; Gadano, AC; Gaite, LA; Galdame, OA; Haddad, L; Longo, C; Marciano, S; Marino, M; Peralta, M; Perez Ravier, R; Reggiardo, MV; Vistarini, C | 1 |
| Deng, X; Li, G; Zang, K; Zhang, G; Zhu, D | 1 |
| Abd El Latif, Y; Alboraie, M; Doss, W; El Kassas, M; El Tahan, A; El-Serafy, M; Elakel, W; Elsaeed, K; ElShazly, Y; Esmat, G; Ezzat, S; Korany, M; Nabeel, MM; Omran, D | 1 |
| Asatryan, A; Asselah, T; Bourlière, M; Bruck, R; Chuang, WL; Dore, GJ; Feld, JJ; Felizarta, F; Flamm, S; Flisiak, R; Foster, GR; Fu, B; Fuster, F; Gane, E; Kaita, K; Kort, J; Kwo, P; Lin, CW; Liu, R; Mensa, FJ; Ng, TI; Paik, SW; Pilot-Matias, T; Pol, S; Poordad, F; Puoti, M; Roberts, SK; Ruane, PJ; Sepulveda-Arzola, G; Soto-Malave, R; Stedman, CA; Tam, E; Trinh, R; Vargas, HE; Vierling, J; Wang, S; Wedemeyer, H; Zeuzem, S | 1 |
| Scott, LJ | 1 |
| Brainard, DM; Cheng, J; Dou, X; Duan, Z; Gao, ZL; German, P; Gong, G; Hou, JL; Hu, P; Jia, J; Jiang, D; Jiang, J; Kersey, K; Knox, SJ; Li, J; Li, L; Li, W; Lin, F; Massetto, B; Mo, H; Mou, Z; Nan, Y; Ning, Q; Niu, JQ; Tang, H; Wang, G; Wei, L; Wu, S; Xie, Q; Xu, M; Yang, JC; Yang, Y; Zhang, LL | 1 |
| Iqbal, S; Raza, A; Yousaf, MI; Yousuf, MH | 1 |
| Bittermann, T; Weinberg, E | 1 |
| Borba, HHL; Ferreira, VL; Leonart, LP; Pontarolo, R; Tonin, FS | 1 |
| Boglione, L; Cariti, G; Di Perri, G; Lupia, T; Pinna, SM | 1 |
| Baka-Ćwierz, B; Belica-Wdowik, T; Berak, H; Białkowska, J; Czauż-Andrzejuk, A; Deroń, Z; Dobracka, B; Dybowska, D; Flisiak, R; Garlicki, A; Gietka, A; Halota, W; Horban, A; Janczewska, E; Jaroszewicz, J; Laurans, Ł; Lorenc, B; Mazur, W; Orłowska, I; Pawłowska, M; Piekarska, A; Simon, K; Sitko, M; Socha, Ł; Staniaszek, A; Tomasiewicz, K; Tronina, O; Tudrujek, M; Wawrzynowicz-Syczewska, M; Zarębska-Michaluk, D | 1 |
| Ferenci, P | 3 |
| Ahmad, A; El Sagheer, G; Hamdy, L; Soliman, E | 1 |
| Ariaudo, A; Avataneo, V; Boglione, L; Carcieri, C; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Favata, F; Guido, F; Mornese Pinna, S | 2 |
| Akuskevich, L; Frazier, LM; Fried, MW; Kuo, A; Levitsky, J; Li, E; Lim, JK; Liu, L; Morelli, G; Nelson, DR; Peter, J; Ramani, A; Reeves, JD; Sherman, KE; Terrault, N; Wang, GP; Zhao, L | 1 |
| Bukh, J; Fahnøe, U; Gottwein, JM; Li, YP; Pedersen, J; Pham, LV; Ramirez, S | 1 |
| Imnadze, T; Mikadze, I; Vashakidze, E | 1 |
| Agarwal, K; Asante-Appiah, E; Barclay, S; Barr, E; Brown, AS; Collier, J; Cramp, ME; Du, J; Forton, DM; Foster, GR; Fox, R; Gilbert, CL; Gordon, F; Haber, B; Moreea, S; Mutimer, DJ; Robertson, MN; Rosenberg, WM; Ryder, SD; Ustianowski, A; Wahl, J | 1 |
| Chawla, Y; De, A; Dhiman, RK; Duseja, A; Gupta, KL; Kohli, HS; Kumar, V; Mehta, M; Ramachandran, R; Taneja, S | 1 |
| Deterding, K; Manns, MP; Wedemeyer, H | 1 |
| Abrams, GA; Gade, AR; Patel, M; West, DR | 1 |
| Cherepanoff, S; Chia, XX; Danta, M; Furlong, T | 1 |
| Chamberland, S; Champsi, JH; Gittleman, LC; Hurley, LB; Korn, DG; Lai, JB; Lam, JO; Marcus, JL; Pauly, MP; Quesenberry, CP; Ready, J; Saxena, V; Seo, SI; Silverberg, MJ; Witt, DJ | 1 |
| Saad, A; Shoaib, S; Siddique, MS | 1 |
| Deeks, ED; Heo, YA | 1 |
| Abdel-Gabbar, M; Abdel-Moneim, A; Aboud, A; Ramadan, M; Zanaty, M | 1 |
| Berthillon, P; Bordes, I; Chemin, I; Crouy, S; Larrat, S; Leroy, V; Maynard, M; Petit, MA; Pradat, P; Scholtès, C; Trépo, C; Virlogeux, V; Zoulim, F | 1 |
| El-Raziky, M; Elsharkawy, A; Fouad, A; Khairy, M; Salama, A; Tantawy, O | 1 |
| Cherian, R; Driscoll, C; Genther, K; Goode, MB; Lee, H; Lewis, S; Luketic, VA; Martin, K; Matherly, S; Patel, V; Puri, P; Sanyal, AJ; Siddiqui, MS; Smith, P; Sterling, RK; Stravitz, RT | 1 |
| Gonzales, GR; Gonzalez, SA; Modi, AA; Nazario, HE | 1 |
| AbdElgawad, MM; Abdo, AM; El-Khayat, HR; El-Shabrawi, MH; Helmy, S; Mahfouz, AA; Yakoot, M | 1 |
| Aoufi-Rabih, S; Fabrizi, F; García-Agudo, R; González-Corvillo, C; Salgueira-Lazo, M | 1 |
| Gotthardt, DN; Hippchen, T; Mehrabi, A; Neuberger, M; Pfeiffenberger, J; Rupp, C; Sauer, P; Stremmel, W; Weiss, KH | 1 |
| Abe, H; Arai, T; Atsukawa, M; Hayama, K; Iio, E; Itokawa, N; Iwakiri, K; Kato, K; Kawamoto, C; Kondo, C; Kumada, T; Nakagawa-Iwashita, A; Okubo, T; Shimada, N; Tanaka, Y; Toyoda, H; Tsubota, A | 1 |
| Abdel-Gabbar, M; Abdel-Moneim, A; Aboud, A; Ramadan, M; Zanaty, MI | 1 |
| Akahane, T; Hasebe, C; Itakura, J; Izumi, N; Joko, K; Kimura, H; Kobashi, H; Kojima, Y; Kondou, M; Kurosaki, M; Kusakabe, A; Mitsuda, A; Mori, N; Nakata, R; Narita, R; Ogawa, C; Sohda, T; Takaki, S; Takezawa, J; Tamada, T; Tsuji, K; Uchida, Y; Yagisawa, H | 1 |
| Masumoto, A; Miyazaki, M; Motomura, K; Tanaka, K; Yada, M | 1 |
| Abergel, A; Besch, C; Botta-Fridlund, D; Cagnot, C; Canva, V; Chevaliez, S; Coilly, A; Conti, F; D'Alteroche, L; De Ledinghen, V; Debette-Gratien, M; Diallo, A; Duclos-Vallee, JC; Dumortier, J; Duvoux, C; Fougerou-Leurent, C; Francoz, C; Habersetzer, F; Houssel-Debry, P; Jezequel, C; Kamar, N; Lebray, P; Leroy, V; Martino, VD; Montialoux, H; Moreno, C; Pageaux, GP; Perre, P; Radenne, S; Rossignol, E; Silvain, C; Tran, A; Veislinger, A | 1 |
| Cory, TJ; Gong, Y; Kodidela, S; Kumar, S; Mu, Y | 1 |
| Brainard, DM; Camus, G; Cheng, J; Duan, Z; Gao, Y; Gong, G; Hou, JL; Hu, P; Jia, J; Jiang, J; Li, J; McNabb, B; Mo, H; Mou, Z; Nan, Y; Ning, Q; Osinusi, A; Tang, H; Wang, G; Wei, L; Wu, S; Xie, Q; Zhang, F; Zhang, L | 1 |
| Jang, H; Jin, YJ; Kim, CW; Kim, L; Yoon, CH | 1 |
| Acharya, C; Bajaj, JS | 1 |
| ElBasiony, M; Hassan, AA; Mikhail, NNH; Shiha, G; Soliman, R | 1 |
| Abdel-Razek, W; Brainard, DM; Doss, W; Elbasiony, M; Elsharkawy, A; Esmat, G; Fouad, R; Hammad, R; Hassany, M; Kersey, K; Lu, S; Massetto, B; McHutchison, JG; Osinusi, A; Shiha, G; Soliman, R; Waked, I; Zakareya, T | 1 |
| Gupta, E; Kataria, A; Nayak, SL; Sarin, SK | 1 |
| Jung, J; Kirchner, VA; Kwon, JH; Lee, SG; Song, GW; Tak, EY | 1 |
| Cervino, L; Hynicka, LM | 1 |
| Furqan, S; Jabeen, S; Rashid, O | 1 |
| AbdElgawad, MMAH; El-Khayat, HR; El-Shabrawi, MHF; Kamal, EM; Kamal, NM; Yakoot, M | 1 |
| Di Cesare, A; Lazzeri, L; Pescitelli, L; Prignano, F; Ricceri, F; Tripo, L | 1 |
| Atsumi, T; Fujieda, Y; Nakai, M; Nakamura, H; Yasuda, S | 1 |
| Aghemo, A; Aglitti, A; Andreone, P; Boccaccio, V; Bollani, S; Brunetto, MR; Bruno, S; Calvaruso, V; Ciancio, A; Coco, B; Conti, F; Degasperi, E; Di Leo, A; Di Marco, V; Giorgini, A; Lampertico, P; Lleo, A; Maisonneuve, P; Marzi, L; Persico, M; Rendina, M; Troshina, G; Villa, E; Zuin, M | 1 |
| Abdo, AA; Al-Hamoudi, WK; Alalwan, AM; Albenmousa, A; Albiladi, H; Alghamdi, AS; AlGhamdi, H; Aljawad, MS; Aljumah, AA; AlMousa, A; Almutairi, NH; Alothmani, HS; Alsahafi, A; AlSaleemi, MS; Alswat, K; Altraif, IH; AlZanbagi, A; Assiri, AM; Awny, A; Babatin, MA; Dahlan, Y; Mousa, WA; Sanai, FM | 1 |
| Abdallah, F; El Tarabily, M; Ibrahim, M; Mohamed, G | 1 |
| Abdel-Gabaar, M; Abdel-Moneim, A; Aboud, A; Ramadan, M; Zanaty, MI | 1 |
| Easley, KA; Kalapila, AG; Kyle, AW; Michal, JL; Miller, LS; Patel, M; Rab, S | 1 |
| Garg, K; Gupta, GK; Maharshi, S; Nijhawan, S; Padhi, S | 1 |
| Honma, T; Imai, M; Ishikawa, T; Iwanaga, A; Nozawa, Y; Owaki, T; Sano, T; Sato, H; Seki, K; Yoshida, T | 1 |
| Huq, M; Jacques, K; Krasner, C; Mambourg, SE; Mikolas, LA | 1 |
| Lu, J; Xie, Q; Zhou, HJ | 1 |
| Zhang, DZ; Zhang, QF | 1 |
| Ojha, RP; Steyerberg, EW | 1 |
| Fujisaki, K; Hashiguchi, M; Hiramine, Y; Hori, T; Ido, A; Ijuin, S; Inada, Y; Kasai, A; Kumagai, K; Kure, T; Mawatari, S; Moriuchi, A; Oda, K; Tabu, K; Tamai, T; Taniyama, O; Uto, H | 1 |
| Waked, I | 1 |
| Bourlière, M; Brainard, DM; Curry, MP; Dvory-Sobol, H; Gordon, SC; Hyland, RH; Landis, CS; Manns, MP; McHutchison, JG; Ravendhran, N; Reddy, KR; Schiff, ER; Sepe, TE; Serfaty, L; Stamm, LM; Subramanian, GM; Thompson, AJ; Tran, TT; Zhang, J | 1 |
| Kamiya, K; Komine, M; Maekawa, T; Murata, S; Ohtsuki, M; Waki, Y | 1 |
| Chae, HB; Jang, JW; Kang, YW; Kim, HS; Kim, SB; Kim, SH; Kim, YM; Ko, SY; Lee, BS; Lee, JD; Lee, SH; Lee, TH; Song, IH; Song, MJ | 1 |
| Abd El Latif, Y; Doss, W; El Kassas, M; El Shazly, Y; El Tahan, A; Elbadry, M; Esmat, G; Farid, AM; Fontanet, A; Funk, AL; Sherief, A; Shimakawa, Y; Vasiliu, A; Youssef, N | 1 |
| Höner Zu Siederdissen, C; Maasoumy, B | 1 |
| Agarwal, K; Arterburn, S; Brainard, DM; Camus, G; Castells, L; Dufour, JF; Forns, X; Mani Subramanian, G; Mariño, Z; McNabb, B; McNally, J; Müllhaupt, B; Rosenberg, WMC; Stamm, LM | 1 |
| Brainard, D; Hedskog, C; Imai, Y; Inao, M; Kouyama, JI; Mo, H; Mochida, S; Motoya, D; Naiki, K; Nakamura, S; Nakayama, N; Sugawara, K; Tomiya, T; Uchida, Y | 1 |
| Bourliere, M; Gordon, SC; Manns, MP; Racila, A; Reddy, R; Schiff, E; Stepanova, M; Tran, T; Younossi, I; Younossi, ZM | 1 |
| Bricks, G; Castelo Filho, A; Figueiredo Senise, J; Grandi, G; Pott-Junior, H | 1 |
| Golonski, N; Jeffrey, P; Lu, CY; Lupton, C; Wagner, AK; Zhang, F | 1 |
| Bhamidimarri, KR; Chu, D; Han, SB; Hu, KQ; Lee, TP; Ma, X; Mohanty, SR; Pan, CQ; Park, J; Tiongson, BC; Tong, M; Wang, D; Xiao, PY | 1 |
| Cerban, R; Ester, C; Gheorghe, C; Gheorghe, L; Iacob, R; Iacob, S; Pietrareanu, C; Popescu, I | 1 |
| Fan, H; Feng, Y; Huang, P; Tian, T; Wang, J; Wu, J; Xia, X; Yu, R; Yue, M; Zhang, Y | 1 |
| Gawęda, B; Kośnik, A; Krawczyk, M; Milkiewicz, P; Raszeja-Wyszomirska, J; Rejowski, S; Remiszewski, P | 1 |
| Agüero, J; Alvarez, S; Ayesa, R; Cabezas, J; Calleja, JL; Chueca, N; Cobo, C; Crespo, J; Crespo-Facorro, B; Cuadrado, A; Echevarría, S; Fortea, JI; Garcia, F; Llerena, S; Lopez-Hoyos, M; Mateo, M; Pallás, JR; Pellón, R; Setién, E | 1 |
| Alper, CJ; Clements, K; Greenwood, BC; Hydery, T; Jeffrey, PL; Kouris, G; Lavitas, P; Lenz, K; Price, M | 1 |
| Chandraker, AK; Cohen, DJ; Ding, Y; Murakami, N; Rennke, HG | 1 |
| Chu, TC; Fasanmi, EO; MacDonald, BR; Moore, JD; Ojha, RP; Stewart, RA | 1 |
| Ahn, SH; Chan, HL; Chuang, WL; Han, KH; Henry, L; Kao, JH; Lai, CL; Lim, YS; Nguyen, KV; Stepanova, M; Wei, L; Younossi, ZM | 1 |
| Abdelmaksoud, A | 2 |
| Barone, CR; Bonamigo, RR; Boza, JC; Oliveira, FB; Pires, GC; Rossi, SD; Silva, M | 1 |
| Almeida, JR; Ancuta, P; de Andrade, TG; de Azeredo, EL; do Rosário, NF; Lacerda, GS; Leite, PEC; Medeiros, T; Saraiva, GN; Silva, AA; Xavier, AR | 1 |
| Brøckner Siggard, C; Chayama, K; Damgaard Sandahl, T; Douglas, MW; George, J; Grønbaek, H; Hagelskjaer Kristensen, L; Hiramatsu, A; Kazankov, K; Lund Laursen, A; Lund Laursen, T; Møller, HJ; Nakahara, T; Ong, A; Tarp, B | 1 |
| Andersen, ES; Bukh, J; Christensen, PB; Fahnøe, U; Gerstoft, J; Kjær, MS; Laursen, AL; Mössner, B; Pedersen, MS; Røge, BT; Schønning, K; Sølund, C; Weis, N | 1 |
| Abdel Wahed, WY; Ahmed, EI; Ahmed, TI; Hassan, EA | 1 |
| Al-Deen Abead, M; Baraka, MA; Gomaa, AA; Hussein, AK; Wahsh, EA | 1 |
| Aikata, H; Arataki, K; Chayama, K; Fujino, H; Hatooka, M; Hayes, CN; Hiramatsu, A; Imamura, M; Ito, H; Katamura, Y; Kawakami, Y; Kawaoka, T; Kohno, H; Miki, D; Morio, K; Morio, R; Moriya, T; Murakami, E; Nakahara, T; Nakamura, T; Nakamura, Y; Ochi, H; Tamura, T; Tsuge, M; Tsuji, K; Waki, K | 1 |
| Brainard, DM; Camus, G; Chayama, K; De-Oertel, S; Enomoto, H; Ide, T; Ikeda, F; Izumi, N; Jiang, D; Kakizaki, S; Kawakami, Y; Kurosaki, M; McHutchison, JG; McNabb, BL; Mizokami, M; Mochida, S; Stamm, LM; Takaguchi, K; Takehara, T; Tanaka, Y; Toyoda, H; Ueno, Y; Yatsuhashi, H | 1 |
| Basile, M; Cicchetti, A; Coretti, S; Drago, C; Rolli, FR; Romano, F; Ruggeri, M | 1 |
| Kikuchi, K | 1 |
| Brieva, T; Frias, M; Rivero, A; Rivero-Juarez, A | 1 |
| Bacca, D; Cenderello, G; Copetti, M; De Stefano, G; Losappio, R; Mangia, A; Mazzola, M; Minerva, N; Palmieri, V; Piazzola, V; Potenza, D; Santoro, R; Sogari, F; Terreni, N | 1 |
| Ladino, M; Roth, D | 1 |
| Arnon, R; Balistreri, WF; Bansal, S; Brainard, DM; Evans, HM; Garrison, KL; Gillis, LA; Gonzalez-Peralta, RP; Jonas, MM; Kersey, K; Lin, CH; Massetto, B; Murray, KF; Narkewicz, MR; Parhy, B; Rosenthal, P; Schwarz, K; Shao, J; Wen, J; Whitworth, S | 1 |
| Gonçalves, CAM; Horta, AMLMFCA; Marques, MSC; Méndez, MJV; Sarmento-Castro, RMDR; Soeiro, CASP; Tavares, APRA | 1 |
| Abdel-Ghafar, TS; Abdelkareem, M; Abdelsameea, E; Abozeid, M; Alsebaey, A; Elfayomy, M; Elhelbawy, M; Fekry, M; Othman, W; Rewisha, E; Rgab, A; Sabry, A; Shebl, N; Waked, I | 1 |
| Abdellatif, Z; Anwar, I; Bekheet, N; El-Nahaas, SM; Elhossary, W; Elsharkawy, A; Esmat, G; Fouad, R; Khairy, M; Maher, RM | 1 |
| Chakraborty, S; Garlapati, P; Gayam, V; Gill, A; Guss, D; Khalid, M; Mandal, AK; Mansour, M; Mohanty, S; Mukhtar, O; Sherigar, J; Shrestha, B; Tiongson, B | 1 |
| Gandhi, M; Jhaveri, A; Merchant, R; Nagral, A; Nagral, N; Parikh, NS; Sawant, S | 1 |
| Bourliere, M; Brainard, DM; Camus, G; Cooper, CL; Doehle, BP; Dvory-Sobol, H; Flamm, SL; Gordon, SC; Hyland, RH; Kowdley, KV; Manns, MP; Martin, R; Mo, H; Reddy, KR; Roberts, SK; Sarrazin, C; Stamm, LM; Svarovskia, E; Zeuzem, S | 1 |
| Bhandari, B; Chopra, D | 1 |
| De, A; Kumar, P; Kumari, S; Singh, A; Singh, V | 1 |
| Borrego, P; Briz, V; Ezeonwumelu, IJ; Marcelino, R; Marinho, RT; Moranguinho, I; Palladino, C; Serejo, F; Taveira, N; Velosa, JF | 1 |
| Brainard, DM; De-Oertel, S; Doehle, B; Duan, Z; Han, KH; Hedskog, C; Hou, JL; Jia, J; Kersey, K; Lim, YS; Martin, R; Massetto, B; Mizokami, M; Mo, H; Omata, M; Svarovskaia, E; Wei, L; Xie, Q; Yang, J | 1 |
| Cabello, V; Juampérez, J; Julio, E; Mercadal-Hally, M; Quintero, J; Rodrigo, C; Segarra, Ó; Soler-Palacín, P | 1 |
| Abdel-Samiee, M; Abdo, M; Elbaz, T; Esmat, G; Gamil, M; Hassan, EA; Moustafa, A; Omar, H; Qawzae, A; Zaghloul, AM | 1 |
| Campbell, J; Jones, KM; Shelton, ME; Soldano, AC | 1 |
| Abid, S; Abraham, P; Abu Bakar, N; Ahmed, T; Arisar, FAQ; Bwa, AH; Chen, KP; Dan, YY; Dhore, P; Eapen, CE; Goh, KL; Hamid, S; Hj Md Said, RB; Ho, SH; Jafri, W; Kamat, M; Koshy, A; Lee, YM; Lim, SG; Madan, K; Mehta, R; Mohamed, R; Phyo, WW; Piratvisuth, T; Shah, SR; Shukla, A; Tan, SS; Tanwandee, T; Tee, HP; Tyagi, S; Wadhawan, M; Win, KM; Yang, WL; Yin, TP | 1 |
| Bischoff, J; Rockstroh, JK | 1 |
| Brainard, DM; Chen, G; Chen, H; Ding, Y; Li, X; Massetto, B; Niu, J; Shen, G; Zhang, H; Zhu, X | 1 |
| Kassem, H; Kassem, N; Talima, S | 1 |
| Yeon, JE | 1 |
| Jacobson, IM | 1 |
| Abedi-Andani, M; Alavian, SM; Anvar, A; Behnava, B; Karimi-Sari, H; Khosravi, A; Namvar, A | 1 |
| Abd-Elsalam, S; Badawi, R; Elfert, A; Elkhouly, RA; Elnawasany, S; Hawash, N; Kobtan, A; Mansour, L; Selim, A; Soliman, S; Yousef, M | 1 |
| Chang, CH; Chen, DS; Chen, PJ; Hong, CM; Huang, YJ; Hung, CC; Kao, JH; Liu, CH; Liu, CJ; Liu, WC; Su, TH; Sun, HY; Tseng, TC; Yang, HC; Yang, SS | 1 |
| Dhiman, RK; Duseja, A; Grover, GS; Premkumar, M; Rathi, S; Satsangi, S; Taneja, S | 1 |
| Abdullatif, H; Baroudy, S; El-Karaksy, H; El-Koofy, N; El-Raziky, MS; El-Shabrawi, M; Ghita, H; Ghobrial, C; Mogahed, EA; Okasha, S | 1 |
| Molenkamp, R; Newsum, AM; Prins, M; Rebers, SP; Schinkel, J; van der Meer, JT; van der Valk, M | 1 |
| Idrees, M; Khalid, I; Rasool, N; Wahid, B; Waqar, M; Wasim, M | 1 |
| Abdel Aziz, H; Ahmed Mohamed, A; Eysa, B; Fouad, HM; Rabea, M; Sabry, M | 1 |
| Chen, DZ; Chen, KD; Li, LJ; Ou, HL; Su, JW; Wu, XX; Xu, XW; Yao, HP; Yu, HY | 1 |
| Buonanno, P; Camera, S; Caporaso, N; Capuano, I; Donnarumma, L; Ferreri, L; Morisco, F; Sabbatini, M | 1 |
| Abdelsameea, E; Essa, M; Sabry, A; Salama, M; Tharwa, ES | 1 |
| Abd Elfatah, AS; Abdalla, NH; Abdel-Raheim, S; Abdulghany, HM; Khairy, RM; Zenhom, NM | 1 |
| Abdurakhmanov, DT; Chulanov, VP; Moiseev, SV; Nabatchikova, EA; Nikulkina, EN; Rozina, TP | 1 |
| Backus, LI; Belperio, PS; Loomis, TP; Mole, LA; Shahoumian, TA | 2 |
| Chen, EQ; Deng, R; Lv, DD; Tang, H; Tao, YC; Wang, ML; Wang, YH; Yuan, M | 1 |
| Hinds, AE; Pearlman, BL | 1 |
| Agarwal, K; Bruce, M; Carey, I; Spaan, M | 1 |
| Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC | 1 |
| Abdullatif, H; El-Karaksy, H; Ghobrial, C; Mogahed, E; Sobhy, R | 1 |
| Fukaya, Y; Hirosawa, T; Imai, M; Isoda, N; Kurata, H; Miura, K; Morimoto, N; Murayama, K; Murohisa, T; Nomoto, H; Numao, N; Okamura, Y; Ozawa, I; Sato, T; Tahara, T; Takaoka, Y; Tano, S; Tsukui, M; Watanabe, S; Yamamoto, H; Yoshizumi, H | 1 |
| Gragnani, L; Monti, M; Zignego, AL | 1 |
| Eibl, MM; Müller, CJ; Wolf, HM | 1 |
| Ghosh, R; Lahiri, G; Paul, R; Roy, D; Ruia, AV; Sarkar, R; Sau, TJ | 1 |
| Cicchetti, A; De Solda, F; Drago, C; Kondili, LA; Nappi, C; Rolli, FR; Ruggeri, M | 1 |
| Amin, J; Applegate, TL; Bruggmann, P; Bruneau, J; Conway, B; Cooper, C; Cunningham, EB; Dalgard, O; Dillon, JF; Dore, GJ; Dunlop, AJ; Feld, JJ; Fraser, C; Gane, E; Grebely, J; Hajarizadeh, B; Hellard, M; Litwin, AH; Marks, P; Matthews, GV; Norton, B; Powis, J; Quiene, S; Read, P; Shaw, D; Siriragavan, S; Thurnheer, MC; Weltman, M | 1 |
| Brooks-Rooney, C; Chen, CY; Chen, JJ; Cheng, PN; Hsieh, TY; Huang, YH; Kao, JH; Lin, CL; Liu, CH; Lo, CC; Ma, Q; Peng, CY; Su, WW; Yu, ML | 1 |
| Chen, J; Deng, H; Huang, H; Shen, J; Tang, H; Wu, J; Xie, W; Zhou, Q | 1 |
| Bahra, M; Blaeker, H; Dürr, M; Eurich, D; Eurich, F; Globke, B; Maurer, MM; Pratschke, J; Teegen, EM; Vollbort, A | 1 |
| Abdel Gawad, M; Abdel Ghaffar, A; Abdel Ghaffar, TY; El Naghi, S; Helmy, S; Moafy, M; Yousef, M | 1 |
| Chen, B; Chen, EQ; Jiang, W; Tang, H; Tao, YC; Wang, ML; Wang, YH; Wu, DB | 1 |
| Ghesquiere, W; Huhn, GD; Linaberry, M; McPhee, F; Noviello, S; Poordad, F; Ramji, A; Shafran, SD; Shiffman, ML; Wong, A; Wong, F; Yang, R | 1 |
| Ali, Q; Imran, M; Iqbal, K; Jamal, A; Kalam, I; Ullah, S; Waqar, AB | 1 |
| Chen, EQ; Lv, DD; Tang, H; Tao, YC; Wang, ML; Wu, DB; Zhang, DM | 1 |
| Aartun, J; Kottilil, S; Masur, H; Meissner, EG; Orr, C | 1 |
| Avril, E; Bouscaillou, J; Butsashvili, M; Etienne, A; Gamezardashvili, A; Inaridze, I; Kamkamidze, G; Kharshiladze, D; Kikvidze, T; Labartkava, K; Le Pluart, D; Luhmann, N | 1 |
| Cong, X; Feng, B; Jiang, HJ; Jin, Q; Luo, BF; Ma, DL; Wang, XX; Wei, L | 1 |
| De Maria, C; Ghidotti, I; Giannini, EG; Grillo, F | 1 |
| Bou Daher, H; Koussa, S; Marrache, M; Rimmani, HH; Rustom, LBO; Sharara, AI; Taher, A | 1 |
| Khaliq, S; Raza, SM | 1 |
| Angelidakis, G; Blechacz, B; Economides, MP; Granwehr, BP; Hosry, J; Jiang, Y; Kaseb, A; Kyvernitakis, A; Mahale, P; Miller, E; Naing, A; Raad, II; Samaniego, F; Torres, HA | 1 |
| Choe, WH; Kim, AR; Kim, JH; Kwon, SY; Park, SJ; Yoo, BC | 1 |
| Algharably, E; Budde, K; Duerr, M; Glander, P; Halleck, F; Hoffmann, F; Jaeger, C; Kreutz, R; Lisec, J; Schrezenmeier, E; Schrezenmeier, J | 1 |
| Khan, AJ; Mohindra, S; Negi, TS; Parmar, D; Ranjan, P; Saraswat, VA | 1 |
| Adamek, B; Baka-Ćwierz, B; Belica-Wdowik, T; Berak, H; Białkowska-Warzecha, J; Buczyńska, I; Citko, J; Czauż-Andrzejuk, A; Deroń, Z; Dobracki, W; Dybowska, D; Flisiak, R; Garlicki, A; Gietka, A; Halota, W; Horban, A; Janczewska, E; Jaroszewicz, J; Laurans, Ł; Lorenc, B; Mazur, W; Piekarska, A; Simon, K; Sitko, M; Socha, Ł; Tomasiewicz, K; Tronina, O; Tudrujek-Zdunek, M; Wawrzynowicz-Syczewska, M; Zarębska-Michaluk, D | 1 |
| Castellano Tortajada, G; Fernández Vázquez, I; Gómez Domínguez, E; Ibarrola de Andrés, C; López Couceiro, L; Muñoz Gómez, R | 1 |
| Borba, HHL; Ferreira, VL; Pontarolo, R; Siqueira, FM | 1 |
| Choi, HY; Chung, W; Jang, ES; Jeong, SH; Ki, M; Kim, KA | 1 |
| Cenderello, G; Di Biagio, A; Taramasso, L | 1 |
| Do, A; Do, S; Levitt, B; Nguyen, E; Nguyen, H; Nguyen, K; Nguyen, M; Nguyen, MH; Purohit, T; Shieh, E; Trinh, H; Trinh, S | 1 |
| Back, DJ; Burger, DM; Colbers, A; de Knegt, RJ; Drenth, JPH; El-Sherif, O; Honkoop, P; Smolders, EJ; van Seyen, M; van Wijngaarden, P; Wouthuyzen-Bakker, M | 1 |
| Chin, B; Khattak, MA; Menon, LL | 1 |
| Fattehi, MR; Ghorbani, M; Hojati, SA; Maserat, E; Safarpour, A | 1 |
| Arends, JE; Boerekamps, A; Dofferhoff, ASM; Florence, E; Koopsen, J; Posthouwer, D; Ramsoekh, D; Rijnders, BJ; Schinkel, J; van den Berk, GE; van der Valk, M; van Hoek, B; van Kasteren, M; Vanwolleghem, T | 1 |
| Aguilar, H; Asatryan, A; Asselah, T; Baumgarten, A; Conway, B; Dore, GJ; Foster, GR; Grebely, J; Gschwantler, M; Hu, Y; Jackson, D; Mensa, FJ; Sherman, KE; Tomasiewicz, K; Wang, S | 1 |
| Chen, X; Deng, H; Hu, C; Huang, H; Li, W; Li, Y; Liu, J; Peng, Y; Ren, Y; Wu, T; Yuan, G; Zhang, YY; Zhou, Y | 1 |
| Chuang, WL; Crawford, DHG; Dokmeci, AK; Hamid, SS; Ibrahim, A; Jindal, A; Kanda, T; Kao, JH; Kumar, M; Lau, GKK; Lesmana, CRA; McCaughan, GW; Moriyama, M; Omata, M; Sarin, SK; Sharma, BC; Sollano, J; Wasim, J; Wei, L; Yokosuka, O; Yu, ML | 1 |
| Cho, HA; Cho, JY; Cho, SB; Choi, SK; Jun, CH; Kim, MW; Lim, SW; Seo, JH; Yoon, JH | 1 |
| Abdelaziz, A; Abdelmoniem, R; Doss, W; El-Serafy, M; Elakel, W; Esmat, G; Gamal Eldeen, H; Kaddah, M; Medhat, E; Mehrez, M; Yosry, A; Zayed, N | 1 |
| Aboufarrag, GA; Lashen, SA; Madkour, MA; Shamseya, MM | 1 |
| Sonderup, MW; Spearman, CW | 1 |
| Camus, G; Damascene, MJ; Grant, PM; Gupta, N; Kabahizi, J; Kateera, F; Mbituyumuremyi, A; Mukabatsinda, C; Mukherjee, J; Musabeyezu, E; Muvunyi, CM; Nsanzimana, S; Ntaganda, F; Ntirenganya, C; Shumbusho, F; Van Nuil, JI | 1 |
| Brainard, DM; Cheng, J; Dao, L; Dou, X; Duan, Z; Dvory-Sobol, H; Gao, Y; Gao, ZL; Gong, G; Hou, JL; Hu, P; Huang, Y; Jia, J; Le Manh, H; Le, TTP; Li, J; Lim, SG; Lin, F; Lu, S; Mao, Y; Mo, H; Mohamed, R; Mou, Z; Nan, Y; Ning, Q; Piratvisuth, T; Shang, J; Sobhonslidsuk, A; Stamm, LM; Su, M; Tan, CK; Tang, H; Tangkijvanich, P; Tanwandee, T; Tee, HP; Thongsawat, S; Văn, KN; Wang, GQ; Wei, L; Wu, S; Xie, Q; Xu, M; Yang, YF; Zhang, L | 1 |
| Muljono, DH | 1 |
| Abd-Elsalam, S; Ahmed, OA; Badawi, R; Elkadeem, M; Elsebaey, MA; Fouad, MHA; Khayyal, A; Negm, MS; Soliman, S | 1 |
| Begovac, J; Bogdanić, N; Krznarić, J; Močibob, L; Zekan, Š | 1 |
| Chen, DS; Chen, PJ; Hong, CM; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC | 2 |
| Alfieri, CM; Campise, MR; D'Ambrosio, R; Fabrizi, F; Gandolfo, MT; Gendia, M; Lampertico, P; Messa, P | 1 |
| Ballestrero, A; Brunacci, M; Crespi, M; Demarzo, MG; Ferrando, F; Giannini, EG; Grillo, F; Pellegatta, G; Savarino, V | 1 |
| Abou El-Khier, NT; Abousamra, NK; Arafa, MM; Eladl, E; Elhammady, D; Esmael, ME; Shahin, D; Shaker, G; Sharaf-Eldeen, O | 1 |
| Gani, RA; Hasan, I; Jasirwan, COM; Kalista, KF; Kurniawan, J; Lesmana, CRA; Nababan, SHH; Sulaiman, AS; Zulkifly, S | 1 |
| Elgouhary, SM; Mowafy, MA; Said-Ahmed, KE | 1 |
| Abushouk, AI; Al-Husseini, M; El-Raey, F; Johar, D; Mohammed, EG; Montasser, MF; Salaheldin, M; Zaky, S | 1 |
| Brainard, DM; Dvory-Sobol, H; Gane, EJ; Hyland, RH; Nyberg, L; Ruane, P; Shafran, S; Shao, J; Stamm, LM; Strasser, SI; Tran, T | 1 |
| Laique, SN; Vargas, HE | 1 |
| Attia, D; El Shabrawi, M; El-Khayat, H; Fouad, Y; Gawad, MA; Haseeb, A; Kamal, EM; Kamal, N; Sameh, Y; Yakoot, M | 1 |
| Alberti, A; Angeli, E; Angelico, M; Badia, L; Belli, L; Biolato, M; Borghi, V; Calvaruso, V; Carrai, P; Craxì, A; D'Offizi, G; Fagiuoli, S; Felder, M; Grieco, A; Guaraldi, G; Lionetti, R; Mancusi, RL; Mazzarelli, C; Milazzo, L; Montalbano, M; Pasulo, L; Persico, M; Piai, G; Puoti, M; Santantonio, T; Verucchi, G; Villa, E | 1 |
| Dohi, T; Jain, A; Kadry, Z; Krok, KL; Miller, D; Riley, TR; Schreibman, I; Sharma, R | 1 |
| Barker, L; Jiles, RB; White, JZ; Yin, S | 1 |
| Ismail, WA; Yousef, AE | 1 |
| El-Hamamsy, M; El-Meteini, M; Mansy, AE; Montasser, IF; Nabet, DE | 1 |
| Althoff, CE; Bergfeld, L; Brakemeier, S; Budde, K; Duerr, M; Eckardt, KU; Glander, P; Halleck, F; Lehner, LJ; Marticorena Garcia, SR; Sack, I; Schrezenmeier, EV | 1 |
| Akarca, US; Akdogan, M; Akhan, S; Aladag, M; Ataseven, H; Cakaloglu, Y; Cavus, B; Demir, M; Erol, C; Ersoz, G; Gunduz, F; Gunsar, F; Idilman, R; Iliaz, R; Karasu, Z; Kaymakoglu, S; Kiyici, M; Koklu, H; Koksal, AS; Koksal, İ; Ozgenel, M; Sahin, M; Tabak, F; Turan, İ | 1 |
| Basha, MAA; Bassiony, MA; Hanafy, AS | 1 |
| Brandão, ABM; Cantisani, GPC; Costabeber, AM; Fleck Junior, AM; Kiss, G; Leipnitz, I; Marroni, CA; Martini, J; Meine, MH; Mucenic, M; Rossato, G; Sacco, FKR; Schlindwein, ES; Zanotelli, ML | 1 |
| Amrose, P; Bhatia, S; Brainard, DM; Camus, G; Chowdhury, A; Duseja, A; Goswami, B; Hyland, RH; Kabrawala, M; Kapoor, D; Koshy, A; Lu, S; Prasad, M; Saraswat, V; Sarin, SK; Shah, SR; Sood, A; Stamm, LM; Subramanian, GM | 1 |
| Abunimeh, M; Bennett, M; Cohen, DE; Cohen, E; Everson, G; Phillips, RW; Pilot-Matias, T; Poordad, F; Reindollar, RW; Sepe, TE; Siddique, A; Sullivan, JG; Younes, Z | 1 |
| Farias, MR; Foppa, AA; Gomes, LO; Rosa, JAD; Rover, MRM; Teixeira, MR | 1 |
| Chen, J; Fang, Z; Li, M; Li, Y; Lin, Q | 1 |
| Cho, M; Han, SY; Heo, J; Kim, DU; Kim, GH; Kim, HH; Park, SG; Park, YJ; Pyeon, SI; Song, GA; Woo, HY | 1 |
| Apple, DB; Burke, MT; Hu, JK; Lin, X; Padidam, S | 1 |
| Abergel, A; Alric, L; Bourliere, M; Bronowicki, JP; Cales, P; Carrat, F; Causse, X; Chazouilleres, O; Diallo, A; Dorival, C; Fontaine, H; Ganne-Carrie, N; Geist, C; Guyader, D; Haour, G; Hezode, C; Larrey, D; Laurain, A; Loustaud-Ratti, V; Luzivika-Nzinga, C; Marcellin, P; Mathurin, P; Metivier, S; Petrov-Sanchez, V; Pol, S; Riachi, G; Samuel, D; Thabut, D; Tran, A; Zarski, JP; Zoulim, F | 1 |
| Atanasov, PK; Buggisch, P; Lee, J; Petersen, J; Stoehr, A; Supiot, R; Ting, J; Wursthorn, K | 1 |
| Aldir, I; Bana E Costa, T; Carvalho, A; Chagas, C; Correia, JM; Falcão, F; Farinha, H; Lebre, L; Lopes, C; Mansinho, K; Marques, S; Miranda, AC; Mirco, A; Peixe, P; Perez, R; Viegas, E | 1 |
| Herring, R; Jacobson, I; Lawitz, E; Muir, AJ; Pol, S; Racila, A; Stepanova, M; Younes, Z; Younossi, I; Younossi, ZM; Zeuzem, S | 1 |
| Afify, S; Alboraie, M; Algaber, MA; Doss, W; El Halwagy, H; El Kassas, M; El Latif, YA; El Tahan, A; Elsaeed, K; Elserafy, M; Omar, H | 1 |
| Birerdinc, A; Curry, MP; de Avila, L; Escheik, C; Estep, JM; Gerber, L; Golabi, P; Stepanova, M; Weinstein, AA; Younossi, ZM | 1 |
| Babudieri, S; Barbarini, G; Candilo, FD; Cariti, G; Dell'Isola, S; Distefano, M; Ettorre, GM; Fontanella, L; Giannelli, V; Iovinella, V; Ippolito, AM; Izzi, A; Marignani, M; Messina, V; Moretti, A; Palitti, VP; Pellicelli, A; Pompili, M; Scifo, G; Tarquini, P; Vennarecci, G; Vignally, P | 1 |
| Kolonko, A; Kwiecień, K; Musialik, J; Owczarek, AJ; Więcek, A | 1 |
| Ansari, MA; Aranday-Cortes, E; Barnes, E; Bibby, DF; Bradshaw, D; da Silva Filipe, A; Gifford, RJ; Hughes, J; Manso, CF; Mbisa, JL; McLauchlan, J; Robertson, DL; Singer, JB; Smith, D; Thomson, EC; Tong, L | 1 |
| Cascio, A; Cervo, A; Colomba, C; Di Carlo, P; Firenze, A; Saporito, L; Tolomeo, M; Trizzino, M | 1 |
| Backus, LI; Belperio, PS; Loomis, TP; Shahoumian, TA | 1 |
| Pawlotsky, JM | 1 |
| El-Kosasy, AM; Hussein, LA; Magdy, N; Youssef, AA | 1 |
| Choi, JW; Ko, SY; Seo, HY; Seo, MS; Yoon, SY | 1 |
| Ansari, A; Aranday-Cortes, E; Bamford, C; Barnes, E; Cheung, M; Cunningham, M; Da Silva Filipe, A; DaSilva, S; Foster, GR; Irving, W; Jason Lee, WY; Jones, M; McLauchlan, J; Smith, D; Wing, PAC | 1 |
| Alexander, K; Anderson, PL; Blum, J; Brooks, KM; Bushman, LR; Castillo-Mancilla, JR; Ellison, L; Huntley, R; Kerr, BJ; Kiser, JJ; MacBrayne, CE; MaWhinney, S | 1 |
| Hinds, A; Pearlman, B; Perrys, M | 1 |
| Buggisch, P; Klinker, H; Lonjon-Domanec, I; Mauss, S; Müller, T; Nalpas, C; Pathil-Warth, A; Sarrazin, C; Schlag, M; Simon, KG; Wegner, S; Zimmermann, T | 1 |
| Choi, DH; Han, KM; Hwang, SB; Lim, YS; Luong, TTD; Mai, HN; Nguyen, HC; Nguyen, LP; Park, C; Park, EM | 1 |
| Amador, J; Di Bisceglie, AM; Evon, DM; Fried, MW; Golin, CE; Lim, JK; Lok, AS; Nelson, DR; Rajender Reddy, K; Reau, N; Reeve, BB; Sarkar, S; Serper, M; Sterling, RK; Stewart, PW | 1 |
| Collado, A; Corma-Gómez, A; De Los Santos Gil, I; Granados, R; Macías, J; Merino Muñoz, D; Morano, LE; Palacios, R; Pineda, JA; Téllez, F; Vera-Méndez, FJ | 1 |
| Chen, JH; Dong, B; Jiang, JD; Li, H; Li, JR; Liu, NN; Lv, XQ; Peng, ZG; Tan, JL; Zou, LL | 1 |
| Bwa, AH; Hlaing, NKT; Kyaw, AMM; Lin, S; Loza, BL; Maung, MZ; Maung, ST; Myint, KT; Nangia, G; Reddy, KR; Sein Win, S; Tun, KT; Win, KM | 1 |
| Bermúdez, C; Cheinquer, H; Coelho Borges, S; de Araujo, A; de Maman, Í; Fleck, A; Gadano, A; Garrastazul, P; Haddad, L; Kliemann, D; Marciano, S; Mendizabal, M; Nader, LA; Piñero, F; Ridruejo, E; Silva, M; Wolff, FH | 1 |
| Allam, AS; Hussein, HA; Moaty, ASA | 1 |
| Angelico, M; Antonucci, F; Armenia, D; Bellocchi, MC; Carioti, L; Ceccherini-Silberstein, F; Cento, V; Ciancio Manuelli, M; De Leonardis, F; Lenci, I; Manzia, TM; Milana, M; Perno, CF; Sforza, D; Sorbo, MC; Tisone, G | 1 |
| Agarwal, K; Gane, E; Janssen, HLA; Nader, F; Nguyen, MH; Papatheodoridis, G; Stepanova, M; Tsai, N; Younossi, I; Younossi, ZM | 1 |
| Abdelrazik, M; Aboushady, M; Alwassief, A; Elbahrawy, A; Elmestikawy, A; Shahba, H; Ziada, D | 1 |
| Chua, J; Comstock, E; Covert, E; Emmanuel, B; Hoffmann, J; Husson, J; Kattakuzhy, S; Kottilil, S; Masur, H; Mathur, P; Price, A; Rosenthal, E; Tang, L; Wilson, E | 1 |
| AbdElgawad, MM; Abdo, AM; El-Khayat, HR; El-Shabrawi, MH; Helmy, S; Kamal, EM; Kamal, NM; Khalil, AF; Mahfouz, AA; Yakoot, M | 1 |
| Agarwal, K; Ampuero, J; Ben-Ari, Z; Borgia, SM; Brown, A; Bruck, R; Calleja, JL; Cooper, C; Cramp, ME; Dearden, J; Dvory-Sobol, H; Esteban, R; Fox, R; Foxton, M; Gane, EJ; Haider, S; Hyland, R; Kirby, BJ; Lu, S; Lurie, Y; Markova, S; Meng, A; Osinusi, AO; Rodriguez, CF; Ryder, SD; Shafran, SD; Shaw, D; Willems, B; Yoshida, EM | 1 |
| Cooke, G; Fawsitt, CG; Vickerman, P; Welton, NJ | 1 |
| Antonio Carrión, J; Arenas, J; Arencibia, A; Badia, E; Bernal, V; Buti, M; Cachero, A; Carmona, I; Conde, I; Delgado, M; Diago, M; Esteban, R; Fernández, I; Fernández-Bermejo, M; Fernández-Rodríguez, C; Figueruela, B; García-Samaniego, J; Gea, F; González-Santiago, JM; Hernández-Guerra, M; Iñarrairaegui, M; Lens, S; Llaneras, J; Llerena, S; Luis Calleja, J; María Morillas, R; Mariño, Z; Montoliu, S; Pascasio, JM; Riveiro-Barciela, M; Rosales, JM; Torras, X; Turnes, J | 1 |
| Asselah, T; Bourgeois, S; Brainard, DM; Davis, MN; Huang, KC; Lai, CL; Mathurin, P; McNally, J; Nguyen, MH; Osinusi, A; Shafran, SD; Shaikh, OS; Svarovskaia, E; Tran, TT; Willems, B | 1 |
| Cong, X; Feng, B; Jiang, HJ; Jin, Q; Kong, XS; Luo, BF; Qin, H; Wang, XX; Wei, L; Zhang, HY | 1 |
| Amiot, X; Arotcarena, R; Cadranel, JF; Causse, X; Garioud, A; Halfon, P; Heng, R; Lucidarme, D; Medmoun, M; Mokhtari, C; Ollivier-Hourmand, I; Pariente, A; Pulwermacher, P; Rémy, AJ; Renou, C; Rosa-Hézode, I; Zanditenas, D; Zougmoré, H | 1 |
| Balistreri, WF; Bansal, S; Brainard, DM; Hague, R; Hardikar, W; Honegger, JR; Hsueh, CH; Massetto, B; Mittal, N; Murray, KF; Narkewicz, MR; Parhy, B; Rao, GS; Rosenthal, P; Schwarz, KB; Shao, J; Whitworth, S | 1 |
| Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Higashi, N; Igarashi, A; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K | 1 |
| Balistreri, WF; Bansal, S; Brainard, DM; Davison, S; Feiterna-Sperling, C; Gillis, LA; Gonzalez-Peralta, RP; Hsueh, CH; Indolfi, G; Jonas, MM; Kelly, DA; Lin, CH; Massetto, B; Murray, KF; Nightingale, S; Parhy, B; Rosenthal, P; Schwarz, KB; Shao, J; Sokal, EM; Wirth, S | 1 |
| Chen, T; Chen, Y; Dong, J; Fu, S; He, Y; Hu, C; Li, J; Liu, J; Tian, Z; Wang, J; Yan, T; Yang, Y; Zhang, R; Zhao, F; Zhao, Y | 1 |
| Wahid, B | 1 |
| Abdullatif, HM; El Rasheed Abd El Zaher, BA; El Raziky, MS; El-Karaksy, HM; Ghobrial, CM; Mogahed, EA; Ramzi, R | 1 |
| Anan, A; Inomata, S; Irie, M; Kunimoto, H; Morihara, D; Sakisaka, S; Shakado, S; Sohda, T; Takata, K; Takeyama, Y; Tanaka, T; Yamauchi, E; Yamauchi, R; Yokoyama, K | 1 |
| Aleem, A; Khan, AA; Sarwar, S; Tarique, S | 1 |
| Amory, C; Gardenier, D; Weiss, JJ; Woody, A | 1 |
| Abdel Aziz, H; Ahmed, A; Al Soda, MF; Fouad, HM; Hassany, M; Sabry, MA | 1 |
| Bagchi, S; Kottilil, S; Nelson, A; Poonia, B; Romani, S; Stafford, K | 1 |
| Arora, S; Dhiman, RK; Duseja, A; Grover, GS; Premkumar, M; Rathi, S; Roy, A; Satsangi, S; Taneja, S | 1 |
| A, M; Abd-Elsamie, E; Badawy, ER; ElMelegy, TT; Hassaballa, AE; Kamal-ElDin, TM; Mekky, MA; Zahran, AM | 1 |
| Bartolini, E; Cangelosi, AM; D'Antiga, L; Dodi, I; Indolfi, G; Mastrangelo, G; Nicastro, E; Resti, M; Ricci, S; Riva, S; Serranti, D; Trapani, S; Vajro, P | 1 |
| Chu, CJ; Hou, MC; Huang, YH; Lee, FY; Lee, SD; Lin, CC; Su, CW; Wang, YJ; Wu, SH | 1 |
| Gao, XH; Jing, P | 1 |
| Gaballah, AH; Ghazy, AA; Mostafa, H; Osman, EM; Rashwan, EA; Tawfik, S | 1 |
| Afendy, A; Gaggar, A; Jacobson, IM; Lalezari, J; Lawitz, EJ; Muir, AJ; Myers, RP; Nader, F; Racila, A; Reddy, KR; Ruane, PJ; Schwabe, C; Stepanova, M; Younossi, I; Younossi, ZM | 1 |
| Adeline, NJF; Geue, C; Hermami, MR | 1 |
| Herbst, DA; Reddy, KR | 1 |
| Cornberg, M; Manns, MP | 1 |
| Abrams, GA; Afdhal, NH; Albanis, E; Bernstein, DE; Berrey, MM; Bzowej, NH; Darling, JM; Dejesus, E; Dieterich, DT; Freilich, B; Hassanein, T; Hindes, R; Hyland, RH; Jacobson, IM; Jensen, D; Kowdley, KV; Lalezari, JP; Lawitz, E; Lin, M; Mader, M; Mo, H; Muir, A; Nelson, DR; Poordad, FF; Reddy, KR; Rodriguez-Torres, M; Sheikh, AM; Sulkowski, MS; Symonds, WT | 1 |
| Burney, T; Dusheiko, G | 1 |
| Afdhal, N; Albanis, E; An, D; Anderson, JK; Bernstein, DE; Berrey, MM; Crespo, I; Davis, MN; DeMicco, M; Dvory-Sobol, H; Gordon, SC; Hassanein, T; Hindes, RG; Hyland, RH; Jacobson, IM; Kowdley, KV; Lawitz, E; Nelson, DR; Symonds, WT; Vierling, JM | 1 |
| Appelman, H; Bifano, M; Dimitrova, D; Fontana, RJ; Hindes, R; Hughes, EA; Symonds, WT | 1 |
| Drenth, JP | 2 |
| Arterburn, S; Brainard, D; Davis, MN; Gane, EJ; Gordon, SC; Hassanein, T; Hyland, RH; Jacobson, IM; Jiang, D; Kayali, Z; Kowdley, KV; Lawitz, E; Mangia, A; McHutchison, JG; McNally, J; Nyberg, L; Reddy, KR; Rodriguez-Torres, M; Schultz, M; Sheikh, AM; Subramanian, GM; Symonds, WT; Wyles, D; Younossi, Z | 1 |
| Al-Assi, MT; An, D; Bennett, M; Brainard, D; Everson, G; Feld, J; Gordon, SC; Jacobson, IM; Kowdley, KV; Lawitz, E; Lin, M; McHutchison, JG; McNally, J; Nelson, DR; Patel, K; Pianko, S; Rodriguez-Torres, M; Schiff, E; Shiffman, ML; Subramanian, GM; Sulkowski, MS; Symonds, WT; Yoshida, EM | 1 |
| Wang, FS; Wang, LF; Zeng, QL; Zhang, JY; Zhang, Z | 1 |
| Borgia, F; Borgia, G; Buonomo, AR; Castaldo, G; Gentile, I; Spera, AM; Zappulo, E | 1 |
| Baronas, V; Haines, K; Klumpp, K; Le Pogam, S; Li, L; Nájera, I; Piso, K; So, SS; Tong, X; Yan, JM | 1 |
| Ding, X; Hyland, RH; Lawitz, E; McHutchison, JG; Membreno, FE; Mo, H; Pang, PS; Poordad, FF; Symonds, WT | 1 |
| Doyle, JS; Hellard, ME | 1 |
| Rodríguez-Torres, M | 1 |
| Gane, E; Gerber, L; Henry, L; Hunt, S; Jacobson, IM; Lawitz, E; Nader, F; Nelson, D; Stepanova, M; Younossi, ZM | 1 |
| Gane, E; Henry, L; Hunt, S; Jacobson, IM; Lawitz, E; Nader, F; Nelson, D; Stepanova, M; Younossi, ZM | 1 |
| Bon, D; Herrmann, E; Kottilil, S; Masur, H; Meissner, EG; O'Brien, TR; Osinusi, A; Prokunina-Olsson, L; Tang, W | 1 |
| Benhamou, Y; Shiffman, ML | 1 |
| Traynor, K | 2 |
| Koff, RS | 1 |
| Eley, T; Everson, GT; Gao, M; Gardiner, DF; Grasela, DM; Hassanein, T; Hernandez, D; Hindes, R; Hinestrosa, F; Huang, SP; Jacobson, I; Lawitz, E; Lok, AS; McPhee, F; Nelson, DR; Pasquinelli, C; Reddy, KR; Rodriguez-Torres, M; Schwartz, H; Sherman, D; Sulkowski, MS; Symonds, W; Thuluvath, PJ; Wind-Rotolo, M | 1 |
| Keating, GM; Vaidya, A | 1 |
| Evon, DM | 1 |
| Dugum, M; O'Shea, R | 1 |
| Asch, DA; Mehta, SJ | 1 |
| Shiffman, ML | 1 |
| Chung, RT; deLemos, AS | 1 |
| Hagan, LM; Schinazi, RF; Sulkowski, MS | 1 |
| Bruno, R; Cabibbo, G; Cammà, C; Craxì, A; Enea, M; Gasbarrini, A; Macaluso, FS; Petta, S; Plaia, A | 1 |
| Dusheiko, G; Esteban, R; Hezode, C; Hunt, SL; Nader, F; Reesink, HW; Stepanova, M; Weiland, O; Younossi, ZM; Zeuzem, S | 1 |
| An, D; Bernstein, DE; Chojkier, M; Di Bisceglie, AM; Fried, MW; Ghalib, R; Gordon, SC; Herring, R; Hyland, RH; Kowdley, KV; Lawitz, E; McHutchison, JG; Muir, AJ; Pang, PS; Pockros, PJ; Pound, D; Reddy, KR; Rossaro, L; Rustgi, V; Ryan, M; Schiff, E; Shiffman, ML; Subramanian, GM; Svarovskaia, E; Symonds, WT | 1 |
| Arends, JE; Burger, DM; de Kanter, CT; de Knegt, RJ; Drenth, JP; Reesink, HW; van der Valk, M | 1 |
| Hoofnagle, JH; Sherker, AH | 1 |
| Afdhal, N; Arora, S; Di Bisceglie, AM; Dvory-Sobol, H; Ghalib, R; Gitlin, N; Gordon, SC; Herring, R; Kwo, P; Lalezari, J; Lawitz, E; McHutchison, JG; Muir, AJ; Nahass, R; Nelson, DR; Pang, PS; Pockros, PJ; Reddy, KR; Schiff, E; Subramanian, GM; Sulkowski, M; Symonds, WT; Yang, JC; Younes, ZH; Zhu, Y | 1 |
| Afdhal, N; Agarwal, K; Bräu, N; Buggisch, P; Buti, M; Chojkier, M; Ding, X; Foster, GR; Gitlin, N; Jacobson, IM; Kwo, P; Mangia, A; Marcellin, P; McHutchison, JG; Mo, H; Muir, AJ; Pang, PS; Puoti, M; Romero-Gomez, M; Subramanian, GM; Symonds, WT; Yang, JC; Zarski, JP; Zeuzem, S | 1 |
| Muir, AJ | 1 |
| Agarwal, K; Austin, A; Barclay, ST; Brown, A; Dillon, JF; Dundas, P; Dusheiko, GM; Foster, GR; Fox, R; Hayes, PC; Leen, C; Miller, MH; Millson, C; Ryder, SD; Tait, J; Ustianowski, A | 1 |
| Grewal, P; Kim, B; Thung, SN; Trivedi, A | 1 |
| Sofia, MJ | 2 |
| Brainard, DM; Dusheiko, GM; Esteban, R; Ferenci, P; Flisiak, R; Hézode, C; Hyland, RH; Illeperuma, A; Mangia, A; McHutchison, JG; Reesink, HW; Salupere, R; Subramanian, GM; Svarovskaia, E; Symonds, WT; Weiland, O; Zeuzem, S | 1 |
| Redberg, RF; Steinbrook, R | 1 |
| Ollendorf, DA; Pearson, SD; Tice, JA | 1 |
| Linas, BP; Pho, MT | 1 |
| Borgia, G; Buonomo, AR; Coppola, N; Gentile, I; Zappulo, E | 1 |
| Chan, J | 1 |
| Alexander, P; James, A; Long, AG; Shiffman, ML | 1 |
| Einecke, D | 3 |
| Fadda, V; Maratea, D; Messori, A; Trippoli, S | 1 |
| Keating, GM | 3 |
| Bon, D; Fauci, AS; Herrmann, E; Hewitt, S; Kottilil, S; Masur, H; McHutchison, J; Meissner, EG; Osinusi, A; Polis, M; Porcella, S; Prokunina-Olsson, L; Sturdevant, D; Suffredini, AF; Virtaneva, K; Wang, H; Wu, D | 1 |
| Rizza, SA; Talwani, R; Temesgen, Z | 1 |
| Andreoli, A; Angelico, M; D'Offizi, G; Durand, C; Ferenci, P; Knop, V; Lenci, I; Lionetti, R; Montalbano, M; Pellicelli, AM; Telese, A; Zeuzem, S | 1 |
| Demko, P; Dickson, V | 1 |
| Goozner, M | 1 |
| Chang, H; Han, Q; Li, N; Liu, X; Liu, Z; Lv, Y; Wang, Y; Zhang, G; Zhu, Q | 1 |
| Brennan, T; Shrank, W | 1 |
| Bourhis, F; Cure, S; Hunt, S; Nader, F; Stepanova, M; Younossi, ZM | 1 |
| Andreone, P; Bernardi, M; Foschi, FG; Loggi, E; Margotti, M; Morelli, MC; Pinna, AD; Vukotic, R | 1 |
| Ahmed, A; Gordon, SC; Park, H; Saab, S; Sulkowski, M; Younossi, Z | 1 |
| Beumont, M; Callewaert, K; Corregidor, A; DeJesus, E; Fevery, B; Ghalib, R; Gitlin, N; Jacobson, IM; Lambrecht, T; Lawitz, E; Lim, JK; Lindsay, KL; Ouwerkerk-Mahadevan, S; Pearlman, B; Picchio, G; Pockros, PJ; Rabinovitz, M; Rodriguez-Torres, M; Scott, JD; Sulkowski, MS; Symonds, WT; Younossi, ZM | 1 |
| Delaney, W; Dvory-Sobol, H; Lawitz, EJ; Mabery, E; McHutchison, J; Miller, MD; Mo, H; Skurnac, T; Svarovskaia, ES; Voitenleitner, C | 1 |
| Aghemo, A; De Francesco, R | 1 |
| Brainard, D; Dvory-Sobol, H; Gao, B; Garrison, KL; Genda, T; Hino, K; Ide, T; Ikeda, F; Ishizaki, A; Izumi, N; Knox, S; McHutchison, JG; Mizokami, M; Mochizuki, H; Nakane, K; Nirei, K; Nishigaki, Y; Nishiguchi, S; Omata, M; Omote, M; Sakamoto, N; Symonds, WT; Takehara, T; Toda, N; Toyoda, H; Ueno, Y; Umemura, T; Yanase, M; Yatsuhashi, H; Yokosuka, O | 1 |
| Kottilil, S; Lee, YJ; Masur, H; McHutchison, J; Meissner, EG; Naggie, S; Osinusi, A; Patel, K; Qin, J; Remaley, AT; Sampson, M; Sims, Z; Sturdevant, D; Subramanian, M | 1 |
| Blachier, M; Leleu, H; Rosa, I | 1 |
| Campos-Varela, I; Peters, MG; Terrault, NA | 1 |
| Buclin, T; Chtioui, H; Moradpour, D | 1 |
| De Silva, S; Foster, GR | 1 |
| Blázquez, A; Gimeno-Ballester, V; Mar, J; San Miguel, R | 1 |
| Dillon, JF; Miller, MH; Paterson, JC | 1 |
| Beavers, KL; Brainard, DM; Chuang, SM; Ding, X; Gane, EJ; Herring, RW; Jacobson, IM; Lawitz, E; Ma, J; McHutchison, JG; McNally, J; Ratziu, V; Reddy, KR; Stamm, LM; Sulkowski, MS; Symonds, WT; Wang, J; Yoshida, EM | 1 |
| An, D; Brainard, DM; Dvory-Sobol, H; Hyland, RH; Lawitz, E; McHutchison, JG; Membreno, FE; Poordad, F; Symonds, WT | 1 |
| Goldhaber-Fiebert, JD; Holodniy, M; Liu, S; Watcha, D | 1 |
| Rojas, Á; Romero-Gómez, M | 1 |
| Fauci, AS; Kohli, A; Kottilil, S; Marti, MM; Masur, H; McHutchison, JG; Meissner, EG; Nelson, A; Osinusi, A; Pang, PS; Silk, R; Subramanian, GM; Townsend, K; Zhang, X | 1 |
| Baak, LC; Bakker, CM; Berden, FA; Beuers, U; Boucher, CA; Brouwer, JT; Burger, DM; de Knegt, RJ; Drenth, JP; Hoepelman, AI; Honkoop, P; Kerbert-Dreteler, MJ; Kievit, W; Koek, GH; Tan, AC; van Erpecum, KJ; van Hoek, B; van Nieuwkerk, CM; van Soest, H; Vrolijk, JM | 1 |
| Cornberg, M; Höner zu Siederdissen, C | 1 |
| Brochot, E; Capron, D; Castelain, S; Duverlie, G; François, C; Helle, F; Nguyen-Khac, E | 1 |
| Feray, C; Hézode, C; Pawlotsky, JM; Ruiz, I | 1 |
| Amin, R; Koroglu, A; McGuey, L; McNutt, LA; Miller, C; Nasiri, M; Patel, N; Roman, M | 1 |
| Jacobson, IM; Kumar, S | 1 |
| Birnkrant, D; Connelly, S; Donaldson, E; Florian, J; Mishra, P; Murray, J; Naeger, LK; O'Rear, J; Price, D; Qi, K; Zeng, W | 1 |
| Ghany, MG; Liang, TJ | 1 |
| Ain, D; Doehle, B; Jiang, D; Kersey, K; Kirby, BJ; Knox, SJ; Massetto, B; McHutchison, JG; Meshrekey, R; Mikhail, S; Riad, J; Ruane, PJ; Soliman, M; Stryker, R; Symonds, WT; Wolfe, PR | 1 |
| Henry, L; Younossi, Z | 2 |
| Alberti, A; Piovesan, S | 1 |
| Mangia, A; Piazzolla, V | 1 |
| Chan, J; Mohammad, RA; Smith, MA | 1 |
| Bodeau, S; Brochot, E; Duverlie, G | 1 |
| Jensen, DM; Welch, NM | 1 |
| Ansaldi, C; Benali, S; Bourlière, M; Le Folgoc, G; Lecomte, L; Riso, A | 1 |
| Abdel-Razek, W; Waked, I | 1 |
| Nelson, DR; Peter, J | 2 |
| Cornberg, J; Cornberg, M; Deterding, K; Höner Zu Siederdissen, C; Kirschner, J; Maasoumy, B; Manns, MP; Mix, C; Port, K; Sollik, L; Wedemeyer, H | 1 |
| Baumert, TF; Brainard, D; Brandt-Sarif, T; Castells, L; Chang, P; Charlton, M; Coilly, A; Denning, J; Fontana, RJ; Forns, X; Habersetzer, F; Kivett, V; Londoño, MC; McHutchison, JG; Prieto, M; Symonds, WT | 1 |
| Ehleben, C; Pearlman, BL; Perrys, M | 1 |
| Terpening, CM | 1 |
| Hunt, DP | 1 |
| Hunt, SL; Naggie, S; Orkin, C; Puoti, M; Stepanova, M; Sulkowski, M; Younossi, ZM | 1 |
| Foster, GR | 1 |
| Abbott, S; Barrett, LL; Bon, D; Chavez, J; Diaz, G; Egerson, D; Fauci, AS; Gross, C; Herrmann, E; Jolley, TA; Kapoor, R; Kleiner, DE; Kohli, A; Kotb, C; Kottilil, S; Kwan, R; Marti, MM; Masur, H; McHutchison, J; Meissner, EG; Nelson, A; Osinusi, A; Pang, PS; Petersen, T; Polis, MA; Proschan, M; Sidharthan, S; Silk, R; Sims, Z; Sneller, M; Spurlin, E; Subramanian, GM; Symonds, WT; Talwani, R; Teferi, G; Townsend, K; Wood, BJ | 1 |
| Childs-Kean, LM; Hand, EO | 1 |
| Haley, SJ; Kreek, MJ | 1 |
| Ahmed, A; Dieterich, D; Gordon, SC; Park, H; Saab, S; Younossi, ZM | 2 |
| Brainard, D; Gaggar, A; Gonzalez, M; Kirby, B; McHutchison, JG; Rodriguez-Orengo, J; Rodriguez-Torres, M; Shen, G; Svarovskaia, E; Symonds, WT | 1 |
| Afdhal, N; Hunt, SL; Kowdley, KV; Marcellin, P; Stepanova, M; Younossi, ZM; Zeuzem, S | 1 |
| Ahmed, A; Daugherty, TJ; Glenn, JS; Ha, LD; Higgins, JP; Kim, WR; Kumari, R; Luong, H; Perumpail, RB; Pham, EA; Wang, U; Wong, RJ; Younossi, ZM | 1 |
| Aghemo, A; Colombo, M; D'Ambrosio, R | 1 |
| Brainard, D; Gaggar, A; Iser, DM; Massetto, B; McHutchison, JG; Molina, JM; Nelson, M; Ni, L; Orkin, C; Puoti, M; Rockstroh, JK; Stephan, C; Subramanian, GM; Svarovskaia, E; Zamora, FX | 1 |
| Kim, AY; Naggie, S | 1 |
| Kumari, R; Nguyen, MH | 1 |
| Beckerman, R; Jiang, Y; Smith, NJ; Stepanova, M; Younossi, ZM | 1 |
| Floreani, A | 1 |
| Füessl, HS | 1 |
| Jäger-Becker, D | 1 |
| Caldwell, SH; Cornella, SL; Kelly, V; Shah, NL; Stine, JG | 1 |
| Asselah, T | 1 |
| Abergel, A; Alric, L; Bourlière, M; Bronowicki, JP; de Ledinghen, V; Doehle, B; Grangé, JD; Guyader, D; Habersetzer, F; Hézode, C; Hyland, RH; Jiang, D; Larrey, DG; Leroy, V; Loustaud-Ratti, V; Marcellin, P; Mathurin, P; McHutchison, JG; Metivier, S; Pang, PS; Pol, S; Ratziu, V; Serfaty, L; Subramanian, GM; Symonds, WT; Tran, A; Zoulim, F | 1 |
| Chhatwal, J; Dunn, MA; Kanwal, F; Roberts, MS | 1 |
| Andersson, K; Avorn, J; Brennan, T; Choudhry, NK; Krumme, AA; Matlin, OS; Najafzadeh, M; Shrank, WH | 1 |
| Liffmann, DK; Rein, DB; Smith, BD; Ward, JW; Wittenborn, JS | 1 |
| Brainard, D; Dvory-Sobol, H; Gane, EJ; Gontcharova, V; Han, B; Hedskog, C; Hyland, RH; Martin, R; Miller, MD; Mo, H; Ouyang, W; Svarovskaia, E | 1 |
| Kattakuzhy, S; Kottilil, S; Levy, R | 1 |
| Afdhal, N; Henry, L; Hunt, SL; Kowdley, KV; Marcellin, P; Stepanova, M; Younossi, ZM; Zeuzem, S | 1 |
| Sekkides, O | 1 |
| Assoumou, SA; Barter, DM; Freedberg, KA; Horsburgh, CR; Kim, AY; Leff, JA; Linas, BP; Morgan, JR; Pho, MT; Salomon, JA; Schackman, BR; Weinstein, MC | 1 |
| Coilly, A; Duclos-Vallée, JC; Roche, B; Samuel, D | 1 |
| Kearney, BP; Kirby, BJ; Mathias, AA; Symonds, WT | 1 |
| Flamm, S; Lawitz, E; McHutchison, JG; Morelli, G; Pang, PS; Pockros, P; Svarovskaia, E; Wyles, D; Yang, JC; Younes, Z; Zhu, Y | 1 |
| Afdhal, N; Bourlière, M; Ding, X; Dvory-Sobol, H; Feld, JJ; Gane, E; Hyland, R; Knox, S; Lawitz, E; Mangia, A; Marcellin, P; McHutchison, JG; Mizokami, M; Omata, M; Pang, P; Pol, S; Reddy, KR; Subramanian, GM; Sulkowski, M; Symonds, W; Welzel, TM; Yang, J; Zeuzem, S | 1 |
| Bennett, M; Brainard, D; Doehle, B; Gane, EJ; Hassanein, T; Jacobson, IM; Kanwar, B; Liu, L; McHutchison, JG; Mo, H; Nahass, RG; Pol, S; Subramanian, GM; Sulkowski, MS; Symonds, WT | 1 |
| Cure, S; Dusheiko, G; Guerra, I | 1 |
| Schiff, L | 1 |
| Borgia, SM; Rowaiye, A | 1 |
| Betular, J; Enomoto, H; Gao, B; Garrison, K; Genda, T; Ide, T; Ikeda, F; Ishizaki, A; Izumi, N; Knox, SJ; Korenaga, M; McHutchison, JG; Mizokami, M; Mo, H; Mochizuki, H; Nakane, K; Nirei, K; Nishigaki, Y; Omata, M; Omote, M; Pang, PS; Sakamoto, N; Symonds, WT; Takehara, T; Toda, N; Toyoda, H; Ueno, Y; Umemura, T; Yanase, M; Yatsuhashi, H; Yokosuka, O | 1 |
| Beinhardt, S; Ferenci, P; Hofer, H; Peck-Radosavljevic, M | 1 |
| Baroni, GS; Belli, L; Bhoori, S; Burra, P; Cillo, U; De Feo, TM; Donato, F; Fagiuoli, S; Lucà, MG; Marianelli, T; Passigato, N; Picciotto, A; Russo, FP; Spolverato, G; Toniutto, P; Vitale, A | 1 |
| Chtioui, H; Decosterd, LA; Giostra, E; Majno, PE; Moradpour, D; Pascual, M; Vionnet, J | 1 |
| Cammà, C; Carosi, G; Craxì, A; Cure, S; Guerra, I | 1 |
| Bau, SN; Busuttil, RW; Durazo, F; El-Kabany, M; Greenberg, A; Han, S; Li, E; Saab, S | 1 |
| Doehle, B; Doss, W; Esmat, G; Fouad, R; Hammad, R; Hassany, M; Jiang, D; Kersey, K; Khairy, M; Knox, SJ; Massetto, B; McHutchison, JG; Samir, W; Shiha, G; Soliman, R | 1 |
| Colombo, M | 1 |
| Afdhal, N; Alqahtani, SA; Ding, X; Fried, M; Gordon, SC; Kowdley, KV; Kwo, P; Mangia, A; Marcellin, P; McHutchison, JG; Pang, PS; Pound, D; Reddy, KR; Sulkowski, M; Yang, JC; Zeuzem, S | 1 |
| Beebe, A; Gicquelais, RE; Haselow, DT; Patil, N; Quattlebaum, T; Smith, NH; Zohoori, N | 1 |
| Buti, M; Esteban, R; Llaneras, J; Riveiro-Barciela, M | 1 |
| Bushman, LR; Jimmerson, LC; Kiser, JJ; Kottilil, S; McHutchison, JG; Meissner, EG; Osinusi, A; Petersen, T; Rower, JE; Sims, Z; Wolfe, P | 1 |
| Cure, S; Guerra, IM; Lavanchy, D; Müllhaupt, B; Negro, F; Pfeil, AM; Reich, O; Schwenkglenks, M | 1 |
| Dusheiko, G; Mehta, G | 1 |
| Afdhal, N; Arterburn, S; Brandt-Sarif, T; Brown, K; Brown, RS; Charlton, M; Denning, J; Dvory-Sobol, H; Everson, GT; Flamm, SL; Fontana, RJ; Fried, MW; Gilroy, R; Korenblat, KM; Kumar, P; Kuo, A; Kwo, P; Landis, C; McHutchison, JG; Muir, AJ; O'Leary, JG; Pang, PS; Pungpapong, S; Reddy, KR; Schiff, E; Sulkowski, MS; Teperman, L; Terrault, NA; Vargas, HE; Watt, KD | 1 |
| Besur, SV; deLemos, AS; Noell, BC | 1 |
| Araz, F; Durand, CM; Gürakar, A | 1 |
| Bunchorntavakul, C; Reddy, KR | 1 |
| Warpakowski, A | 4 |
| Feld, JJ; Shah, H; Sheehan, K; Sockalingam, S | 1 |
| Halász, T; Horváth, G; Hunyady, B; Makara, M | 1 |
| Barreiro, P; de Mendoza, C; Peña, JM; Soriano, V | 1 |
| Stingl, W | 1 |
| Hunt, S; Lam, B; Nader, F; Stepanova, M; Younossi, ZM | 1 |
| Bourlière, M; Bronowicki, JP; Carrieri, MP; Pol, S; Stepanova, M; Younossi, ZM | 1 |
| Kmietowicz, Z | 1 |
| Anania, FA; Cartwright, EJ; Collins, JM; Farley, MM; Pillai, A; Raphael, KL; Terry, C | 1 |
| Balagopal, A; Thio, CL | 1 |
| Buggisch, P; Eißing, C; Hartl, J; Jordan, S; Lohse, AW; Lüth, S; Petersen, J; Schulze Zur Wiesch, J; Stoehr, A; Wehmeyer, MH | 1 |
| Murfin, M | 1 |
| Barua, S; Dore, GJ; Grebely, J; Greenwald, R; Swan, T; Taylor, LE | 1 |
| Canary, LA; Holmberg, SD; Klevens, RM | 1 |
| Aristizabal, P; Carlin, AF; Paulson, MS; Schooley, RT; Song, Q; Stamm, LM; Wang, H; Wyles, DL | 1 |
| Bau, S; Busuttil, RW; Durazo, F; El Kabany, M; Goo, T; Han, S; Jimenez, M; Kaldas, F; Saab, S; Tong, MJ; Zhao, D | 1 |
| Bailly, F; Pradat, P; Virlogeux, V; Zoulim, F | 1 |
| Beinhardt, S; Ferenci, P; Ferlitsch, A; Freissmuth, C; Hofer, H; Kozbial, K; Mandorfer, M; Peck-Radosavljevic, M; Reiberger, T; Schwabl, P; Schwarzer, R; Stättermayer, AF; Trauner, M | 1 |
| Albert, ML; Casrouge, A; Decalf, J; Duffy, D; Kottilil, S; Masur, H; Meissner, EG | 1 |
| Mohammad, RA; Smith, MA | 1 |
| Gross, C; Kapoor, R; Kohli, A; Kotb, C; Kottilil, S; Lam, B; Masur, H; Nelson, A; Osinusi, A; Pang, PS; Polis, MA; Rustgi, V; Sidharthan, S; Silk, R; Sims, Z; Sugarman, K; Teferi, G | 1 |
| Forns, X; Lens, S; Mariño, Z | 1 |
| Ackerman, P; Dieterich, D; Dretler, R; Fishbein, D; Gathe, JC; Henn, S; Hinestrosa, F; Hughes, E; Huynh, C; Liu, Z; Luetkemeyer, A; McDonald, C; McPhee, F; Mills, A; Morgan, TR; Noviello, S; Overton, ET; Ramgopal, M; Rashbaum, B; Ray, G; Ruane, PJ; Scarsella, A; Sherman, KE; Sulkowski, MS; Wyles, DL; Yin, PD; Yozviak, J | 1 |
| Baden, RP; Bräu, N; Colson, AE; Cooper, C; Dieterich, D; Dvory-Sobol, H; Gane, E; German, P; Jayaweera, D; Luetkemeyer, A; Marks, K; McHutchison, JG; Morales-Ramirez, JO; Naggie, S; Ni, L; Pang, PS; Ruane, P; Saag, M; Santana-Bagur, J; Sax, PE; Stamm, LM; Stedman, CA; Sulkowski, M; Tebas, P; Towner, WJ; Wong, DK; Workowski, K; Yang, JC | 1 |
| Brunetto, MR; De Luca, A; Messori, A; Zignego, AL | 1 |
| Hikita, H; Hiramatsu, N; Kai, Y; Morishita, N; Nakabori, T; Nawa, T; Oze, T; Saito, Y; Sakamori, R; Suemizu, H; Takehara, T; Tanaka, S; Tatsumi, T; Yakushijin, T | 1 |
| Ballestri, S; Bertolotti, M; Lonardo, A; Marrazzo, A; Romagnoli, D | 1 |
| Ende, AR; Harper, J; Kim, NH; Landis, CS; Yeh, MM | 1 |
| Alexander, PC; James, AM; Long, AG; Shiffman, ML | 1 |
| Forns, X; Gambato, M; Lens, S; Mariño, Z | 1 |
| Gissel, C; Götz, G; Mahlich, J; Repp, H | 1 |
| Byrne, TJ; Helmers, RA; Leslie, KO; Wesselius, LJ | 1 |
| Bastian, ND; Griffin, PM; Zhang, S | 1 |
| Antoni, C; Eisenbach, C; Galle, PR; Pathil, A; Schattenberg, JM; Sprinzl, MF; Stein, K; Steinebrunner, N; Stremmel, W; Wörns, MA; Zimmerer, T; Zimmermann, T | 1 |
| Escheik, C; Estep, M; Gerber, L; Stepanova, M; Weinstein, A; Younossi, ZM | 1 |
| Agarwal, K; Barnes, E; Brainard, DM; Brown, A; Cooper, C; Forton, D; Foster, GR; George, J; Han, B; Lin, M; Massetto, B; McHutchison, JG; Nahass, RG; Pianko, S; Subramanian, GM | 1 |
| Cornberg, J; Cornberg, M; Deterding, K; Höner Zu Siederdissen, C; Kirschner, J; Manns, MP; Mix, C; Mix, H; Port, K; Solbach, P; Sollik, L; Wedemeyer, H; Worzala, D | 1 |
| An, D; Brainard, D; Gane, EJ; Hyland, RH; Pang, PS; Stedman, CA; Svarovskaia, E | 1 |
| Brainard, DM; Elsheikh, E; Gerber, L; McHutchinson, JG; Nader, F; Stamm, LM; Stepanova, M; Younossi, ZM | 1 |
| Chopp, S; Hult, A; Klepser, M; Vanderwall, R | 1 |
| Aghemo, A; Bruno, R | 1 |
| Buti, M; Esteban, R; Riveiro-Barciela, M | 1 |
| Alavi, M; Day, R; Dore, GJ; Martinello, M; Matthews, GV; Schteinman, A; Williams, K | 1 |
| Bertuccio, C; Chau, H; Ciarleglio, M; Cohen, E; Deng, Y; Do, A; Drozd, K; Eggers, C; Liapakis, A; Lim, JK; Mittal, Y; Sapir, D; Wright, J | 1 |
| Barnes, M; Gautam, M; Gonzalez, S; Habib, A; Mantry, P; McAfee, J; Modi, AA; Nazario, H; Teachenor, O; Trotter, JF; Tujague, L; Weinstein, J | 1 |
| Brainard, DM; Clark, PJ; Estep, M; Hunt, S; McHutchison, JG; Negro, F; Patel, K; Paulson, M; Song, Q; Stamm, LM; Stepanova, M; Subramanian, GM; Younossi, ZM | 1 |
| Qureshi, K; Trakroo, S | 1 |
| Chung, RT; Corey, KE; Friedman, LS; Hundemer, GL; Sise, ME; Ufere, N; Wisocky, J | 1 |
| Farfour, E; Hillaire, S; Kahn, JE; Peytavin, G; Sené, T; Zucman, D | 1 |
| Bronowicki, JP; Hézode, C | 1 |
| Buti, M; Esteban, R | 2 |
| Goeree, R; Martel, MJ; Moshyk, A; Tahami Monfared, AA | 1 |
| Rino, Y; Yamamoto, N; Yukawa, N | 1 |
| Hubbard, H; Lawitz, E; Vizuete, J | 1 |
| Aggarwal, A; Ahmed, A; Chao, DT; Jayasekera, CR; Perumpail, RB; Pham, EA; Wong, RJ | 1 |
| Feld, JJ; Kottilil, S; O'Brien, TR; Pfeiffer, RM | 1 |
| Bloom, AK; Chung, RT; Gustafson, JL; Hashemi, N; Kim, AY; Lin, MV; Lundquist, AL; Sise, ME; Steele, D; Thadhani, R; Thiim, M; Williams, WW; Wisocky, J | 1 |
| Beckerman, R; Brown, A; Buti, M; Fagiuoli, S; Mauss, S; Rosenberg, W; Serfaty, L; Smith, N; Srivastava, A; Stepanova, M; Younossi, Z | 1 |
| Calabuig, M; Hernández-Boluda, JC; Navarro, D; Piñana, JL; Serra, MÁ; Solano, C | 1 |
| Mohammad, RA; Regal, RE; Smith, MA | 1 |
| Akoth, E; Chavez, J; Emmanuel, B; Gross, C; Kattakuzhy, S; Kohli, A; Kottilil, S; Lam, B; Masur, H; McLaughlin, M; McManus, M; Mo, H; Nelson, A; Osinusi, A; Polis, MA; Price, A; Shrivastava, S; Sidharthan, S; Silk, R; Sims, Z; Tang, L; Teferi, G; Wilson, E | 1 |
| Bernuth, S; Galle, PR; Kittner, JM; Knapstein, J; Schad, A; Schattenberg, JM; Schuppan, D; Sprinzl, MF; Weyer, V; Wörns, MA; Yagmur, E; Zimmermann, A; Zimmermann, T | 1 |
| Akoth, E; Gross, C; Kattakuzhy, S; Kohli, A; Kottilil, S; Masur, H; McHutchison, JG; McLaughlin, M; Mo, H; Nelson, A; Osinusi, A; Pang, PS; Price, A; Sidharthan, S; Silk, R; Sims, Z; Subramanian, GM; Tang, L; Wilson, EM | 1 |
| Bryce, CL; Chidi, AP; Fine, MJ; Good, CB; Myaskovsky, L; Rogal, S; Rustgi, VK; Smith, KJ; Tsung, A | 1 |
| Bagate, F; Boueyre, E; Corouge, M; Duboc, D; Fontaine, H; Lazarus, A; Mallet, V; Pecriaux, C; Pol, S; Sogni, P; Sultanik, P; Vallet-Pichard, A | 1 |
| Kao, JH; Yang, SS | 1 |
| Afdhal, N; Gitlin, N; Howell, C; Jeffers, LJ; Kowdley, K; McHutchison, JG; Muir, AJ; Pang, PS; Poulos, J; Ravendhran, N; Reddy, KR; Shiffman, ML; Sulkowski, MS; Wilder, JM; Workowski, K; Yang, JC; Zhu, Y | 1 |
| Brainard, DM; Chung, RT; Davis, MN; Doehle, B; Etzkorn, K; Everson, GT; Han, L; Hinestrosa, F; McHutchison, JG; McNally, J; Morgan, T; Nahass, RG; Rabinovitz, M; Thuluvath, PJ; Tong, M; Towner, WJ; Tran, TT; Wyles, DL | 1 |
| Brainard, DM; Doehle, B; Dore, GJ; Flamm, SL; Gane, EJ; Han, L; Kumar, S; McHutchison, JG; McNally, J; Mogalian, E; Pianko, S; Rabinovitz, M; Reddy, KR; Roberts, SK; Shiffman, ML; Stedman, CA; Strasser, SI; Towner, WJ | 1 |
| Kattakuzhy, S; Kottilil, S; Tang, L; Ward, H; Wilson, E | 1 |
| Kohli, A; Kottilil, S; Masur, H; Meissner, EG; Osinusi, A; Remaley, AT; Sampson, M; Sidharthan, S; Tang, L; Townsend, K | 1 |
| Kowdley, KV; Sundaram, V | 1 |
| Borgia, G; Buonomo, AR; Gentile, I; Maraolo, AE; Zappulo, E | 1 |
| An, D; Brainard, DM; Brown, RS; Bzowej, N; Charlton, M; Curry, MP; Doehle, B; Fenkel, JM; Flamm, SL; Fontana, R; Fried, M; Korenblat, KM; Lawitz, E; McHutchison, JG; McNally, J; Muir, AJ; O'Leary, JG; Osinusi, A; Reddy, KR; Schiano, T; Schiff, E; Teperman, L | 1 |
| Abergel, A; Agarwal, K; Asselah, T; Brainard, DM; Chan, HL; Feld, JJ; Gruener, N; Hézode, C; Jacobson, IM; Lai, CL; Mangia, A; Mazzotta, F; McHutchison, JG; McNally, J; Moreno, C; Osinusi, A; Ruane, PJ; Shafran, SD; Svarovskaia, E; Towner, WJ; Tran, TT; Yoshida, E; Zeuzem, S; Zhu, Y | 1 |
| Duh, D; Van Genechten, D | 1 |
| Afdhal, N; Agarwal, K; Asselah, T; Berg, T; Bourlière, M; Brainard, DM; Bräu, N; Conway, B; Cooper, C; Dvory-Sobol, H; Foster, GR; Gane, EJ; Gordon, SC; Han, L; Lawitz, E; Mangia, A; Mazzotta, F; McHutchison, JG; McNally, J; Mo, H; Osinusi, A; Patel, K; Pianko, S; Reau, N; Roberts, SK; Rosenberg, W; Ruane, P; Shiffman, ML; Stedman, CA; Sulkowski, M; Thompson, A; Towner, WJ; Tran, TT; Wang, J; Zeuzem, S | 1 |
| Mermin, JH; Ward, JW | 1 |
| Bruni, R; Ciccaglione, AR; Coppola, N; Costantino, A; Equestre, M; Sagnelli, C; Sagnelli, E; Spada, E; Tritarelli, E | 1 |
| Modi, AA; Nazario, HE; Ndungu, M | 1 |
| Abbott, S; Akoth, E; Chavez, J; Emmanuel, B; Gross, C; Jolley, TA; Kattakuzhy, S; Kohli, A; Kottilil, S; Masur, H; McLaughlin, M; Meissner, EG; Mo, H; Nelson, A; Osinusi, A; Polis, MA; Price, A; Proschan, M; Seamon, C; Sidharthan, S; Silk, R; Sims, Z; Tang, L; Teferi, G; Wilson, E | 1 |
| Chahal, HS; Fox, RK; Kahn, JG; Marseille, EA; Ollendorf, DA; Pearson, SD; Tice, JA | 1 |
| Ahmadyar, S; Babusis, D; Barauskas, O; Feng, JY; McCutcheon, K; Park, Y; Perron, M; Perry, JK; Ray, AS; Sakowicz, R; Schultz, BE; Stepan, G; Xu, Y; Yu, H | 1 |
| Awni, WM; Cohen, D; Ding, B; Dutta, S; King, JR; Menon, RM; Podsadecki, TJ | 1 |
| Butt, AA; Chung, RT; Shaikh, OS; Sherman, KE; Yan, P | 2 |
| Abdo, AM; Helmy, S; Yakoot, M; Yousry, A | 1 |
| McCarthy, M | 1 |
| Jiang, X; Li, J; Ogah, CA; Shen, J; Xie, Y | 1 |
| Gimeno-Ballester, V; Mar, J; Mar-Barrutia, L; San Miguel, R | 1 |
| Gish, R; Kohli, A; Manch, R; Nafisi, S; Roy, S | 1 |
| Farnik, H; Herrmann, E; Lange, CM; Luhne, S; Sarrazin, C; Vermehren, J; Welker, MW; Welzel, T; Zeuzem, S | 1 |
| Burger, J; Dranitsaris, G; Fraser, I; Lubbe, M; Sonderup, M; Stander, T | 1 |
| Dyson, JK; McPherson, S | 1 |
| Dominguez-Dominguez, L; Jarrin-Estupiñan, ME; Kessler-Saiz, P; Marchan-Lopez, A | 1 |
| Gordon, LA; Gross, C; Kohli, A; Kottilil, S; Masur, H; Nelson, A; Osinusi, A; Petersen, T; Polis, MA; Seamon, C; Tang, L; Townsend, K | 1 |
| De La Rosa, G; DeJesus, E; Felizarta, F; Fevery, B; Ghalib, R; Godofsky, E; Herring, RW; Kalmeijer, R; Kugelmas, M; Lawitz, E; Lenz, O; Matusow, G; Peeters, M; Poleynard, G; Scott, J; Sheikh, A; Sinha, R; Tobias, H; Witek, J; Yoshida, EM | 1 |
| Afdhal, NH; Eggleton, E; Knox, SJ; Kowdley, K; Mangia, A; Mizokami, M; Omata, M; Pang, P; Park, SH; Saab, S; Subramanian, M; Zhu, Y | 1 |
| Luo, R; Nong, J; Qing, J; Shao, Y; Sun, Y; Tang, R; Wang, Y; Wu, M; Yin, Z; Yu, X | 1 |
| Asselah, T; Boyer, N; Marcellin, P; Martinot-Peignoux, M; Saadoun, D | 1 |
| Kahveci, AM; Tahan, V | 1 |
| Chang, PW; Huynh, TT; Rosinski, AA; Tong, LT; Tong, MJ | 1 |
| Fontana, RJ; Hughes, EA; Landis, C; McPhee, F; Noviello, S; Poordad, F; Schiff, ER; Swenson, ES; Vierling, JM; Yang, R | 1 |
| Aichelburg, MC; Bucsics, T; Chromy, D; Grabmeier-Pfistershammer, K; Mandorfer, M; Peck-Radosavljevic, M; Reiberger, T; Scheiner, B; Schwabl, P; Stättermayer, AF; Steiner, S; Trauner, M | 1 |
| Craft, ZN; Kamal, KM; Koerner, PH; Miller, RT; Trombatt, WD | 1 |
| Salman, AG | 1 |
| Cho, EJ; Cho, Y; Kim, YJ; Lee, JH; Yoon, JH; Yu, SJ | 1 |
| Arleo, A; Copetti, M; Mangia, A; Miscio, M; Piazzolla, V; Santoro, R; Squillante, MM | 1 |
| Banerjee, D; Reddy, KR | 1 |
| Cheung, A; Hong, LK; Huddleston, L; Poerzgen, P; Roytman, MM; Trujillo, R; Tsai, NC; Wu, CJ | 1 |
| Kelley, C; McPhee, F; Signorovitch, J; Swallow, E; Wygant, G | 1 |
| Hoofnagle, JH | 1 |
| Bernstein, D; Davis, M; De La Rosa, G; Etzkorn, K; Fevery, B; Gitlin, N; Kalmeijer, R; Kwo, P; Lenz, O; Nahass, R; Peeters, M; Rojter, S; Ruane, P; Schiff, E; Scott, J; Sinha, R; Witek, J; Younes, Z | 1 |
| Rivero, A; Rivero-Juárez, A | 1 |
| Abergel, A; Asselah, T; Jiang, D; Kersey, K; Loustaud-Ratti, V; Metivier, S; Mo, H; Pang, PS; Samuel, D | 1 |
| Birati, EY; Forde, KA; Goldberg, LR; Padegimas, A | 1 |
| Rieger, KE; Scott, GD | 1 |
| Angus, P; Bhore, R; Bronowicki, JP; Dore, GJ; Hezode, C; Jimenez-Exposito, MJ; Leroy, V; McPhee, F; Pianko, S; Pol, S; Stuart, K; Thompson, AJ; Tse, E | 1 |
| Alkhouri, N; Anthony, S; Guirguis, J; Hanouneh, IA; Rivas, J; Singh, T | 1 |
| Cheng, G; Corsa, A; Delaney, W; Doehle, B; Dvory-Sobol, H; Gong, R; Han, B; Lee, YJ; Link, JO; Mo, H; Pagratis, N; Peng, B; Perron, M; Tian, Y; Xu, S; Xu, Y; Yu, M | 1 |
| Henry, L; Nader, F; Stepanova, M; Younossi, ZM | 1 |
| André, P; Burmeister, WP; Caporossi, A; François, O; Fusillier, K; Geneletti, L; Larrat, S; Leroy, V; Morand, P; Ramière, C; Santoni, E; Tarbouriech, N; Thélu, MA; Trémeaux, P | 1 |
| Agarwal, K; Brown, A; Cheung, MC; Foster, GR; Gelson, WT; Hudson, BE; Irving, WL; MacDonald, DC; McLauchlan, J; Mutimer, DJ; Verma, S; Walker, AJ | 1 |
| Cheng, N; Ford, R; Norvell, JP; Parekh, S; Pillai, AA; Spivey, JR; Wedd, J; Young, N | 1 |
| Brainard, DM; Chang, TT; Chen, JJ; Chien, RN; Chu, CJ; Chuang, WL; Han, L; Hsu, YC; Hu, TH; Kao, JH; Knox, SJ; Lo, GH; Mathias, A; Mo, H; Peng, CY; Sheen, IS; Wang, HY; Yang, JC | 1 |
| Ackerman, P; Kalsekar, A; Kelley, C; Mu, F; Peeples, M; Signorovitch, J; Song, J; Swallow, E; Yuan, Y | 1 |
| Bacon, BR; Dieterich, DT; Flamm, SL; Kowdley, K; Milligan, S; Nezam, A; Tsai, N; Younossi, ZM | 1 |
| Chang, TT; Chen, JJ; Chien, RN; Chu, CJ; Chuang, WL; Gao, B; Garrison, KL; Hsu, YC; Hu, TH; Kao, JH; Knox, SJ; Lo, GH; Mo, H; Pang, PS; Peng, CY; Sheen, IS; Wang, HY; Yang, JC | 1 |
| Bouvier-Alias, M; Chevaliez, S; Féray, C; Hézode, C; Mallat, A; Pawlotsky, JM; Roudot-Thoraval, F; Ruiz, I; Scoazec, G; Soulier, A; Varaut, A | 1 |
| Ahn, SH; Brainard, DM; Byun, KS; Han, KH; Han, L; Han, SY; Heo, J; Jeong, SH; Kim, JH; Kim, YJ; Kim, YS; Knox, SJ; Lee, KS; Lee, YJ; Lim, YS; Mathias, A; Mo, H; Paik, SW; Tak, WY; Yang, JC; Yim, HJ; Yoon, SK | 1 |
| Bahirwani, R; Berg, C; Brown, RS; Castells, L; Chacko, KR; Durand, CM; ElSharkawy, AM; Emond, B; Ferenci, P; Fontana, RJ; Herzer, K; Ionescu-Ittu, R; Jafri, SM; Joshi, S; Knop, V; Lionetti, R; Loiacono, L; Londoño, MC; Montalbano, M; Moreno-Zamora, A; Mubarak, A; Pellicelli, AM; Prieto, M; Reddy, KR; Stadler, B; Stauber, RE; Stenmark, S; Torti, C; Vekeman, F; Weiland, O | 1 |
| Afdhal, N; Charlton, M; Denning, J; Everson, GT; Flamm, SL; Hyland, R; Lin, M; McHutchison, JG; Pang, PS; Reddy, KR; Welzel, TM; Zeuzem, S | 1 |
| Dickinson, K; Harrison, P; Ryder, S; Simpson, EL; Stevens, JW; Tappenden, P; Thokala, P | 1 |
| Kottilil, S; Polis, MA; Rosenthal, ES | 1 |
| Andreone, P; Gamal, N | 1 |
| Agarwal, K; Angus, P; Arterburn, S; Brainard, D; Buti, M; Calleja, JL; Colombo, M; Denning, J; Dufour, JF; Dvory-Sobol, H; Forns, X; Gane, EJ; Manns, M; McCaughan, G; McHutchison, JG; Müllhaupt, B; Mutimer, D; Pang, PS; Peck-Radosavljevic, M; Prieto, M; Rizzetto, M; Samuel, D; van Hoek, B; Van Vlierberghe, H; Yoshida, EM | 1 |
| Araújo, ES; Bourliere, M; Canini, L; Chiche, L; Coquet, E; Cotler, SJ; Dahari, H; Graw, F; Halfon, P; Penaranda, G; Renou, C; Riso, A; Uprichard, SL | 1 |
| Ferriols-Lisart, R; Guglieri-López, B; Merino-Sanjuán, M; Pérez-Pitarch, A | 1 |
| Barve, A; Brock, G; Buchanan, LA; Cave, B; Cave, MC; Crittenden, NE; Davis, EG; Gedaly, R; Jones, CM; Kuns-Adkins, CB; Marsano, L; Marvin, MR; McClain, CJ; Pinkston, CM; Rosenau, J; Shah, MB | 1 |
| Chung, RT; Fried, MW; Koraishy, FM; Liapakis, A; Lim, JK; Nelson, DR; Saxena, V; Schmidt, M; Sise, ME; Terrault, NA | 1 |
| Fischler, B; Priftakis, P; Sundin, M | 1 |
| Chan, HLY; Choi, MS; Dan, YY; Henry, L; Lee, MH; Stepanova, M; Younossi, ZM; Yu, ML | 1 |
| Pérez Garrido, I; Rodríguez Gil, FJ | 1 |
| Bernard Chabert, B; Descamps, D; Desnoyer, A; Fontaine, H; Gervais, A; Harent, S; Heurgué-Berlot, A; Hillaire, S; Laradi, A; Larrouy, L; Lê, MP; Muret, P; Peytavin, G; Pinto, A; Pospai, D; Salmon, D; Simonpoli, AM; Yazdanpanah, Y; Zucman, D | 1 |
| Sankawa, Y | 1 |
| Benhaourech, S; Borentain, P; Bregigeon, S; Colson, P; Darque, A; Gaubert, MR; Habib, G; Laugier, D; Maille, B; Renard, S; Salaun, E | 1 |
| Ackens, R; Posthouwer, D | 1 |
| Bichoupan, K; Branch, AD; Chang, C; Dieterich, DT; Grewal, P; Harty, A; Khaitova, V; Ku, L; Liu, L; Motamed, D; Patel, N; Perumalswami, PV; Schiano, TD; Woodward, M; Yalamanchili, R | 1 |
| de Lagarde-Sebastián, M; de Miguel-Campo, B; Domínguez-Domínguez, L; Pulido, F | 1 |
| Kahveci, AS; Tahan, V | 1 |
| Henry, L; Hunt, S; Nader, F; Stepanova, M; Younossi, ZM | 1 |
| Holle, LM; Jensen, CM | 1 |
| Badia, E; Sáez-Royuela, F | 1 |
| Johnson, S; Marx, SE; Misurski, D; Parisé, H; Saab, S; Sanchez Gonzalez, Y; Virabhak, S; Wang, A | 1 |
| Nehra, V; Rizza, SA; Tan, EM; Temesgen, Z | 1 |
| Arora, S; Box, T; Deming, P; Gish, R; Khaderi, S; Kohli, A; Manch, RA; Mera, J; Moore, A; Qualls, C; Scott, J; Sedillo, M; Sussman, NL; Thornton, K | 1 |
| Baños, I; Bellot, P; Bhamidimarri, KR; Brainard, DM; Campos-Varela, I; Castells, L; Grewal, P; Guaraldi, G; Hasson, H; McHutchison, JG; Morbey, A; Moreno, A; Terrault, NA | 1 |
| Daniels, N; Porteny, T; Urrutia, J | 1 |
| Foster, GR; Mangia, A; Sulkowski, M | 1 |
| Assy, N; Barhoum, M | 1 |
| André-Garnier, E; Besse, B; Billaud, E; Biron, C; Coste-Burel, M; Gournay, J; Imbert-Marcille, BM; Mabille-Archambeaud, I; Pineau, S; Raffi, F; Ribeyrol, O | 1 |
| Charlton, M; Curry, MP | 1 |
| Feld, JJ; Zeuzem, S | 1 |
| Ferenci, P; Freissmuth, C; Graziadei, I; Gschwantler, M; Hametner, S; Hofer, H; Karpi, A; Kozbial, K; Laferl, H; Maieron, A; Moser, S; Ramona, AZ; Stauber, RE; Stern, R; Vogel, W; Zoller, HM | 1 |
| Bhore, R; Box, T; Gitlin, N; Kowdley, KV; Lalezari, JP; Nelson, DR; Noviello, S; Poleynard, G; Rabinovitz, M; Rana, K; Ravendhran, N; Sheikh, AM; Siddique, A | 1 |
| Brainard, D; German, P; Kearney, BP; Mathias, A | 1 |
| Brainard, DM; De-Oertel, S; Doehle, B; Dvory-Sobol, H; Izumi, N; Knox, S; Miller, MD; Mizokami, M; Mo, H; Nishiguchi, S; Omata, M; Sakamoto, N; Svarovskaia, ES; Takehara, T | 1 |
| Cohen, AF; Hessel, MH; Rissmann, R | 1 |
| Ahn, SH; Byun, KS; Gao, B; Garrison, KL; Han, KH; Han, SY; Heo, J; Jeong, SH; Kim, JH; Kim, YJ; Kim, YS; Knox, SJ; Lee, KS; Lee, YJ; Lim, YS; Mo, H; Paik, SW; Pang, PS; Tak, WY; Yang, JC; Yim, HJ; Yoon, SK | 1 |
| Al Zoairy, R; Beinhardt, S; Ferenci, P; Freissmuth, C; Hofer, H; Kozbial, K; Maieron, A; Schmidt, A; Stättermayer, AF; Stauber, R; Stern, R; Strasser, M; Trauner, M; Watschinger, B; Zoller, H | 1 |
| Cooper, C; Dieterich, D; Dvory-Sobol, H; Han, L; McHutchison, JG; Naggie, S; Pang, PS; Saag, M; Stamm, LM; Sulkowski, M; Yang, JC | 1 |
| Bashir, A; Jarrad, A; Moog, G; Obed, A | 1 |
| Brainard, DM; Byrne, S; Copans, A; Dvory-Sobol, H; Fuchs, M; Guyer, W; Ho, SB; Kaplan, DE; Le, H; Monto, A; Moon, S; Morgan, TR; Peyton, A; Rossaro, L; Roy, A; Shaikh, O; Zhu, Y | 1 |
| 't Hoen, EFM | 1 |
| Cotler, SJ; Dahari, H; Halfon, P | 1 |
| Rosenthal, P; Smith, SK | 1 |
| Gschwantler, M; Haltmayer, H; Marchart, K; Moser, S; Schìtz, A | 1 |
| Bischoff, M | 1 |
| Neumaier, J | 1 |
| Gleason, PP; Karmarkar, TD; Qiu, Y; Starner, CI; Tiberg, K | 1 |
| Ahmed, A; Dieterich, D; Ferguson, JR; Gordon, SC; Park, H; Saab, S; Younossi, ZM | 1 |
| Kanda, T | 1 |
| Flemming, JA; Lowe, CE | 1 |
| Henry, L; Hunt, S; Naggie, S; Stepanova, M; Sulkowski, M; Younossi, ZM | 1 |
| Biasi, L; Casari, S; Castelli, F; Chirico, C; Festa, E; Izzo, I; Salemme, M; Villanacci, V; Zanotti, P | 1 |
| Burger, D; Gevers, TJ; Kooistra, MP; Richter, C; Schipper-Reintjes, E | 1 |
| Akushevich, L; Di Bisceglie, AM; Feld, JJ; Frazier, LM; Fried, MW; Kuo, A; Maan, R; Mailliard, M; Manns, MP; Nelson, DR; Schmidt, M; Sherman, K; Sterling, R; Vainorius, M; Zeuzem, S | 1 |
| Gerber-Grote, A; Hanke, G; Luhnen, M; Waffenschmidt, S | 1 |
| Aguilera, A; Arias, A; Benítez-Gutiérrez, L; Cuervas-Mons, V; de Mendoza, C; Lledó, G; Navarro, D; Otero, E; Peña, JM; Soriano, V; Treviño, A | 1 |
| Gonzalez, YS; Johnson, S; Juday, T; Misurski, D; Parisé, H; Saab, S; Virabhak, S; Wang, A | 1 |
| Al-Tarawneh, M; Bader, G; Cook, E; Pourmorteza, M; Shams, W; Tawadros, F; Young, M | 1 |
| Brainard, DM; Dvory-Sobol, H; Gutierrez, JA; Hyland, RH; Lawitz, E; Liu, L; McHutchison, JG; Poordad, F; Wang, J | 1 |
| Abergel, A; Asselah, T; Jiang, D; Kersey, K; Knox, SJ; Loustaud-Ratti, V; Metivier, S; Pang, PS; Samuel, D; Svarovskaia, E | 1 |
| Ross, JS; Sangaralingham, LR; Shah, ND; Talwalkar, JA; Yao, X | 1 |
| Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 2 |
| Bakulin, I; Chulanov, V; Isakov, V; Kersey, K; Knox, SJ; Massetto, B; Svarovskaia, E; Zhdanov, K; Zhu, Y | 1 |
| Aichelburg, MC; Bucsics, T; Chromy, D; Grabmeier-Pfistershammer, K; Mandorfer, M; Peck-Radosavljevic, M; Reiberger, T; Scheiner, B; Schwabl, P; Steiner, S; Trauner, M | 1 |
| Arai, M; Haga, Y; Kanda, T; Katsuno, T; Nakamoto, S; Nakamura, M; Ohta, Y; Sasaki, R; Wu, S; Yasui, S; Yokosuka, O | 1 |
| Baak, LC; Depla, AC; Kuiken, SD; Kwa, D; Lettinga, KD; Reesink, HW; Schinkel, CJ; Tuynman, H; van der Meer, JT; van der Sluys Veer, A; van der Valk, M; van Nieuwkerk, CM; Willemse, SB | 1 |
| Leshno, M; Malnick, SD; Maor, Y; Melzer, E | 1 |
| Amundsen, BM; Chandraker, A; Chung, RT; Chute, D; Curry, MP; Elias, N; Gabardi, S; Hanifi, JM; Heher, EC; Lin, MV; Pavlakis, M; Riella, LV; Rutherford, AE; Sise, ME | 1 |
| Berg, T; Ende, K; Kullig, U; Schiefke, I; Stein, K; Wiegand, J | 1 |
| Akushevich, L; Alqahtani, S; Darling, J; Di Bisceglie, A; Frazier, LM; Fried, MW; Galati, JS; Kuo, A; Lim, JK; Morelli, G; Nelson, DR; Pockros, P; Reddy, RK; Sulkowski, MS; Vainorius, M; Welzel, TM; Zeuzem, S | 1 |
| Henry, L; Hunt, S; Nader, F; Stepanova, M; Younossi, Y; Younossi, ZM | 1 |
| Buggisch, P; Cornberg, M; Günther, R; John, C; Klinker, H; Lutz, T; Mauss, S; Niederau, C; Pfeiffer-Vornkahl, H; Sarrazin, C; Schober, A; Tacke, F | 1 |
| Aghemo, A; Carrinola, R; Colombo, M; D'Ambrosio, R; Rossetti, V | 1 |
| Afdhal, N; Bräu, N; Foster, GR; Henry, L; Hunt, S; Mangia, A; Nader, F; Patel, K; Reau, N; Roberts, SK; Stepanova, M; Sulkowski, M; Younossi, ZM | 1 |
| Aba Alkhail, F; Ajlan, A; Al-Hamoudi, W; Al-Jedai, A; Al-Sebayel, M; Alarieh, R; Alkortas, D; Broering, D; Elsiesy, H | 1 |
| Bannan, C; Bergin, C; Coghlan, M; De Gascun, CF; Dean, J; Farrell, G; Murray, C; Sevastianova, K | 1 |
| Maasoumy, B; Sarrazin, C; Vermehren, J; Wedemeyer, H | 1 |
| Desnoyer, A; Lê, MP; Peytavin, G; Yazdanpanah, Y | 1 |
| D'Ambrosio, R; De Nicola, S; Degasperi, E; Rumi, M | 1 |
| Blumberg, EA; Doyle, AM; Lee, DH; Sawinski, D | 1 |
| Chtioui, H; Decosterd, LA; Moradpour, D; Pascual, M; Saouli, AC; Stucker, F; Vionnet, J | 1 |
| Casato, M; Ceccotti, G; Colantuono, S; De Santis, A; Del Padre, M; Fiorilli, M; Fognani, E; Gianni, E; Gragnani, L; Mitrevski, M; Monti, M; Perez, M; Petraccia, L; Pulsoni, A; Stasi, C; Urraro, T; Visentini, M; Zignego, AL | 1 |
| Bennett, M; Brainard, DM; Curry, M; Dvory-Sobol, H; Hawkins, T; Herring, R; Hinestrosa, F; Jacobson, I; Lawitz, E; Lu, S; McHutchison, JG; Nahass, R; Pearlman, B; Rabinovitz, M; Reau, N; Reddy, KR; Schiff, E; Sheikh, A; Shiffman, M; Stamm, LM; Tran, T; Yang, JC; Younes, Z | 1 |
| Beavers, K; Bernstein, D; Brainard, DM; Chung, RT; Davis, M; Dvory-Sobol, H; Etzkorn, K; Everson, G; Gane, EJ; Gordon, SC; Khalid, O; Kowdley, KV; Kwo, PY; Lu, S; McHutchison, JG; Nguyen, MH; Poulos, JE; Pound, D; Rodriguez-Torres, M; Stamm, LM; Stedman, CA; Tong, M; Tsai, N; Yang, JC | 1 |
| Afdhal, NH; Buti, M; Curry, MP; Dufour, JF; Firdoos, S; Flamm, S; Hughes, MS; Tapper, EB | 1 |
| Appolo, B; Bloom, R; Patel, N; Sawinski, D | 1 |
| Bienholz, A; Eisenberger, U; Gerken, G; Guberina, H; Herzer, K; Kribben, A; Willuweit, K; Witzke, O | 1 |
| Bailly, F; Choupeaux, L; Gagnieu, MC; Maynard, M; Pradat, P; Scholtès, C; Virlogeux, V; Zoulim, F | 1 |
| El-Amin, H; El-Khayat, HR; Fouad, YM; Maher, M; Muhammed, H | 1 |
| Burger, DM; D'avolio, A; de Kanter, CT; Di Perri, G; Smolders, EJ; van 't Veer, N; van Wijngaarden, P | 1 |
| Afdhal, NH; Bacon, BR; Curry, MP; Dieterich, DT; Flamm, SL; Guest, LE; Kowdley, KV; Lee, Y; Tapper, EB; Tsai, NC; Younossi, ZM | 2 |
| Baumgarten, A; Berger, F; Boesecke, C; Busch, H; Christensen, S; Hueppe, D; Ingiliz, P; Kimhofer, T; Lutz, T; Mauss, S; Rockstroh, JK; Schewe, K; Schmutz, G; Schulze zur Wiesch, J; Simon, KG; Wehmeyer, MH | 1 |
| Hunt, S; Mizokami, M; Omata, M; Stepanova, M; Walters, M; Younossi, ZM | 1 |
| Asante-Appiah, E; Barr, E; Flisiak, R; Gerstoft, J; Halota, W; Horvath, G; Jancoriene, L; Kazenaite, E; Kileng, H; Koklu, S; Leiva, R; Nguyen, BY; Patel, S; Platt, HL; Prinzing, R; Qiu, J; Ruiz-Tapiador, JA; Sperl, J; Streinu-Cercel, A; Urbanek, P; Wahl, J; Werling, K | 1 |
| Ahn, J; Branch, A; Gripshover, J; Hassan, MA; Kwok, RM; Lee Sang, M; Patel, N; Potosky, DR; Robertazzi, S; Rodigas, C; Satoskar, R; Schiano, TD; Smith, CI; Te, HS; Tierney, A; Wiegel, J | 1 |
| A Jimenez, M; Busuttil, RW; Choi, G; Durazo, FA; Han, SB; M El-Kabany, M; N Bau, S; Saab, S | 1 |
| Brainard, DM; Bronowicki, JP; Brown, A; Carr, V; Dore, GJ; Grebely, J; Kreter, B; Mauss, S; Natha, M; Puoti, M; Wyles, D; Yang, J; Yun, C; Zhu, Y | 1 |
| Aspinall, RJ; Brainard, DM; Dore, GJ; Feld, JJ; Foster, GR; Fox, R; Grebely, J; Han, L; Mangia, A; McNally, J; Natha, M; Osinusi, A; Subramanian, GM; Sulkowski, M; Zeuzem, S | 1 |
| Christensen, S; Heinzow, H; Hüsing, A; Kabar, I; Schmidt, HH; Seifert, LL | 1 |
| Akushevich, L; Ben Ari, Z; Di Bisceglie, AM; Frazier, LM; Fried, MW; Kuo, A; Lim, JK; Lok, AS; Nelson, DR; Pockros, PJ; Shiffman, ML; Sulkowski, MS; Terrault, NA; Vainorius, M; Zeuzem, S | 1 |
| Drago, F; Gasparini, G; Marenco, S; Parodi, A; Picciotto, A | 1 |
| Chen, J; Fang, Z; Ou, P | 1 |
| Alric, L; Arcaini, L; Besson, C; Bruno, R; Carrat, F; Casato, M; Dorival, C; Fabris, P; Ferretti, VV; Fontaine, H; Frigeni, M; Goldaniga, M; Hermine, O; Jaccard, A; Loustaud-Ratti, V; Merli, M; Peveling-Oberhag, J; Pol, S; Rattotti, S; Rigacci, L; Rossotti, R; Torres, HA; Visco, C; Visentini, M; Zaja, F | 1 |
| Berg, T; Ferenci, P; Gschwantler, M; Herzer, K; Jimenez-Exposito, MJ; Peck-Radosavljevic, M; Petersen, J; Rockstroh, J; Spengler, U; van der Valk, M; Wedemeyer, H; Weiland, O; Welzel, TM; Zeuzem, S; Zhao, Y | 1 |
| Cure, S; Guerra, I; Igarashi, A; Lopresti, M; Marié, L; Tang, W; Tsutani, K | 1 |
| Cure, S; Guerra, I; Igarashi, A; Lopresti, M; Marié, L; Tang, W | 1 |
| He, QF; Zhang, DZ; Zhang, QF | 1 |
| Alric, L; Billaud, E; Bourcier, V; Bourliere, M; Bronowicki, JP; Carrat, F; Causse, X; Chazouilleres, O; D'Alteroche, L; Diallo, A; Dorival, C; Fontaine, H; Fouchard-Hubert, I; Geist, C; Gournay, J; Guyader, D; Habersetzer, F; Hezode, C; Larrey, D; Ledinghen, VD; Loustaud-Ratti, V; Lucier, S; Marcellin, P; Mathurin, P; Metivier, S; Minello, A; Petrov-Sanchez, V; Pol, S; Riachi, G; Rosa, I; Saillard, E; Samuel, D; Thabut, D; Tran, A; Zarski, JP; Zoulim, F | 1 |
| Chawla, Y; Dhiman, RK; Duseja, A; Mehta, M; Satsangi, S; Taneja, S | 1 |
| Gimeno-Ballester, V; Mar, J; San Miguel, R; Simón, MÁ; Trigo, C | 1 |
| Abou Mrad, R; Alkhouri, N; Carey, WD; Eghtesad, B; Elfeki, MA; Hanouneh, IA; Modaresi Esfeh, J; O'Shea, R; Zein, NN; Zervos, X | 1 |
| Damrah, I; Eurich, D; Gül-Klein, S; Pratschke, J; Raschzok, N; Reutzel-Selke, A; Sauer, IM; Schott, E; Stockmann, M; Strücker, B | 1 |
| Furusyo, N; Hayashi, J; Hotta, T; Murata, M; Ogawa, E; Shimizu, M; Toyoda, K; Uchiumi, T | 1 |
| Capuano, B; Chivers, S; Lubel, J; Taylor, D | 1 |
| Bashir, A; Jarrad, A; Obed, A | 1 |
| Davis, MM; Johnson, SW; Priest, DH; Stever, LM | 1 |
| De Weggheleire, A; Dorlo, TP; Francque, S; Lynen, L; Meessen, B; Newton, PN; Pouget, C; Ravinetto, R; Sokkab, A; Tabernero, P | 1 |
| Beck, R; Berg, CP; Egetemeyr, DP; Lauer, UM; Malek, NP; Schwarz, JM; Werner, CR | 1 |
| da Silveira, E; Garcia, RT; Gish, RG; Huynh, A; Levitt, B; Ly, MT; Nguyen, HA; Nguyen, KK; Nguyen, MT; Trinh, HN; Wong, RJ; Yang, J | 1 |
| Abdel Rehim, S; Abdo, M; Doss, W; El Kassas, M; El Raziky, M; El Serafy, M; El-Sayed, MH; Elakel, W; Elbaz, T; Eletreby, R; ElShazly, Y; Esmat, G; Fouad, R; Gamal Eldeen, H; Korany, M; Said, M; Seif, S; Waked, I; Yosry, A; Zaky, S | 1 |
| Britnell, SR; Britt, RB; Vanderman, AJ; Willets, AE; Woodard, CL | 1 |
| Greig, SL | 1 |
| Song, YK; Tong, Y; Tyring, S | 1 |
| Brainard, DM; Chodavarapu, K; Hedskog, C; Isakov, V; Martin, R; Miller, MD; Mo, H; Molina, JM; Sarrazin, C; Sulkowski, MS; Svarovskaia, ES | 1 |
| Arias, A; Baños, I; Benítez-Gutiérrez, L; Citores, MJ; Cuervas-Mons, V; de Mendoza, C; Duca, A; Requena, S; Treviño, A | 1 |
| Beck, KR; Khalili, M; Kim, N | 1 |
| Shi, KQ; Wang, BQ; Wang, YL | 1 |
| Alric, L; Bailly, F; Dumortier, J; Gagnieu, MC; Grangé, JD; Guillaud, O; Habersetzer, F; Kamar, N; Leroy, V; Minello, A; Pageaux, GP; Radenne, S; Vallet-Pichard, A | 1 |
| Berry, K; Green, PK; Ioannou, GN; Su, F | 1 |
| Ascione, A; Barbarini, G; Ceccherini-Silberstein, F; D'Ambrosio, C; Ettorre, GM; Fondacaro, L; Giannelli, V; Ialongo, P; Izzi, A; Marignani, M; Messina, V; Moretti, A; Pace Palitti, V; Pellicelli, AM; Perno, CF; Sacco, R; Scifo, G; Siciliano, M; Tarquini, P; Vignally, P | 1 |
| Mendes, LC; Miotto, N; Stucchi, RS; Vigani, AG; Zanaga, LP | 1 |
| Assis Jarek, NA; Borba, HH; Ferreira, VL; Muzzillo, DA; Pontarolo, R; Tonin, FS; Wiens, A | 1 |
| Kaur, K; Mahajan, R; Mehta, V; Midha, V; Narang, V; Sharma, S; Singh, D; Sood, A; Wander, P | 1 |
| Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Higashi, N; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K | 2 |
| Akuschevich, L; Brown, RS; Di Bisceglie, AM; Everson, GT; Fried, MW; Galati, JS; Kuo, A; Kwo, PY; Lim, JK; Lok, AS; Manns, MP; Morelli, G; Nelson, DR; Pockros, PJ; Reddy, KR; Sulkowski, MS; Terrault, NA; Vainorius, M | 1 |
| Ashour, MK; DeMasi, R; Doss, W; El Raziky, M; Gamil, M; Hamada, Y; Hammad, R; Hashim, MS; Hassany, M; Keim, S; Lonjon-Domanec, I; Sameea, EA; Van Dooren, G; Waked, I | 1 |
| Gul, A; Mahmood, S; Saif, T | 1 |
| Butt, AA; Marks, K; Ren, Y; Shaikh, OS; Sherman, KE | 1 |
| de Ruiter, PE; Hakim, MS; Huang, F; Nair, VP; Pan, Q; Peppelenbosch, MP; Sprengers, D; Surjit, M; Van Der Laan, LJ; Wang, W | 1 |
| Aikata, H; Amano, H; Arataki, K; Chayama, K; Hayes, CN; Hiramatsu, A; Imamura, M; Ito, H; Kawakami, Y; Kawaoka, T; Kohno, H; Makokha, GN; Morio, K; Moriya, T; Nagaoki, Y; Nakahara, T; Nakamura, T; Ochi, H; Tamura, T; Tsuge, M; Tsuji, K; Waki, K | 1 |
| Bhayani, V; Kabrawala, M; Mehta, R; Nandaniya, P; Nandwani, S; Shah, M; Tekriwal, R | 1 |
| Christiansen, H; Graf Einsiedel, H; Wiegand, J | 1 |
| Bang, BR; Chopra, S; Cook, L; Elmasry, S; Feng, Z; Harper, T; Jerome, KR; Kahn, JA; Kanel, G; Kim, B; Saito, T; Wadhwa, S | 1 |
| Aghemo, A; Bourlière, M; Brainard, DM; Colombo, M; Dvory-Sobol, H; Hyland, R; Liu, H; Manns, M; Massetto, B; McHutchison, JG; Peck-Radosavljevic, M; Pol, S; Yun, C; Zhang, J | 1 |
| Ingiliz, P; Jimenez-Exposito, MJ; Peck-Radosavljevic, M; Petersen, J; Rockstroh, JK; Van der Valk, M; Welzel, TM; Zeuzem, S; Zhao, Y | 1 |
| Charlton, M; Curry, MP; Feld, J; Foster, GR; Henry, L; Hunt, S; Mangia, A; Nader, F; O'Leary, JG; Stepanova, M; Sulkowski, M; Younossi, ZM; Zeuzem, S | 1 |
| Boglione, L; Carcieri, C; Cardellino, CS; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Pinna, SM | 1 |
| Elsheikh, E; Estep, JM; Gerber, L; Golabi, P; Karrar, A; Stepanova, M; Younossi, I; Younossi, ZM | 1 |
| Beets, G; Beumont, M; Gutierrez, JA; Jacquemyn, B; Kakuda, TN; Lawitz, E; Luo, D; Ouwerkerk-Mahadevan, S; Picchio, G; Poordad, F; Van Eygen, V; Van Remoortere, P; Vandevoorde, A; Vijgen, L | 1 |
| Buti, M; Calleja, JL; Corbett, C; Crespo, J; Diago, M; Fevery, B; Jessner, W; Kalmeijer, R; Kurland, D; Lens, S; Ortega, E; Pascasio, JM; Planas, R; Rodríguez, FG; Romero-Gómez, M | 1 |
| Bassit, L; Benhamou, Y; Chen, G; Chen, J; Hou, J; Hsiao, HM; Ji, D; Jiang, Y; Ke, R; Lau, G; Li, B; Li, F; Li, J; Liu, J; Perelson, AS; Schinazi, RF; Shao, Q; Sun, J; Tao, S; Tsang, ST; Wang, C; Wang, Y; Wong, A; Wong, CL; Wu, V | 1 |
| Afdhal, NH; Brainard, DM; Doehle, BP; Dvory-Sobol, H; Gane, EJ; Kowdley, KV; Lawitz, E; Martin, R; Miller, MD; Mo, H; Svarovskaia, ES; Wyles, D | 1 |
| Anania, FA; Pearlman, BL; Pillai, AA | 1 |
| Kahn, JG; Lai, JC; Mehta, N; Roberts, JP; Salazar, J; Saxena, V; Volk, M | 1 |
| Kottilil, S; Lee, R; Wilson, E | 1 |
| Castells, L; Fernandez Vazquez, I; Herrero, JI; Londoño, M; Narvaez Rodriguez, I; Otero, A; Pascasio, JM; Prieto, M; Sanchez Antolin, G; Testillano, M | 1 |
| Deng, G; Li, Q; Liu, D; Ma, J; Meng, S; Peng, L; Shen, S; Wu, J; Zhou, J | 1 |
| Acharya, SK; Chowdhury, A; Doehle, B; Duseja, A; Jiang, D; Kanwar, B; Kapoor, D; Kersey, K; Koshy, A; Madan, K; Mehta, R; Nijhawan, S; Pawan, R; Prasad, M; Sarin, S; Shah, SR; Shukla, A; Sood, A; Subramanian, M; Sud, R; Svarovskaia, E | 1 |
| Alonso, S; Ampuero, J; Badia, E; Baliellas, C; Buti, M; Carrión, JA; Castro, Á; Devesa, MJ; Esteban, R; Fernandez, I; Fernandez-Carrillo, C; Fernández-Rodríguez, CM; Gea, F; Gómez, A; Granados, R; Lens, S; Llerena, S; Montero, JL; Olveira, A; Pascasio, JM; Planas, JM; Polo, B; Real, Y; Rincón, D; Riveiro-Barciela, M; Rubín, A; Salmeron, J; Turnes, J | 1 |
| Eurich, D; Globke, B; Pratschke, J; Raschzok, N; Schott, E; Teegen, EM | 1 |
| Flamm, S; Hughes, EA; Kayali, Z; Kwo, P; Lawitz, EJ; Linaberry, M; McPhee, F; Sulkowski, MS; Swenson, ES; Torbeyns, A; Yin, PD | 1 |
| Clayton, CW; Jimmerson, LC; Kiser, JJ; Kottilil, S; MaWhinney, S; Meissner, EG; Sims, Z | 1 |
| Arterburn, S; Brainard, DM; Bzowej, NH; Dvory-Sobol, H; Hyland, RH; Levitsky, J; McHutchison, JG; Moonka, DK; O'Leary, JG; Terrault, NA; Verna, EC | 1 |
| Agostinacchio, E; Arleo, A; Carraturo, I; Copetti, M; De Stefano, G; Losappio, R; Mangia, A; Miscio, M; Palmieri, V; Piazzolla, V; Potenza, D; Santoro, R; Sarrazin, C; Spinzi, G; Susser, S | 1 |
| Arizumi, T; Chishina, H; Hagiwara, S; Ida, H; Iwanishi, M; Komeda, Y; Kudo, M; Minami, T; Minami, Y; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Watanabe, T | 1 |
| Hanabusa, H; Nagao, A | 1 |
| Hashimoto, S; Hayashida, S; Honda, M; Inomata, Y; Isono, K; Oya, Y; Sasaki, Y; Sugawara, Y; Tanaka, M; Watanabe, T; Yamamoto, H; Yoshii, D; Yoshimaru, Y | 1 |
| Balistreri, WF; Bansal, S; Brainard, DM; German, P; Gonzalez-Peralta, RP; Jonas, MM; Kanwar, B; Kersey, K; Lin, CH; Massetto, B; Murray, KF; Rosenthal, P; Schwarz, K; Svarovskaia, E; Wen, J; Zhu, Y | 1 |
| Ariaudo, A; Bonora, S; Castagna, A; D'Avolio, A; Galli, L; Hasson, H; Lazzarin, A; Marinaro, L; Merli, M; Messina, E; Uberti-Foppa, C | 1 |
| Alberti, A; Bonfanti, M; Croce, D; Lazzarin, A; Nappi, C; Restelli, U | 1 |
| Berg, T; Ferenci, P; Herzer, K; Hinrichsen, H; Inderson, A; Jimenez-Exposito, MJ; Klinker, H; Peck-Radosavljevic, M; Spengler, U; Welzel, TM; Zeuzem, S; Zhao, Y | 1 |
| Gan, T; Lu, J; Tao, W; Zhong, J | 1 |
| Buggisch, P; Chaiyakunapruk, N; Curry, MP; Jeon, CY; Kowdley, KV; Latt, NL; Lee, Y; Lott, S; Petersen, J; Qureshi, K; Sahota, A; Sundaram, V; Tsai, N | 1 |
| Backstedt, D; Choi, M; Patel, A; Pedersen, MR; Seetharam, AB | 1 |
| Chen, Y; Jiang, X; Song, Y; Tao, T | 1 |
| Guerra, I; Krauth, C; Liersch, S; Rossol, S; Stahmeyer, JT | 1 |
| Flisiak, R; Flisiak-Jackiewicz, M; Pogorzelska, J | 1 |
| Lange, CM; Mücke, MM; Mücke, VT; Zeuzem, S | 1 |
| Dusheiko, G | 1 |
| Bucher, HC; Calleja, JL; Castells, L; Evans, D; Giostra, E; Hofer, H; Irving, W; Lefevre, C; Pascasio, JM; Postema, R; Prieto, M; Weiland, O; Weis, N; Young, J | 1 |
| Abdelaziz, AO; Doss, W; El Akel, W; El Demerdash, T; El Raziky, M; El Serafy, M; El Shazly, Y; Elsharkawy, A; Esmat, G; Fouad, R; Gaballah, A; Hassany, M; Makhlouf, MA; Motawea, I; Said, M; Seif, S; Shiha, G; Thursz, M; Waked, I; Yosry, A | 1 |
| Jones, D; Massoud, O; Orr, J; Shoreibah, M; Venkata, K; Zhang, J | 1 |
| Baldanti, F; Ludovisi, S; Mondelli, MU; Paolucci, S; Premoli, M | 1 |
| Jacobson, IM; Weisberg, IS | 1 |
| Altraif, IH | 1 |
| Andreoni, M; Angelico, M; Antonucci, F; Aragri, M; Babudieri, S; Barbaliscia, S; Bellocchi, MC; Bertoli, A; Brancaccio, G; Calvaruso, V; Caporaso, N; Ceccherini-Silberstein, F; Cento, V; Cozzolongo, R; Craxì, A; Di Biagio, A; Di Maio, VC; Francioso, S; Gianserra, L; Grieco, A; Landonio, S; Lenci, I; Loggi, E; Magni, CF; Masetti, C; Mastroianni, CM; Melis, M; Merli, M; Micheli, V; Morisco, F; Pace Palitti, V; Paoloni, M; Parruti, G; Pasquazzi, C; Pellicelli, AM; Perno, CF; Picciotto, A; Puoti, M; Rizzardini, G; Romagnoli, D; Rossi, P; Santopaolo, F; Sarmati, L; Siciliano, M; Taliani, G; Tarquini, P; Teti, E; Vecchiet, J; Verucchi, G; Vullo, V | 1 |
| Enomoto, M; Hagihara, A; Hai, H; Kawada, N; Kawamura, E; Kozuka, R; Morikawa, H; Motoyama, H; Murakami, Y; Tamori, A; Teranishi, Y; Uchida-Kobayashi, S | 1 |
| El Kassas, M; Farag, A; Shepherd, A; Youssef, NF | 1 |
| Durante-Mangoni, E; Nigro, G; Pafundi, PC; Parrella, A; Rago, A; Russo, V; Utili, R; Vitrone, M | 1 |
| Balba, G; Bowlus, CL; Brainard, DM; Cohen, A; Fried, MW; Han, B; Hyland, RH; Kim, AY; Kouides, P; McHutchison, JG; Reddy, KR; Rhame, F; Sax, PE; Stamm, LM; Terrault, NA; von Drygalski, A; Walsh, CE; Wang, J; Workowski, K | 1 |
| Bourgeois, S; de Galocsy, C; Degré, D; Delwaide, J; Geerts, A; Gustot, T; Laleman, W; Langlet, P; Lasser, L; Lepida, A; Moreno, C; Negrin Dastis, S; Orlent, H; Reynaert, H; Sersté, T; Starkel, P; Van Steenkiste, C; Vanwolleghem, T | 1 |
| Aichelburg, MC; Bucsics, T; Ferenci, P; Grabmeier-Pfistershammer, K; Mandorfer, M; Peck-Radosavljevic, M; Reiberger, T; Scheiner, B; Schwabl, P; Steiner, S; Trauner, M | 1 |
| Brainard, DM; Gane, EJ; Hyland, RH; McHutchison, JG; Stamm, LM; Stedman, CAM; Svarovskaia, E; Yang, Y | 1 |
| Akamatsu, N; Eguchi, S; Goto, R; Ikegami, T; Kitagawa, Y; Kokudo, N; Maehara, Y; Okajima, H; Shinoda, M; Soyama, A; Taketomi, A; Ueda, Y; Uemoto, S; Yoshizumi, T | 1 |
| Hunt, S; Mizokami, M; Omata, M; Stepanova, M; Walters, M; Younossi, Z | 1 |
| Booth, M | 1 |
| Behmanesh, M; Bokharaei-Salim, F; Karbalaie Niya, MH; Keyvani, H; Salman-Tabar, S | 1 |
| Angarano, G; Bruno, G; Buccoliero, G; Dell'Acqua, R; Fabrizio, C; Fasano, M; Giammario, A; Ladisa, N; Milano, E; Milella, M; Minniti, S; Saracino, A; Scudeller, L; Tartaglia, A | 1 |
| Abe, M; Hiasa, Y; Hirooka, M; Horiike, N; Joko, K; Kisaka, Y; Michitaka, K; Nakanishi, S; Nonaka, T; Tada, F; Tanaka, Y; Tokumoto, Y; Watanabe, T; Yamauchi, K | 1 |
| Albillos, A; Arenas, J; Badia, E; Baliellas, C; Blé, M; Buti, M; Calleja, JL; Carrión, JA; Castells, L; Crespo, J; de la Mata, M; Fernández Bermejo, M; Fernández Carrillo, C; Fernández, I; Fernández-Rodriguez, C; García-Samaniego, J; Granados, R; Herrero, JI; Lens, S; Llop, E; Mariño, Z; Moreno-Palomares, JJ; Moreno-Planas, JM; Pascasio, JM; Pons, C; Prieto, M; Romero, M; Salcedo, M; Salmerón, J; Turnes, J | 1 |
| Akremi, R; Bennai, Y; Botta-Fridlund, D; Bourliere, M; Boyer, N; Bronowicki, JP; D'Alteroche, L; De Ledinghen, V; Di Martino, V; Fedchuk, L; Filipovics, A; Fontaine, H; Guyader, D; Hézode, C; Hubert-Fouchard, I; Larrey, D; Lebray, P; Leroy, V; Nguyen-Khac, E; Rosa, I; Silvain, C; Zhao, Y; Zoulim, F | 1 |
| AbdAllah, M; Abdo, M; Alem, SA; Bourliere, M; El Akel, W; El Raziky, M; Elsharkawy, A; Esmat, G; Fouad, R; Tantawi, O | 1 |
| Ahmed, A; Chang, CY; Daugherty, T; Garcia, G; Kumari, R; Le, A; Lutchman, G; Nguyen, MH; Nguyen, P; Zhao, C | 1 |
| Albillos, A; Ampuero, J; Arenas, J; Bañares, R; Calleja, JL; Crespo, J; Diago, M; Fernandez, I; García-Eliz, M; García-Samaniego, J; Gea, F; Jorquera, F; Lens, S; Llaneras, J; Llerena, S; Mariño, Z; Morillas, RM; Muñoz, R; Navascues, CA; Pascasio, JM; Perelló, C; Rincón, D; Rodriguez, CF; Ruiz-Antorán, B; Sacristán, B; Serra, MA; Simon, MA; Torras, X; Turnes, J | 1 |
| Li, CX; Li, W; Li, ZQ; Liang, HX; Xu, GH; Yu, ZJ; Zeng, QL; Zhang, DW; Zhang, JY | 1 |
| Afendy, M; Cable, R; Esteban, R; Henry, L; Hunt, S; Jacobson, I; Nader, F; Stepanova, M; Sulkowski, M; Younossi, ZM; Zeuzem, S | 1 |
| Bach, TA; Zaiken, K | 1 |
| Brainard, DM; Dvory-Sobol, H; Gutierrez, J; Hyland, RH; Landaverde, C; Lawitz, E; McHutchison, JG; Poordad, F; Stamm, LM; Wells, J; Yang, Y | 1 |
| Chen, N; Li, X; Pan, X; Ren, H; Weng, Q; Xie, J; Xu, J | 1 |
| Aikata, H; Chayama, K; Imamura, M; Ishiyama, K; Kawakami, Y; Kawaoka, T; Morio, K; Nakamura, Y; Nelson Hayes, C; Ochi, H; Ohdan, H; Tsuge, M | 1 |
| Menéndez Naranjo, L; Vicente-Sánchez, S | 1 |
| Hassan, M; Lalos, A; Liriano-Ward, L; Morales, AL; Nair, V; Sang, M; Satoskar, R; Schiano, T; Smith, C; Tierney, A | 1 |
| Ahmed, A; Beckerman, R; Dieterich, D; Gordon, SC; Saab, S; Younossi, Z | 1 |
| Bourlière, M; Brainard, DM; Hyland, RH; Jiang, D; Marcellin, P; Pol, S; Vermehren, J; Welzel, TM; Zeuzem, S | 1 |
| Ibdah, JA; Kahveci, AS; Mir, F; Tahan, V | 1 |
| Bui, E; di Biase, L; Fasano, A; Freitas, ME; Picillo, M | 1 |
| Castedal, M; Cederberg, S; Segenmark, M; Skoglund, C; Weiland, O | 1 |
| Akremi, R; Allegre, T; Antonini, T; Aumaitre, H; Batisse, D; Bennai, Y; Billaud, E; Chas, J; Dabis, F; De Ledinghen, V; De Truchis, P; Dhiver, C; Dominguez, S; Fedchuk, L; Filipovics, A; Fontaine, H; Harent, S; Lacombe, K; Lafeuillade, A; Leroy, V; Metivier, S; Miailhes, P; Pageaux, GP; Perre, P; Rosenthal, E; Salmon Ceron, D; Sogni, P; Valantin, MA; Zhao, Y | 1 |
| Buti, M; Casado, MA; Domínguez-Hernández, R; Esteban, R; Oyagüez, I | 1 |
| Audibert, C; Livoti, C; Palak, A | 1 |
| Bansal, SB; Bodh, V; Choudhary, NS; Jain, M; Kumar, A; Saigal, S; Saraf, N; Sharma, R | 1 |
| Chen, J; Ou, P | 1 |
| An, D; Brainard, D; Gane, EJ; Hyland, RH; McHutchison, JG; Svarovskaia, ES | 1 |
| Mangia, A; Mottola, L | 1 |
| Barreiro, P; Fernández-Montero, JV; Poveda, E; Soriano, V; Vispo, E | 1 |
| Albanis, E; Berrey, MM; Cornpropst, MT; Dejesus, E; Hebner, CM; Jiang, D; Kowdley, KV; Lalezari, J; Lawitz, E; Mader, M; McHutchison, JG; Nelson, DR; Rodriguez-Torres, M; Symonds, WT | 1 |
| Berrey, MM; Ding, X; Gane, EJ; Hindes, RG; Hyland, RH; Stedman, CA; Svarovskaia, E; Symonds, WT | 1 |
152 review(s) available for sofosbuvir and Chronic Hepatitis C
| Article | Year |
|---|---|
Recent advances in the chromatographic determination of the most commonly used anti-hepatitis C drug sofosbuvir and its co-administered drugs in human plasma.
Topics: Antiviral Agents; Chromatography; Hepatitis C, Chronic; Humans; Plasma; Sofosbuvir | 2022 |
Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lipoproteins, LDL; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Clinical outcomes of sofosbuvir-based antivirals in patients with COVID-19: a systematic review and meta-analysis of randomized trials.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Randomized Controlled Trials as Topic; SARS-CoV-2; Sofosbuvir | 2022 |
Road to elimination of HCV: Clinical challenges in HCV management.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Homosexuality, Male; Humans; Male; Sex Workers; Sexual and Gender Minorities; Sofosbuvir | 2022 |
Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides | 2022 |
Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2022 |
Defer no more: advances in the treatment and prevention of chronic hepatitis C virus infection in children.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Infant, Newborn; Pregnancy; Sofosbuvir | 2022 |
Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Quinoxalines; Renal Insufficiency, Chronic; Sofosbuvir; Sustained Virologic Response | 2022 |
Treatment of hepatitis C in children and adolescents: how far have we reached?
Topics: Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Treatment Outcome | 2023 |
Daclatasvir as a hepatitis C infection treatment option: an up-to-date evaluation.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study.
Topics: Anilides; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmacovigilance; Recurrence; Ribavirin; Ritonavir; Sofosbuvir; Sustained Virologic Response | 2023 |
Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Neoplasms; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2023 |
Direct-Acting Antiviral Therapy for Treatment of Acute and Recent Hepatitis C Virus Infection: A Narrative Review.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir | 2023 |
Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6.
Topics: Antiviral Agents; Benzimidazoles; Databases, Factual; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2019 |
Overview of hepatitis C infection, molecular biology, and new treatment.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins | 2020 |
New approaches in viraemic organ transplantation and antiviral therapies.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Guanine; Hepatitis B, Chronic; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Neoplasms; Liver Transplantation; Macrocyclic Compounds; Proline; Quinoxalines; Salvage Therapy; Sofosbuvir; Sulfonamides; Tenofovir; Transplants | 2020 |
Progress Toward Hepatitis C Virus Elimination: Therapy and Implementation.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzofurans; Carbamates; Drug Therapy, Combination; Global Health; Health Care Costs; Hepatitis C, Chronic; Humans; Imidazoles; Proline; Pyrrolidines; Sofosbuvir; Sulfonamides; Uracil; Valine; World Health Organization | 2020 |
Public funding for transformative drugs: the case of sofosbuvir.
Topics: Antiviral Agents; Drug Costs; Drug Development; Financing, Government; Hepatitis C, Chronic; Humans; National Institutes of Health (U.S.); Sofosbuvir; United States | 2021 |
An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease.
Topics: Antiviral Agents; Hepatitis C; Hepatitis C, Chronic; Humans; Renal Insufficiency, Chronic; Sofosbuvir; Treatment Outcome | 2021 |
Hepatitis C-Associated Osteosclerosis: Improvement After Treatment with Sofosbuvir, Daclatasvir, and Ibandronate: Case Report and Literature Review.
Topics: Carbamates; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ibandronic Acid; Imidazoles; Male; Middle Aged; Osteosclerosis; Pyrrolidines; Sofosbuvir; Valine | 2021 |
Treatment failure with DAA therapy: Importance of resistance.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Macrocyclic Compounds; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure | 2021 |
Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Renal Dialysis; Renal Insufficiency, Chronic; Sofosbuvir; United States | 2022 |
Breakthroughs and challenges in the management of pediatric viral hepatitis.
Topics: Adult; Antiviral Agents; Child; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir | 2021 |
A Review on Analytical Strategies for the Assessment of Recently Approved Direct Acting Antiviral Drugs.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir | 2022 |
Sofosbuvir plus velpatasvir combination for the treatment of chronic hepatitis C in patients with end stage renal disease on renal replacement therapy: A systematic review and meta-analysis.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Kidney Failure, Chronic; Renal Replacement Therapy; Sofosbuvir; Treatment Outcome | 2022 |
The Challenge of Treating Children With Hepatitis C Virus Infection.
Topics: Administration, Oral; Adolescent; Antiviral Agents; Benzimidazoles; Child; Drug Therapy, Combination; Fluorenes; Hepatitis C, Chronic; Humans; Interferon Type I; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2017 |
Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Sofosbuvir | 2017 |
Sofosbuvir/velpatasvir fixed-dose combination for the treatment of chronic hepatitis C virus infection.
Topics: Animals; Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Patient Safety; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins | 2017 |
Sofosbuvir and velpatasvir for the treatment of hepatitis C.
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Risk Factors; Sofosbuvir; Sustained Virologic Response; Viral Load | 2017 |
Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2017 |
Sofosbuvir-velpatasvir: A single-tablet treatment for hepatitis C infection of all genotypes.
Topics: Animals; Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Drug Combinations; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir; Tablets; Treatment Outcome | 2017 |
Ledipasvir + Sofosbuvir for Liver Transplant Recipients With Recurrent Hepatitis C: A Systematic Review and Meta-analysis.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Recurrence; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2017 |
Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2017 |
Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil.
Topics: Antiviral Agents; Brazil; Carbamates; Costs and Cost Analysis; Drug Costs; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Valine | 2017 |
Efficacy and safety of Sofosbuvir-containing regimens in patients co-infected with chronic hepatitis C virus and human immunodeficiency virus: a meta-analysis.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Publication Bias; Sofosbuvir; Viral Load | 2018 |
Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Combinations; Drug Therapy, Combination; Fluorenes; Genotype; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2018 |
Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2018 |
[Current drug treatment of hepatitis C : Useful therapy algorithms taking into consideration economical aspects].
Topics: Algorithms; Antiviral Agents; Drug Costs; Germany; Hepatitis C, Chronic; Humans; Liver Cirrhosis; National Health Programs; Protease Inhibitors; Sofosbuvir; Viral Nonstructural Proteins | 2018 |
Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Approval; Drug Combinations; Drug Resistance, Viral; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; United States; United States Food and Drug Administration; Viral Nonstructural Proteins | 2018 |
Efficacy and safety of sofosbuvir-containing regimens in chronic hepatitis C patients with genotype 2 and 3: a comprehensive analysis of 18 randomized controlled trials.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Randomized Controlled Trials as Topic; Sofosbuvir; Sustained Virologic Response | 2018 |
Treatment of Hepatitis C Virus Infection in Dialysis Patients.
Topics: Antiviral Agents; Contraindications, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Japan; Renal Dialysis; Renal Insufficiency, Chronic; Sofosbuvir | 2018 |
Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2018 |
2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.
Topics: Benzimidazoles; Carbamates; Dose-Response Relationship, Drug; Drug Interactions; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Kidney; Protease Inhibitors; Pyrrolidines; Sofosbuvir; Sulfonamides; Valine | 2018 |
Sofosbuvir: Really Meets the Unmet Needs for Hepatitis C Treatment?
Topics: Administration, Oral; Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Sofosbuvir; Treatment Outcome | 2020 |
Are there any challenges left in hepatitis C virus therapy of HIV-infected patients?
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Drug Interactions; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sexual and Gender Minorities; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2020 |
Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials, Phase III as Topic; Cyclopropanes; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection.
Topics: Adult; Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Fatigue; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Multicenter Studies as Topic; Nasopharyngitis; Nausea; Pain; Patient Reported Outcome Measures; Sofosbuvir; Tablets; Young Adult | 2018 |
Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan.
Topics: Antiviral Agents; Drug Therapy, Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Pakistan; Prevalence; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2018 |
Treatment of hepatitis C virus genotype 4 in the DAA era.
Topics: Aminoisobutyric Acids; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Interferons; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2018 |
Improvement in Waldenström's Macroglobulinemia after Successful Treatment of HCV with Direct-acting Antivirals.
Topics: Antiviral Agents; Biopsy, Needle; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Immunohistochemistry; Liver Cirrhosis; Middle Aged; Severity of Illness Index; Simeprevir; Sofosbuvir; Treatment Outcome; Waldenstrom Macroglobulinemia | 2018 |
Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Viral Load | 2019 |
Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Prospective Studies; Renal Insufficiency, Chronic; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2019 |
Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Macrocyclic Compounds; Pyrrolidines; Quinoxalines; Retreatment; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure | 2019 |
Cost-effectiveness of treating hepatitis C in Seychelles.
Topics: Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Markov Chains; Quality-Adjusted Life Years; Sex Factors; Seychelles; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate | 2019 |
Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection.
Topics: Antiviral Agents; Enzyme Inhibitors; Hepatitis C, Chronic; Humans; Nucleotidyltransferases; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2013 |
Sofosbuvir and ABT-450: terminator of hepatitis C virus?
Topics: Animals; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Hepatitis Viruses; Humans; Interferons; Interleukins; Lactams, Macrocyclic; Macrocyclic Compounds; Patient Selection; Phenotype; Polymorphism, Genetic; Precision Medicine; Proline; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate | 2013 |
Efficacy and Safety of Sofosbuvir in the Treatment of Chronic Hepatitis C: The Dawn of a New Era.
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Hepatitis C, Chronic; Humans; Sofosbuvir | 2014 |
Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection.
Topics: Antiviral Agents; Biomarkers, Pharmacological; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2013 |
HCV F1/F2 patients: treat now or continue to wait.
Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Treatment Outcome; Uridine Monophosphate | 2014 |
Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Enzyme Inhibitors; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Sofosbuvir: first global approval.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Sofosbuvir (Sovaldi) for chronic hepatitis C.
Topics: Animals; Clinical Trials as Topic; Hepatitis C, Chronic; Humans; Prodrugs; Sofosbuvir; Uridine Monophosphate | 2014 |
Hepatitis C virus therapy in the direct acting antiviral era.
Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; Sofosbuvir; Thiazoles; Uridine Monophosphate | 2014 |
Hepatitis C treatment: an incipient therapeutic revolution.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Molecular Targeted Therapy; Oligopeptides; Proline; Protease Inhibitors; Sofosbuvir; Uridine Monophosphate | 2014 |
Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations.
Topics: Antiviral Agents; Drug Interactions; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
The rapid evolution of treatment strategies for hepatitis C.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate | 2014 |
Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks.
Topics: Administration, Oral; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sofosbuvir; Viral Nonstructural Proteins | 2014 |
The comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection.
Topics: Antiviral Agents; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus.
Topics: Animals; Antiviral Agents; Disease Progression; Drug Design; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2014 |
Hepatitis C.
Topics: Adult; Age Distribution; Anti-HIV Agents; Communicable Disease Control; Disease Management; Female; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Needs Assessment; Prisoners; Prisons; Ribavirin; Risk Assessment; Sex Distribution; Simeprevir; Sofosbuvir; Sulfonamides; Telemedicine; Treatment Outcome; United States; Uridine Monophosphate; Young Adult | 2014 |
Sofosbuvir: a review of its use in patients with chronic hepatitis C.
Topics: Antiviral Agents; Enzyme Inhibitors; Hepatitis C, Chronic; Humans; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Sofosbuvir for the treatment of chronic hepatitis C virus infection.
Topics: Administration, Oral; Animals; Antiviral Agents; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Patient Safety; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2014 |
Efficacy and safety of sofosbuvir-based therapy for the treatment of chronic hepatitis C in treatment-naïve and treatment-experienced patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Hepatitis C, Chronic; Humans; Middle Aged; Recurrence; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult | 2014 |
Advances in therapy for HIV/hepatitis C virus-coinfected patients in the liver transplant setting.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Liver Transplantation; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2015 |
Hepatitis C genotype 1.
Topics: Antiviral Agents; Cost-Benefit Analysis; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Viral Load | 2014 |
Update on the treatment of hepatitis C genotypes 2-6.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Global Health; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate; Viral Load | 2014 |
Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era.
Topics: Antiviral Agents; Clinical Trials as Topic; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Liver Cirrhosis; Practice Guidelines as Topic; Protease Inhibitors; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
[All-oral, interferon-free therapies for patients with chronic genotype 1 hepatitis C virus infection].
Topics: 2-Naphthylamine; Administration, Oral; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Drug Combinations; Fluorenes; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2014 |
Which therapeutic option for hepatitis C virus genotype 1?
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Oligopeptides; Proline; Randomized Controlled Trials as Topic; Simeprevir; Sofosbuvir; Viral Load | 2015 |
Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C.
Topics: Antiviral Agents; DNA, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Nucleic Acid Synthesis Inhibitors; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2014 |
The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Quality of Life; Randomized Controlled Trials as Topic; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate | 2014 |
The evolution of the therapeutic strategy in hepatitis C: features of sofosbuvir and indications.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir; Uridine Monophosphate; Virus Replication | 2014 |
Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2014 |
Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.
Topics: Adult; Animals; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Nausea; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Viral Nonstructural Proteins | 2015 |
Optimal therapy of genotype-2 chronic hepatitis C: what's new?
Topics: Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Prevalence; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Optimal therapy in genotype 4 chronic hepatitis C: finally cured?
Topics: Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine; Viral Nonstructural Proteins | 2015 |
Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Precision Medicine; Pyrrolidines; Sofosbuvir; Uridine Monophosphate; Valine | 2015 |
Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Genotype; Headache; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Nausea; Polyethylene Glycols; Protease Inhibitors; Ribavirin; Simeprevir; Sofosbuvir | 2015 |
Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2015 |
Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1.
Topics: Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Drug Combinations; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Meta-Analysis as Topic; Recurrence; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2015 |
Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series.
Topics: Administration, Oral; Adult; Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Uridine Monophosphate | 2015 |
Sofosbuvir for treatment of chronic hepatitis C.
Topics: Antiviral Agents; Clinical Trials as Topic; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir | 2015 |
Management of post transplant hepatitis C in the direct antiviral agents era.
Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Liver Transplantation; Oligopeptides; Postoperative Complications; Proline; Protease Inhibitors; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Valine; Viral Nonstructural Proteins | 2015 |
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir.
Topics: Animals; Antiviral Agents; Drug Interactions; Hepatitis C, Chronic; Humans; Prodrugs; Sofosbuvir; Viral Nonstructural Proteins | 2015 |
Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Sofosbuvir | 2015 |
Finding Truth in a World Full of Spin: Myth-Busting in the Case of Sovaldi.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Health Care Costs; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Sofosbuvir; Treatment Outcome; United States | 2015 |
Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cholestasis, Intrahepatic; Clinical Trials as Topic; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferons; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2015 |
Interferon-free therapy for hepatitis C: The hurdles amid a golden era.
Topics: 2-Naphthylamine; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil | 2015 |
Therapy for hepatitis C genotype 3: moving forward.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Health Care Costs; Health Services Accessibility; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Viral Load | 2015 |
Changing the face of hepatitis C management - the design and development of sofosbuvir.
Topics: Antiviral Agents; Drug Combinations; Drug Design; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir | 2015 |
New modalities in the treatment of HCV in pre and post - transplantation setting.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Transplantation; Postoperative Complications; Recurrence; RNA, Viral; Sofosbuvir; Viral Load | 2015 |
Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection.
Topics: Antiviral Agents; Carbamates; Drug Interactions; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine | 2015 |
[New era in the treatment of chronic hepatitis C - novel direct acting antivirals].
Topics: 2-Naphthylamine; Administration, Oral; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferons; Isoquinolines; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Nucleic Acid Synthesis Inhibitors; Proline; Protease Inhibitors; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine; Viral Load; Viral Nonstructural Proteins; Virus Replication | 2015 |
New medications for treatment of chronic hepatitis C.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Simeprevir; Sofosbuvir | 2015 |
Advances in hepatitis C therapies.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Transplantation; Liver Transplantation; Pyrrolidines; Simeprevir; Sofosbuvir; Valine | 2015 |
Simeprevir and sofosbuvir for treatment of hepatitis C infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Simeprevir; Sofosbuvir; Virus Replication | 2015 |
Management of direct-acting antiviral agent failures.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Protease Inhibitors; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Failure; Uracil; Uridine Monophosphate; Valine | 2015 |
Ideal oral combinations to eradicate HCV: The role of ribavirin.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Valine | 2016 |
Does herbal medicine reduce the risk of hepatocellular carcinoma?
Topics: Animals; Anti-Inflammatory Agents; Benzimidazoles; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cysteine; Drug Combinations; Drugs, Chinese Herbal; Fatty Liver; Fluorenes; Glycine; Glycyrrhetinic Acid; Glycyrrhizic Acid; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; Phytotherapy; Plant Preparations; Sofosbuvir; Tablets | 2015 |
Next-Generation Regimens: The Future of Hepatitis C Virus Therapy.
Topics: Amides; Antiviral Agents; Benzazepines; Benzofurans; Carbamates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Discovery; Drug Therapy, Combination; Forecasting; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Indoles; Isoquinolines; MicroRNAs; Molecular Targeted Therapy; Nucleic Acid Synthesis Inhibitors; Protease Inhibitors; Pyrrolidines; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Valine; Viral Nonstructural Proteins | 2015 |
Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Headache; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Nausea; Pyrrolidines; Sofosbuvir; Valine; Viral Nonstructural Proteins | 2016 |
Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection.
Topics: Administration, Oral; Antiviral Agents; Benzazepines; Carbamates; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Pyrrolidines; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine | 2016 |
Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Failure; Liver Transplantation; Recurrence; Renal Insufficiency; Ribavirin; Sofosbuvir | 2016 |
Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection.
Topics: Antiviral Agents; Carbamates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Valine | 2016 |
Nucleoside Inhibitors of Hepatitis C Virus NS5B Polymerase: A Systematic Review.
Topics: Animals; Antiviral Agents; Drug Design; Drug Discovery; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir; Structure-Activity Relationship; Viral Nonstructural Proteins | 2016 |
Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?
Topics: Antiviral Agents; Benzimidazoles; Disease Management; Drug Administration Schedule; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load | 2016 |
Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.
Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Protease Inhibitors; Quinoxalines; Sofosbuvir; Sulfonamides; Uracil; Valine; Viral Nonstructural Proteins | 2016 |
Hepatitis C virus: how to provide the best treatment with what I have.
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Protease Inhibitors; Quinoxalines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Young Adult | 2016 |
Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy.
Topics: Aged; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Protease Inhibitors; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides | 2016 |
Ledipasvir + sofosbuvir (Harvoni). A therapeutic advance in genotype 1 hepatitis C virus infection, despite uncertainties.
Topics: Animals; Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir; Uridine Monophosphate | 2015 |
Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.
Topics: Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal-An Evidence Review Group Perspective.
Topics: Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Sofosbuvir; Time Factors; Uridine Monophosphate | 2016 |
Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Sofosbuvir | 2016 |
Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Safety; Sofosbuvir | 2016 |
A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Models, Theoretical; Pyrrolidines; Simeprevir; Sofosbuvir; Valine | 2016 |
Ledipasvir-Sofosbuvir: A Once-Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection.
Topics: Administration, Oral; Benzimidazoles; Drug Combinations; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Sofosbuvir | 2016 |
Ledipasvir/sofosbuvir fixed-dose combination for treatment of hepatitis C virus genotype 4 infection.
Topics: Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir | 2016 |
Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C.
Topics: Animals; Antiviral Agents; Area Under Curve; Benzimidazoles; Dose-Response Relationship, Drug; Drug Interactions; Fluorenes; Half-Life; Hepatitis C, Chronic; Humans; Hydrogen-Ion Concentration; Liver Failure; Metabolic Clearance Rate; Renal Insufficiency; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2016 |
Interferon-free treatment for HCV-infected patients with decompensated cirrhosis.
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Combinations; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Observational Studies as Topic; Prospective Studies; Sofosbuvir; Treatment Outcome | 2017 |
Health Economic Evaluations of Sofosbuvir for Treatment of Chronic Hepatitis C: a Systematic Review.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Health Care Costs; Hepatitis C, Chronic; Humans; Sofosbuvir | 2016 |
Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Lung Transplantation; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Daclatasvir: A Review in Chronic Hepatitis C.
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2016 |
Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Patient Selection; Risk Factors; Simeprevir; Sofosbuvir; Treatment Outcome | 2016 |
Rapid Virological Response After Early Treatment with a Combined Therapy of Ledipasvir and Sofosbuvir in HCV Genotype 4 After Living Donor Liver Transplantation in a HCC Downstaged Patient: Case Report and Review of the Literature.
Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorenes; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Living Donors; Male; Middle Aged; Sofosbuvir | 2016 |
Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Fluorenes; Hepatitis C, Chronic; Humans; Medication Adherence; Sofosbuvir; Treatment Outcome; United States | 2016 |
Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C.
Topics: Adult; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis.
Topics: Antiviral Agents; Benzimidazoles; Databases, Bibliographic; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Randomized Controlled Trials as Topic; Ribavirin; Sofosbuvir; Treatment Outcome | 2017 |
Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir | 2017 |
Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.
Topics: Adult; Benzimidazoles; Biopsy, Needle; Cohort Studies; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunohistochemistry; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Recurrence; Risk Assessment; Severity of Illness Index; Sofosbuvir; Time Factors; Treatment Outcome | 2017 |
Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2017 |
Hepatitis C: efficacy and safety in real life.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2017 |
Special populations: treating hepatitis C in patients with decompensated cirrhosis and/or advanced renal impairment.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Randomized Controlled Trials as Topic; Renal Insufficiency; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2017 |
The impact of antiviral therapy for hepatitis C on the quality of life: a perspective.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Quality of Life; Sofosbuvir; Sustained Virologic Response | 2017 |
Management of direct antiviral agent failures.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Recurrence; Ribavirin; Sofosbuvir | 2016 |
A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection.
Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Liver Neoplasms; Sofosbuvir; Tablets; Treatment Outcome | 2017 |
Membranous nephropathy associated with hepatitis C virus infection treated with corticosteroids and Ledipasvir-Sofosbuvir: a case report and review of literature.
Topics: Aged; Anti-Inflammatory Agents; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Glomerulonephritis, Membranous; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Prednisolone; Prognosis; Sofosbuvir | 2017 |
Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure.
Topics: Antiviral Agents; Carbamates; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir | 2017 |
Treatment of chronic hepatitis C--are interferons really necessary?
Topics: Antiviral Agents; Carbamates; Cyclophilins; Cyclosporine; Drug Substitution; Hepatitis C, Chronic; Humans; Imidazoles; Immunologic Factors; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Serine Proteinase Inhibitors; Sofosbuvir; Uridine Monophosphate; Valine | 2012 |
What's new in HCV genotype 2 treatment.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load | 2012 |
229 trial(s) available for sofosbuvir and Chronic Hepatitis C
| Article | Year |
|---|---|
Nonadherence to Ledipasvir/Sofosbuvir Did Not Predict Sustained Virologic Response in a Randomized Controlled Trial of Human Immunodeficiency Virus/Hepatitis C Virus Coinfected Persons Who Use Drugs.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Pharmaceutical Preparations; Sofosbuvir; Substance-Related Disorders; Sustained Virologic Response; Treatment Outcome | 2022 |
A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial.
Topics: Adolescent; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; RNA; Sofosbuvir; Treatment Outcome; United States | 2022 |
Ledipasvir-sofosbuvir in Adolescents With Chronic Hepatitis C and Hematological Malignancies Undergoing Chemotherapy.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Diarrhea; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hematologic Neoplasms; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Sofosbuvir; Treatment Outcome | 2022 |
Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial.
Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Death, Sudden; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Prospective Studies; Quinoxalines; Rwanda; Sofosbuvir; Sulfonamides; Treatment Failure | 2022 |
Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial.
Topics: Adolescent; Adult; Antiviral Agents; Carbamates; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Prospective Studies; Rwanda; Sofosbuvir | 2022 |
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial.
Topics: Antiviral Agents; Benzimidazoles; COVID-19 Drug Treatment; Drug Therapy, Combination; Egypt; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2022 |
Comparative Real Life Egyptian Experience of the Combination of Sofosbuvir Plus Daclatasvir or Simeprevir for 12 Weeks in Naïve Cirrhotic Patients Infected with HCV Genotype 4.
Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome | 2023 |
Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial.
Topics: Amides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Nausea; Quinoxalines; Sofosbuvir; Sulfonamides | 2022 |
Statins Increase the Bioavailability of Fixed-Dose Combination of Sofosbuvir/Ledipasvir by Inhibition of P-glycoprotein.
Topics: Antiviral Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; Biological Availability; Cross-Over Studies; Drug Combinations; Fluorenes; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Sofosbuvir | 2022 |
Second-Phase Hepatitis C Plasma Viral Kinetics Directly Reflects Reduced Intrahepatic Burden of Hepatitis C Virus.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kinetics; Lactams, Macrocyclic; RNA, Viral; Sofosbuvir; Viremia | 2023 |
The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Sofosbuvir; Treatment Outcome | 2023 |
A randomized-controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Retreatment; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial).
Topics: Adolescent; Adult; Antiviral Agents; Equivalence Trials as Topic; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Sofosbuvir; Treatment Outcome | 2023 |
Efficacy and safety of treatment with sofosbuvir/velpatasvir in patients aged 6-18 years with chronic hepatitis C-Results of the PANDAA-PED study.
Topics: Antiviral Agents; Child; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2023 |
Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Republic of Korea; Sofosbuvir; Treatment Outcome | 2023 |
Community-Based Point-of-Diagnosis Hepatitis C Treatment for Marginalized Populations: A Nonrandomized Controlled Trial.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; RNA; Sofosbuvir; Treatment Outcome | 2023 |
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins | 2019 |
Relationships among neurotransmitters, cytokines and cognitive performance for individuals with hepatitis C achieving sustained virologic response: A pilot study.
Topics: Adult; Antiviral Agents; Benzimidazoles; Cognition; Cytokines; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Neurotransmitter Agents; Pilot Projects; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2019 |
SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Iran; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Tablets; Treatment Outcome; Valine | 2020 |
Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2020 |
Addition of Epigallocatechin Gallate 400 mg to Sofosbuvir 400 mg + Daclatisvir 60 mg With or Without Ribavirin in Treatment of Patients with Chronic Hepatitis C Improves the Safety Profile: A Pilot Study.
Topics: Adult; Catechin; Daclizumab; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pilot Projects; Random Allocation; Ribavirin; Sofosbuvir; Standard of Care; Sustained Virologic Response; Tablets; Treatment Outcome; Viral Load | 2019 |
Effects of sofosbuvir/ledipasvir therapy on chronic hepatitis C virus genotype 4, infected children of 3-6 years of age.
Topics: Antiviral Agents; Benzimidazoles; Child; Child, Preschool; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Prospective Studies; Sofosbuvir; Treatment Outcome | 2020 |
Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial.
Topics: Antiviral Agents; Carbamates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Outcome and Process Assessment, Health Care; Prospective Studies; Pyrrolidines; Renal Dialysis; Sofosbuvir; Valine | 2019 |
High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life exp
Topics: Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine | 2020 |
Efficacy of Sofosbuvir/Ledipasvir in Adolescents With Chronic Hepatitis C Genotypes 1, 3, and 4: A Real-world Study.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Prospective Studies; Sofosbuvir; Treatment Outcome | 2021 |
Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Japan; Liver Cirrhosis; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial.
Topics: Adult; Antiviral Agents; China; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome | 2020 |
Short-duration treatment with the novel non-nucleoside inhibitor CDI-31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: An open-label study.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Pilot Projects; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Time Factors | 2021 |
Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Killer Cells, Natural; Longitudinal Studies; Male; Neutrophils; Recurrence; Ribavirin; Sofosbuvir; T-Lymphocytes; Transcriptome; Treatment Outcome | 2020 |
Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single-arm, open-label, phase 3 trial.
Topics: Adult; Antiviral Agents; China; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins | 2021 |
Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Patient-Centered Care; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2022 |
Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Malaysia; Male; Middle Aged; RNA, Viral; Safety; Sofosbuvir; Sustained Virologic Response; Thailand; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2021 |
Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
Topics: Aged; Antiviral Agents; Carbamates; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Japan; Liver Cirrhosis; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response | 2021 |
Eliminating hepatitis C in a rural Appalachian county: protocol for the Kentucky Viral Hepatitis Treatment Study (KeY Treat), a phase IV, single-arm, open-label trial of sofosbuvir/velpatasvir for the treatment of hepatitis C.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Kentucky; Pregnancy; Sofosbuvir; Treatment Outcome | 2021 |
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.
Topics: 2-Naphthylamine; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Male; Middle Aged; Proline; Quinoxalines; Ribavirin; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine; Young Adult | 2021 |
Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial).
Topics: Age Factors; Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Comorbidity; Double-Blind Method; Female; Fluorenes; Health Status; Hepatitis C, Chronic; Humans; Male; Mental Health; Middle Aged; Oligopeptides; Patient Reported Outcome Measures; Polyethylene Glycols; Proline; Quality of Life; Severity of Illness Index; Sex Factors; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2017 |
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Young Adult | 2017 |
Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Intention to Treat Analysis; Liver Cirrhosis; Male; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult | 2016 |
Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir | 2017 |
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2017 |
Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection.
Topics: Adolescent; Antiviral Agents; Child; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2017 |
Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Thalassemia; Treatment Failure; Uridine Monophosphate | 2017 |
Directly observed therapy of sofosbuvir/ribavirin +/- peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Directly Observed Therapy; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; India; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sofosbuvir; Substance-Related Disorders; Sustained Virologic Response; Treatment Outcome; Viral Load; Young Adult | 2018 |
Efficacy and safety of sofosbuvir-based, interferon-free therapy : The Management of rheumatologic extrahepatic manifestations associated with chronic hepatitis C virus infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Prospective Studies; Retrospective Studies; Rheumatic Diseases; Sofosbuvir; Treatment Outcome | 2018 |
Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir.
Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Sequence Analysis, DNA; Sofosbuvir; Sustained Virologic Response; Viral Nonstructural Proteins | 2018 |
The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; Humans; Kinetics; Male; Models, Theoretical; Quinolines; Sofosbuvir; Sustained Virologic Response; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Load | 2017 |
Health-related Quality of Life in Adolescent Patients With Hepatitis C Genotype 1 Treated With Sofosbuvir and Ledipasvir.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Caregivers; Child; Female; Fluorenes; Follow-Up Studies; Health Status Indicators; Hepatitis C, Chronic; Humans; Male; Prospective Studies; Quality of Life; Self Report; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2018 |
Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cytochrome P-450 CYP3A; Drug Interactions; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Photosensitivity Disorders; Simeprevir; Sofosbuvir; Solute Carrier Organic Anion Transporter Family Member 1B3; Treatment Outcome; Uridine Monophosphate; Viral Load | 2017 |
Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Imidazoles; Interferons; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; RNA, Viral; Sofosbuvir; Valine; Viral Load | 2017 |
Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.
Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Quinoxalines; Retreatment; Ribavirin; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure | 2018 |
Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naïve or Experienced Patients.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response | 2017 |
Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Fatigue; Female; Fluorenes; Headache; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Pregnancy; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2018 |
IFNL4 Genotype Is Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir.
Topics: Aminoisobutyric Acids; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Interleukins; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Recurrence; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2017 |
Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens.
Topics: Antiviral Agents; Carbamates; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins | 2018 |
Shortened 8 Weeks Course of Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients, With Chronic Hepatitis C Infection.
Topics: Adolescent; Antiviral Agents; Carbamates; Child; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Imidazoles; Male; Pilot Projects; Prospective Studies; Pyrrolidines; Sofosbuvir; Treatment Outcome; Valine | 2018 |
Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin.
Topics: Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Male; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Treatment Outcome | 2018 |
The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Asia, Eastern; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Linear Models; Liver Cirrhosis; Male; Middle Aged; Quality of Life; Ribavirin; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Time Factors | 2018 |
Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Fatigue; Female; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pakistan; Prospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Viral Load; Young Adult | 2017 |
Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).
Topics: Aged; Benzimidazoles; Coinfection; Drug Administration Schedule; Female; Fibrosis; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Pilot Projects; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; High-Throughput Nucleotide Sequencing; Humans; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Treatment Outcome; Viral Nonstructural Proteins | 2018 |
Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial.
Topics: Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2018 |
Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kinetics; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Uridine Monophosphate; Valine; Viral Load; Viral Nonstructural Proteins | 2018 |
The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Mutation, Missense; Sequence Analysis, DNA; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Viral Nonstructural Proteins | 2018 |
Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Simeprevir; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Young Adult | 2018 |
Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Cirrhosis; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult | 2018 |
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
Topics: Administration, Oral; Adult; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Packaging; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Medication Adherence; Middle Aged; Recurrence; Risk Factors; Sofosbuvir; Substance Abuse, Intravenous; Sustained Virologic Response | 2018 |
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Valine; Viral Load | 2018 |
Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China.
Topics: Adult; Aged; Antiviral Agents; Asian People; China; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult | 2018 |
Sofosbuvir Adverse Events Profile in a Subset of Pakistani Population.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Neutropenia; Pancytopenia; Ribavirin; Sofosbuvir; Thrombocytopenia; Treatment Outcome | 2018 |
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.
Topics: Adult; Aged; Antiviral Agents; Benzofurans; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; Ribavirin; Sofosbuvir | 2018 |
Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2018 |
A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure.
Topics: Adult; Antiviral Agents; Carbamates; Cohort Studies; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Treatment Outcome; Valine | 2018 |
12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation.
Topics: Adult; Aged; Belgium; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; France; Graft Survival; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prognosis; Prospective Studies; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins | 2018 |
Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Resistance, Viral; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Patient Safety; RNA, Viral; Sofosbuvir; Tablets; Treatment Outcome; Uridine Monophosphate; Young Adult | 2018 |
Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Egypt; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2019 |
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Treatment Failure; Viral Nonstructural Proteins | 2018 |
Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Linear Models; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Multivariate Analysis; Patient Reported Outcome Measures; Proline; Quality of Life; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; RNA, Viral; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2019 |
Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Disease Eradication; Environmental Exposure; Female; Fluorenes; Follow-Up Studies; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Male; Middle Aged; Practice Guidelines as Topic; Prisoners; Prisons; Program Evaluation; Sofosbuvir; Spain; Sustained Virologic Response; Uridine Monophosphate; Viral Load; Viremia; Young Adult | 2018 |
Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; China; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Quality of Life; Republic of Korea; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Taiwan; Treatment Outcome | 2018 |
Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.
Topics: 2-Naphthylamine; Adult; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Fluorenes; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine; Viral Load | 2018 |
Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Japan; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Young Adult | 2018 |
Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.
Topics: Antiviral Agents; Benzimidazoles; Child; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2018 |
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; High-Throughput Nucleotide Sequencing; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome; Viral Nonstructural Proteins | 2018 |
Pharmacokinetics, Safety, and Tolerability of the Direct-acting Hepatitis C Antiviral Sofosbuvir in HealthyChineseSubjects.
Topics: Adult; Antiviral Agents; Asian People; Female; Healthy Volunteers; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Uridine; Young Adult | 2018 |
Sofosbuvir, Pegylated Interferon and Ribavirin in the Treatment of an Egyptian Cohort with Hepatitis C Virus Infection in Real-Life Clinical Practice.
Topics: Adolescent; Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2019 |
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Medication Adherence; Middle Aged; Sofosbuvir; Substance Abuse, Intravenous | 2018 |
Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin.
Topics: Antiviral Agents; Biopsy; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Kupffer Cells; Liver; Parenchymal Tissue; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2019 |
Sofosbuvir/velpatasvir for chronic hepatitis C infection in patients with transfusion-dependent thalassemia.
Topics: Antiviral Agents; Blood Transfusion; Carbamates; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Sofosbuvir; Thalassemia; Young Adult | 2019 |
Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Drug Users; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Young Adult | 2019 |
Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial.
Topics: Adult; Antiviral Agents; Carbamates; China; Drug Combinations; Female; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Respiratory Tract Infections; RNA, Viral; Singapore; Sofosbuvir; Sustained Virologic Response; Thailand; Treatment Outcome; Vietnam | 2019 |
Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment study.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Biopsy, Needle; Calcineurin Inhibitors; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Glucose Intolerance; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Kidney Failure, Chronic; Kidney Transplantation; Lactams, Macrocyclic; Leucine; Liver; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; RNA, Viral; Salvage Therapy; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine; Viral Load; Viral Nonstructural Proteins; Viremia | 2019 |
Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India.
Topics: Adult; Aged; Carbamates; Drug Combinations; Drug Monitoring; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; India; Male; Middle Aged; Recurrence; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2019 |
Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapy.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2019 |
Cytokine balance is restored as patient-reported outcomes improve in patients recovering from chronic hepatitis C.
Topics: Adult; Antiviral Agents; Benzimidazoles; Biomarkers; Cytokines; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Ribavirin; Severity of Illness Index; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Uridine Monophosphate | 2019 |
Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Internationality; Liver Cirrhosis; Male; Middle Aged; Patient Reported Outcome Measures; Pteridines; Quality of Life; Sofosbuvir; Surveys and Questionnaires; Treatment Outcome; Viral Load; Virus Replication | 2019 |
A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Pilot Projects; Proline; Quinoxalines; Recurrence; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Drug Monitoring; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Kidney Failure, Chronic; Liver Cirrhosis; Male; Middle Aged; Renal Dialysis; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2019 |
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Monitoring; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2019 |
Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Placebos; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2019 |
Efficacy and safety of treatment of chronic hepatitis C with sofosbuvir and ribavirin with or without peginterferon: a French prospective real-life cohort study of unselected 211 patients.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; France; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load | 2019 |
Changes in the Serum Hepcidin-to-ferritin Ratio with Erythroferrone after Hepatitis C Virus Eradication Using Direct-acting Antiviral Agents.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Female; Ferritins; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Hepcidins; Humans; Iron; Iron Overload; Male; Middle Aged; Peptide Hormones; Prospective Studies; Sofosbuvir; Uridine Monophosphate | 2019 |
Generic Ledipasvir-Sofosbuvir Treatment for Adolescents With Chronic Hepatitis C Virus Infection.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Blood Transfusion; Child; Drug Combinations; Drugs, Generic; Egypt; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Prospective Studies; Sofosbuvir; Uridine Monophosphate | 2020 |
Peripheral PD-1
Topics: Adult; Antiviral Agents; Benzimidazoles; CD8-Positive T-Lymphocytes; Cytokines; Drug Therapy, Combination; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pilot Projects; Programmed Cell Death 1 Receptor; Quinolines; Receptors, Immunologic; Sofosbuvir; Sustained Virologic Response; T-Lymphocytes; Thiophenes; Viral Load | 2019 |
Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting.
Topics: Adult; Antiviral Agents; Benzimidazoles; Clinical Protocols; Delivery of Health Care; Disease Eradication; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; India; Liver Cirrhosis; Male; Public Health; Ribavirin; Sofosbuvir; Sustained Virologic Response; Telemedicine | 2019 |
Shortened 8-Week Course of Sofosbuvir/Ledipasvir Therapy in Adolescents With Chronic Hepatitis C Infection.
Topics: Adolescent; Adolescent Health Services; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Female; Fluorenes; Hepatitis C, Chronic; Humans; Italy; Male; Prospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load | 2019 |
Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2020 |
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Nausea; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Young Adult | 2013 |
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Puerto Rico; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; United States; Uridine Monophosphate | 2013 |
Sofosbuvir for previously untreated chronic hepatitis C infection.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Young Adult | 2013 |
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Young Adult | 2013 |
In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.
Topics: Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Polyethylene Glycols; Recombinant Proteins; Replicon; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
Topics: Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Combinations; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Protease Inhibitors; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mental Health; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2014 |
IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin.
Topics: Antiviral Agents; Gene Expression Regulation; Genetic Predisposition to Disease; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interleukins; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2014 |
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Protease Inhibitors; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Young Adult | 2014 |
Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Patient Outcome Assessment; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2014 |
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load; Young Adult | 2014 |
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Nucleotidyltransferases; RNA-Dependent RNA Polymerase; Sofosbuvir; Uridine Monophosphate; Viral Load; Viral Nonstructural Proteins | 2014 |
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load; Young Adult | 2014 |
Sofosbuvir and ribavirin in HCV genotypes 2 and 3.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load | 2014 |
Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome.
Topics: Antiviral Agents; Chemokine CXCL10; Drug Therapy, Combination; Endopeptidases; Gene Expression; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver; Recurrence; Ribavirin; RNA, Messenger; Sofosbuvir; Treatment Outcome; Ubiquitin Thiolesterase; Uridine Monophosphate | 2014 |
Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Recurrence; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Valine | 2014 |
Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens.
Topics: Adolescent; Antiviral Agents; Drug Therapy, Combination; Female; Health Surveys; Hepatitis C, Chronic; Humans; Interferons; Male; Patient Preference; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Uridine Monophosphate | 2014 |
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
Topics: Adult; Antiviral Agents; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reference Values; Ribavirin; Risk Assessment; Severity of Illness Index; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate | 2014 |
Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase.
Topics: Adult; Antiviral Agents; Base Sequence; Benzimidazoles; Cell Line; Drug Resistance, Viral; Female; Fluorenes; Furans; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Microbial Sensitivity Tests; Molecular Sequence Data; Protein Binding; Quinolines; Ribavirin; Sequence Analysis, RNA; Sofosbuvir; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.
Topics: Adult; Aged; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Young Adult | 2014 |
Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.
Topics: Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lipid Metabolism; Lipoproteins, LDL; Male; Middle Aged; Ribavirin; Sofosbuvir; Uridine Monophosphate; Virus Replication | 2015 |
Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Female; France; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Young Adult | 2015 |
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Recurrence; RNA, Viral; Sofosbuvir; Uridine Monophosphate | 2015 |
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Mutation; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate | 2014 |
Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA-Dependent RNA Polymerase; RNA, Viral; Sofosbuvir; Treatment Outcome; United States; Viral Load; Viral Nonstructural Proteins | 2015 |
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation.
Topics: Antiviral Agents; Compassionate Use Trials; Female; Hepatitis C, Chronic; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Severity of Illness Index; Sofosbuvir; Treatment Failure; Uridine Monophosphate | 2015 |
The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Viral Load | 2015 |
Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes.
Topics: Antiviral Agents; Coinfection; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Quality of Life; Ribavirin; Self Report; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2015 |
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Male; Middle Aged; Quinolines; Ribavirin; RNA, Viral; Sofosbuvir; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Load | 2015 |
Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV.
Topics: Adult; Aged; Animals; Anti-Retroviral Agents; Antiviral Agents; Cohort Studies; Drug Interactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load | 2015 |
Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.
Topics: Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult | 2015 |
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Topics: Adolescent; Adult; Aged; Antiviral Agents; Benzimidazoles; Double-Blind Method; Female; Fluorenes; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Placebos; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult | 2015 |
Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy.
Topics: Antiviral Agents; Drug Resistance, Viral; Evolution, Molecular; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Longitudinal Studies; Mutation, Missense; Phylogeny; Recurrence; RNA, Viral; Sofosbuvir; Viral Nonstructural Proteins | 2015 |
Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Failure; Uridine Monophosphate | 2015 |
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Young Adult | 2015 |
Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed.
Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Failure; Uridine Monophosphate; Young Adult | 2015 |
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Benzimidazoles; Drug-Related Side Effects and Adverse Reactions; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Young Adult | 2015 |
Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir | 2015 |
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Uridine Monophosphate; Young Adult | 2015 |
Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin.
Topics: Adult; Aged; Anemia; Antiviral Agents; Erythrocytes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Serum; Sofosbuvir; Treatment Outcome; Viral Load | 2015 |
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
Topics: Antiviral Agents; Benzimidazoles; Cholestasis, Intrahepatic; Disease Progression; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; United States; Uridine Monophosphate | 2015 |
[Healing rate after 12 weeks over 90% for the first time].
Topics: Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Uridine Monophosphate; Valine | 2015 |
[In Process Citation].
Topics: Anti-HIV Agents; Antiviral Agents; Carbamates; Cost Savings; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Valine; Viral Load | 2015 |
The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Monitoring; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Patient Outcome Assessment; Ribavirin; RNA, Viral; Sofosbuvir | 2016 |
Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy.
Topics: Adult; Antiviral Agents; Benzimidazoles; Chemokine CXCL10; Convalescence; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Protein Processing, Post-Translational; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load; Virus Replication | 2015 |
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.
Topics: Aged; Benzimidazoles; DNA, Viral; Drug Combinations; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Viral Load | 2015 |
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.
Topics: Adult; Aged; Anti-Retroviral Agents; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Valine; Viral Load | 2015 |
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
Topics: Anti-Retroviral Agents; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load | 2015 |
Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Severity of Illness Index; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load | 2015 |
Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; New Zealand; Random Allocation; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load | 2015 |
Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels.
Topics: Antiviral Agents; Apolipoproteins; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir | 2015 |
Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Quinolines; Sofosbuvir; Treatment Outcome; Young Adult | 2016 |
Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Retreatment; Sequence Analysis, DNA; Sofosbuvir; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2016 |
Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Black or African American; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Young Adult | 2016 |
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome; Young Adult | 2015 |
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Young Adult | 2015 |
Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.
Topics: Antiviral Agents; Benzimidazoles; Cardiovascular Diseases; Cholesterol, LDL; Coinfection; Drug Therapy, Combination; Dyslipidemias; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolines; Ribavirin; Sofosbuvir; Thiophenes; Uridine Monophosphate | 2016 |
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Recurrence; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins | 2015 |
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2015 |
Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.
Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Furans; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Quinolines; RNA, Viral; Sofosbuvir; Thiophenes; Treatment Outcome; Viral Load | 2015 |
Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2016 |
The very-rapid and the ultra-rapid virologic response to two treatment options in patients with chronic hepatitis C: an interim report of a prospective randomized comparative effectiveness study.
Topics: Adult; Antiviral Agents; Comparative Effectiveness Research; Drugs, Generic; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; RNA, Viral; Sofosbuvir; Therapeutic Equivalency; Time Factors; Treatment Outcome; Viral Load | 2015 |
Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Sofosbuvir; Urban Population | 2016 |
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2).
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Simeprevir; Sofosbuvir; Treatment Outcome | 2016 |
Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Valine | 2016 |
Ocular Surface Changes With Sofosbuvir in Egyptian Patients With Hepatitis C Virus Infection.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Dry Eye Syndromes; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sofosbuvir; Tears | 2016 |
Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Simeprevir; Sofosbuvir; Treatment Outcome; Young Adult | 2016 |
Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
Topics: Administration, Oral; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; RNA, Viral; Sofosbuvir; Treatment Outcome; Viral Load | 2016 |
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon- and Ribavirin-Free Regimens.
Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferons; Male; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Gastroenterology; Genotype; Graft vs Host Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Treatment Outcome; Viral Load | 2016 |
A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Taiwan; Treatment Outcome; Viral Load; Young Adult | 2016 |
Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus.
Topics: Adult; Aged; Benzimidazoles; Carbamates; Drug Combinations; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Sofosbuvir; Tablets; Taiwan; Treatment Outcome | 2016 |
Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pilot Projects; Pyrrolidines; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Valine | 2016 |
A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load; Young Adult | 2016 |
On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load | 2016 |
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Global Health; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Viral Load | 2016 |
[Complication sequelae prevented, morbidity decreased].
Topics: Carbamates; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Sofosbuvir; Valine; Viremia | 2015 |
An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Patient Reported Outcome Measures; Retrospective Studies; Ribavirin; Sofosbuvir | 2016 |
[Daclatasvir/sofosbuvir is effective also in advanced liver disease].
Topics: Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Time Factors; United States; Valine; Viral Load; Young Adult | 2016 |
A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Republic of Korea; Sofosbuvir; Sustained Virologic Response; Tablets; Treatment Outcome; Uridine Monophosphate; Young Adult | 2016 |
Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Veterans | 2017 |
[In HIV-HCV co-infection check for drug interactions].
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus.
Topics: Adult; Antiviral Agents; Benzimidazoles; Efficiency; Fatigue; Female; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Patient Satisfaction; Sofosbuvir; Treatment Outcome | 2016 |
Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase II studies.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Sofosbuvir | 2016 |
Efficacy of sofosbuvir plus ribavirin in treatment-naive patients with genotype-1 and -3 HCV infection: results from a Russian Phase IIIb study.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir | 2016 |
Interferon-free treatment of chronic hepatitis C virus infection in patients with inherited bleeding disorders.
Topics: Adult; Antiviral Agents; Blood Coagulation Disorders, Inherited; Female; Hemorrhage; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Sofosbuvir; Treatment Outcome | 2017 |
Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.
Topics: Adult; Carbamates; Comorbidity; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load | 2016 |
Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Period; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome | 2016 |
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Ribavirin; Serine Proteases; Sofosbuvir; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2016 |
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Serine Proteases; Sofosbuvir; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2016 |
Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Germany; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Sofosbuvir; Viral Load; Young Adult | 2016 |
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial.
Topics: Antiviral Agents; Benzofurans; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Quinoxalines; Ribavirin; RNA, Viral; Sofosbuvir | 2016 |
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.
Topics: Adult; Antiviral Agents; Benzimidazoles; Data Interpretation, Statistical; Drug Therapy, Combination; Drug Users; Enzyme-Linked Immunosorbent Assay; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Opiate Substitution Treatment; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Viral Load | 2016 |
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.
Topics: Adult; Antiviral Agents; Carbamates; Data Interpretation, Statistical; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Medication Adherence; Middle Aged; Opiate Substitution Treatment; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2016 |
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.
Topics: Antiviral Agents; Disease-Free Survival; Female; Hepatitis C, Chronic; Humans; Lymphoma, B-Cell; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Survival Rate | 2016 |
The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C.
Topics: Administration, Oral; Aged; Antiviral Agents; Biopsy; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Liver; Liver Cirrhosis; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Tacrolimus; Transaminases; Valine | 2016 |
Results of sofosbuvir-based combination therapy for chronic hepatitis C cohort of Indian patients in real-life clinical practice.
Topics: Adult; Antiviral Agents; Asian People; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; India; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome | 2017 |
Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naïve and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis.
Topics: Adolescent; Adult; Aged; Animals; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Simeprevir; Sofosbuvir; Treatment Outcome; Young Adult | 2017 |
Efficacy and safety of sofosbuvir-based therapy for chronic hepatitis C infection in "real-life" cohort.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Sofosbuvir | 2017 |
Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug-Related Side Effects and Adverse Reactions; Female; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Simeprevir; Sofosbuvir; Treatment Outcome; United States; Valine | 2017 |
Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO).
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2017 |
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Imidazoles; Intention to Treat Analysis; Isoquinolines; Male; Middle Aged; Proof of Concept Study; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine; Viral Load | 2016 |
Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir.
Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Fluorenes; Genes, Viral; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Mutation; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Uridine Monophosphate; Viral Nonstructural Proteins | 2017 |
Sofosbuvir plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; India; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2017 |
Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study).
Topics: Adult; Antiviral Agents; Benzazepines; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; United States; Valine; Viral Load; Young Adult | 2017 |
Perioperative Ledipasvir-Sofosbuvir for HCV in Liver-Transplant Recipients.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Transplantation; Perioperative Care; RNA, Viral; Sofosbuvir | 2016 |
Ledipasvir and sofosbuvir for recurrent hepatitis C after liver transplantation.
Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Liver Transplantation; Male; Middle Aged; Pilot Projects; Sofosbuvir; Treatment Outcome | 2017 |
The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection.
Topics: Administration, Oral; Adolescent; Antiviral Agents; Benzimidazoles; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Patient Safety; Risk Assessment; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Viral Load | 2017 |
The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease.
Topics: Antiviral Agents; Bayes Theorem; Carbamates; Cohort Studies; Drug Therapy, Combination; Europe; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2017 |
Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.
Topics: Antiviral Agents; Benzimidazoles; Drug Combinations; Fatigue; Female; Fluorenes; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Nausea; Sofosbuvir; Sustained Virologic Response | 2017 |
Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Treatment Outcome; Work Performance | 2017 |
Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Confidence Intervals; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Quinoxalines; Ribavirin; Severity of Illness Index; Sofosbuvir; Sulfonamides; Treatment Outcome; Young Adult | 2017 |
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Young Adult | 2013 |
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load; Viral Nonstructural Proteins | 2013 |
944 other study(ies) available for sofosbuvir and Chronic Hepatitis C
| Article | Year |
|---|---|
Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Administration Schedule; Drug Combinations; Female; Fluorenes; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Quinoxalines; Retrospective Studies; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2021 |
Seronegative Chronic Hepatitis C Virus Infection: A Teachable Moment.
Topics: Adult; Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Immunocompetence; Liver Cirrhosis; Liver Function Tests; Parvoviridae Infections; Serologic Tests; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; End Stage Liver Disease; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Retrospective Studies; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2021 |
Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso.
Topics: Antiviral Agents; Burkina Faso; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Seroepidemiologic Studies; Sofosbuvir; Treatment Outcome; Viral Load | 2022 |
Evaluation of the genetic toxicity of sofosbuvir and simeprevir with and without ribavirin in a human-derived liver cell line.
Topics: Antiviral Agents; Cell Line; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Simeprevir; Sofosbuvir | 2021 |
Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides | 2021 |
Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Iran; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons.
Topics: Antiviral Agents; Area Under Curve; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrrolidines; Sofosbuvir; Valine | 2022 |
[Glecaprevir/Pibrentasvir + Sofosbuvir + Ribavirin as a salvage regimen after Sofosbuvir + Velpatasvir + Voxilaprevir re-treatment failure].
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Child; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Failure; Treatment Outcome | 2022 |
Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure.
Topics: Antiviral Agents; Genome, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Polymorphism, Genetic; Sofosbuvir; Treatment Failure; Viral Load; Viral Nonstructural Proteins | 2021 |
Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus.
Topics: Adult; Aged; Antiviral Agents; Ascites; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interleukin-10; Liver Cirrhosis; Liver Neoplasms; Lymphadenitis; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Splenomegaly; Valine | 2021 |
Factors associated with a reduction in the quality of life of patients with chronic hepatitis C treated by ledipasvir/sofosbuvir therapy.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Quality of Life; Sofosbuvir | 2021 |
Real-life experience of treating HCV co-infection among HIV-infected population in Egypt: single-center experience.
Topics: Antiviral Agents; Coinfection; Egypt; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Retrospective Studies; Sofosbuvir; Treatment Outcome | 2022 |
Sofosbuvir-based antiviral therapy provided highly treatment efficacy, safety, and good tolerability for Taiwanese chronic hepatitis C patients with decompensated cirrhosis.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Outcome Assessment, Health Care; Safety; Sofosbuvir; Sustained Virologic Response; Taiwan; Treatment Outcome | 2022 |
Diagnostic approach to elucidate the efficacy and side effects of direct-acting antivirals in HCV infected patients.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Sofosbuvir; Sustained Virologic Response; Valine | 2021 |
The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Immunity, Innate; Nerve Tissue Proteins; Ribavirin; Sofosbuvir; Treatment Outcome | 2022 |
The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals.
Topics: Adult; Aged; Alaska; American Indian or Alaska Native; Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Female; Fluorenes; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Prognosis; Sofosbuvir; Sustained Virologic Response | 2021 |
Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; DNA, Viral; Fluorenes; Follow-Up Studies; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Taiwan | 2022 |
Hepatitis C Virus Treatment Response to Direct-acting Antivirals Among Adolescents With HIV/HCV Coinfection: Real-world Data From Ukraine.
Topics: Adolescent; Antiviral Agents; Child; Cohort Studies; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Sofosbuvir; Treatment Outcome; Ukraine | 2022 |
Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAAs?
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2022 |
Monitoring of iron, lipid and liver profiles in Egyptian hepatitis C virus patients on sofosbuvir therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Iron; Lipids; Sofosbuvir | 2022 |
Patient-specific genetic factors predict treatment failure in sofosbuvir-treated patients with chronic hepatitis C.
Topics: Antiviral Agents; Canada; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interleukins; Ribavirin; Sofosbuvir; Treatment Failure; Treatment Outcome | 2022 |
Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection.
Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Child; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2022 |
Case Report of Hepatitis C Treatment Success in Male With Decompensated Cirrhosis and Polysubstance Abuse: The Important Role of the Pharmacist in Active Care Coordination.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Pharmacists; Sofosbuvir; Treatment Outcome | 2023 |
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Registries; Ribavirin; Sofosbuvir; Taiwan; Uridine Monophosphate | 2022 |
Assessment of outcome for sample of Iraqi patients with chronic hepatitis C virus infection treated by Ledipasvir/sofosbuvir drug.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Pharmaceutical Preparations; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2021 |
Application of different spectrophotometric methods for quantitative analysis of direct acting antiviral drugs simeprevir and sofosbuvir.
Topics: Antiviral Agents; COVID-19; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; SARS-CoV-2; Simeprevir; Sofosbuvir | 2022 |
Retrospective multicentre study on the effectiveness of first-line direct-acting antivirals against hepatitis C virus genotype-1.
Topics: Aged; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Retrospective Studies; Sofosbuvir | 2022 |
Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir; World Health Organization | 2022 |
Sofosbuvir-based direct-acting antivirals for patients with decompensated hepatitis C virus-related cirrhosis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2022 |
The Influence of Treatment with Ledipasvir/Sofosbuvir on Growth Parameters in Children and Adolescents with Chronic Hepatitis C.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Sofosbuvir; Treatment Outcome | 2022 |
Impact of proton pump inhibitors on sustained virologic response in veterans treated with sofosbuvir/velpatasvir for chronic hepatitis C virus: A retrospective cohort study.
Topics: Antiviral Agents; Carbamates; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Proton Pump Inhibitors; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Veterans | 2022 |
Real-Life Data on Sofosbuvir/Ledipasvir in Patients with Chronic Viral Hepatitis C Genotype 1b: A Single-Center Experience.
Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2022 |
Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2022 |
Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzopyrans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Lipids; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sugars; Sulfonamides; Treatment Outcome | 2022 |
Sofosbuvir-based therapy for late pregnant women and infants with severe chronic hepatitis C: A case series study.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Infant, Newborn; Pregnancy; Pregnant Women; Sofosbuvir; Treatment Outcome | 2022 |
Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study.
Topics: Antiviral Agents; Cohort Studies; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Republic of Korea; RNA; Sofosbuvir; Treatment Outcome | 2022 |
Hepatitis C viral clearance with coadministration of crushed sofosbuvir/velpatasvir and high-dose pantoprazole after liver transplantation.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Transplantation; Pancreatitis; Pantoprazole; Sofosbuvir | 2022 |
Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Iran; Liver Cirrhosis; Sofosbuvir; Treatment Outcome | 2022 |
[Efficacy and tolerance of direct-acting antiviral drugs for the treatment of hepatitis C in Joseph Raseta Befelatanana Teaching Hospital in Antananarivo, Madagascar].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hospitals, Teaching; Humans; Madagascar; Retrospective Studies; Ribavirin; Sofosbuvir | 2021 |
Comparative Effectiveness of Direct-Acting Antivirals for Posttraumatic Stress Disorder in Veterans Affairs Patients With Hepatitis C Virus Infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Stress Disorders, Post-Traumatic; Sustained Virologic Response; Treatment Outcome; Veterans | 2022 |
Sofosbuvir-based direct-acting antivirals and changes in cholesterol and low density lipoprotein-cholesterol.
Topics: Antiviral Agents; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2022 |
Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Registries; Sofosbuvir; Sulfonamides; Treatment Outcome | 2022 |
Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzopyrans; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2022 |
Sofosbuvir induces gene expression for promoting cell proliferation and migration of hepatocellular carcinoma cells.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cell Proliferation; Gene Expression; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Sofosbuvir; Treatment Outcome | 2022 |
Safety and Efficacy of Ledipasvir/Sofosbuvir in the Treatment of Chronic Hepatitis C Virus Infection in Treatment-Naïve Children without and with Comorbidities.
Topics: Antiviral Agents; Benzimidazoles; Child; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Quality of Life; Sofosbuvir; Treatment Outcome | 2022 |
Identification of NS5B resistance against SOFOSBUVIR in hepatitis C virus genotype 3a, naive and treated patients.
Topics: Antiviral Agents; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; RNA; Sofosbuvir; Viral Nonstructural Proteins | 2022 |
Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China.
Topics: Adult; Antiviral Agents; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Kidney; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Viremia | 2022 |
Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Turkey | 2022 |
Effects of aged garlic and ginkgo biloba extracts on the pharmacokinetics of sofosbuvir in rats.
Topics: Animals; Antioxidants; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromatography, Liquid; Garlic; Ginkgo biloba; Hepatitis C, Chronic; Plant Extracts; Rats; Sofosbuvir; Tandem Mass Spectrometry | 2022 |
RNA-Dependent RNA Polymerase of the Second Human Pegivirus Exhibits a High-Fidelity Feature.
Topics: Antiviral Agents; Coinfection; Flaviviridae Infections; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Nucleosides; Pegivirus; Phylogeny; RNA Viruses; RNA-Dependent RNA Polymerase; RNA, Viral; Sofosbuvir | 2022 |
Severe impairment of patient-reported outcomes in patients with chronic hepatitis C virus infection seen in real-world practices across the world: Data from the global liver registry.
Topics: Antiviral Agents; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatigue; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Patient Reported Outcome Measures; Quality of Life; Registries; Sofosbuvir | 2022 |
Dual versus triple therapy in treatment of hepatitis C virus (HCV).
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Real-world Safety and Effectiveness of 24-week Sofosbuvir and Ribavirin Treatment in Patients Infected with Rare Chronic Hepatitis C Virus Genotypes 3, 4, 5, or 6 in Japan.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Japan; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
High sustained virologic response rate after 8 weeks of direct-acting antivirals in cancer patients with chronic hepatitis C virus.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Neoplasms; Male; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2022 |
Drug-drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study.
Topics: Aged; Antiviral Agents; Cohort Studies; Drug Interactions; Hepacivirus; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Sofosbuvir | 2022 |
Three regimens for re-treatment failure of Sofosbuvir-based therapy for chronic hepatitis-C genotype-4: a cohort study.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Failure; Treatment Outcome | 2022 |
Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents.
Topics: Aged; alpha-Fetoproteins; Antiviral Agents; Carbamates; Cross-Sectional Studies; Drug Therapy, Combination; Egypt; Fibrosis; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Leukocytes, Mononuclear; Pyrrolidines; Ribavirin; RNA; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2022 |
Long-Term Follow-Up of Thalassemia Major Patients with Hepatitis C Virus Treated with Sofosbuvir and Daclatasvir: A Cohort Study.
Topics: Antiviral Agents; beta-Thalassemia; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Iron Overload; Male; Pyrrolidines; Sofosbuvir; Treatment Outcome | 2022 |
Distribution of chronic hepatitis C genotype and evaluation of clinical factors affecting direct-acting antiviral treatment responses in the Western Black Sea Region, Turkey.
Topics: Antiviral Agents; Black Sea; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Macrocyclic Compounds; Retrospective Studies; Ritonavir; RNA; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Turkey | 2022 |
Direct-acting antiviral agent use and gastrointestinal safety in patients with chronic hepatitis C: a pharmacovigilance study based on FDA Adverse Event Reporting System.
Topics: Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmacovigilance; Sofosbuvir | 2023 |
Serial changes in renal indices in chronic HCV patients with and without HIV co-infection receiving sofosbuvir and tenofovir-based therapies.
Topics: Antiviral Agents; Coinfection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Prospective Studies; Sofosbuvir; Tenofovir | 2023 |
Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Neoplasm Recurrence, Local; Ribavirin; Sofosbuvir | 2023 |
Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Sofosbuvir; Spain | 2022 |
Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients.
Topics: Antiviral Agents; Circulating MicroRNA; Egypt; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; MicroRNAs; Ribavirin; Sofosbuvir | 2022 |
Early post-liver transplant use of direct-acting antivirals in naive and NS5A inhibitor-experienced HCV patients.
Topics: Aminoisobutyric Acids; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Liver Transplantation; Middle Aged; Neoplasm Recurrence, Local; Sofosbuvir | 2023 |
Treatment-experienced patient with Roux-en-Y gastric bypass successfully treated with sofosbuvir/velpatasvir/voxilaprevir: A case report.
Topics: Antiviral Agents; Gastric Bypass; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir | 2023 |
Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Romania; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2022 |
Selective profiling of liver-related specific proteins based on sofosbuvir-modified magnetic separation material.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Genotype; Hepatitis C, Chronic; Humans; Liver Neoplasms; Magnetic Phenomena; Silicon Dioxide; Sofosbuvir | 2023 |
A rare case report of iatrogenic Cushing syndrome caused by direct anti-hepatitis C virus therapy with sofosbuvir/velpatasvir.
Topics: Adrenocorticotropic Hormone; Antiviral Agents; Cushing Syndrome; Female; Genotype; Hepacivirus; Hepatitis A; Hepatitis C, Chronic; Humans; Hydrocortisone; Middle Aged; Sofosbuvir; Treatment Outcome | 2022 |
Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interleukins; Pilot Projects; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2023 |
Cardiac toxicity associated with pharmacokinetic drug-drug interaction between crizotinib and sofosbuvir/velpatasvir: A case report.
Topics: Aged; Antiviral Agents; Carcinoma, Non-Small-Cell Lung; Cardiotoxicity; Crizotinib; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lung Neoplasms; Macrocyclic Compounds; Male; Sofosbuvir | 2023 |
Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis.
Topics: Antiviral Agents; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Humans; Hypertension, Portal; Liver Cirrhosis; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2023 |
Antiviral Treatment Failures After Transplantation of Organs From Donors With Hepatitis C Infection: A Report of 4 Cases.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Sustained Virologic Response; Tissue Donors; Treatment Failure | 2023 |
Hepatitis C micro-elimination through the retrieval strategy of patients lost to follow-up.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lost to Follow-Up; Sofosbuvir | 2023 |
Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Porphyria Cutanea Tarda; Porphyrins; RNA; Sofosbuvir; Treatment Outcome | 2023 |
Next-generation sequencing analysis of hepatitis C virus resistance-associated substitutions in direct-acting antiviral failure in South Korea.
Topics: Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Ribavirin; Sofosbuvir; Viral Nonstructural Proteins | 2023 |
Visual symptoms with Sofosbuvir in hepatitis C treatment - a case report from Pakistan.
Topics: Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pakistan; Sofosbuvir; Treatment Outcome | 2023 |
Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Malaysia; Sofosbuvir | 2023 |
Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Viral Nonstructural Proteins | 2023 |
Comorbidities and the use of comedications among patients with chronic hepatitis C in Korea: A nationwide cross-sectional study.
Topics: Aged; Antiviral Agents; Comorbidity; Cross-Sectional Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Republic of Korea; Sofosbuvir | 2023 |
Non-ANCA Leucocytoclasic Vasculitis Induced by Sofosbuvir/Ledipasvir Treatment: A Case Report.
Topics: Antibodies, Antineutrophil Cytoplasmic; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Sofosbuvir; Treatment Outcome; Vasculitis | 2024 |
Human pegivirus viremia in HCV/HIV co-infected patients: Direct acting antivirals exert anti-pegivirus effects.
Topics: Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferons; Male; Pegivirus; Polyethylene Glycols; RNA, Viral; Sofosbuvir; Viremia | 2023 |
Newly diagnosed hepatitis C infection after pancreas transplantation with multiple treatment failures.
Topics: Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pancreas Transplantation; Pyrrolidines; Quinoxalines; Sofosbuvir; Treatment Failure | 2023 |
[A case of chronic hepatitis C treated with sofosbuvir/velpatasvir combined with ribavirin among 3-year-old children with low body weight].
Topics: Antiviral Agents; Body Weight; Child, Preschool; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Impact of oral antiviral therapy against HCV on gut microbiota. A prospective study.
Topics: Antiviral Agents; Drug Therapy, Combination; Gastrointestinal Microbiome; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Macrocyclic Compounds; Male; Prospective Studies; Sofosbuvir | 2023 |
Efficacy and safety of pan-genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on dolutegravir-based antiretroviral therapy.
Topics: Adult; Antiviral Agents; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome; Young Adult | 2023 |
Treatment effectiveness and side effects of patients with hepatitis C in the prisons of Southern Taiwan: a real-life retrospective analysis.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Prisons; Retrospective Studies; Sofosbuvir; Taiwan; Treatment Outcome | 2023 |
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interleukins; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Pre-existing, treatment-specific resistance-associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct-acting antivirals.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2023 |
Fitness-Dependent, Mild Mutagenic Activity of Sofosbuvir for Hepatitis C Virus.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Mutagens; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Sofosbuvir; Treatment Outcome | 2023 |
Prediction of response to sofosbuvir-based therapy using serum interleukin-12 and single nucleotide polymorphism of the interleukin 28B gene as predictive factors in HCV positive genotype-4 patients.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukin-12; Interleukins; Polymorphism, Single Nucleotide; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Evaluation Of Left Ventricular Function After Sofosbuvir And Daclatasvir Regimen For Chronic Hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Pyrrolidines; Sofosbuvir; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2023 |
Cardiovascular Risk Assessment After Sofosbuvir And Daclatasvir Regimen For Chronic Hepatitis C Virus Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cardiovascular Diseases; Drug Therapy, Combination; Female; Genotype; Heart Disease Risk Factors; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Pyrrolidines; Risk Factors; Sofosbuvir; Treatment Outcome | 2023 |
CD4/CD8 Ratio could be predictor of burden hepatocellular carcinoma in Egyptian chronic hepatitis C after combined sofosbuvir and daclatasvir therapy.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Egypt; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Prospective Studies; Sofosbuvir | 2023 |
An insight into the hepatoprotective role of Velpatasvir and Sofosbuvir per se and in combination against carbon tetrachloride-induced hepatic fibrosis in rats.
Topics: Animals; Antioxidants; Antiviral Agents; Carbon Tetrachloride; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Interleukin-6; Liver Cirrhosis; NF-kappa B; Rats; Sofosbuvir | 2023 |
Dismal prognosis for cirrhotic patients with hepatitis C after initial failure of direct acting anti-virals, but salvage therapy may be life-saving.
Topics: Adult; Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Salvage Therapy; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2023 |
Sofosbuvir plus glecaprevir/pibrentasvir as salvage therapy after liver transplantation in NS5A inhibitor-experienced patients. A case series.
Topics: Antiviral Agents; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Transplantation; Retrospective Studies; Salvage Therapy; Sofosbuvir | 2023 |
Construction and characterization of a new hepatitis C virus genotype 6a subgenomic replicon that is prone to render the sofosbuvir resistance.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Subgenomic RNA | 2023 |
Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017-2021.
Topics: Analgesics, Opioid; Antiviral Agents; Fentanyl; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Hydrocodone; Oxycodone; Sofosbuvir | 2023 |
Real-world value of direct-acting antivirals for hepatitis C at Kaiser Permanente Southern California.
Topics: Antiviral Agents; California; Drug Therapy, Combination; Fibrosis; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Sofosbuvir | 2023 |
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2023 |
Direct-Acting Antiviral Drug Modulates the Mitochondrial Biogenesis in Different Tissues of Young Female Rats.
Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Organelle Biogenesis; Rats; Rats, Wistar; Sofosbuvir; Treatment Outcome | 2023 |
Carbonized aerogel/ZnO-based dispersive solid phase extraction of daclatasvir and sofosbuvir from biological samples prior to liquid chromatography-tandem mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Hepatitis C, Chronic; Humans; Reproducibility of Results; Sofosbuvir; Solid Phase Extraction; Tandem Mass Spectrometry; Zinc Oxide | 2024 |
Usefulness Of Sofosbuvir And Daclatasvir Combination In The Treatment Of HCV Infection In Childhood Cancer Patients: Experience From A Tertiary Care Hospital.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Neoplasms; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Tertiary Care Centers; Treatment Outcome | 2023 |
Effectiveness of generic sofosbuvir in the treatment of chronic hepatitis C virus infection in Saudi patients.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Drugs, Generic; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Saudi Arabia; Sofosbuvir; Treatment Outcome | 2023 |
Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-naïve subjects.
Topics: Antiviral Agents; Cell Line; Clinical Trials as Topic; Genetic Vectors; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Mutation; Nucleosides; Polymorphism, Genetic; Sofosbuvir; Transfection; Viral Nonstructural Proteins | 2019 |
Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Black People; Drug Resistance, Viral; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; London; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins | 2019 |
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Male; Middle Aged; Retreatment; Risk Factors; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Viral Nonstructural Proteins | 2019 |
Real-world effectiveness and safety of ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Safety; Sofosbuvir; Taiwan; Treatment Outcome | 2020 |
Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Mutation; Quinoxalines; Ribavirin; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins | 2019 |
Sustained virological response with 16-week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post-transplant severe HCV recurrence in HIV.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Phosphoproteins; Pyrrolidines; Quinoxalines; Recurrence; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Viral Load; Viral Nonstructural Proteins | 2019 |
Flecainide plasma level modifications during ledipasvir/sofosbuvir coadministration in two patients affected by chronic hepatitis C.
Topics: Aged; Anti-Arrhythmia Agents; Antiviral Agents; Arrhythmias, Cardiac; Benzimidazoles; Drug Interactions; Drug Therapy, Combination; Flecainide; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir | 2019 |
Time-dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C.
Topics: Antiviral Agents; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Inflammation; Liver; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Prospective Studies; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome | 2020 |
Generic sofosbuvir/ledipasvir for the treatment of genotype 4 chronic hepatitis C in Egyptian children (9-12 years) and adolescents.
Topics: Administration, Oral; Adolescent; Adolescent Health Services; Antiviral Agents; Benzimidazoles; Child; Child Health Services; Drug Administration Schedule; Egypt; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Male; Prospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2019 |
Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
Topics: Antiviral Agents; Brazil; Carbamates; Cohort Studies; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Mutation; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Simultaneous targeted therapy for metastatic melanoma and hepatitis C.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Melanoma; Oximes; Pyridones; Pyrimidinones; Skin Neoplasms; Sofosbuvir; Uridine Monophosphate | 2020 |
Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case r
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Mutation; Sofosbuvir; Virus Activation | 2019 |
Drug-drug interactions in anti-HCV therapy: a comparison among options available in Italy.
Topics: Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Drug Combinations; Drug Interactions; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Interferon-alpha; Italy; Polypharmacy; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides | 2019 |
Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015-March 2018.
Topics: Adolescent; Adult; Antiviral Agents; Georgia; Georgia (Republic); Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Sustained Virologic Response | 2020 |
Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Egypt; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Random Allocation; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Cell Line; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Mutation; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Valine | 2020 |
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
Topics: 2-Naphthylamine; Acute Disease; Adult; Aged; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Fluorenes; Germany; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Hypertension; Imidazoles; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Pleural Effusion; Proline; Pyrrolidines; Registries; Renal Insufficiency, Chronic; Ribavirin; Ritonavir; RNA, Viral; Severity of Illness Index; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Uridine Monophosphate; Valine | 2019 |
Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases.
Topics: 2-Naphthylamine; Antiviral Agents; Biomarkers, Pharmacological; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Retrospective Studies; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil | 2019 |
Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies.
Topics: Age Factors; Antiviral Agents; Benzimidazoles; British Columbia; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Logistic Models; Lost to Follow-Up; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2020 |
Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Mongolia; Sofosbuvir; Treatment Failure; Treatment Outcome; Uridine Monophosphate | 2020 |
Resistance Mutations A30K and Y93N Associated with Treatment Failure with Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection Non-Responder Patients: Case Reports.
Topics: Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Mutation; Pyrrolidines; Sofosbuvir; Treatment Failure; Valine; Viral Nonstructural Proteins | 2019 |
[QOL Assessment in Chronic Hepatitis C Patients Receiving Ledipasvir/ Sofosbuvir or Simeprevir/Peginterferon/Ribavirin in Clinical Practice].
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Surveys and Questionnaires | 2019 |
Retreatment of chronic hepatitis C virus genotype-4 patients after non-structural protein 5A inhibitors' failure: efficacy and safety of different regimens.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retreatment; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2020 |
Predictors of adverse drug reactions associated with ribavirin in direct-acting antiviral therapies for chronic hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antiviral Agents; Brazil; Carbamates; Drug Therapy, Combination; Fatigue; Female; Headache; Hepatitis C, Chronic; Humans; Imidazoles; Longitudinal Studies; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Pyrrolidines; Ribavirin; Risk Factors; Sofosbuvir; Valine | 2019 |
Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Egypt; Genotype; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Early fibrosis regression by shear wave elastography after successful direct-acting anti-HCV therapy.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Egypt; Elasticity Imaging Techniques; Feasibility Studies; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Sofosbuvir; Treatment Outcome | 2020 |
A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2020 |
The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin.
Topics: Carbamates; Drug Therapy, Combination; Egypt; Endpoint Determination; Gene Frequency; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Logistic Models; Middle Aged; Polymorphism, Single Nucleotide; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2020 |
High risk of hepatitis B virus reactivation among patients treated with direct-acting antivirals and coinfected with HCV and HIV.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Fluorenes; Hepatitis B virus; Hepatitis C, Chronic; HIV Infections; Humans; Recurrence; Sofosbuvir | 2020 |
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Logistic Models; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Young Adult | 2020 |
Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cell Line, Tumor; Culture Media; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Heterocyclic Compounds, 4 or More Rings; Humans; Microbial Sensitivity Tests; Mutation; Pyrrolidines; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Viral Nonstructural Proteins | 2020 |
NS5A-P32 Deletion in Hepatitis C Genotype 1b Infection is the Most Refractory Treatment-Mediated Amino Acid Change Exhibiting Resistance to all NS5A Inhibitors.
Topics: Aminoisobutyric Acids; Animals; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Mice; Sofosbuvir | 2020 |
Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment.
Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2020 |
Effects of Sofosbuvir-Based Hepatitis C Treatment Regimens on Calcineurin Inhibitor Dosing in Liver and Kidney Transplant Recipients.
Topics: Antiviral Agents; Calcineurin Inhibitors; Graft Rejection; Hepatitis C, Chronic; Humans; Kidney Transplantation; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Transplant Recipients | 2021 |
Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience.
Topics: Aged; Carcinoma, Hepatocellular; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Taiwan; Treatment Outcome | 2020 |
Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Georgia (Republic); Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Lost to Follow-Up; Male; Middle Aged; National Health Programs; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Young Adult | 2020 |
Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
Effectiveness of crushed sofosbuvir-velpatasvir in a patient with dysphagia.
Topics: Administration, Oral; Antiviral Agents; Carbamates; Deglutition Disorders; Drug Combinations; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Medication Adherence; Middle Aged; Sofosbuvir; Viral Load | 2020 |
[Progress of antiviral therapy for hepatitis C virus-related decompensated cirrhosis].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Failure; Ribavirin; Sofosbuvir; Treatment Outcome | 2019 |
Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Italy; Male; Middle Aged; Pyrrolidines; Regression Analysis; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2020 |
Hepatitis C virus therapy in children: No one should be left behind.
Topics: Benzimidazoles; Child; Child, Preschool; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir | 2020 |
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Treatment Outcome | 2020 |
Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Republic of Korea; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2020 |
Safety and Efficacy of 8 Weeks Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 4 in Children Aged 4-10 Years.
Topics: Antiviral Agents; Benzimidazoles; Child; Child, Preschool; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Prospective Studies; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate | 2020 |
Glecaprevir/pibrentasvir+sofosbuvir: an optimal retreatment strategy in the setting of HCV NS5A resistance.
Topics: Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Resistance, Viral; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pyrrolidines; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides; Viral Nonstructural Proteins | 2020 |
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; United States; Uridine Monophosphate; Viral Load | 2020 |
Ledipasvir/Sofosbuvir in Adolescents With Chronic Hepatitis C Genotype 4 With and Without Hematological Disorders: Virological Efficacy and Impact on Liver Stiffness.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Fluorenes; Hematologic Diseases; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Male; Sofosbuvir; Treatment Outcome | 2021 |
Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients.
Topics: Adult; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Donor Selection; Drug Combinations; Female; Fluorenes; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Outcome and Process Assessment, Health Care; Postoperative Complications; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Viremia | 2020 |
Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir.
Topics: Acute Kidney Injury; Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Egypt; Female; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney; Lipocalin-2; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2020 |
Prediction of sofosbuvir response using interleukin-6 serum level and single nucleotide polymorphism of interferon lambda- 4.
Topics: Adult; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukin-6; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Predictive Value of Tests; Sofosbuvir | 2020 |
Chronic hepatitis C treatment in HIV co-infection in Portugal: Results from a cohort OF 2133 patients presented by GEPCOI (Portuguese Coinfection Study Group).
Topics: Adult; Aged; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Nigeria; Portugal; Quality of Life; Sofosbuvir; Treatment Outcome; Young Adult | 2020 |
Pharmacological management of adverse events during treatment of chronic viral hepatitis in three Ivorian university hospitals
.
Topics: Antiviral Agents; Carbamates; Cote d'Ivoire; Cross-Sectional Studies; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Hospitals, University; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Thailand; Time Factors; Treatment Outcome; Uridine Monophosphate | 2020 |
Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study.
Topics: Adiponectin; Aged; Alanine Transaminase; Benzimidazoles; Blood Glucose; Carbamates; Cholesterol; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Insulin; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine; Viral Nonstructural Proteins | 2020 |
Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Azerbaijan; Cyclopropanes; Drug Therapy, Combination; Female; Genes, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Turkey; Uracil; Valine | 2020 |
Crushed application of sofosbuvir and velpatasvir in a patient with swallowing disorder.
Topics: Antiviral Agents; Carbamates; Deglutition Disorders; Drug Combinations; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Sofosbuvir; Stroke | 2020 |
Screening and Treatment Program to Eliminate Hepatitis C in Egypt.
Topics: Adolescent; Adult; Antiviral Agents; Carbamates; Egypt; Female; Health Care Costs; Hepatitis C, Chronic; Humans; Imidazoles; Male; Mass Screening; Middle Aged; Pyrrolidines; Seroepidemiologic Studies; Sofosbuvir; Valine; Young Adult | 2020 |
Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.
Topics: Adult; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Pakistan; Polyethylene Glycols; Proportional Hazards Models; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Tomography, X-Ray Computed; Valine | 2020 |
Effect of Hemodialysis on Efficacy and Pharmacokinetics of Sofosbuvir Coformulated with Either Daclatasvir or Ledipasvir in Patients with End-Stage Renal Disease.
Topics: Adult; Aged; Benzimidazoles; Carbamates; Clinical Trials as Topic; Drug Monitoring; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; France; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Quality of Life; Sofosbuvir; Sustained Virologic Response; Young Adult | 2021 |
Sofosbuvir Activates EGFR-Dependent Pathways in Hepatoma Cells with Implications for Liver-Related Pathological Processes.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Liver; Risk Factors; Sofosbuvir | 2020 |
Retreatment of chronic hepatitis C patients who failed previous therapy with directly acting antivirals: A multicenter study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retreatment; Retrospective Studies; Sofosbuvir; Treatment Outcome | 2020 |
Real-life experience of ledipasvir and sofosbuvir single-tablet regimen among chronic hepatitis C patients in Turkey.
Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Tablets; Treatment Outcome; Turkey | 2020 |
Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Taiwan | 2020 |
Cost-effectiveness of Oral Regimens for Adolescents With Chronic Hepatitis C Virus Infection.
Topics: Administration, Oral; Adolescent; Antiviral Agents; Benzimidazoles; Child; China; Cost-Benefit Analysis; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Markov Chains; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; United States | 2020 |
Wirelessly Observed Therapy to Optimize Adherence and Target Interventions for Oral Hepatitis C Treatment: Observational Pilot Study.
Topics: Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Sofosbuvir; Treatment Outcome | 2020 |
Modeling-Based Response-Guided Glecaprevir-Pibrentasvir Therapy for Chronic Hepatitis C to Identify Patients for Ultrashort Treatment Duration.
Topics: Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Duration of Therapy; Female; Fluorenes; Hepatitis C, Chronic; Humans; Kinetics; Male; Middle Aged; Models, Theoretical; Pyrrolidines; Quinoxalines; Retrospective Studies; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Time Factors | 2020 |
Successful fourth line treatment of a relapse patient with chronic hepatitis C virus infection genotype 3a using sofosbuvir, glecaprevir/pibrentasvir, and ribavirin: a case report.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Middle Aged; Neoplasm Recurrence, Local; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome | 2020 |
Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine.
Topics: Animals; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Imidazoles; Liver Cirrhosis; Models, Animal; Pyrrolidines; Ribavirin; Sofosbuvir; Swine; Valine | 2020 |
Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Vietnam; Viral Load | 2020 |
Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Prospective Studies; Pyrrolidines; Sofosbuvir; Valine | 2020 |
Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2020 |
Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia.
Topics: Africa South of the Sahara; Antiviral Agents; Asia, Eastern; Benzimidazoles; Benzofurans; Carbamates; Drug Resistance, Viral; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Pyrrolidines; RNA-Dependent RNA Polymerase; Sofosbuvir; Valine; Viral Nonstructural Proteins | 2020 |
Sustained Virologic Suppression After 4 Weeks of Ledipasvir/Sofosbuvir in Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Co-Infection.
Topics: Adult; Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Male; Sofosbuvir; Sustained Virologic Response | 2020 |
The impact of direct-acting antiviral treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients: temporary? permanent?
Topics: Aged; Anilides; Antiviral Agents; Benzimidazoles; Blood Glucose; Cholesterol; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Lactams, Macrocyclic; Lipid Metabolism; Lipoproteins, LDL; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Triglycerides; Valine | 2020 |
Anti-rod and ring antibodies in patients with chronic hepatitis C using direct-acting antivirals.
Topics: Aged; Antibodies, Antinuclear; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Fluorescent Antibody Technique, Indirect; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2020 |
Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2021 |
M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
Topics: Adult; Antigens, Neoplasm; Antiviral Agents; Biomarkers; Biomarkers, Tumor; Carbamates; Drug Combinations; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Follow-Up Studies; Glycosylation; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; ROC Curve; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Taiwan | 2020 |
Can successful treatment by direct-acting antivirals improve depression in chronic HCV patients?
Topics: Aged; Antiviral Agents; Depression; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir; Sustained Virologic Response | 2021 |
Real-world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor-based therapies.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Prospective Studies; Retreatment; Ribavirin; Sofosbuvir; Treatment Outcome | 2020 |
Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Drug Combinations; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Quinoxalines; Recurrence; Sofosbuvir; Sulfonamides; Treatment Failure | 2020 |
Severe Bradycardia Induced by Sofosbuvir and Amiodarone which Resolved after the Discontinuation of Both Drugs.
Topics: Amiodarone; Antiviral Agents; Bradycardia; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Male; Middle Aged; Severity of Illness Index; Sofosbuvir | 2020 |
Successful treatment of resistant HCV in a patient with Child-Pugh B cirrhosis using sofosbuvir and glecaprevir/pibrentasvir.
Topics: Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides | 2020 |
Chronic Hepatitis C Virus Infection After Kidney Transplantation With or Without Direct-Acting Antivirals in a Real-Life Setting: A French Multicenter Experience.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Female; Fluorenes; France; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
Cure or curd: Modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication.
Topics: Aged; Antiviral Agents; Carbamates; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Dyslipidemias; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Risk; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Triglycerides; Valine | 2020 |
Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2020 |
Long-term clinical benefits of Sofosbuvir-based direct antiviral regimens for patients with chronic hepatitis C in Central and West Africa.
Topics: Africa South of the Sahara; Antiviral Agents; Cote d'Ivoire; Hepatitis C, Chronic; Humans; Liver Neoplasms; Ribavirin; Sofosbuvir | 2020 |
Acute Renal Failure in a Patient on Ledipasvir-Sofosbuvir Therapy for Hepatitis C.
Topics: Acute Kidney Injury; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Treatment Outcome | 2020 |
Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir.
Topics: Antiviral Agents; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2021 |
Effectiveness of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and virologic failure to direct-acting antivirals.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2021 |
Cost-utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China.
Topics: Antiviral Agents; Carbamates; China; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir | 2020 |
Real-world safety and effectiveness of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C virus genotype 1 in Japan.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Neoplasms; Sofosbuvir; Sustained Virologic Response | 2021 |
A decrease in hepatitis C virus RNA to undetectable levels in chronic hepatitis C patients after PegIFNα + RVB or sofosbuvir + NS5A inhibitor treatment is associated with decreased insulin resistance and persistent oxidative stress.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Oxidative Stress; Pilot Projects; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Viral Nonstructural Proteins | 2020 |
Fitness-associated substitutions following failure of direct-acting antivirals assessed by deep sequencing of full-length hepatitis C virus genomes.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Cohort Studies; DNA Mutational Analysis; Drug Resistance, Viral; Genetic Fitness; Genome, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Phenotype; Polymorphism, Single Nucleotide; Sofosbuvir; Treatment Failure; Viral Nonstructural Proteins; Virus Replication | 2020 |
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2021 |
Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Taiwan; Treatment Outcome | 2021 |
Incidence and predictors for abnormal liver function during direct-acting antiviral agents in chronic hepatitis C patients.
Topics: Adult; Alanine Transaminase; Amides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Liver; Liver Cirrhosis; Liver Function Tests; Logistic Models; Male; Middle Aged; Prospective Studies; Pyrrolidines; Quinoxalines; Retrospective Studies; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2020 |
The interrelation between lipid profile in chronic HCV patients and their response to antiviral agents.
Topics: Adult; Antiviral Agents; Carbamates; Female; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Lipid Metabolism; Lipids; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Recombinant Proteins; Ribavirin; Sofosbuvir; Valine | 2021 |
Treatment outcomes and costs of a simplified antiviral treatment strategy for hepatitis C among monoinfected and HIV and/or hepatitis B virus-co-infected patients in Myanmar.
Topics: Antiviral Agents; Coinfection; Hepacivirus; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Myanmar; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Successful DAA therapy for chronic hepatitis C reduces HLA-DR on monocytes and circulating immune mediators: A long-term follow-up study.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Brazil; Case-Control Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HLA-DR Antigens; Humans; Inflammation Mediators; Male; Middle Aged; Monocytes; Prospective Studies; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Young Adult | 2020 |
Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R).
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Registries; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2020 |
Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir | 2020 |
Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance haemodialysis.
Topics: Adult; Antiviral Agents; Carbamates; Drug Combinations; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Kidney Failure, Chronic; Macrocyclic Compounds; Male; Middle Aged; Prospective Studies; Renal Dialysis; Sofosbuvir; Sulfonamides; Treatment Outcome | 2021 |
Treatment of chronic hepatitis C virus infection with crushed ledipasvir/sofosbuvir administered through a percutaneous endoscopic gastrostomy tube in a patient with HIV coinfection.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Fluorenes; Gastrostomy; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Sofosbuvir; Treatment Outcome | 2021 |
Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms.
Topics: Antiviral Agents; Benzimidazoles; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Fluorenes; Hepatitis C, Chronic; Limit of Detection; Simeprevir; Sofosbuvir; Temperature | 2020 |
Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis.
Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Infant, Newborn; Liver Cirrhosis; Liver Neoplasms; Ribavirin; Sofosbuvir; Treatment Outcome | 2021 |
Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study.
Topics: Anilides; Antiviral Agents; Benzimidazoles; Coinfection; Cyclopropanes; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2021 |
Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sofosbuvir; Treatment Outcome; Valine; Young Adult | 2020 |
Ledipasvir/sofosbuvir-associated photosensitivity in a case with chronic hepatitis C.
Topics: Aged; Antiviral Agents; Benzimidazoles; Biopsy; Diagnosis, Differential; Fluorenes; Hepatitis C, Chronic; Humans; Male; Photosensitivity Disorders; Sofosbuvir | 2021 |
Direct-acting antiviral treatment failure in genotype 2 hepatitis C chronic infection.
Topics: Antiviral Agents; Carbamates; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Treatment Failure; Valine | 2021 |
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Topics: Age Factors; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; Quinoxalines; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Taiwan; Treatment Outcome; Valine | 2021 |
Interleukin-17 haplotyping predicts hepatocellular carcinoma in sofosbuvir, pegylated interferon-alpha-2a & ribavirin treated chronic hepatitis C patients.
Topics: alpha-Fetoproteins; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Haplotypes; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-17; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Receptors, Interleukin-17; Recombinant Proteins; Ribavirin; Sofosbuvir | 2021 |
Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection.
Topics: Antiviral Agents; Child; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmaceutical Preparations; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2020 |
Real-world efficacy and safety of direct-acting antiviral drugs in patients with chronic hepatitis C and inherited blood disorders.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C.
Topics: Antiviral Agents; China; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir | 2021 |
Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients.
Topics: Antiviral Agents; Carbamates; Child; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Neoplasms; Male; Morbidity; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort.
Topics: Adult; Carbamates; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Europe; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Retreatment; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome | 2021 |
Sofosbuvir-based Treatment for HCV: A Safe Option in Patients Undergoing Hemodialysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Renal Dialysis; Ribavirin; Sofosbuvir; Treatment Outcome | 2020 |
Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome | 2021 |
Successful use of generic direct acting antiviral medications to treat hepatitis C-a New Zealand-wide study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drugs, Generic; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Seropositivity; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; New Zealand; Pyrrolidines; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load | 2020 |
Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C.
Topics: Alanine Transaminase; Amides; Antiviral Agents; Aspartate Aminotransferases; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Quinoxalines; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; RNA, Viral; Sofosbuvir; Sulfonamides; Valine; Viral Load | 2020 |
Improving access to the treatment of hepatitis C in low- and middle-income countries: evaluation of a patient assistance programme.
Topics: Antiviral Agents; Developing Countries; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir | 2021 |
Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre- or post-liver transplant.
Topics: Antiviral Agents; Child; Coinfection; End Stage Liver Disease; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Liver Transplantation; Prospective Studies; Retrospective Studies; Severity of Illness Index; Sofosbuvir; Treatment Outcome | 2021 |
Concomitant use of direct-acting antivirals (DAA) and central nervous system drugs in patients with hepatitis C virus infection.
Topics: Antiviral Agents; Central Nervous System Agents; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir | 2022 |
Changes in Liver Stiffness and Noninvasive Fibrosis Scores in Egyptian Adolescents Successfully Treated with Ledipasvir-Sofosbuvir for Chronic Hepatitis C Virus Infection.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Biomarkers; Egypt; Elasticity Imaging Techniques; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Prospective Studies; Severity of Illness Index; Sofosbuvir; Treatment Outcome | 2021 |
Rapid and sensitive UHPLC-DAD method for simultaneous determination of sofosbuvir and ledipasvir in human serum.
Topics: Antiviral Agents; Benzimidazoles; Chromatography, High Pressure Liquid; Fluorenes; Hepatitis C, Chronic; Humans; Reproducibility of Results; Sofosbuvir | 2021 |
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Combinations; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Young Adult | 2022 |
Risk factors for difficult-to-treat hepatitis C virus genotype 4r in Rwanda and implications for elimination in sub-Saharan Africa.
Topics: Adult; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Infant, Newborn; Prospective Studies; Risk Factors; Rwanda; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Sofosbuvir plus ribavirin combination regimen boost liver functions and antioxidant profile in hepatitis C virus patients.
Topics: Antioxidants; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2021 |
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Male; Phylogeny; Sofosbuvir; Sustained Virologic Response; Viral Nonstructural Proteins | 2021 |
Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis C.
Topics: Antigens, Neoplasm; Antiviral Agents; Cell Adhesion Molecules; Cohort Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir | 2022 |
"If I Get Cured, My Whole Quality of Life Will Change": Patients' Anticipated and Actualized Benefits Following Cure from Chronic Hepatitis C.
Topics: Anticipation, Psychological; Antiviral Agents; Benzimidazoles; Disease Eradication; Disease Transmission, Infectious; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Mental Health; Middle Aged; Motivation; Quality of Life; Social Interaction; Sofosbuvir; Treatment Outcome | 2022 |
Sofosbuvir/Ledipasvir for Treatment of Chronic Hepatitis C Infection in Adult Patients with β- Thalassemia Major: A Real-Life Study.
Topics: Adult; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Drug Therapy, Combination; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Retrospective Studies; Sofosbuvir; Thalassemia; Treatment Outcome; Uridine Monophosphate | 2022 |
Deinduction of P-glycoprotein resulting in delayed viral response during hepatitis C treatment.
Topics: Anti-Retroviral Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamates; Carbamazepine; Cell Membrane; Drug Combinations; Drug Interactions; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir | 2021 |
[Use of sofosbuvir-based regimens in the treatment of adolescents and children with chronic hepatitis C].
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; China; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2021 |
Improvement in Liver Stiffness in Pediatric Patients with Hepatitis C Virus after Treatment with Direct Acting Antivirals.
Topics: Adolescent; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Child; Elasticity Imaging Techniques; Female; Fluorenes; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Prospective Studies; Sofosbuvir | 2021 |
Effect of Direct-Acting Antiviral Drugs on Erectile Functions among Hepatitis C Patients: A Prospective Interventional Study.
Topics: Antiviral Agents; Erectile Dysfunction; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Prospective Studies; Quality of Life; Silymarin; Sofosbuvir | 2022 |
Ribavirin Improves NK Cell IFNγ Response During Sofosbuvir-based DAA Therapy in HCV-infected Liver Transplant Recipients.
Topics: Antiviral Agents; Case-Control Studies; Cell Degranulation; Cells, Cultured; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-gamma; Killer Cells, Natural; Liver Transplantation; Phosphorylation; Ribavirin; Sofosbuvir; STAT1 Transcription Factor; STAT4 Transcription Factor; Time Factors; Treatment Outcome | 2021 |
Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience.
Topics: Aged; Anilides; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Male; Middle Aged; Proline; Prospective Studies; Retrospective Studies; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Turkey; Valine | 2020 |
Improvement of Skeletal Muscle Mass after Ledipasvir and Sofosbuvir Treatment for Hepatitis C Virus in Decompensated Liver Cirrhosis.
Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Muscle, Skeletal; Quality of Life; Sofosbuvir; Treatment Outcome | 2021 |
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Neoplasms; Middle Aged; Registries; Sofosbuvir; Sustained Virologic Response; Taiwan; Treatment Failure; Treatment Outcome | 2021 |
Real-World Outcomes of Direct-Acting Antiviral Treatment and Retreatment in United Kingdom-Based Patients Infected With Hepatitis C Virus Genotypes/Subtypes Endemic in Africa.
Topics: Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Retreatment; Sofosbuvir; Sustained Virologic Response | 2022 |
Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry.
Topics: Aminoisobutyric Acids; Antiviral Agents; Canada; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Prospective Studies; Quinoxalines; Registries; Salvage Therapy; Sofosbuvir; Sulfonamides | 2021 |
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan.
Topics: Antiviral Agents; Carbamates; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir; Sustained Virologic Response; Taiwan | 2021 |
Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Mutation; Proline; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Viral Nonstructural Proteins | 2021 |
Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Failure; Viral Nonstructural Proteins | 2021 |
Responsible Inclusion of Pregnant Individuals in Eradicating HCV.
Topics: Antiviral Agents; Benzimidazoles; Biomedical Research; Female; Fluorenes; Hepatitis C, Chronic; Humans; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Sofosbuvir | 2021 |
Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection: A prospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Black People; Carbamates; Drug Therapy, Combination; Egypt; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine; Young Adult | 2021 |
Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages.
Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Young Adult | 2021 |
Affordable treatment and political commitment are crucial to eliminate hepatitis C globally.
Topics: Benzimidazoles; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Sofosbuvir; Valine | 2021 |
Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase.
Topics: Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; World Health Organization | 2021 |
Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report.
Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2021 |
Pregnancy outcome of anti-HCV direct-acting antivirals: Real-life data from an Egyptian cohort.
Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Infant, Newborn; Pregnancy; Pregnancy Outcome; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Treatment of chronic hepatitis C with sofosbuvir in a hemodialysis patient: a case report.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Follow-Up Studies; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Sofosbuvir; Sustained Virologic Response | 2021 |
Single-pill sofosbuvir and daclatasvir for treating hepatis C in patients co-infected with human immunodeficiency virus.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2021 |
Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome; Turkey | 2021 |
Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.
Topics: Antiviral Agents; Cohort Studies; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Reactivation of hepatitis C virus with severe hepatitis flare during steroid administration for interstitial pneumonia.
Topics: Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; Humans; Lung Diseases, Interstitial; Sofosbuvir; Symptom Flare Up | 2021 |
Hepatitis B Surface Antigen Decline during Sofosbuvir and Ribavirin Therapy in Hepatitis B Inactive Carriers Who Were Co-infected with Hepatitis C.
Topics: Antiviral Agents; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; Humans; Retrospective Studies; Ribavirin; Sofosbuvir | 2021 |
Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Neoplasms; Retreatment; Sofosbuvir; Sustained Virologic Response | 2021 |
Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Monitoring; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Medication Therapy Management; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2021 |
Health-related quality of life in patients with chronic hepatitis C treated with sofosbuvir-based treatment at 1-year post-sustained virological response.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Infant; Quality of Life; Ribavirin; Sofosbuvir; Treatment Outcome | 2021 |
Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome | 2021 |
Impact of sofosbuvir and daclastavir on health-related quality of life in patients co-infected with hepatitis C and human immunodeficiency virus.
Topics: Adult; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Indonesia; Male; Prospective Studies; Pyrrolidines; Quality of Life; Sofosbuvir; Treatment Outcome; Valine | 2021 |
Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy.
Topics: Carbamates; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Renal Dialysis; Sofosbuvir | 2021 |
Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Quinoxalines; Republic of Korea; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2021 |
Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Italy; Macrocyclic Compounds; Prevalence; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides | 2021 |
Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy.
Topics: Adult; Analgesics, Opioid; Antiviral Agents; Carbamates; Directly Observed Therapy; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response | 2021 |
Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan.
Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Sofosbuvir; Sustained Virologic Response; Taiwan; Treatment Outcome | 2021 |
Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China.
Topics: Adult; Antiviral Agents; China; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2021 |
Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Valine | 2021 |
Beta-thalassemia major alters sofosbuvir/ledipasvir exposure in Hepatitis C virus infected adolescent patients.
Topics: Adolescent; Adult; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmaceutical Preparations; Prospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2021 |
Effective Treatment of Chronic Hepatitis C Virus Infection With Ledipasvir/Sofosbuvir in 2 Teenagers With HIV Coinfection: A Brief Report.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Fluorenes; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis.
Topics: Antiviral Agents; Carbamates; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2021 |
Reply to: "Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy".
Topics: Carbamates; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Renal Dialysis; Sofosbuvir | 2021 |
[Treatment of hepatitis C virus infection with new direct-acting antivirals agents in pediatrics. Case report].
Topics: Adolescent; Adult; Antiviral Agents; Child; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Pediatrics; Sofosbuvir; Treatment Outcome | 2021 |
Effective and Safe Daclatasvir Drug Exposures Predicted in Children Using Adult Formulations.
Topics: Adolescent; Adult; Antiviral Agents; Carbamates; Child; Dose-Response Relationship, Drug; Egypt; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Pyrrolidines; Sofosbuvir; Treatment Outcome; Valine | 2021 |
A novel fixed-dose combination treatment for chronic hepatitis C, based on NS5A inhibitor fopitasvir and NS5B inhibitor sofosbuvir.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir; Tablets | 2021 |
Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals.
Topics: Aged; Antiviral Agents; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Kidney; Lipocalin-2; Male; Middle Aged; Sofosbuvir | 2021 |
One-Year Outcomes after Ledipasvir/Sofosbuvir Treatment of Chronic Hepatitis C in Teenagers with and without Significant Liver Fibrosis-A Case Series Report.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Case-Control Studies; Child; Female; Fluorenes; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Prospective Studies; Sofosbuvir; Tertiary Healthcare; Treatment Outcome | 2021 |
Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Prospective Studies; Pyrrolidines; Retreatment; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine | 2017 |
Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions.
Topics: Analgesics; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pharmacists; Pharmacy; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome | 2017 |
Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Donor Selection; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Postoperative Care; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Tissue Donors; Treatment Outcome; Valine | 2017 |
Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment.
Topics: Adult; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Drug Combinations; Female; Fluorenes; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Macrocyclic Compounds; Male; Patient Participation; Patient-Centered Care; Prospective Studies; Pyrrolidines; Quinoxalines; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Uridine Monophosphate; Valine | 2017 |
Sofosbuvir faces fresh patent challenge in Europe.
Topics: Antiviral Agents; Drug Industry; Europe; Hepatitis C, Chronic; Humans; Organizations; Patents as Topic; Sofosbuvir | 2017 |
Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study.
Topics: Adult; Antiviral Agents; Asia; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; India; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA Viruses; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Viral Load | 2017 |
Acute fulminant hepatitis B during hepatitis C virus therapy with direct-acting antivirals in a patient co-infected with HIV.
Topics: Anti-HIV Agents; Antiviral Agents; Benzimidazoles; Coinfection; Drug Substitution; Fatal Outcome; Fluorenes; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Liver Failure, Acute; Male; Middle Aged; Oligopeptides; Ribavirin; Sofosbuvir; Virus Activation | 2017 |
Real-World Experiences With a Direct-Acting Antiviral Agent for Patients With Hepatitis C Virus Infection.
Topics: Aged; Anemia; Antiviral Agents; California; Drug Therapy, Combination; Fatigue; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Patient Selection; Retrospective Studies; Ribavirin; Sex Factors; Sofosbuvir; Viral Load | 2017 |
Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2017 |
New Rule Requires Some Physicians to Report on Postoperative Visits.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Insurance Claim Reporting; Kidney Transplantation; Postoperative Care; Practice Patterns, Physicians'; Recurrence; Sofosbuvir; United States; Uridine Monophosphate | 2017 |
Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C.
Topics: Administration, Oral; Antiviral Agents; Hepatitis C, Chronic; Humans; Insurance, Health, Reimbursement; Medicaid; Sofosbuvir; United States | 2017 |
The Role of e-Health in Optimizing Task-Shifting in the Delivery of Antiviral Therapy for Chronic Hepatitis C.
Topics: Antiviral Agents; California; Carbamates; Communication; Computer Security; Confidentiality; Drug Combinations; Electronic Health Records; Health Services Accessibility; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Licensed Practical Nurses; Medically Underserved Area; Patient Portals; Retrospective Studies; Safety-net Providers; Sofosbuvir; Telemedicine | 2017 |
Interferon free antiviral treatment of chronic hepatitis C in patients affected by β-thalassemia major.
Topics: Adult; Antiviral Agents; Benzimidazoles; Benzoates; beta-Thalassemia; Cryoglobulinemia; Deferasirox; Deferoxamine; Elasticity Imaging Techniques; Female; Ferritins; Fluorenes; Hepatitis C, Chronic; Humans; Iron Chelating Agents; Iron Overload; Liver Cirrhosis; Male; Quality of Life; Sofosbuvir; Triazoles; Viral Load | 2017 |
Sofosbuvir-based regimens against an "easy" villain: HCV genotype 2.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome | 2017 |
Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Logistic Models; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Viral Load | 2017 |
Effectiveness of ledipasvir/sofosbuvir in real-world patients with chronic hepatitis C: a collaborative treatment approach.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug-Related Side Effects and Adverse Reactions; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Young Adult | 2017 |
Sustained virological response in a treatment-experienced patient with hepatitis C virus genotype 6 infection: Follow-up on a reported case.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Sustained Virologic Response; Viral Load | 2017 |
Experience and Outcomes of Hepatitis C Treatment in a Cohort of Homeless and Marginally Housed Adults.
Topics: Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ill-Housed Persons; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Viral Load | 2017 |
Restrictions of Hepatitis C Treatment for Substance-Using Medicaid Patients: Cost Versus Ethics.
Topics: Antiviral Agents; Drug Costs; Eligibility Determination; Health Services Accessibility; Hepatitis C, Chronic; Humans; Insurance Coverage; Insurance, Health, Reimbursement; Medicaid; Sofosbuvir; Substance-Related Disorders; United States | 2017 |
Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease.
Topics: Adult; Antiviral Agents; beta-Thalassemia; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Severity of Illness Index; Simeprevir; Sofosbuvir; Valine | 2017 |
Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4
Topics: Aged; Antiviral Agents; Asian People; Benzimidazoles; Carrier Proteins; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Intracellular Signaling Peptides and Proteins; Japan; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins | 2017 |
Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Hong Kong; Humans; Interferon-alpha; Markov Chains; Middle Aged; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome | 2017 |
Response to Real life Egyptian experience of efficacy / safety of Simeprevir\\ Sofosbuvir in HCV genotype IV.
Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome | 2017 |
Reply to Letter: Influence of Liver and Kidney Disease on Sofosbuvir Electrophysiological Effects.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Diseases; Sofosbuvir | 2017 |
The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens.
Topics: Acute Kidney Injury; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Oligopeptides; Proline; Risk Factors; Sofosbuvir | 2017 |
Rising relapse rate in hepatitis C virus type 3a-infected patients against sofosbuvir and ribavirin combination therapy: a Pakistani experience.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Recurrence; Ribavirin; Sofosbuvir; Treatment Failure | 2017 |
Cure with ledipasvir/sofosbuvir for chronic hepatitis C virus in an individual with gastric bypass.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Fluorenes; Gastric Bypass; Hepatitis C, Chronic; Humans; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2017 |
Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Fluorenes; Gastrectomy; Hepatitis C, Chronic; Humans; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate | 2017 |
Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Biomarkers; Blood Coagulation; Drug Therapy, Combination; Egypt; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Leukocyte Count; Liver Function Tests; Male; Middle Aged; Platelet Count; Prothrombin; Retrospective Studies; Serum Albumin, Human; Sofosbuvir; Time Factors; Treatment Outcome | 2017 |
Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2017 |
Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease.
Topics: Adult; Anemia, Sickle Cell; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Young Adult | 2017 |
Relationship of hepatitis B virus infection to the recurrence of hepatocellular carcinoma after direct acting antivirals.
Topics: Aged; Aged, 80 and over; Antibodies, Viral; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis B Core Antigens; Hepatitis C, Chronic; Humans; Imidazoles; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Pyrrolidines; Retrospective Studies; Ribavirin; Risk Factors; Sofosbuvir; Valine | 2017 |
Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure.
Topics: Amino Acid Substitution; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Middle Aged; Mutation, Missense; Sofosbuvir; Suppression, Genetic; Treatment Failure; Viral Nonstructural Proteins | 2017 |
Increased warfarin requirements in a patient with chronic hepatitis C infection receiving sofosbuvir and ribavirin.
Topics: Anticoagulants; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; International Normalized Ratio; Male; Middle Aged; Ribavirin; Sofosbuvir; Warfarin | 2017 |
Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection.
Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Administration Schedule; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Lipids; Male; Middle Aged; Quinoxalines; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2018 |
Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV.
Topics: Aged; Antiviral Agents; Benzimidazoles; DNA, Viral; Female; Fluorenes; Hepacivirus; Hepatitis B; Hepatitis B Antibodies; Hepatitis B virus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; Sofosbuvir; Time Factors; Treatment Outcome; Virus Activation | 2018 |
Successful treatment of sexually acquired acute HCV reinfection with ledipasvir/sofosbuvir in a HIV-infected patient.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Fluorenes; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome | 2017 |
Influence of baseline MELD score in the efficacy of treatment of hepatitis C with simeprevir and sofosbuvir.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Male; Middle Aged; Models, Theoretical; Prospective Studies; Severity of Illness Index; Simeprevir; Sofosbuvir; Treatment Outcome | 2018 |
Assessing the Budget Impact and Economic Outcomes of the Introduction of Daclatasvir + Asunaprevir and Sofosbuvir/Ledipasvir for the Treatment of Chronic Hepatitis C Virus Infection in Japan.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Male; Protease Inhibitors; Pyrrolidines; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine | 2017 |
Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fibrosis; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2017 |
The elderly and direct antiviral agents: Constraint or challenge?
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Logistic Models; Male; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2017 |
Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; India; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Young Adult | 2017 |
Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Fluorenes; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Lipids; Macrocyclic Compounds; Male; Middle Aged; Mutation; Proline; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Uridine Monophosphate; Valine; Young Adult | 2017 |
Improvement of glycemic state among responders to Sofosbuvir-based treatment regimens: Single center experience.
Topics: Aged; Antiviral Agents; Blood Glucose; Diabetes Mellitus, Type 2; Egypt; Female; Glycated Hemoglobin; Glycemic Index; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir | 2017 |
Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.
Topics: Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2017 |
Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Scandinavian and Nordic Countries; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2017 |
A not so easy genotype-striking regional differences in SOF/RBV treatment responses in HCV GT2.
Topics: Antiviral Agents; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir | 2017 |
Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
Ventricular Extrasystoles after First Dose of Sofosbuvir in a Patient Treated with Propranolol but not with Amiodarone: A Case Report.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antiviral Agents; Dose-Response Relationship, Drug; Echocardiography; Electrocardiography; Hepatitis C, Chronic; Humans; Male; Propranolol; Sofosbuvir; Ventricular Premature Complexes | 2017 |
Re: Saint-Laurent Thibault C, Moorjaney D, Ganz ML, et al. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States. J Med Econ 2017;20:692-702.
Topics: Carbamates; Cost-Benefit Analysis; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; United States; Valine | 2017 |
Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.
Topics: Carbamates; Cost-Benefit Analysis; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; United States; Valine | 2017 |
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
Topics: Aged; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response | 2018 |
Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience.
Topics: Drug Therapy, Combination; Egypt; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sofosbuvir; Withholding Treatment | 2017 |
Intra-Hepatic Depletion of Mucosal-Associated Invariant T Cells in Hepatitis C Virus-Induced Liver Inflammation.
Topics: Antiviral Agents; Biopsy; Carbamates; Case-Control Studies; Cytokines; Drug Combinations; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Leukocyte Count; Liver; Lymphocyte Activation; Monocytes; Mucosal-Associated Invariant T Cells; Paracrine Communication; Phenotype; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome | 2017 |
Successful treatment of chronic hepatitis C with ground ledipasvir/sofosbuvir in a patient with Crohn's disease and short bowel syndrome.
Topics: Antiviral Agents; Benzimidazoles; Crohn Disease; Fluorenes; Hepatitis C, Chronic; Humans; Short Bowel Syndrome; Sofosbuvir | 2018 |
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes.
Topics: Analysis of Variance; Antiviral Agents; Cohort Studies; Compassionate Use Trials; Confidence Intervals; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Liver Function Tests; Logistic Models; Male; Multivariate Analysis; Prognosis; Recurrence; Ribavirin; Risk Assessment; Severity of Illness Index; Sofosbuvir; Treatment Outcome | 2017 |
Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse.
Topics: Adult; Antiviral Agents; Carbamates; Drug Combinations; Female; Heart Failure; Heart Transplantation; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir; Tissue Donors; Viremia | 2017 |
Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2017 |
Modeling the fiscal costs and benefits of alternative treatment strategies in the United Kingdom for chronic hepatitis C.
Topics: Adult; Benzimidazoles; Cohort Studies; Complementary Therapies; Cost of Illness; Cost-Benefit Analysis; Early Diagnosis; Female; Fluorenes; Health Care Costs; Hepatitis C, Chronic; Humans; Male; Middle Aged; Models, Economic; Prospective Studies; Severity of Illness Index; Sofosbuvir; United Kingdom; Uridine Monophosphate | 2018 |
Reduction in warfarin effect associated with sofosbuvir-velpatasvir.
Topics: Anticoagulants; Antiviral Agents; Carbamates; Drug Combinations; Drug Interactions; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Sofosbuvir; Thrombosis; Treatment Outcome; Warfarin | 2017 |
"Empirical" retreatment of patients with chronic hepatitis C who failed a first direct-acting antiviral-based regimen.
Topics: Antiviral Agents; Drug Resistance, Viral; Female; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retreatment; Sofosbuvir; Time Factors; Treatment Failure; Treatment Outcome; Viral Nonstructural Proteins | 2017 |
Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Chemokine CXCL10; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Male; MicroRNAs; Middle Aged; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Valine; Young Adult | 2017 |
Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA exper
Topics: Adult; Antiviral Agents; Benzimidazoles; Disease Eradication; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Fluorenes; Genotype; Georgia (Republic); Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2017 |
Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Resistance, Viral; Female; Fluorenes; Genotype; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Republic of Korea; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uridine Monophosphate; Valine | 2017 |
Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2017 |
Disappearance of multiple hyperechoic liver nodules in sporadic porphyria cutanea tarda after treatment with ledipasvir/sofosbuvir for hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Liver; Male; Middle Aged; Porphyria Cutanea Tarda; Sofosbuvir; Uridine Monophosphate | 2017 |
Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVES.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Propensity Score; Proportional Hazards Models; Ritonavir; Sofosbuvir; Sulfonamides; Survival Rate; Sustained Virologic Response; Uracil; Valine | 2017 |
The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real-life experience.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Compassionate Use Trials; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Waiting Lists | 2018 |
Treatment of Chronic Hepatitis C Virus Infection With Crushed Ledipasvir/Sofosbuvir Administered via a Percutaneous Endoscopic Gastrostomy Tube.
Topics: Antiviral Agents; Benzimidazoles; Drug Compounding; Endoscopy, Gastrointestinal; Fluorenes; Gastrostomy; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2018 |
Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Carbamates; China; Drug Therapy, Combination; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Transplantation; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Transplant Recipients; Treatment Outcome; Valine | 2017 |
Use of sofosbuvir in chronic kidney disease: Is it necessary?
Topics: Genotype; Hepatitis C, Chronic; Humans; Renal Insufficiency, Chronic; Sofosbuvir | 2017 |
Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Carbamates; Drug Therapy, Combination; Egypt; End Stage Liver Disease; Female; Hepatitis C, Chronic; Humans; Imidazoles; International Normalized Ratio; Male; Middle Aged; Platelet Count; Prospective Studies; Pyrrolidines; Ribavirin; Serum Albumin; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Valine | 2017 |
Predictors of hepatitis C virus recurrence after living donor liver transplantation: Mansoura experience.
Topics: Adult; Age Factors; Antiviral Agents; Cold Ischemia; Drug Therapy, Combination; Female; Graft Survival; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Living Donors; Male; Polyethylene Glycols; Postoperative Period; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Warm Ischemia; Young Adult | 2017 |
Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Renal Dialysis; Sofosbuvir; Treatment Outcome; Young Adult | 2018 |
Mavyret and Vosevi--two new combinations for chronic HCV infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Outcome | 2017 |
Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult | 2017 |
Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: Highly effective in a predominantly black male patient population.
Topics: Aged; Antiviral Agents; Benzimidazoles; Black or African American; Clinical Trials as Topic; Coinfection; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Male; Maryland; Middle Aged; Prospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Veterans | 2018 |
Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4.
Topics: Amino Acid Substitution; Antiviral Agents; Benzimidazoles; Carbamates; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; High-Throughput Nucleotide Sequencing; Humans; Sequence Analysis, DNA; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Nonstructural Proteins | 2018 |
Let's Make a Deal: Shortening the Solid Organ Transplant Waiting Time in Exchange for Transmitting and Treating Hepatitis C Infection in the Era of Safe and Effective Directly Acting Antivirals.
Topics: Antiviral Agents; Heart Transplantation; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Sofosbuvir; Waiting Lists | 2018 |
Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Fluorenes; Heart Transplantation; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Sofosbuvir; Sustained Virologic Response; Transplant Recipients; Treatment Outcome; Valine; Young Adult | 2018 |
Comparison of Sofosbuvir Plus Ribavirin Treatment with Pegylated Interferon Plus Ribavirin Treatment for Chronic Hepatitis C Genotype 2.
Topics: alpha-Fetoproteins; Antiviral Agents; Biomarkers, Tumor; Bone Morphogenetic Protein 7; Carcinoma, Hepatocellular; Connective Tissue Growth Factor; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Function Tests; Liver Neoplasms; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2017 |
The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Glucose; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Insulin Resistance; Insulin-Secreting Cells; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2017 |
Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia.
Topics: Absenteeism; Antiviral Agents; Asia; Benzimidazoles; Efficiency; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir; Treatment Outcome; Work Performance | 2018 |
Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Risk Assessment; Sofosbuvir; Sulfonamides; Sustained Virologic Response; United States; United States Food and Drug Administration; Viral Nonstructural Proteins | 2018 |
Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Drug Therapy, Combination; Egypt; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Models, Statistical; Pyrrolidines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Ribavirin; Sofosbuvir; Uridine Monophosphate; Valine | 2017 |
Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV).
Topics: Antiviral Agents; Benzimidazoles; Cell Line; Combined Modality Therapy; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Models, Theoretical; Sofosbuvir; Uridine Monophosphate | 2017 |
Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
Topics: Antiviral Agents; Benzimidazoles; Cohort Studies; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Spain; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate | 2017 |
Resolution of porphyria cutanea tarda in HIV and mixed HCV coinfection after direct-acting antiviral (DAA) therapy.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Middle Aged; Porphyria Cutanea Tarda; Sofosbuvir; Uridine Monophosphate | 2017 |
MSF pushes down price of generic hepatitis C drugs to new low level.
Topics: Antiviral Agents; Carbamates; Developing Countries; Drug Costs; Drug Industry; Drugs, Generic; Hepatitis C, Chronic; Humans; Imidazoles; International Cooperation; Pyrrolidines; Sofosbuvir; Valine | 2017 |
Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world.
Topics: 2-Naphthylamine; Anilides; Anti-Retroviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.
Topics: Antiviral Agents; Benzimidazoles; Calcineurin Inhibitors; Carbamates; Cell Line; Cyclosporine; Everolimus; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Liver Transplantation; Pyrrolidines; Sirolimus; Sofosbuvir; Valine; Virus Replication | 2018 |
Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in children.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Drug Combinations; Fluorenes; Hepatitis C, Chronic; Humans; Sofosbuvir; Uridine Monophosphate | 2017 |
Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate | 2018 |
Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient.
Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Tissue Donors; Transplant Recipients; Viral Load | 2018 |
Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C.
Topics: Aged; Aged, 80 and over; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir | 2018 |
Direct antiviral treatment of chronic hepatitis C in heart transplant recipients.
Topics: Antiviral Agents; Comorbidity; Drug Therapy, Combination; Female; Genotype; Heart Transplantation; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Patient Reported Outcome Measures; Placebos; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Surveys and Questionnaires; Sustained Virologic Response | 2018 |
Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Multicenter Studies as Topic; Patient Reported Outcome Measures; Proline; Quinoxalines; Randomized Controlled Trials as Topic; Self Report; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2018 |
Classical Kaposi's sarcoma concurrent with ledipasvir-sofosbuvir therapy for hepatitis C infection.
Topics: Aged; Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Male; Sarcoma, Kaposi; Sofosbuvir; Uridine Monophosphate | 2019 |
Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation.
Topics: Aged; Antiviral Agents; Austria; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2018 |
Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ≥ 15).
Topics: Antiviral Agents; Australia; Carbamates; Compassionate Use Trials; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Survival Analysis; Treatment Outcome; Valine | 2018 |
Histological assessment of the liver explant in transplanted hepatitis C virus patients achieving sustained virological response with direct-acting antiviral agents.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Inflammation; Liver Transplantation; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir; Uridine Monophosphate | 2018 |
Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Drug Utilization; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Longitudinal Studies; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Valine; Young Adult | 2018 |
Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV.
Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Skin Diseases; Sofosbuvir; Steroids; Treatment Outcome; Uridine Monophosphate | 2018 |
Eight-Week Outcomes of Ledipasvir/Sofosbuvir in Noncirrhotic Treatment-Naive Patients with Hepatitis C: Analysis of Pharmacy-Based Data.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Prescriptions; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pharmacies; Retrospective Studies; Sofosbuvir; Time Factors; Treatment Outcome; United States; Uridine Monophosphate; Viral Load; Young Adult | 2018 |
Future Considerations for the Evaluation of Hepatitis C Virus Treatments in Pan-Genotypic Therapy for Noncirrhotic Treatment-Naive Patients.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Genetic Testing; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Managed Care Programs; Microbial Sensitivity Tests; Practice Guidelines as Topic; Sofosbuvir; United States; United States Food and Drug Administration | 2018 |
Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Opiate Substitution Treatment; Patient Reported Outcome Measures; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotype-1 and 6: real-world experience in Vietnam.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Patient Safety; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Vietnam; Viral Load | 2018 |
Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; North America; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2018 |
Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Prognosis; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2018 |
Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk of nonadherence to direct-acting antivirals.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Directly Observed Therapy; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Medication Adherence; Middle Aged; Sofosbuvir; Substance Abuse, Intravenous; Sustained Virologic Response; Treatment Outcome; Young Adult | 2018 |
Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cryoglobulinemia; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Diabetes Complications; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin; Serum Albumin; Sofosbuvir; Uridine Monophosphate | 2018 |
Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min.
Topics: Adult; Antiviral Agents; Carbamates; Comorbidity; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; India; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Renal Insufficiency, Chronic; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2019 |
Remission of Psoriasis After Treatment of Chronic Hepatitis C Virus Infection With Direct-Acting Antivirals.
Topics: Aged, 80 and over; Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Male; Psoriasis; Remission Induction; Sofosbuvir; Uridine Monophosphate | 2018 |
Editorial: direct-acting antivirals significantly improve quality of life in patients with hepatitis C virus infection-Author's reply.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Patient Reported Outcome Measures; Proline; Quality of Life; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Editorial: direct-acting antivirals significantly improve quality of life in patients with hepatitis C virus infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Patient Reported Outcome Measures; Proline; Quality of Life; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2018 |
Effectiveness and safety of original and generic sofosbuvir for the treatment of chronic hepatitis C: A real world study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Argentina; Carbamates; Drug-Related Side Effects and Adverse Reactions; Drugs, Generic; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2018 |
Spur-of-the-Moment Modification in National Treatment Policies Leads to a Surprising HCV Viral Suppression in All Treated Patients: Real-Life Egyptian Experience.
Topics: Antiviral Agents; Carbamates; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Microbial Sensitivity Tests; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Valine | 2018 |
Complete Response of Diffuse Large B Cell Lymphoma After Direct-Acting Antiviral Therapy for Hepatitis C Virus.
Topics: Aged; Antiviral Agents; Carbamates; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Neoplasms; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Male; Radiography, Abdominal; Ribavirin; Sofosbuvir; Treatment Outcome | 2019 |
Retreatment with sofosbuvir/velpatasvir in cirrhotic patients with genotype-4 who failed a previous interferon-free regimen: a case series.
Topics: Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Resistance, Viral; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Interferons; Liver Cirrhosis; Male; Recurrence; Sofosbuvir; Sustained Virologic Response; Viral Nonstructural Proteins | 2018 |
Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals?
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Microbial Sensitivity Tests; Middle Aged; Poland; Sofosbuvir | 2018 |
Editorial: are additional tests needed to predict sustained virologic response in hepatitis C treated with interferon-free direct-acting antiviral combinations?
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Kinetics; Sofosbuvir; Sustained Virologic Response; Treatment Failure | 2018 |
Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs.
Topics: Adult; Aged; Antiviral Agents; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin; Insulin Resistance; Liver Cirrhosis; Male; Middle Aged; Simeprevir; Sofosbuvir; Triglycerides; Viral Load; Young Adult | 2018 |
Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients.
Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Antiviral Agents; Drug Monitoring; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Receptors, Calcitriol; Retrospective Studies; Sofosbuvir; Vitamin D; Vitamin D-Binding Protein; Vitamin D3 24-Hydroxylase | 2018 |
Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection.
Topics: Aged; Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Drug Resistance, Viral; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prevalence; Simeprevir; Sofosbuvir | 2018 |
HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.
Topics: Amino Acid Substitution; Antiviral Agents; Benzimidazoles; Carbamates; Cell Culture Techniques; Cell Line, Tumor; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Pyrrolidines; Sofosbuvir; Viral Nonstructural Proteins | 2018 |
EFFECTIVE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTIONS WITH DIRECT ACTING ANTIVIRALS IN PRISONS SYSTEM.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; gamma-Glutamyltransferase; Genotype; Georgia (Republic); Hepacivirus; Hepatitis C, Chronic; Humans; Liver Function Tests; Male; Middle Aged; Prisoners; Prisons; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2018 |
Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease.
Topics: Adult; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Pyrrolidines; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Prevalence of HCV Infection in Adults with Congenital Heart Disease and Treatment with Direct Antiviral Agents.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Blood Safety; Female; Fluorenes; Follow-Up Studies; Heart Defects, Congenital; Hepatitis C, Chronic; Humans; Male; Middle Aged; Postoperative Complications; Prevalence; Retrospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2018 |
Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study.
Topics: Alleles; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Female; Genome; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Hepatocyte Nuclear Factor 4; Humans; Male; Middle Aged; Neoplasm Proteins; Pharmacogenetics; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Sofosbuvir | 2018 |
Successful treatment of HCV-related glomerulonephritis with sofosbuvir and daclatasvir.
Topics: Antiviral Agents; Carbamates; Glomerulonephritis; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Treatment Outcome; Valine; Viral Load | 2018 |
No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Black People; California; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Time Factors; Treatment Outcome | 2018 |
Qualitative Versus Quantitative PCR in Establishing Response to Chronic Hepatitis C Treatment with Sofosbuvir.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pakistan; Poverty Areas; Real-Time Polymerase Chain Reaction; RNA, Viral; Sofosbuvir; Treatment Outcome | 2018 |
Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy.
Topics: Aged; Antibodies; Antiviral Agents; Biomarkers; Carbamates; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Peptides; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Retrospective Studies; Ribavirin; Seroepidemiologic Studies; Sofosbuvir; Valine; Viral Load | 2018 |
Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing Regimens.
Topics: Antiviral Agents; Female; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Microbial Sensitivity Tests; Middle Aged; Ribavirin; Sofosbuvir | 2018 |
Treatment of HCV in the Department of Corrections in the Era of Oral Medications.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prisons; Ribavirin; Sex Factors; Socioeconomic Factors; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate | 2018 |
Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir.
Topics: Abdominal Pain; Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Esophageal and Gastric Varices; Fatigue; Female; Fluorenes; Gastrointestinal Hemorrhage; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Nausea; Prospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2018 |
Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients With Chronic Hepatitis C Infection.
Topics: Adolescent; Antiviral Agents; Carbamates; Child; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Prospective Studies; Pyrrolidines; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load | 2018 |
'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Valine | 2018 |
Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.
Topics: Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; End Stage Liver Disease; Female; Genotype; Germany; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Creatinine; Drug Resistance, Viral; Fluorenes; Genotype; Glomerular Filtration Rate; Hepatitis B virus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Young Adult | 2018 |
Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Red Cross; Retrospective Studies; Risk; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins; Young Adult | 2018 |
Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Japan; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2018 |
Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Bullous pemphigoid associated with chronic hepatitis C virus infection in a hepatitis B virus endemic area: A case report.
Topics: Administration, Oral; Aged; Antibodies, Viral; Antiviral Agents; Diagnosis, Differential; DNA, Viral; Glucocorticoids; Hepacivirus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Male; Methylprednisolone; Pemphigoid, Bullous; Republic of Korea; Ribavirin; Sofosbuvir; Treatment Outcome | 2018 |
Editorial: patient-reported outcomes in chronic HCV-a PROMISing approach to an ongoing problem.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Patient Reported Outcome Measures; Psychometrics; Sofosbuvir | 2018 |
Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.
Topics: Administration, Oral; Adult; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2018 |
Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drugs, Generic; Female; Fluorenes; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; India; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Renal Insufficiency, Chronic; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load; Young Adult | 2018 |
Pre-emptive Treatment of HCV after Living Donor Liver Transplantation with Direct-Acting Antiviral Agents.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Retrospective Studies; Secondary Prevention; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uridine Monophosphate; Valine | 2018 |
Direct-Acting Antivirals to Prevent Vertical Transmission of Viral Hepatitis C: When Is the Optimal Time to Treat?
Topics: Antiviral Agents; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Pregnancy; Ribavirin; Sofosbuvir; Time Factors | 2018 |
Sofosbuvir Causing Diabetes Mellitus: Is there a Link?
Topics: Antiviral Agents; Benzimidazoles; Blood Glucose; Carbamates; Diabetes Mellitus; Drug Therapy, Combination; Female; Glycated Hemoglobin; Hepatitis C, Chronic; Humans; Imidazoles; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2018 |
A pilot single arm observational study of sofosbuvir/ledipasvir (200 + 45 mg) in 6- to 12- year old children.
Topics: Antiviral Agents; Benzimidazoles; Child; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Pilot Projects; Prospective Studies; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate | 2018 |
Safety and efficacy of HCV eradication during etanercept treatment for severe psoriasis.
Topics: Aged; Antiviral Agents; Carbamates; Etanercept; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Male; Psoriasis; Pyrrolidines; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Tumor Necrosis Factor-alpha; Valine | 2018 |
Remission of Nephrotic Syndrome After Therapy for Chronic Hepatitis C Virus Infection in a Patient With Systemic Lupus Erythematosus.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Glucocorticoids; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Lupus Nephritis; Nephrotic Syndrome; Prednisolone; Remission Induction; Ribavirin; Sofosbuvir; Tacrolimus | 2018 |
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Valine | 2018 |
Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate | 2018 |
Effectiveness of Sofosbuvir, Ribavirin and PEG-IFNα-2a in the Treatment of Naïve Egyptian Patients With Chronic Hepatitis C Virus Genotype 4.
Topics: Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2018 |
Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4.
Topics: Adult; Antiviral Agents; Carbamates; Cohort Studies; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Registries; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Incidence of Acute Kidney Injury in Patients Coinfected with HIV and Hepatitis C Virus Receiving Tenofovir Disoproxil Fumarate and Ledipasvir/Sofosbuvir in a Real-World, Urban, Ryan White Clinic.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Georgia; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Sofosbuvir; Tenofovir; Young Adult | 2018 |
Efficacy and Safety of Direct Acting Antiviral Therapy for Chronic Hepatitis C in Thalassemic Children.
Topics: Adolescent; Antiviral Agents; beta-Thalassemia; Carbamates; Child; Child, Preschool; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; India; Male; Prospective Studies; Pyrrolidines; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load | 2018 |
Successful Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin Retreatment for a Chronic Hepatitis C Genotype 2a Patient Who Relapsed after Sofosbuvir Plus Ribavirin Treatment.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine | 2018 |
Utilizing Clinical Pharmacist Specialist to Manage Hepatitis C Virus Patients on Direct-Acting Antiviral Therapy.
Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pharmacists; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2019 |
[Daclatasvir-sofosbuvir combination therapy for chronic hepatitis C virus infection: progress in clinical studies].
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Treatment Outcome; Valine | 2018 |
[Potential application of sofosbuvir-based treatment for chronic hepatitis C in China].
Topics: Adolescent; Aged; Antiviral Agents; China; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir | 2018 |
Real-world data on antiviral treatments for hepatitis C virus infections: Can we define intention to treat or per protocol analyses?
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Sofosbuvir | 2018 |
The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir.
Topics: Adult; Aged; Aged, 80 and over; Benzimidazoles; Cohort Studies; Drug Resistance, Multiple, Viral; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Uridine Monophosphate; Viral Nonstructural Proteins | 2018 |
Retreatment of hepatitis C virus: can it get any better?
Topics: Aminoisobutyric Acids; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides | 2018 |
Localized scleroderma occurring after treatment of chronic hepatitis C with sofosbuvir and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Scleroderma, Localized; Skin; Sofosbuvir; Treatment Outcome | 2019 |
Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study.
Topics: Aged; Anemia; Antiviral Agents; Dizziness; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Protease Inhibitors; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2018 |
Letter: concordance of SVR4 and SVR12 following direct-acting anti-viral treatment in Egypt.
Topics: Antiviral Agents; Carbamates; Egypt; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2018 |
Editorial: retreatment of DAA-failures-no problem at all?
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Retreatment; Ribavirin; Simeprevir; Sofosbuvir | 2018 |
Significance of NS5B Substitutions in Genotype 1b Hepatitis C Virus Evaluated by Bioinformatics Analysis.
Topics: Amino Acid Substitution; Antiviral Agents; Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Molecular Dynamics Simulation; Mutation, Missense; Protein Conformation; Recurrence; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Viral Nonstructural Proteins | 2018 |
State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015.
Topics: Ambulatory Care; Antiviral Agents; Hepatitis C, Chronic; Humans; Insurance, Health, Reimbursement; Medicaid; Sofosbuvir; United States | 2018 |
Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic Hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian; Benzimidazoles; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Young Adult | 2019 |
100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Uridine Monophosphate; Valine | 2018 |
Successful DAA-Based Treatment of Hcv-Related Fibrosing Cholestatic Hepatitis After Liver Transplantation Due to a Fulminant Liver Failure.
Topics: Adult; Antiviral Agents; Benzimidazoles; Diagnosis, Differential; Drug Therapy, Combination; Fluorenes; Hepatitis C, Chronic; Humans; Jaundice, Obstructive; Liver Failure, Acute; Liver Transplantation; Male; Postoperative Complications; Sofosbuvir | 2018 |
Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Medicaid; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Failure; United States; Uridine Monophosphate; Viral Load | 2018 |
Recurrent membranous nephropathy and acute cellular rejection in a patient treated with direct anti-HCV therapy (ledipasvir/sofosbuvir).
Topics: Aged; Allografts; Antiviral Agents; Benzimidazoles; Biopsy; Fluorenes; Glomerulonephritis, Membranous; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Kidney; Male; Recurrence; Sofosbuvir; Uridine Monophosphate | 2018 |
Comparative effectiveness of 8- and 12-week ledipasvir/sofosbuvir regimens for HCV infection.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Black or African American; Drug Administration Schedule; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Hispanic or Latino; Humans; Male; Middle Aged; Odds Ratio; Practice Guidelines as Topic; Sofosbuvir; Sustained Virologic Response; Texas; Uridine Monophosphate; Viral Load; White People | 2018 |
Recurrent deep venous thrombosis in a leprosy patient on Sofosbuvir regimen for HCV: a lepra reaction?
Topics: Aged; Antiviral Agents; Diagnosis, Differential; Drug Eruptions; Hepatitis C, Chronic; Humans; Leprosy, Borderline; Leprosy, Lepromatous; Male; Peripheral Nervous System Diseases; Recurrence; Sofosbuvir; Venous Thrombosis | 2018 |
Direct-acting antiviral drugs are triggers for psoriasis: report of three cases.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Psoriasis; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Symptom Flare Up; Valine | 2018 |
Restoring Inflammatory Mediator Balance after Sofosbuvir-Induced Viral Clearance in Patients with Chronic Hepatitis C.
Topics: Chemokine CCL2; Cytokines; Hepatitis C, Chronic; Humans; Inflammation; Inflammation Mediators; Interleukin-10; Interleukin-15; Interleukin-1beta; Interleukin-4; Plasminogen Activator Inhibitor 1; Sofosbuvir | 2018 |
Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology.
Topics: Aged; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Cross-Sectional Studies; Female; Fibrosis; Hepatitis C, Chronic; Humans; Internationality; Liver; Male; Middle Aged; Platelet Count; Predictive Value of Tests; Prospective Studies; Receptors, Cell Surface; ROC Curve; Sofosbuvir; Sustained Virologic Response | 2018 |
Study of Adverse Drug Effects of Direct-Acting Antivirals for Chronic HCV Infection at Fayoum Governorate, Egypt - A Pharmacovigilance Study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Male; Middle Aged; Pharmacovigilance; Prospective Studies; Pyrrolidines; Ribavirin; Severity of Illness Index; Sofosbuvir; Valine | 2018 |
Real Life Egyptian Experience of Daclatasvir Plus Sofosbuvir with Ribavirin in Naïve Difficult to Treat HCV Patients.
Topics: Administration, Oral; Adult; Carbamates; Case-Control Studies; Drug Combinations; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load | 2020 |
Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Japan; Liver Cirrhosis; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2018 |
Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Health Care Costs; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Italy; Male; Markov Chains; Middle Aged; Patient Acceptance of Health Care; Quality-Adjusted Life Years; Sofosbuvir; Young Adult | 2018 |
Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Liver Cirrhosis; Polymorphism, Genetic; Prospective Studies; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine | 2018 |
Hepatitis C Virus Infection in ESKD Patients.
Topics: Aged; Antiviral Agents; Benzimidazoles; Benzofurans; Drug Combinations; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Kidney Transplantation; Male; Mass Screening; Quinoxalines; Sofosbuvir; Uridine Monophosphate | 2018 |
Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study.
Topics: Benzimidazoles; Coinfection; Fluorenes; Glomerular Filtration Rate; Hepatitis C, Chronic; HIV Infections; Humans; Prospective Studies; Sofosbuvir; Uridine Monophosphate | 2018 |
High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
High sustained virologic response rate using generic directly acting antivirals in the treatment of chronic hepatitis C virus Egyptian patients: single-center experience.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load | 2018 |
Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Black or African American; Carbamates; Community Health Centers; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response | 2018 |
Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Carbamates; Child; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load | 2019 |
Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Female; Fluorenes; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Renal Insufficiency; Sofosbuvir; Treatment Outcome; Valine; Viral Nonstructural Proteins; Young Adult | 2018 |
Epidemic history of hepatitis C virus genotypes and subtypes in Portugal.
Topics: 2-Naphthylamine; Adult; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Molecular Epidemiology; Polymorphism, Genetic; Portugal; Sofosbuvir; Sulfonamides; Uracil; Viral Nonstructural Proteins | 2018 |
HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China.
Topics: Amino Acid Substitution; Antiviral Agents; Asia; China; Drug Resistance, Viral; Europe; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; North America; Phylogeny; Prevalence; Sofosbuvir; Viral Nonstructural Proteins | 2018 |
[Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents].
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load | 2019 |
Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2019 |
Resolution of Atypical Lichen Myxedematosus Following Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir-Velpatasvir Combination Therapy.
Topics: Aged; Antiviral Agents; Carbamates; Drug Combinations; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Scleromyxedema; Sofosbuvir | 2018 |
Findings from a large Asian chronic hepatitis C real-life study.
Topics: Adult; Antiviral Agents; Asia; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
Chemotherapy and targeted therapy for breast cancer patients with hepatitis C virus infection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Breast Neoplasms; Breast Neoplasms, Male; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lapatinib; Liver; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Trastuzumab; Virus Replication | 2019 |
Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Retrospective Studies; Ribavirin; Sofosbuvir | 2018 |
Does Ribavirin Still Have a Role in Sofosbuvir and Velpatasvir Therapy for Patients With HCV Genotype 3 Infection and Cirrhosis?
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome | 2018 |
Acute changes in cardiac function by direct acting antiviral therapy for hepatitis C-infected patients with thalassemia.
Topics: Adolescent; Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Heart; Heart Diseases; Heart Function Tests; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Prospective Studies; Sofosbuvir; Thalassemia; Young Adult | 2019 |
Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Taiwan | 2018 |
Direct-acting antiviral Therapy Is Safe and Effective in Pediatric Chronic Hepatitis C: The Public Health Perspective.
Topics: Adolescent; Antiviral Agents; Carbamates; Child; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; India; Male; Program Evaluation; Public Health; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2019 |
Sustained Viral Response in Genotype 4 Chronic Hepatitis C Virus-infected Children and Adolescents Treated With Sofosbuvir/Ledipasvir.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Egypt; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Load | 2018 |
Persistence of NS5B-S282T, a sofosbuvir resistance-associated substitution, in a HIV/HCV-coinfected MSM with risk of onward transmission.
Topics: Aged; Antiviral Agents; Coinfection; Drug Resistance, Viral; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Male; Mutation; RNA, Viral; Sofosbuvir; Viral Nonstructural Proteins | 2018 |
Prevalence of thyroid stimulating hormone dysfunction among sofosbuvir-treated HCV-infected patients: A real-world clinical experience.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hyperthyroidism; Male; Middle Aged; Pakistan; Prevalence; Sofosbuvir; Thyroid Diseases; Thyroid Gland; Thyrotropin | 2019 |
The Effectiveness of Ledipasvir/Sofosbuvir in Youth With Genotype 4 Hepatitis C Virus: A Single Egyptian Center Study.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Egypt; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interleukins; Male; Polymorphism, Genetic; Product Surveillance, Postmarketing; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Load | 2019 |
Patients with chronic hepatitis C receiving sofosbuvir and ribavirin-based treatment, with or without interferon in Zhejiang, China: An observational study.
Topics: Adult; Antiviral Agents; China; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Viral Load; Young Adult | 2018 |
Eradication of HCV in Renal Transplant Recipients and Its Effects on Quality of Life.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Italy; Kidney Transplantation; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Treatment Outcome | 2018 |
Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis.
Topics: Antiviral Agents; Benzimidazoles; Biomarkers; Carbamates; Case-Control Studies; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Prospective Studies; Prothrombin Time; Pyrrolidines; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate; Valine | 2019 |
Association of IL-1β, IL-1RN, and ESR1 genes polymorphism with risk of infection and response to sofosbuvir plus daclatasvir combination therapy in hepatitis C virus genotype-4 patients.
Topics: Antiviral Agents; Carbamates; Case-Control Studies; Drug Therapy, Combination; Egypt; Estrogen Receptor alpha; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Infections; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Liver Cirrhosis; Polymorphism, Genetic; Pyrrolidines; Sofosbuvir; Valine | 2018 |
Sofosbuvir-based salvage therapy for HCV infection in cirrhotic patients with DAA failure and multidrug resistance.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Retreatment; Salvage Therapy; Sofosbuvir; Treatment Failure; Treatment Outcome | 2018 |
Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Topics: Antiviral Agents; Carbamates; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Registries; Retrospective Studies; Sofosbuvir; Treatment Outcome; Valine | 2019 |
Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study.
Topics: Adult; Antiviral Agents; Asian People; Carbamates; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
The role of anti-HBs in hepatitis B reactivation during direct-acting antiviral therapy for chronic hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; DNA, Viral; Female; Fluorenes; Hepacivirus; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Sofosbuvir; Viremia; Virus Activation | 2018 |
Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Taiwan; Valine | 2019 |
Is sofosbuvir/ledipasvir safe for the hearts of children with hepatitis C virus?
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Bradycardia; Cardiovascular System; Child; Drug Monitoring; Egypt; Electrocardiography; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Prospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load | 2019 |
No Regional Disparities in Sofosbuvir Plus Ribavirin Therapy for HCV Genotype 2 Infection in Tochigi Prefecture and Its Vicinity.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Geography; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Japan; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2019 |
Oral direct-acting antiviral therapy for hepatitis C virus infection in X-linked agammaglobulinemia.
Topics: 2-Naphthylamine; Administration, Oral; Adult; Agammaglobulinemia; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Genetic Diseases, X-Linked; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunoglobulin G; Immunoglobulins, Intravenous; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Pyrrolidines; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2019 |
A Patient of Chronic Hepatitis C Complicated by Thalassemia Major and Chronic Osteomyelitis: A Therapeutic Challenge for a Clinician.
Topics: Adolescent; Antiviral Agents; beta-Thalassemia; Blood Transfusion; Carbamates; Chronic Disease; Female; Hepatitis C, Chronic; Humans; Imidazoles; Osteomyelitis; Pyrrolidines; Sofosbuvir; Valine | 2018 |
Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Markov Chains; Pyrrolidines; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; Uridine Monophosphate; Valine | 2019 |
Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan.
Topics: Aged; Anti-Infective Agents; Antiviral Agents; Benzimidazoles; Cardiovascular Agents; Comorbidity; Cross-Sectional Studies; Drug Interactions; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Prospective Studies; Sofosbuvir; Taiwan; Uridine Monophosphate | 2018 |
Treatment of chronic hepatitis C viral infection with sofosbuvir and daclatasvir in kidney transplant recipients.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Transplantation; Liver; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Transplant Recipients; Treatment Outcome; Valine; Viral Load | 2019 |
Evaluation of histological dynamics, kidney function and diabetes in liver transplant patients after antiviral treatment with direct-acting antivirals: Therapy of HCV-recurrence.
Topics: Aged; Aged, 80 and over; Allografts; Antiviral Agents; Biopsy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; End Stage Liver Disease; Female; Fibrosis; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney; Liver; Liver Transplantation; Male; Middle Aged; Recurrence; Sofosbuvir; Sustained Virologic Response | 2019 |
Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4.
Topics: Adolescent; Antiviral Agents; Carbamates; Child; Combined Modality Therapy; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Pilot Projects; Prospective Studies; Pyrrolidines; Sofosbuvir; Sustained Virologic Response; Valine | 2019 |
Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; China; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2019 |
Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C).
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine | 2019 |
Predictive value of IL-28B rs12979860 variants for peg-IFN, sofosbuvir plus ribavirin treatment of HCV infection in Pakistani population.
Topics: Adult; Antiviral Agents; Biomarkers, Pharmacological; Cross-Sectional Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Pakistan; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate; Valine; Viral Load; Viral Nonstructural Proteins | 2019 |
Direct acting antiviral-based treatment of hepatitis C virus infection among people who inject drugs in Georgia: A prospective cohort study.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Drug Users; Female; Genotype; Georgia; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Substance Abuse, Intravenous | 2018 |
Recovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvir.
Topics: Adult; Antiviral Agents; Benzimidazoles; Case-Control Studies; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Innate; Killer Cells, Natural; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response | 2018 |
Successful DAA Treatment and Global Improvement in a Cirrhotic Patient with Concomitant HCV Infection and Autoimmune Hepatitis.
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Carbamates; Female; gamma-Globulins; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Imidazoles; Liver; Liver Cirrhosis; Middle Aged; Pyrrolidines; Ribavirin; RNA, Viral; Serum Albumin; Sofosbuvir; Valine; Viral Load | 2019 |
Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Breast Neoplasms; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Fluorenes; Head and Neck Neoplasms; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Interferons; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Neoplasms; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2019 |
The Efficacy and Safety of Direct-acting Antiviral Treatment for Chronic Hepatitis C Patients: A Single Center Study.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Dyspepsia; Elasticity Imaging Techniques; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus-Positive Kidney Transplant Recipients.
Topics: Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Sofosbuvir; Transplant Recipients; Uridine; Valine | 2019 |
Polymorphism in interferon λ3/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Case-Control Studies; Female; Genetic Predisposition to Disease; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Male; Middle Aged; Pyrrolidines; Recurrence; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2019 |
The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Poland; Proline; Protease Inhibitors; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Uridine Monophosphate; Valine; Young Adult | 2018 |
Healing of autoimmune hepatitis associated with hepatitis C virus infection treated with direct-acting antivirals.
Topics: Antiviral Agents; Azathioprine; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Interferons; Middle Aged; Prednisone; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2019 |
Quality of life of Brazilian chronic hepatitis C patients treated with interferon-free therapies.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Quality of Life; Simeprevir; Socioeconomic Factors; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Cost-effectiveness of sofosbuvir plus ribavirin therapy for hepatitis C virus genotype 2 infection in South Korea.
Topics: Aged; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Ribavirin; Sofosbuvir; Treatment Outcome | 2019 |
Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir.
Topics: Aged; Antiviral Agents; Asia; Benzimidazoles; Carbamates; Cohort Studies; Drug Combinations; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2019 |
Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoring.
Topics: Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir | 2019 |
Drug pricing: still a barrier to elimination of HCV.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Disease Eradication; Drug Combinations; Drug Costs; Fluorenes; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir; United States; Uridine Monophosphate | 2018 |
Safety of pembrolizumab while commencing treatment for hepatitis C with Harvoni (ledipasvir and sofosbuvir).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antiviral Agents; Benzimidazoles; Clinical Decision-Making; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2018 |
Hepatitis C Treatment in Patients with Drug Addiction Is Effective or Not Effective?
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Drug Users; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load | 2018 |
8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study).
Topics: Antiviral Agents; Benzimidazoles; Drug Monitoring; Duration of Therapy; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Netherlands; Outcome Assessment, Health Care; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2019 |
Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; China; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Valine; Viral Nonstructural Proteins | 2018 |
APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzofurans; Contraindications, Drug; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
Sofosbuvir plus ribavirin for the treatment of hepatitis C virus genotype 2 in Korea: What's the optimal dosage of ribavirin in real-world setting?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Republic of Korea; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2019 |
Efficacy and safety of sofosbuvir-based therapy in hepatitis C virus recurrence post living donor liver transplant: A real life egyptian experience.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Egypt; Female; Hepatitis C, Chronic; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Sofosbuvir; Sustained Virologic Response; Transplant Recipients; Treatment Outcome; Young Adult | 2019 |
Tolerability and effectiveness of generic direct-acting antiviral drugs in eradication of hepatitis C genotype 4 among Egyptian patients.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Valine | 2019 |
Direct-acting antiviral therapy in sub-Saharan Africa.
Topics: Africa South of the Sahara; Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Rwanda; Sofosbuvir | 2019 |
Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial.
Topics: Aged; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; RNA, Viral; Rwanda; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Viral Load | 2019 |
Effective drugs on the road to HCV elimination and a therapeutic gap to close.
Topics: Asia; Carbamates; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir | 2019 |
Outcomes of Treatment and Predictors of Response to Sofosbuvir Plus Simeprevir in Hepatitis C Virus with Genotype-4 Infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; RNA, Viral; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2020 |
Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir: A case report.
Topics: Antiviral Agents; Carbamates; Coinfection; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Renal Dialysis; Sofosbuvir | 2018 |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Safety; Sofosbuvir; Sustained Virologic Response; Taiwan; Treatment Outcome; Uridine Monophosphate | 2018 |
Impact of hepatitis C virus and direct acting antivirals on kidney recipients: a retrospective study.
Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney; Kidney Failure, Chronic; Kidney Transplantation; Liver; Male; Middle Aged; Patient Safety; Proteinuria; Retrospective Studies; Simeprevir; Sofosbuvir; Sustained Virologic Response | 2019 |
Th17 and IL-17 as Predictors of Hepatic Inflammation in Patients with Chronic Hepatitis C Virus Infection and Treated With Direct Antiviral Therapy.
Topics: Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Inflammation; Interleukin-17; Ribavirin; Sofosbuvir; Sustained Virologic Response; Th17 Cells; Treatment Outcome | 2018 |
Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Health Services Accessibility; Hepatitis C, Chronic; Humans; Imidazoles; Indonesia; Male; Medically Underserved Area; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Viral Nonstructural Proteins; Young Adult | 2018 |
Anatomical and Functional Retinal Complications of Combined Sofosbuvir and Ribavirin Therapy in Patients With Chronic Hepatitis C Virus.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Electroretinography; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Retina; Ribavirin; Sofosbuvir; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity; Young Adult | 2019 |
Fib-4 Predicts Early Hematological Adverse Events Induced by Interferon-Based Triple Therapy in Chronic Hepatitis C Virus Patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2019 |
Hepatitis C Virus: No Longer a Barrier to Oncology Care.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Neoplasms; Prospective Studies; Sofosbuvir; Sustained Virologic Response | 2019 |
Effectiveness of 8-week sofosbuvir/ledipasvir in the adolescent chronic hepatitis C-infected patients.
Topics: Administration, Oral; Adolescent; Antiviral Agents; Benzimidazoles; Child; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Elasticity Imaging Techniques; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Liver; Male; Prospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2019 |
Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Italy; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2019 |
Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?
Topics: Aged; Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response | 2019 |
Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Comparative Effectiveness Research; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Taiwan; Time Factors; Treatment Outcome; Uridine Monophosphate; Valine | 2019 |
Sofosbuvir-Based Regimens for Chronic Hepatitis C in a Well-Insured U.S. Population: Patient Characteristics, Treatment Adherence, Effectiveness, and Health Care Costs, 2013-2015.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Costs; Drug Therapy, Combination; Female; Fluorenes; Health Care Costs; Hepatitis C, Chronic; Humans; Insurance, Health; Interferon-alpha; Male; Medicare; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; United States; Uridine Monophosphate; Young Adult | 2019 |
Effect of sofosbuvir plus daclatasvir for treatment of chronic hepatitis C on patients with psoriasis.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Psoriasis; Pyrrolidines; Quality of Life; Sofosbuvir; Treatment Outcome; Valine; Viral Load; Young Adult | 2019 |
Effect of cyclosporine A versus tacrolimus on the response to antiviral therapy after hepatitis C genotype-4 recurrence post-liver transplantation: A prospective cohort trial.
Topics: Adult; Aged; Antiviral Agents; Calcineurin Inhibitors; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Sofosbuvir; Tacrolimus; Young Adult | 2019 |
Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate | 2019 |
Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?
Topics: Adult; Antiviral Agents; Ascites; Carbamates; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Patient Selection; Pyrrolidines; Quality of Life; Ribavirin; RNA, Viral; Severity of Illness Index; Sofosbuvir; Survival Rate; Sustained Virologic Response; Ultrasonography; Valine | 2019 |
The benefits of a public pharmacist service in chronic hepattis C treatment: The real-life results of sofosbuvir-based therapy.
Topics: Antiviral Agents; Carbamates; Community Pharmacy Services; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Medication Adherence; Middle Aged; Pharmacists; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine | 2020 |
The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Neoplasm Recurrence, Local; Ribavirin; Sofosbuvir; Treatment Outcome | 2021 |
Association of Ledipasvir-Sofosbuvir Treatment With Uveitis in Patients Treated for Hepatitis C.
Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Hepatitis C, Chronic; Humans; Male; Middle Aged; Optic Disk; Retina; Severity of Illness Index; Sofosbuvir; Time Factors; Tomography, Optical Coherence; Uridine Monophosphate; Uveitis, Posterior; Visual Acuity | 2019 |
Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Simeprevir; Sofosbuvir; Treatment Outcome | 2019 |
Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Administration Schedule; Drug Combinations; Female; Fluorenes; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Safety; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Young Adult | 2019 |
Experience of a Portuguese Center: Effectiveness of Direct-Acting Antiviral Therapy for Hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Portugal; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Young Adult | 2019 |
Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening Patient-reported Outcomes.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Quality of Life; Sofosbuvir | 2020 |
High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results.
Topics: Adult; Anemia; Anilides; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2022 |
High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
Effectiveness and safety of sofosbuvir-based therapy against chronic hepatitis C infection after successful kidney transplantation.
Topics: Adult; Antiviral Agents; Calcineurin Inhibitors; Cohort Studies; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Kidney Transplantation; Liver; Male; Middle Aged; Sofosbuvir; Treatment Outcome | 2019 |
Interpreting Viral Deep Sequencing Data with GLUE.
Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; Drug Resistance, Viral; Genome, Viral; Genomics; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Mutation; Sequence Alignment; Sequence Analysis, DNA; Sofosbuvir; Software; Viral Nonstructural Proteins | 2019 |
Direct-acting antivirals and visceral leishmaniasis: a case report.
Topics: Aged; Amphotericin B; Antiprotozoal Agents; Antiviral Agents; Coinfection; Hepatitis C, Chronic; Humans; Leishmania infantum; Leishmaniasis, Visceral; Male; Ribavirin; Sofosbuvir | 2019 |
Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Cohort Studies; Drug Combinations; Drug Substitution; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Macrocyclic Compounds; Male; Middle Aged; Sofosbuvir; Sulfonamides; Sustained Virologic Response; United States; Veterans Health Services; Viral Nonstructural Proteins | 2019 |
Validated RP-HPLC Method for Simultaneous Determination of Ribavirin, Sofosbuvir and Daclatasvir in Human Plasma: A Treatment Protocol Administered to HCV Patients in Egypt.
Topics: Carbamates; Chromatography, High Pressure Liquid; Egypt; Hepatitis C, Chronic; Humans; Imidazoles; Limit of Detection; Linear Models; Pyrrolidines; Reproducibility of Results; Ribavirin; Sofosbuvir; Valine | 2019 |
Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Renal Dialysis; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2020 |
Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir.
Topics: Amino Acid Substitution; Antiviral Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Mutation; Phenotype; Polymorphism, Genetic; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Nonstructural Proteins | 2019 |
Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Benzimidazoles; Blood Chemical Analysis; Chromatography, Liquid; Drug Interactions; Female; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Phosphorous Acids; Sofosbuvir; Tandem Mass Spectrometry; Tenofovir; Young Adult | 2019 |
Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Proline; Pyrrolidines; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome | 2019 |
Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Prospective Studies; Registries; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2019 |
5-Oxo-1-[(2,3,6,7-tetramethoxy-9-phenanthrenyl)methyl]-L-proline Inhibits Hepatitis C Virus Entry.
Topics: Alkaloids; Antiviral Agents; Cell Line, Tumor; Cell Survival; Drug Synergism; Drug Therapy, Combination; HEK293 Cells; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Indolizines; Interferon-alpha; Phenanthrenes; Primary Cell Culture; Proline; Sofosbuvir; Tetraspanin 28; Tylophora; Viral Envelope Proteins; Virus Internalization | 2019 |
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Amides; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Patient Reported Outcome Measures; Proline; Prospective Studies; Quinoxalines; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult | 2019 |
Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 vs 12 weeks.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Recurrence; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2019 |
A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimens.
Topics: Antiviral Agents; Carbamates; Cell Death; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Intracellular Space; Pyrrolidines; Recurrence; Simeprevir; Sofosbuvir; Valine; Virus Replication | 2019 |
High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Male; Middle Aged; Myanmar; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine | 2019 |
B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): Effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Argentina; Brazil; Carbamates; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2019 |
Evaluation of Glycated Haemoglobin (HbA1c) Level in Type 2 Diabetic Chronic HCV Non-cirrhotic Treatment-Naïve Egyptian Patients Eradicated with Sofosbuvir Plus Daclatasvir.
Topics: Antiviral Agents; Blood Glucose; Carbamates; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Egypt; Female; Glycated Hemoglobin; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Risk Factors; Sofosbuvir; Treatment Outcome; Valine | 2020 |
HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma.
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Coinfection; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Phylogeny; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins | 2019 |
Retreatment of Egyptian Chronic Hepatitis C Patients Not Responding to Pegylated Interferon and Ribavirin Dual Therapy.
Topics: Antiviral Agents; Carbamates; Egypt; Female; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine | 2019 |
Effects of Dual Sofosbuvir/Daclatasvir Therapy on Weight and Linear Growth in Adolescent Patients with Chronic Hepatitis C Virus Infection.
Topics: Adolescent; Antiviral Agents; Body Height; Body Weight; Carbamates; Child; Child Development; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Pyrrolidines; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2019 |
A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Decision Trees; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Markov Chains; Proline; Quinoxalines; Sofosbuvir; State Medicine; Sulfonamides; United Kingdom | 2019 |
Direct antiviral agents upregulate natural killer cell potential activity in chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Immunity, Innate; Killer Cells, Natural; Longitudinal Studies; Male; Middle Aged; Natural Cytotoxicity Triggering Receptor 1; NK Cell Lectin-Like Receptor Subfamily C; Sofosbuvir; Time Factors; Young Adult | 2019 |
Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Child; Child, Preschool; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate | 2020 |
Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan.
Topics: Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2019 |
Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection.
Topics: Antiviral Agents; Child; Child, Preschool; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2020 |
Recurrent hyperkalemia in patients with chronic kidney disease and hepatitis C treated with direct antiviral agents.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hyperkalemia; Male; Middle Aged; Recurrence; Renal Insufficiency, Chronic; Sofosbuvir; Sustained Virologic Response | 2019 |
Successful treatment of HBV, HCV, & HEV, with 12-week long use of tenofovir, sofosbuvir, daclatasvir, and ribavirin: A case report.
Topics: Aged; Antiviral Agents; Asthma; Carbamates; Coinfection; Diabetes Complications; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis B; Hepatitis C, Chronic; Hepatitis E; Humans; Imidazoles; Male; Pyrrolidines; Ribavirin; Sofosbuvir; Tenofovir; Treatment Outcome; Valine; Viral Load | 2020 |
Drug-Drug Interactions in Children and Adolescents Receiving Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Virus Infection.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Drug Interactions; Female; Fluorenes; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Risk Assessment; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2019 |
Effect of adding daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis C: real-world experience in Pakistan.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Male; Middle Aged; Pakistan; Pyrrolidines; Retrospective Studies; RNA, Viral; Sofosbuvir; Treatment Outcome; Valine; Viral Load | 2019 |
Interprofessional team-based approach to patients with chronic hepatitis C and personality disorder: Three case studies.
Topics: Adult; Anemia; Antiviral Agents; Comorbidity; Delivery of Health Care, Integrated; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Interprofessional Relations; Male; Middle Aged; Personality Disorders; Polyethylene Glycols; Primary Health Care; Recombinant Proteins; Ribavirin; Sofosbuvir; Substance-Related Disorders | 2019 |
Effect of Combined HCV Therapy on Natural Killer Cell Activity.
Topics: Adult; Antiviral Agents; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Killer Cells, Natural; Male; Middle Aged; Natural Cytotoxicity Triggering Receptor 3; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2019 |
Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Valine | 2019 |
[Effectiveness and safety of sofosbuvir+daclatasvir in the treatment of chronic hepatitis C virus infection in Yan'an, Shaanxi].
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2019 |
Relation between microRNA-21, transforming growth factor β and response to treatment among chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Biomarkers; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; MicroRNAs; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Transforming Growth Factor beta; Treatment Outcome; Valine; Viral Load | 2019 |
Sofosbuvir: the final nail in the coffin for hepatitis C?
Topics: Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2013 |
Hepatitis C treatment: interferon free or interferon freer?
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2013 |
Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C.
Topics: Carbamates; Cholestasis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; RNA, Viral; Sofosbuvir; Transplantation, Homologous; Uridine Monophosphate; Valine | 2013 |
HCV treatment--no more room for interferonologists?
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2013 |
Interferon-free hepatitis C treatment: one pill to fit all?
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Protease Inhibitors; Ribavirin; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C.
Topics: Antiviral Agents; Efficiency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Quality of Life; Randomized Controlled Trials as Topic; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Treatment Outcome; Uridine Monophosphate | 2014 |
Sofosbuvir approved for chronic hepatitis C infection.
Topics: Drug Approval; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate | 2014 |
Incorporating patient-reported outcomes into hepatitis C virus treatment studies.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Sofosbuvir; Uridine Monophosphate | 2014 |
Hepatitis C virus: here comes all-oral treatment.
Topics: Administration, Oral; Antiviral Agents; DNA-Directed RNA Polymerases; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Protease Inhibitors; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
When are effective medications just too expensive?
Topics: Antiviral Agents; DNA-Directed RNA Polymerases; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Protease Inhibitors; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferons; Liver Cirrhosis; Markov Chains; Middle Aged; Quality-Adjusted Life Years; Retreatment; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Quality-Adjusted Life Years; Sofosbuvir; Uridine Monophosphate | 2014 |
Chronic viral hepatitis. Treatment progress, hopes for cures.
Topics: Antiviral Agents; Diagnostic Imaging; Hepatitis B, Chronic; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Liver; Serologic Tests; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
The price of good health.
Topics: Antiviral Agents; Drug Costs; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferons; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
Therapy for hepatitis C--the costs of success.
Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Sofosbuvir; Uridine Monophosphate | 2014 |
Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy.
Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Interferons; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate | 2014 |
Sovaldi ushers in wave of costly hepatitis C drugs.
Topics: Antiviral Agents; Fees, Pharmaceutical; Hepatitis C, Chronic; Humans; Sofosbuvir; Uridine Monophosphate | 2014 |
Case report of successful treatment of fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin after liver transplantation.
Topics: Antiviral Agents; Biopsy; Cholestasis, Intrahepatic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2014 |
Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?
Topics: Antiviral Agents; Benzimidazoles; Drug Approval; Drug Discovery; Fluorenes; Hepatitis C, Chronic; Humans; Nucleosides; Nucleotides; Sofosbuvir; Uridine Monophosphate | 2014 |
The high price of the new hepatitis C virus drugs.
Topics: Antiviral Agents; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy.
Topics: Drug Costs; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
My treatment approach to chronic hepatitis C virus.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate | 2014 |
[Naturopathy consultation. Soon all patients will be curable. Decisive breakthrough in therapy of hepatitis C ].
Topics: Antiviral Agents; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2014 |
Letter: estimating the cost-neutral price of sofosbuvir-based triple therapy for the treatment of naïve patients with genotype 1 HCV infection in Italy.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
[Therapy spectrum in hepatitis C extended. Newer NS3/4A protease inhibitor in chronic hepatitis C-GT1/4 infection].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferons; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Secondary Prevention; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
Insurers brace for high-cost Sovaldi.
Topics: Drug Costs; Hepatitis C, Chronic; Humans; Insurance, Health; Medicaid; Sofosbuvir; United States; Uridine Monophosphate | 2014 |
Why Sovaldi shouldn't cost $84,000.
Topics: Drug Costs; Hepatitis C, Chronic; Humans; Sofosbuvir; United States; Uridine Monophosphate | 2014 |
New expensive treatments for hepatitis C infection.
Topics: Antiviral Agents; Drug Costs; Hepatitis C, Chronic; Humans; Nucleic Acid Synthesis Inhibitors; Sofosbuvir; Uridine Monophosphate | 2014 |
Letter: calcineurin inhibitor level reduction during treatment with sofosbuvir in liver transplanted patients.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C.
Topics: Antiviral Agents; Benzazepines; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Indoles; Protease Inhibitors; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine; Viral Nonstructural Proteins | 2015 |
[New hepatitis C treatments: pharmacological considerations and potential for drug interactions].
Topics: Antiviral Agents; Carbamates; Drug Interactions; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Protease Inhibitors; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine; Viral Nonstructural Proteins | 2014 |
Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Health Care Costs; Hepatitis C, Chronic; Humans; Markov Chains; Middle Aged; Sofosbuvir; Spain; Uridine Monophosphate | 2015 |
Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Prisoners; Proline; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States; Uridine Monophosphate | 2014 |
Sofosbuvir modulates the intimate relationship between hepatitis C virus and lipids.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Lipid Metabolism; Male; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Drug Approval; Drug Combinations; Drug Interactions; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate | 2014 |
Gilead's interferon-free HCV combo approved.
Topics: Benzimidazoles; Drug Approval; Drug Combinations; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Sofosbuvir; United States; United States Food and Drug Administration | 2014 |
Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Remission Induction; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load; Waiting Lists | 2015 |
Viral hepatitis: cure of chronic hepatitis C--required length of follow-up?
Topics: Antiviral Agents; Continuity of Patient Care; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate | 2015 |
Prevalence of drug-drug interactions upon addition of simeprevir- or sofosbuvir-containing treatment to medication profiles of patients with HIV and hepatitis C coinfection.
Topics: Adult; Antiviral Agents; Coinfection; Cross-Sectional Studies; Drug Interactions; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Prevalence; Risk Factors; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2015 |
FDA perspective on sofosbuvir therapy for patients with chronic hepatitis C virus genotype 1 infection who did not respond to treatment with pegylated interferon and ribavirin.
Topics: Antiviral Agents; Drug Approval; Hepatitis C, Chronic; Humans; Sofosbuvir; Uridine Monophosphate | 2014 |
Building bridges and providing transparency to the hepatitis C virus drug approval process.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Approval; Hepatitis C, Chronic; Humans; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate | 2014 |
Does Therapeutic Drug Monitoring of Ribavirin in HCV Genotype 3 Treatment With Sofosbuvir and Ribavirin Still Have a Role?
Topics: Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir | 2015 |
[Is more expensive always better?].
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2014 |
Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Eligibility Determination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitalization; Humans; Interferon-alpha; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Prospective Studies; Ribavirin; Risk Factors; Sofosbuvir; Time Factors; Treatment Outcome | 2015 |
No to greed.
Topics: Antiviral Agents; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Costs; Drug Industry; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Practice Patterns, Physicians'; Public Health; Sofosbuvir; United States; Uridine Monophosphate | 2015 |
Commentary on "no to greed".
Topics: Antiviral Agents; Costs and Cost Analysis; Drug Costs; Drug Industry; Hepatitis C, Chronic; Humans; Practice Patterns, Physicians'; Sofosbuvir; Uridine Monophosphate | 2015 |
Shorter treatments for hepatitis C: another step forward?
Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Furans; Hepatitis C, Chronic; Humans; Male; Quinolines; Ribavirin; RNA, Viral; Sofosbuvir; Thiophenes; Uridine Monophosphate | 2015 |
A window of opportunity: maximizing the effectiveness of new HCV regimens in the United States with the expansion of the Affordable Care Act.
Topics: Adult; Antiviral Agents; Comorbidity; Drug Approval; Drug Therapy, Combination; Genotype; Health Services Accessibility; Hepatitis B; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Insurance Coverage; Mental Disorders; Patient Protection and Affordable Care Act; Population Surveillance; Poverty; Prevalence; Risk Factors; Simeprevir; Sofosbuvir; Substance Abuse, Intravenous; Sulfonamides; United States; Uridine Monophosphate | 2015 |
[Chronic hepatitis C. Interferon free therapy also in patients with liver cirrhosis].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Liver Cirrhosis; Randomized Controlled Trials as Topic; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2014 |
Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.
Topics: Adult; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Drug Therapy, Combination; Fluorenes; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2015 |
Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Liver Transplantation; Male; Middle Aged; Renal Dialysis; Simeprevir; Sofosbuvir; Transplant Recipients; Treatment Outcome; Viral Load | 2015 |
PHOTON-2: hope for patients with HIV and HCV co-infection?
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate | 2015 |
Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States.
Topics: Antiviral Agents; Benzimidazoles; Costs and Cost Analysis; Efficiency; Fluorenes; Hepatitis C, Chronic; Humans; Models, Economic; Sofosbuvir; United States; Uridine Monophosphate | 2015 |
Perspectives of fixed daily dose of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Combinations; Fluorenes; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Randomized Controlled Trials as Topic; Recurrence; Sofosbuvir; Uridine Monophosphate | 2015 |
No compelling reason to adopt new antivirals whenever it is reasonable to wait.
Topics: Antiviral Agents; Enzyme Inhibitors; Evidence-Based Medicine; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Patient Safety; Risk Assessment; Risk Factors; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins | 2015 |
Sofosbuvir (Sovaldi°). Active against hepatitis C virus, but evaluation is incomplete .
Topics: Antiviral Agents; Enzyme Inhibitors; Evidence-Based Medicine; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Patient Safety; Risk Assessment; Risk Factors; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins | 2015 |
[A new era in therapy of chronic hepatitis C].
Topics: Antiviral Agents; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Randomized Controlled Trials as Topic; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2015 |
[New combination therapy increases chances of recovery].
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Liver Cirrhosis; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2015 |
[Interferon free recovery for almost all patients].
Topics: Antiviral Agents; Benzimidazoles; Drug Approval; Fluorenes; Germany; Hepatitis C, Chronic; Humans; Interferons; Sofosbuvir; Uridine Monophosphate | 2015 |
Optimism for patients with genotype 4 HCV infection: clinical trials with direct-acting antivirals finally available.
Topics: Benzazepines; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Interferon-alpha; Isoquinolines; Male; Polyethylene Glycols; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides | 2015 |
Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.
Topics: Antiviral Agents; Benzimidazoles; Budgets; Cost-Benefit Analysis; Drug Costs; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insurance, Health, Reimbursement; Interferon-alpha; Markov Chains; Patient-Specific Modeling; Quality-Adjusted Life Years; Sofosbuvir; United States; Uridine Monophosphate | 2015 |
Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Patient-Specific Modeling; Pyrrolidines; Ribavirin; Sensitivity and Specificity; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine | 2015 |
The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; United States; Uridine Monophosphate; Young Adult | 2015 |
Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.
Topics: Antiviral Agents; Benzimidazoles; DNA, Viral; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Quality of Life; Sofosbuvir; Surveys and Questionnaires | 2015 |
Assessing a broader user base for new HCV drug.
Topics: Antiviral Agents; Benzimidazoles; Clinical Trials, Phase IV as Topic; Drug Utilization; Fluorenes; Hepatitis C, Chronic; Humans; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2015 |
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Markov Chains; Monte Carlo Method; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States; Uridine Monophosphate | 2015 |
Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients.
Topics: Antiviral Agents; Cost-Benefit Analysis; Health Care Costs; Hepatitis C, Chronic; Humans; Sofosbuvir; United Kingdom | 2015 |
Increased eligibility for treatment of chronic hepatitis C infection with shortened duration of therapy: Implications for access to care and elimination strategies in Canada.
Topics: Administration, Oral; Antiviral Agents; Benzimidazoles; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Eligibility Determination; Fluorenes; Health Services Accessibility; Hepatitis C, Chronic; Humans; Mathematical Computing; Ontario; Reproducibility of Results; Research Design; Risk Assessment; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load | 2015 |
Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation.
Topics: Antiviral Agents; Chronic Disease; Cost-Benefit Analysis; End Stage Liver Disease; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Kaplan-Meier Estimate; Liver Failure; Liver Transplantation; Male; Markov Chains; Middle Aged; Preoperative Period; Probability; Recurrence; Research Design; Retrospective Studies; Sofosbuvir; Treatment Outcome; Waiting Lists | 2015 |
Sofosbuvir and ribavirin before liver re-transplantation for graft failure due to recurrent hepatitis C: a case report.
Topics: Antiviral Agents; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Preoperative Care; Recurrence; Reoperation; Ribavirin; Sofosbuvir | 2015 |
Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Italy; Markov Chains; Patient Acceptance of Health Care; Polyethylene Glycols; Quality-Adjusted Life Years; Ribavirin; Severity of Illness Index; Sofosbuvir | 2015 |
Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Regression Analysis; Retrospective Studies; RNA, Viral; Simeprevir; Sofosbuvir; Transplant Recipients; Treatment Outcome; Viral Load | 2015 |
Hepatitis C in Arkansas: updates on epidemiology, testing and treatment.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Arkansas; Cross-Sectional Studies; Drug Costs; Female; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Male; Middle Aged; Predictive Value of Tests; Ribavirin; Risk Factors; Sofosbuvir; Uridine Monophosphate; Young Adult | 2015 |
Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C.
Topics: Antiviral Agents; Cost-Benefit Analysis; Hepatitis C, Chronic; Humans; Markov Chains; Quality of Life; Quality-Adjusted Life Years; Sofosbuvir; Switzerland | 2015 |
Hepatitis C treatment and quality of life - You can't always get what you want, but you might get what you need.
Topics: Benzimidazoles; DNA, Viral; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Quality of Life; Sofosbuvir | 2015 |
Psychiatric care during hepatitis C treatment: the changing role of psychiatrists in the era of direct-acting antivirals.
Topics: Antidepressive Agents; Antiviral Agents; Citalopram; Comorbidity; Cooperative Behavior; Delirium; Depressive Disorder; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Forecasting; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interdisciplinary Communication; Interferon alpha-2; Interferon-alpha; Male; Mianserin; Middle Aged; Mirtazapine; Physician's Role; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate | 2015 |
Hepatic decompensation with sofosbuvir plus simeprevir in a patient with Child-Pugh B compensated cirrhosis.
Topics: Aged; Antiviral Agents; Hepatitis C, Chronic; Humans; Kidney Function Tests; Liver Cirrhosis; Liver Function Tests; Male; Severity of Illness Index; Simeprevir; Sofosbuvir; Treatment Outcome | 2016 |
The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life.
Topics: Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Mental Health; Middle Aged; Prospective Studies; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Withholding Treatment | 2015 |
Thousands of patients in England to get new hepatitis C drugs.
Topics: Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; England; Fluorenes; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Public Health; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine | 2015 |
Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir.
Topics: Administration, Oral; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepatitis B; Hepatitis B virus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Risk Factors; Simeprevir; Sofosbuvir | 2015 |
Editorial Commentary: Another Call to Cure Hepatitis B.
Topics: Antiviral Agents; Coinfection; Hepatitis B; Hepatitis B virus; Hepatitis C, Chronic; Humans; Male; Simeprevir; Sofosbuvir | 2015 |
Efficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Tertiary Care Centers; Treatment Outcome; Viral Load | 2015 |
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States.
Topics: Antiviral Agents; Drug Costs; Eligibility Determination; Health Policy; Hepatitis C, Chronic; Humans; Insurance, Health, Reimbursement; Medicaid; Sofosbuvir; United States; Uridine Monophosphate | 2015 |
Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs.
Topics: Antiviral Agents; Budgets; Drug Costs; Eligibility Determination; Health Policy; Hepatitis C, Chronic; Humans; Insurance, Health, Reimbursement; Medicaid; Sofosbuvir; United States; Uridine Monophosphate | 2015 |
Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection.
Topics: Antiviral Agents; Case-Control Studies; Chemokines; Cytokines; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Time Factors | 2015 |
Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis.
Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Cholestasis, Intrahepatic; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Survival; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Matched-Pair Analysis; Middle Aged; Postoperative Complications; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2015 |
Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Protease Inhibitors; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2015 |
Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hypertension, Portal; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Portal Pressure; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine | 2015 |
Ledipasvir-sofosbuvir for hepatitis C genotype 4 infection.
Topics: Benzimidazoles; DNA, Viral; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Sofosbuvir | 2015 |
Beyond the achievement of sustained virological response after liver transplantation.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Liver Transplantation; Male; Simeprevir; Sofosbuvir | 2015 |
Direct antiviral agents for treatment-naïve patients with genotype 1 hepatitis C: A statistical model for comparing outcomes between real world and clinical trials.
Topics: Antiviral Agents; Bayes Theorem; Benzimidazoles; Clinical Trials as Topic; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Models, Statistical; Sofosbuvir | 2015 |
Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice.
Topics: Animals; Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Resistance, Multiple, Viral; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Hepatitis, Viral, Animal; Hepatocytes; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Sulfonamides; Transplantation Chimera; Treatment Failure; Valine | 2015 |
Sofosbuvir-based therapy cures hepatitis C virus infection after prior treatment failures in a patient with concurrent lymphoma.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Recurrence; Ribavirin; Sofosbuvir; Time Factors; Treatment Failure; Treatment Outcome | 2015 |
Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis C, Chronic; Humans; Liver Failure, Acute; Liver Transplantation; Middle Aged; Recurrence; Simeprevir; Sofosbuvir | 2015 |
Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Contraindications; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Hyperbilirubinemia; Intention to Treat Analysis; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sepsis; Simeprevir; Sofosbuvir; Sulfonamides; Time Factors; Uridine Monophosphate | 2015 |
Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany--an application of the efficiency frontier approach.
Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Female; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Proline; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome | 2015 |
Serious Pulmonary Toxicity Secondary to Novel Hepatitis C Antiviral Therapy in a Liver Transplant Recipient.
Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Liver Transplantation; Male; Pulmonary Fibrosis; Risk Factors; Simeprevir; Sofosbuvir; Treatment Outcome | 2015 |
Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
Topics: Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Macrocyclic Compounds; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Quality-Adjusted Life Years; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate | 2015 |
Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2015 |
Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Biomarkers; Blood Chemical Analysis; Cytokines; Enzyme-Linked Immunosorbent Assay; Fatigue; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Ultrasonography; Uridine Monophosphate; Valine | 2015 |
Hepatitis C virus post-exposure prophylaxis: A reasonable option in the era of pangenotypic direct-acting antivirals?
Topics: Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir | 2015 |
The impact of ribavirin plasma concentration on the efficacy of the interferon-sparing regimen, sofosbuvir and ribavirin.
Topics: Antiviral Agents; Drug Inverse Agonism; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir | 2016 |
Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade.
Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Insurance Claim Review; Insurance, Pharmaceutical Services; Logistic Models; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Time Factors; United States; Uridine Monophosphate | 2015 |
Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Hepatitis Viruses; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Texas; Time Factors; Treatment Outcome | 2016 |
Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Cholesterol; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir | 2016 |
[New combination attains a response rate of 90].
Topics: Antiviral Agents; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Simeprevir; Sofosbuvir; Viral Load | 2015 |
Successful Treatment of Chronic Hepatitis C Infection With Direct-Acting Antivirals in a Heart Transplant Recipient: A Case Report.
Topics: Adult; Antiviral Agents; Biopsy; Heart Transplantation; Hepatitis C, Chronic; Humans; Male; Simeprevir; Sofosbuvir | 2015 |
Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Viral Load | 2015 |
Antihepatitis C virus treatments for HIV-hepatitis C virus coinfected cirrhotic patients: a need to look beyond the sustained viral response.
Topics: Antiviral Agents; Coinfection; Fatal Outcome; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Viral Load | 2015 |
Early Patterns of Sofosbuvir Utilization by State Medicaid Programs.
Topics: Antiviral Agents; Drug Utilization; Health Expenditures; Hepatitis C, Chronic; Humans; Medicaid; Sofosbuvir; United States; Uridine Monophosphate | 2015 |
Therapy with direct-acting antivirals for genotype 3 patients: interferon's last gasp?
Topics: Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Ribavirin; RNA, Viral; Sofosbuvir | 2015 |
Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
Topics: Adult; Aged; Antiviral Agents; Canada; Carbamates; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Markov Chains; Middle Aged; Pyrrolidines; Quality-Adjusted Life Years; Sofosbuvir; Valine | 2016 |
Task-Shifting: An Approach to Decentralized Hepatitis C Treatment in Medically Underserved Areas.
Topics: Aged; Aged, 80 and over; Antiviral Agents; California; Female; Health Services Accessibility; Hepatitis C, Chronic; Humans; Male; Medically Underserved Area; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir | 2015 |
No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; RNA, Viral; Sofosbuvir; Time Factors | 2016 |
Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents.
Topics: Adult; Aged; Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir | 2016 |
Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Disease Eradication; Efficiency; Europe; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Models, Economic; Sofosbuvir; Surveys and Questionnaires; Young Adult | 2016 |
Successful treatment of hepatitis C virus infection with sofosbuvir and simeprevir in the early phase of an allogeneic stem cell transplant.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir; Stem Cell Transplantation; Transplant Recipients; Transplantation, Homologous; Viral Load; Virus Replication | 2016 |
Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir.
Topics: Antiviral Agents; Aspartate Aminotransferases; Elasticity Imaging Techniques; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; RNA, Viral; Sofosbuvir; Treatment Outcome; Viral Load | 2016 |
Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C.
Topics: Aged; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Drug Combinations; Fluorenes; Hepatitis C, Chronic; Humans; Middle Aged; Quality-Adjusted Life Years; Sofosbuvir; United States; Veterans Health | 2016 |
Bradyarrhythmias Associated with Sofosbuvir Treatment.
Topics: Aged; Amiodarone; Antiviral Agents; Bradycardia; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Uridine Monophosphate | 2015 |
The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C.
Topics: Animals; Antiviral Agents; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Sofosbuvir | 2015 |
[Sofosbuvir (Sovaldi), oral administration].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Sofosbuvir | 2015 |
Simple, Effective, but Out of Reach? Public Health Implications of HCV Drugs.
Topics: Antiviral Agents; Carbamates; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Sofosbuvir | 2015 |
Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Resistance, Viral; Emigrants and Immigrants; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Male; Middle Aged; Mutation, Missense; Polymorphism, Genetic; Protease Inhibitors; RNA, Viral; Sequence Analysis, DNA; Sofosbuvir; Viral Nonstructural Proteins; Young Adult | 2015 |
Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml/min.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Liver Cirrhosis; Male; Middle Aged; Renal Dialysis; Simeprevir; Sofosbuvir; Sustained Virologic Response; Texas | 2016 |
Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Middle Aged; Quality-Adjusted Life Years; Severity of Illness Index; Sofosbuvir; Treatment Outcome; United States; Viral Load; Young Adult | 2016 |
Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus.
Topics: Antiviral Agents; Cell Line; Deoxycytidine; DNA Polymerase gamma; DNA-Directed DNA Polymerase; DNA-Directed RNA Polymerases; Guanosine Monophosphate; Hepacivirus; Hepatitis C, Chronic; Humans; Mitochondria; Nucleosides; Oxygen Consumption; Protein Biosynthesis; RNA; RNA, Mitochondrial; Sofosbuvir; Transcription, Genetic; Virus Replication | 2016 |
Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES.
Topics: Aged; Antiviral Agents; Benzimidazoles; Comorbidity; Databases, Factual; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; United States | 2016 |
Hepatitis C drug maker puts profit ahead of patients, US Senate report charges.
Topics: Advisory Committees; Benzimidazoles; Conflict of Interest; Drug Costs; Drug Industry; Ethics, Pharmacy; Federal Government; Fees, Pharmaceutical; Fluorenes; Hepatitis C, Chronic; Humans; Research Report; Sofosbuvir; United States; Uridine Monophosphate | 2015 |
[Cost-effectiveness analysis of sofosbuvir-simeprevir regimens for chronic hepatitis C genotype 1 patients with advanced fibrosis].
Topics: Antiviral Agents; Cost Savings; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Markov Chains; Quality-Adjusted Life Years; Simeprevir; Sofosbuvir; Spain | 2016 |
Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment.
Topics: Acidosis, Lactic; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir | 2016 |
Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
Topics: Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Interferon-alpha; Markov Chains; Models, Statistical; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Sofosbuvir; South Africa; Uridine Monophosphate | 2016 |
Reply to "Liver failure in human immunodeficiency virus - Hepatitis C virus coinfection treated with sofosbuvir, ledipasvir and antiretroviral therapy".
Topics: Antiviral Agents; Coinfection; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Failure; Sofosbuvir; Uridine Monophosphate | 2016 |
Liver failure in human immunodeficiency virus - Hepatitis C virus coinfection treated with sofosbuvir, ledipasvir and antiretroviral therapy.
Topics: Antiviral Agents; Coinfection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Liver Failure; Sofosbuvir; Uridine Monophosphate | 2016 |
Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older.
Topics: Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Clinical Trials, Phase III as Topic; Cohort Studies; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Patient Safety; Randomized Controlled Trials as Topic; Retrospective Studies; Ribavirin; Risk Assessment; Sex Factors; Sofosbuvir; Treatment Outcome | 2016 |
Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
Topics: Adenosine; Antiviral Agents; Cell Line; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Oligopeptides; Protease Inhibitors; Replicon; Ribavirin; RNA, Viral; Sofosbuvir; Viral Nonstructural Proteins; Virus Replication | 2016 |
Daclatasvir plus sofosbuvir regimen sheds promising light on future hepatitis C virus genotype 3 therapies.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir | 2016 |
Adverse events associated with ribavirin in sofosbuvir-based therapies for patients with chronic hepatitis C: A community practice experience.
Topics: Aged; Antiviral Agents; Community Health Services; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Patient Dropouts; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2016 |
Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease.
Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Retrospective Analysis of the Medication Utilization and Clinical Outcomes of Patients Treated with Various Regimens for Hepatitis C Infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Drug Utilization; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Nausea; Polyethylene Glycols; Recombinant Proteins; Renal Insufficiency; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Young Adult | 2017 |
Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Fatigue; Female; Genotype; Headache; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Republic of Korea; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome | 2015 |
The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin.
Topics: Aged; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Fatigue; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Liver Cirrhosis; Male; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load | 2016 |
Real-world Experience with Sofosbuvir-based Regimens for Chronic Hepatitis C, Including Patients with Factors Previously Associated with Inferior Treatment Response.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Hawaii; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Sofosbuvir; Viral Load | 2015 |
Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sofosbuvir; Sulfonamides; Valine | 2016 |
Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2016 |
Sustained virological response with sofosbuvir and ledipasvir for hepatitis C virus genotype 5.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2016 |
Myo-pericarditis secondary to ledipasvir-sofosbuvir therapy.
Topics: Antiviral Agents; Benzimidazoles; Echocardiography; Electrocardiography; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Male; Middle Aged; Myocarditis; Pericarditis; Sofosbuvir | 2016 |
New-onset cutaneous lichen planus following therapy for hepatitis C with ledipasvir-sofosbuvir.
Topics: Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Lichen Planus; Male; Middle Aged; Sofosbuvir; Uridine Monophosphate | 2016 |
Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Male; Middle Aged; Ohio; Renal Dialysis; Simeprevir; Sofosbuvir; Sustained Virologic Response | 2016 |
In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir.
Topics: Antiviral Agents; Benzimidazoles; Carrier Proteins; Cell Line, Tumor; Drug Combinations; Drug Resistance, Viral; Drug Synergism; Fluorenes; Genotype; HeLa Cells; Hepacivirus; Hepatitis C, Chronic; Humans; Intracellular Signaling Peptides and Proteins; Microbial Sensitivity Tests; Sofosbuvir; Viral Nonstructural Proteins | 2016 |
Amplification and pyrosequencing of near-full-length hepatitis C virus for typing and monitoring antiviral resistant strains.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Genotype; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Mutation, Missense; Nucleic Acid Amplification Techniques; Pyrrolidines; RNA, Viral; Sequence Analysis, DNA; Sofosbuvir; Valine | 2016 |
Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Outcome Assessment, Health Care; Retrospective Studies; Sofosbuvir; Sustained Virologic Response | 2016 |
Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Health Services Accessibility; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Sofosbuvir; United States; Young Adult | 2016 |
Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Topics: Aged; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Diseases; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine | 2016 |
HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Kinetics; Male; Middle Aged; Models, Theoretical; Pyrrolidines; Retrospective Studies; RNA, Viral; Simeprevir; Sofosbuvir; Time Factors; Valine | 2016 |
Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Patient Safety; Polymorphism, Genetic; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Transplant Recipients; Treatment Outcome | 2016 |
Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Databases, Factual; Drug Therapy, Combination; Europe; Female; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Multivariate Analysis; North America; Regression Analysis; Renal Dialysis; Renal Insufficiency, Chronic; Simeprevir; Sofosbuvir; Sustained Virologic Response; Young Adult | 2016 |
Sofosbuvir and Simeprevir Treatment of a Stem Cell Transplanted Teenager With Chronic Hepatitis C Infection.
Topics: Adolescent; Anemia, Sickle Cell; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Edema; Hepatitis C, Chronic; Humans; Male; Protease Inhibitors; Simeprevir; Sofosbuvir; Stem Cell Transplantation; Sustained Virologic Response; Transplant Recipients | 2016 |
Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.
Topics: Aged; Antiviral Agents; Databases, Factual; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Medication Adherence; Middle Aged; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; United States; Veterans | 2016 |
Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir.
Topics: Antiviral Agents; Asia; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Patient Outcome Assessment; Quality of Life; Sofosbuvir; Surveys and Questionnaires | 2016 |
Sofosbuvir antiviral therapy in HCV patients with severe renal failure.
Topics: Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Male; Middle Aged; Severity of Illness Index; Sofosbuvir | 2017 |
Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Prospective Studies; Renal Dialysis; Ribavirin; Simeprevir; Sofosbuvir | 2016 |
Severe Pulmonary Arterial Hypertension in Patients Treated for Hepatitis C With Sofosbuvir.
Topics: Antiviral Agents; Carbamates; Comorbidity; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Hypertension, Portal; Hypertension, Pulmonary; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2016 |
Treatment of chronic hepatitis C with direct acting antiviral agents in patients with haemophilia, end-stage liver disease and coinfected with HIV.
Topics: Adult; Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Coinfection; Drug Interactions; Hemophilia A; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Pyrrolidines; RNA, Viral; Sofosbuvir; Treatment Outcome; Valine; Viral Load | 2016 |
High baseline bilirubin and low albumin predict liver decompensation and serious adverse events in HCV-infected patients treated with sofosbuvir-containing regimens.
Topics: Aged; Antiviral Agents; Bilirubin; Case-Control Studies; Decision Support Techniques; Female; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Incidence; Male; Middle Aged; Prognosis; Serum Albumin; Serum Albumin, Human; Simeprevir; Sofosbuvir; Survival Analysis | 2016 |
Streptococcus salivarius spontaneous bacterial peritonitis in a HIV/HCV-co-infected patient treated with direct antiviral agents.
Topics: Anti-Bacterial Agents; Antiviral Agents; Bacterial Translocation; Benzimidazoles; Ceftriaxone; Coinfection; Disease Susceptibility; Esophageal and Gastric Varices; Esophagoscopy; Female; Fluorenes; Gastrointestinal Hemorrhage; Hepatitis C, Chronic; HIV Infections; Humans; Immunocompromised Host; Middle Aged; Peritonitis; Sofosbuvir; Streptococcus salivarius; Substance Abuse, Intravenous | 2017 |
Sofosbuvir and Velpatasvir: A complete pan-genotypic treatment for HCV patients.
Topics: Antiviral Agents; Carbamates; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Randomized Controlled Trials as Topic; Sofosbuvir | 2016 |
Sofosbuvir plus ribavirin in Asian patients with chronic genotype 2 hepatitis C virus infection: history of a success?
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir | 2016 |
Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Fibrosis; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Male; Markov Chains; Middle Aged; Models, Econometric; Proline; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2016 |
[Sofosbuvir/ledipasvir is also effective in routine general practice].
Topics: Benzimidazoles; Fluorenes; General Practice; Germany; Guideline Adherence; Hepatitis C, Chronic; Humans; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load | 2016 |
Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment.
Topics: Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Viral Load | 2016 |
Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.
Topics: Adult; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Transplant Recipients; Treatment Outcome; Valine | 2016 |
What does it mean to put new hepatitis C drugs on a list of essential medicines?
Topics: Antiviral Agents; Carbamates; Drug Costs; Drugs, Essential; Health Priorities; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir; World Health Organization | 2016 |
Sofosbuvir and Velpatasvir for Patients with HCV Infection.
Topics: Antiviral Agents; Carbamates; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Sofosbuvir | 2016 |
Sofosbuvir and Velpatasvir for Patients with HCV Infection.
Topics: Antiviral Agents; Carbamates; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Sofosbuvir | 2016 |
[New combination heals still more patients in an even shorter period of time].
Topics: Carbamates; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir | 2016 |
Emergence of HCV resistance-associated variants in patients failing sofosbuvir-based regimens: an observational cohort.
Topics: Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Mutation; Sofosbuvir; Treatment Failure; Viral Nonstructural Proteins | 2016 |
Sofosbuvir and Velpatasvir for Patients with HCV Infection.
Topics: Antiviral Agents; Carbamates; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Sofosbuvir | 2016 |
Sofosbuvir and Velpatasvir for Patients with HCV Infection.
Topics: Antiviral Agents; Carbamates; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Sofosbuvir | 2016 |
Interferon/Ribavirin-Free Antiviral Treatment in Septuagenarians and Octogenarians With Chronic Hepatitis C.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fatigue; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Male; Pruritus; Pyrrolidines; Recurrence; Simeprevir; Sleep Initiation and Maintenance Disorders; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2016 |
Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
Topics: Amino Acid Substitution; Antiviral Agents; Benzimidazoles; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Japan; Sequence Analysis, DNA; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins | 2016 |
Sofosbuvir and daclatasvir.
Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Valine | 2016 |
DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Kidney; Kidney Function Tests; Kidney Transplantation; Liver; Liver Transplantation; Male; Middle Aged; Postoperative Period; Preoperative Period; Pyrrolidines; Renal Dialysis; Renal Insufficiency; RNA, Viral; Simeprevir; Sofosbuvir; Valine | 2016 |
Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Middle Aged; Recurrence; Ribavirin; Salvage Therapy; Sofosbuvir; Treatment Failure | 2016 |
Combination Therapy of Simeprevir and Sofosbuvir in Recurrent HCV Genotype 4 After Liver Retransplantation: Case Report.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Transplantation; Male; Middle Aged; Reoperation; Simeprevir; Sofosbuvir | 2016 |
Indian hepatitis C drug patent decision shakes public health community.
Topics: Antiviral Agents; Drugs, Generic; Hepatitis C, Chronic; Humans; India; Patents as Topic; Public Health; Sofosbuvir | 2016 |
Resurrection of response-guided therapy for sofosbuvir combination therapies.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir | 2016 |
Clearance of Hepatitis C Virus After Fixed-Dose Combination Ledipasvir/Sofosbuvir in an Adolescent Female With Decompensated Cirrhosis.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Sofosbuvir; Viral Load | 2016 |
Direct Observed Therapy of Chronic Hepatitis C With Interferon-Free All-Oral Regimens at a Low-Threshold Drug Treatment Facility-a New Concept for Treatment of Patients With Borderline Compliance Receiving Opioid Substitution Therapy.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Directly Observed Therapy; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Male; Medication Adherence; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Pyrrolidines; Severity of Illness Index; Sofosbuvir; Substance Abuse Treatment Centers; Valine | 2016 |
[LDV/SOF successful in general practice test].
Topics: Benzimidazoles; Cohort Studies; Fluorenes; General Practice; Germany; Hepatitis C, Chronic; Humans; Sofosbuvir; Uridine Monophosphate | 2016 |
Sofosbuvir initial therapy abandonment and manufacturer coupons in a commercially insured population.
Topics: Antiviral Agents; Cost Sharing; Cost-Benefit Analysis; Cross-Sectional Studies; Hepatitis C, Chronic; Humans; Insurance Claim Review; Insurance, Pharmaceutical Services; Logistic Models; Medication Adherence; Multivariate Analysis; Prescription Fees; Sofosbuvir | 2016 |
Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Longitudinal Studies; Male; Middle Aged; Multicenter Studies as Topic; Outcome Assessment, Health Care; Prospective Studies; Registries; Sofosbuvir; Sustained Virologic Response; United States; Uridine Monophosphate; Young Adult | 2016 |
Successful treatment of hepatitis C, genotype 3, with sofosbuvir/ledipasvir in decompensated cirrhosis complicated by mixed cryoglobulinaemia.
Topics: Benzimidazoles; Cryoglobulinemia; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate | 2016 |
Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Black or African American; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult | 2016 |
Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C.
Topics: Aged; Antiviral Agents; Colitis; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Ribavirin; Simeprevir; Sofosbuvir | 2016 |
Full-dose sofosbuvir and daclatasvir for chronic hepatitis C infection in haemodialysis patients.
Topics: Antiviral Agents; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load | 2016 |
Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Young Adult | 2016 |
Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Prognosis; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Sofosbuvir; Treatment Failure; Uridine Monophosphate | 2017 |
Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Markov Chains; Middle Aged; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; United States; Uracil; Valine | 2016 |
Successful Treatment of Pyoderma Gangrenosum with Cryoglobulinemia and Hepatitis C.
Topics: Aged; Anti-Inflammatory Agents; Antiviral Agents; Benzimidazoles; Cryoglobulinemia; Fluorenes; Hepatitis C, Chronic; Humans; Male; Prednisone; Pyoderma Gangrenosum; Sofosbuvir; Uridine Monophosphate; Viral Load | 2016 |
Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Time Factors; Treatment Outcome | 2016 |
Adoption of new agents and changes in treatment patterns for hepatitis C: 2010-2014.
Topics: Adult; Antiviral Agents; Databases, Factual; Drug Therapy, Combination; Female; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Insurance Claim Review; Interferons; Logistic Models; Male; Middle Aged; Oligopeptides; Predictive Value of Tests; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; United States | 2016 |
Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Retreatment; Retrospective Studies; Sofosbuvir; Treatment Outcome; Young Adult | 2017 |
Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study.
Topics: Antiviral Agents; Austria; Benzimidazoles; Carbamates; Coinfection; Fatigue; Female; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Quality of Life; Retrospective Studies; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report.
Topics: Antiviral Agents; Colitis, Ulcerative; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir | 2016 |
Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Netherlands; Protease Inhibitors; Recurrence; Retrospective Studies; Simeprevir; Sofosbuvir; Treatment Outcome | 2016 |
Treatment of Chronic Hepatitis C in the Aged - Does It Impact Life Expectancy? A Decision Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Decision Support Techniques; Disease Progression; Female; Fluorenes; Hepatitis C, Chronic; Humans; Life Expectancy; Male; Markov Chains; Middle Aged; Quality-Adjusted Life Years; Sofosbuvir; Uridine Monophosphate | 2016 |
Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Kidney Transplantation; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Transplant Recipients; Treatment Outcome | 2016 |
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Serum Albumin; Sofosbuvir; Sustained Virologic Response; Young Adult | 2017 |
Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens.
Topics: Antiviral Agents; Benzimidazoles; Clinical Trials, Phase III as Topic; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Interferons; Male; Medication Adherence; Middle Aged; Multicenter Studies as Topic; Patient Reported Outcome Measures; Ribavirin; Sofosbuvir | 2016 |
Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Prospective Studies; Registries; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Young Adult | 2017 |
Oral therapy approved for chronic HCV infection of all genotypes.
Topics: Administration, Oral; Antiviral Agents; Carbamates; Drug Approval; Drug Combinations; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir | 2016 |
NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient.
Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Male; Middle Aged; Mutation, Missense; Ribavirin; Sofosbuvir; Treatment Failure; Viral Nonstructural Proteins | 2016 |
Reply to: "HCV RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin".
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kinetics; Ribavirin; RNA; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2016 |
Reply to: "Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal disease".
Topics: Antiviral Agents; Carbamates; Drug Monitoring; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Transplant Recipients; Treatment Outcome; Valine | 2016 |
HCV-RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kinetics; Ribavirin; RNA; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2016 |
Successful Posttransplant Treatment of Hepatitis C With Ledipasvir-Sofosbuvir in HIV+ Kidney Transplant Recipients.
Topics: Adult; Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; HIV Infections; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Postoperative Care; Retrospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2017 |
Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal disease.
Topics: Antiviral Agents; Carbamates; Drug Monitoring; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Transplant Recipients; Treatment Outcome; Valine | 2016 |
Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia.
Topics: Aged; Antiviral Agents; B-Lymphocytes; Cryoglobulinemia; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Practice Guidelines as Topic; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Vasculitis | 2016 |
The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis.
Topics: Antiviral Agents; Benzimidazoles; Combined Modality Therapy; Cost-Benefit Analysis; Decision Support Techniques; Drug Administration Schedule; Fluorenes; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Models, Economic; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; Treatment Outcome; United States; Uridine Monophosphate | 2017 |
Use of HCV+ Donors Does Not Affect HCV Clearance With Directly Acting Antiviral Therapy But Shortens the Wait Time to Kidney Transplantation.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Time Factors; Tissue Donors; Treatment Outcome; Uridine Monophosphate | 2017 |
Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Ledipasvir in Renal Transplant Recipients.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Retrospective Studies; Sofosbuvir; Treatment Outcome | 2017 |
Sofosbuvir plus daclatasvir with or without ribavirin for chronic hepatitis C infection: Impact of drug concentration on viral load decay.
Topics: Aged; Antiviral Agents; Carbamates; Drug Monitoring; Drug Therapy, Combination; Female; France; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Linear Models; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Viral Load | 2016 |
Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Egypt; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Simeprevir; Sofosbuvir; Treatment Outcome; Young Adult | 2017 |
Effective treatment of hepatitis C virus infection with sofosbuvir and daclatasvir 90 mg in a patient with severe epilepsy on oxcarbazepine.
Topics: Anticonvulsants; Antiviral Agents; Carbamates; Carbamazepine; Drug Interactions; Drug Therapy, Combination; Epilepsy; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Oxcarbazepine; Pyrrolidines; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study.
Topics: Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Interactions; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Proton Pump Inhibitors; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires | 2016 |
Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients.
Topics: Aged; Antiviral Agents; Benzimidazoles; Calcineurin Inhibitors; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Pragmatic Clinical Trials as Topic; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2016 |
Use of Sofosbuvir-Based Treatment of Chronic Hepatitis C in Liver Transplant Recipients on Hemodialysis.
Topics: Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Renal Dialysis; Retrospective Studies; Sofosbuvir; Sustained Virologic Response | 2017 |
Successful Anti-HCV Therapy of a Former Intravenous Drug User with Sofosbuvir and Daclatasvir in a Peritranspant Setting: A Case Report.
Topics: Adult; Antiviral Agents; Carbamates; Hepatitis C, Chronic; Humans; Imidazoles; Liver Transplantation; Male; Perioperative Care; Pyrrolidines; Sofosbuvir; Substance Abuse, Intravenous; Valine | 2016 |
Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Bilirubin; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Ribavirin; Risk Factors; Serum Albumin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Failure; Uridine Monophosphate; Young Adult | 2016 |
Porphyrin Elevation in a Patient on Treatment With Simeprevir: Could It Be a Possible Explanation for Simeprevir-Associated Photosensitivity?
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Graft Rejection; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Photosensitivity Disorders; Porphyrins; Recurrence; Ribavirin; Simeprevir; Sofosbuvir | 2016 |
Hepatitis B reactivation in a chronic hepatitis C patient treated with ledipasvir and sofosbuvir: A case report.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Hepatitis B; Hepatitis C, Chronic; Humans; Recurrence; Sofosbuvir; Time Factors; Treatment Outcome | 2017 |
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Compassionate Use Trials; Drug Monitoring; Drug Therapy, Combination; Europe; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Failure; Male; Middle Aged; Pyrrolidines; Ribavirin; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan.
Topics: Antiviral Agents; Cost-Benefit Analysis; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir | 2017 |
Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan.
Topics: Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir | 2017 |
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; France; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2017 |
Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
Topics: Administration, Oral; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome | 2017 |
Sofosbuvir/Ledipasvir Without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence After Liver Transplantation: Two-Center Experience.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Female; Fluorenes; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate | 2017 |
Comparison of the Abbott RealTime HCV and Roche COBAS Ampliprep/COBAS TaqMan HCV assays for the monitoring of sofosbuvir-based therapy.
Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kinetics; Male; Middle Aged; Real-Time Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load | 2017 |
Testing of direct acting antiviral agents purchased overseas: a necessary precaution to protect patients?
Topics: Aged; Antiviral Agents; Counterfeit Drugs; Hepatitis C, Chronic; Humans; Male; Mass Spectrometry; Sofosbuvir | 2016 |
Enter Sofosbuvir: The Path to Curing HCV.
Topics: Antiviral Agents; Drug Discovery; Drug Industry; Hepacivirus; Hepatitis C, Chronic; History, 20th Century; History, 21st Century; Humans; Sofosbuvir | 2016 |
Curing the historically incurable: treatment success with ledipasvir/sofosbuvir for chronic hepatitis C virus in a heavily treatment-experienced individual.
Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Sofosbuvir; Treatment Outcome | 2016 |
Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Industry; Drug Therapy, Combination; Fees, Pharmaceutical; Fluorenes; Health Services Accessibility; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Public Health; Pyrrolidines; Quality Assurance, Health Care; Quality Control; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2016 |
Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Community-based real-world treatment outcomes of sofosbuvir/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; United States; Young Adult | 2017 |
Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Severity of Illness Index; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Viral Load | 2017 |
Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans.
Topics: Aged; Anticoagulants; Antiviral Agents; Benzimidazoles; Dose-Response Relationship, Drug; Drug Interactions; Fluorenes; Hepatitis C, Chronic; Humans; International Normalized Ratio; Male; Middle Aged; Pharmaceutical Services; Pharmacists; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Veterans; Warfarin | 2016 |
Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Young Adult | 2017 |
Resolution of Porphyria Cutanea Tarda in Patients With Hepatitis C Following Ledipasvir-Sofosbuvir Combination Therapy.
Topics: Benzimidazoles; Biopsy; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Porphyria Cutanea Tarda; Skin; Sofosbuvir; Uridine Monophosphate | 2016 |
Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Phylogeny; Prevalence; Recurrence; Retreatment; RNA, Viral; Sequence Analysis, DNA; Sofosbuvir; Treatment Outcome; Viral Load; Viral Nonstructural Proteins; Viremia | 2017 |
Drug-Induced Lung Injury in a Liver Transplant Patient Treated With Sofosbuvir.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Transplantation; Lung Injury; Middle Aged; Pyrrolidines; Retrospective Studies; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Pyrrolidines; Retrospective Studies; Ribavirin; San Francisco; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Vulnerable Populations; Young Adult | 2016 |
Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in HCV genotype IV infected patients.
Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome | 2017 |
Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure.
Topics: Antiviral Agents; Female; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Renal Insufficiency; Retrospective Studies; Sofosbuvir | 2017 |
The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; Asian; Black People; Cohort Studies; Databases, Factual; Drug Therapy, Combination; Ethnicity; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Prognosis; Racial Groups; Ribavirin; Risk Assessment; Simeprevir; Sofosbuvir; Survival Rate; Treatment Outcome; United States; White People | 2017 |
Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response | 2017 |
Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis.
Topics: Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Failure; Treatment Outcome | 2016 |
All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database.
Topics: Administration, Oral; Adult; Antiviral Agents; Databases, Factual; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Internationality; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir | 2017 |
The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society?
Topics: Administration, Oral; Antiviral Agents; Benzimidazoles; Decision Making; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Markov Chains; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; United States; Uridine Monophosphate | 2017 |
Regression of hepatocellular carcinoma after treatment with Sofosbuvir - A case report.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES.
Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Diseases; Liver Cirrhosis; Liver Transplantation; Male; Risk Factors; Ritonavir; Simeprevir; Sofosbuvir | 2017 |
Distinct Antiviral Potency of Sofosbuvir Against Hepatitis C and E Viruses.
Topics: Antiviral Agents; Cell Line, Tumor; DNA, Viral; Dose-Response Relationship, Drug; Genotype; HEK293 Cells; Hepacivirus; Hepatitis C, Chronic; Hepatitis E; Hepatitis E virus; Hepatocytes; Humans; RNA, Viral; Sofosbuvir; Virus Replication | 2016 |
ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Sofosbuvir; Treatment Outcome | 2017 |
Eight Weeks Treatment With Sofosbuvir/Ledipasvir in a 4-year-old Child With Chronic Hepatitis C Virus Genotype 1 Infection.
Topics: Antiviral Agents; Benzimidazoles; Child, Preschool; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Sofosbuvir; Uridine Monophosphate | 2016 |
Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation.
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Limit of Detection; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load; Virus Replication | 2017 |
Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Imidazoles; Liver Diseases; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Viral Load | 2017 |
Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Patient Reported Outcome Measures; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Treatment Outcome | 2017 |
Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors.
Topics: Antiviral Agents; Carbamates; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Protease Inhibitors; Pyrrolidines; Sofosbuvir; Valine | 2017 |
The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV).
Topics: Affective Symptoms; Antiviral Agents; Benzimidazoles; Biomarkers; Cytokines; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Mental Disorders; Middle Aged; Neurotransmitter Agents; Retrospective Studies; Ribavirin; Sofosbuvir | 2016 |
NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Risk Factors; Sex Factors; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins; Young Adult | 2017 |
Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Male; Middle Aged; Simeprevir; Sofosbuvir; Tenofovir; Viral Load; Virus Activation | 2016 |
Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma.
Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Administration Schedule; Drug Therapy, Combination; Fluorenes; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Middle Aged; Models, Economic; Postoperative Care; Preoperative Care; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States; Uridine Monophosphate | 2017 |
Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort.
Topics: Antiviral Agents; Drug Combinations; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Patient Safety; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Spain; Treatment Outcome | 2016 |
Sofosbuvir Monotherapy for Asymptomatic and Noncirrhotic Hepatitis C Infection in a Renal Retransplantation Recipient: A Case Report.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Transplantation; Male; Middle Aged; Renal Dialysis; Renal Insufficiency; Reoperation; Sofosbuvir; Treatment Outcome | 2016 |
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2017 |
Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Interactions; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir | 2017 |
Effects of ribavirin/sofosbuvir treatment and ITPA phenotype on endogenous purines.
Topics: Adenosine Triphosphate; Anemia, Hemolytic; Female; Guanosine Triphosphate; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Inosine Triphosphate; Male; Middle Aged; Nucleotides; Phenotype; Polymorphism, Single Nucleotide; Purines; Pyrophosphatases; Retrospective Studies; Ribavirin; Sofosbuvir | 2017 |
Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Recombination, Genetic; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Young Adult | 2017 |
Outcome of Combination Therapy with Sofosbuvir and Ledipasvir for Chronic Type C Liver Disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome | 2017 |
Brief Report: The Impact of Ledipasvir/Sofosbuvir on HIV-Positive and HIV-Negative Japanese Hemophilia Patients With 1, 4, and Mixed-Genotype HCV.
Topics: Antiviral Agents; Asian People; Benzimidazoles; Coinfection; Fluorenes; Hemophilia A; Hemophilia B; Hepatitis C, Chronic; HIV Infections; Humans; Japan; Male; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load | 2017 |
Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis.
Topics: Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; Rilpivirine; RNA, Viral; Simeprevir; Sofosbuvir; Viral Load | 2017 |
Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.
Topics: Antiviral Agents; Carbamates; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine | 2018 |
Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2017 |
A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals.
Topics: Adenosine; Antiviral Agents; Carbamates; Drug Discovery; Drug Resistance, Viral; Enzyme Inhibitors; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Mutation; Pyrrolidines; Sofosbuvir; Sulfonamides; Valine | 2017 |
Genotype specific peripheral lipid profile changes with hepatitis C therapy.
Topics: Aged; Alanine Transaminase; Antiviral Agents; Benzimidazoles; Cholesterol; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Triglycerides | 2016 |
Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.
Topics: Adult; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Fluorenes; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Markov Chains; Middle Aged; Models, Theoretical; Public Health; Quality of Life; Quality-Adjusted Life Years; Sensitivity and Specificity; Sofosbuvir | 2017 |
Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sofosbuvir | 2017 |
Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Combinations; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; RNA, Viral; Salvage Therapy; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Treatment Outcome; Uridine Monophosphate; Viral Load; Viral Nonstructural Proteins | 2017 |
Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Retrospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2017 |
HCV intergenotype 2k/1b recombinant detected in a DAA-treated patient in Italy.
Topics: Alanine Transaminase; Antiviral Agents; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Middle Aged; Phylogeny; Reassortant Viruses; Ribavirin; Sequence Analysis, RNA; Sofosbuvir; Treatment Failure | 2017 |
Sofosbuvir plus ledipasvir for recurrent hepatitis C in liver transplant recipients.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Transplantation; Sofosbuvir | 2017 |
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.
Topics: Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Italy; Male; Middle Aged; Mutation; Recurrence; Ribavirin; Sequence Analysis, DNA; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins | 2017 |
Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic; Antiviral Agents; Asian People; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Male; Middle Aged; Multivariate Analysis; Polymorphism, Genetic; Pyrophosphatases; Ribavirin; Sofosbuvir | 2017 |
Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in Egypt.
Topics: Antiviral Agents; Anxiety; Depression; Drug Therapy, Combination; Egypt; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Quality of Life; Social Support; Sofosbuvir | 2017 |
Electrophysiological Adverse Effects of Direct Acting Antivirals in Patients With Chronic Hepatitis C.
Topics: Aged; Antiviral Agents; Bradycardia; Cohort Studies; Electrocardiography; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Risk Factors; Sofosbuvir | 2017 |
Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult | 2017 |
Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Belgium; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Treatment Outcome | 2017 |
Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna.
Topics: 2-Naphthylamine; Adult; AIDS-Related Opportunistic Infections; Anilides; Anti-HIV Agents; Antiviral Agents; Austria; Benzimidazoles; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; HIV Seropositivity; Humans; Lactams, Macrocyclic; Liver; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2017 |
Anti-HCV for porphyria cutanea tarda.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Porphyria Cutanea Tarda; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2017 |
Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Transplantation; Living Donors; Male; Middle Aged; Postoperative Period; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Viral Nonstructural Proteins | 2017 |
Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials.
Topics: Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Psychometrics; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Treatment Outcome | 2017 |
Costly Cures.
Topics: Budgets; Hepatitis C; Hepatitis C, Chronic; Humans; Medicaid; Severity of Illness Index; Sofosbuvir; State Government; United States | 2017 |
Prevalence of resistant associated variants (RAVs) in the naïve HCV patient candidate for direct acting antiviral (DAA) therapy.
Topics: Adolescent; Adult; Antiviral Agents; Cross-Sectional Studies; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Phylogeny; Point Mutation; Polymerase Chain Reaction; Prevalence; RNA, Viral; Sequence Analysis, DNA; Sofosbuvir; Viral Load; Viral Nonstructural Proteins; Young Adult | 2017 |
Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Italy; Male; Middle Aged; Protease Inhibitors; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2017 |
Predictors of treatment efficacy and ALT non-normalization with sofosbuvir/ribavirin therapy for patients with hepatitis C virus genotype 2.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antigens, Neoplasm; Antiviral Agents; Drug Monitoring; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Membrane Glycoproteins; Middle Aged; Prognosis; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Withholding Treatment | 2017 |
Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cause of Death; Cohort Studies; Disease Progression; End Stage Liver Disease; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Function Tests; Logistic Models; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Registries; Retrospective Studies; Ribavirin; Risk Assessment; Severity of Illness Index; Sofosbuvir; Spain; Survival Analysis; Treatment Outcome | 2017 |
Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine | 2017 |
Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon.
Topics: Adult; Antiviral Agents; Elasticity Imaging Techniques; Female; Fibrosis; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; Middle Aged; Regression Analysis; Retrospective Studies; Sofosbuvir; Treatment Outcome | 2017 |
Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease.
Topics: Aged; Antiviral Agents; Asian; Dose-Response Relationship, Drug; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Sustained Virologic Response | 2017 |
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Male; Middle Aged; Neoplasm Recurrence, Local; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Uridine Monophosphate; Valine; Young Adult | 2017 |
Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.
Topics: Antiviral Agents; Benzimidazoles; China; Drug Costs; Drug Therapy, Combination; Drugs, Generic; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Medical Tourism; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Therapeutic Equivalency; Treatment Outcome; Uridine Monophosphate; Viral Load | 2017 |
Outcomes of treatment with direct-acting antivirals for infection with hepatitis C virus genotypes 1-4 in an ambulatory care setting.
Topics: Aged; Ambulatory Care; Ambulatory Care Facilities; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load | 2017 |
Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation.
Topics: Aged; Antiviral Agents; Benzimidazoles; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Recurrence; RNA, Viral; Sofosbuvir; Viral Load | 2017 |
[Debut in diabetic patients with hepatitis C treatment with ledipasvir/ sofosbuvir (Harvoni®)].
Topics: Antiviral Agents; Benzimidazoles; Diabetes Complications; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir | 2017 |
Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Follow-Up Studies; Glomerular Filtration Rate; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Function Tests; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Prognosis; Retrospective Studies; Risk Factors; Sofosbuvir; Uridine Monophosphate | 2017 |
Treating Medicaid patients with hepatitis C: clinical and economic impact.
Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Insurance, Health, Reimbursement; Male; Markov Chains; Medicaid; Quality-Adjusted Life Years; Sofosbuvir; Treatment Outcome; United States; Uridine Monophosphate; Viral Load | 2017 |
Comparison of on-treatment HCV RNA during direct antiviral therapy using two different COBAS TaqMan HCV assays.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Automation, Laboratory; Benzimidazoles; Drug Monitoring; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Molecular Diagnostic Techniques; RNA, Viral; Sofosbuvir; Viral Load; Young Adult | 2017 |
Hepatitis C Virus-Related Hepatic Myelopathy After Treatment With Sofosbuvir and Ribavirin: A Case Report.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Ribavirin; Sofosbuvir; Spinal Cord Diseases; Viral Load | 2017 |
INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; End Stage Liver Disease; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sweden; Treatment Outcome; Valine | 2017 |
Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Drug-Related Side Effects and Adverse Reactions; Female; France; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2017 |
Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.
Topics: Antiviral Agents; Benzimidazoles; Cohort Studies; Cost-Benefit Analysis; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Middle Aged; Quality-Adjusted Life Years; Sofosbuvir; Spain; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate | 2017 |
Considerations on bringing warehoused HCV patients into active care following interferon-free, direct-acting antiviral drug approval.
Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Insurance Claim Review; Insurance, Pharmaceutical Services; Male; Practice Patterns, Physicians'; Sofosbuvir; Surveys and Questionnaires; United States; Uridine Monophosphate | 2017 |
Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Sofosbuvir; Treatment Outcome | 2017 |
Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Male; Markov Chains; Middle Aged; Models, Economic; Pyrrolidines; Quality-Adjusted Life Years; Sofosbuvir; Survival Analysis; United States; Valine | 2017 |
Hepatitis B reactivation in chronic hepatitis C patients during treatment with ledipasvir and sofosbuvir.
Topics: Benzimidazoles; Coinfection; Fluorenes; Hepatitis B; Hepatitis B virus; Hepatitis C, Chronic; HIV Infections; Humans; Sofosbuvir | 2018 |
Author reply to: Hepatitis B reactivation in chronic hepatitis C patients during treatment with ledipasvir and sofosbuvir.
Topics: Benzimidazoles; Coinfection; Fluorenes; Hepatitis B; Hepatitis B virus; Hepatitis C, Chronic; HIV Infections; Humans; Sofosbuvir | 2018 |
Hepatitis C therapy: highlights from the 2012 annual meeting of the European Association for the Study of the Liver.
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Congresses as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Interleukins; Protease Inhibitors; Pyrrolidines; Sofosbuvir; Uridine Monophosphate; Valine; Viral Load; Viral Nonstructural Proteins | 2013 |